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ABSTRACT
Brain trauma occurs frequently in children and its consequences cause significant
health and financial burden to the patients, their carers and society.  This thesis
assessed the modulating effects of physiological, genetic, and biochemical factors on
the sequelae of childhood brain trauma.
Primary brain injury from the mechanical forces of trauma and secondary brain
insults consequent on the primary injury are determinants of brain trauma outcome.
The most important secondary insults recognised are reduced cerebral perfusion
pressure (CPP) and raised intracranial pressure (ICP).  CPP is governed by the mean
arterial blood pressure and the ICP.  During childhood these physiological measures
change with age.  With continuous physiological recordings, ‘critical’ age-related
minimum CPP thresholds for children aged 2-6, 7-10 and 11-15 years were defined
as 48, 54 and 58mmHg respectively.  Utilising these thresholds and a novel
cumulative pressure-time index (PTIc), we have demonstrated that CPP insult still
remains a feature in 80% of the severe brain trauma patients and significantly relates
to global outcome.
Brain trauma and cerebral ischaemia are stimuli to the inflammatory cascade leading
to further brain damage.  Serum adhesion molecule levels after brain trauma indicate
injury severity and predict outcome better than brain specific proteins.  Predictability
is improved using more than one serum biomarker level.  Neuro-inflammatory
pathways involving adhesion molecules may have a strong modulating effect on
brain trauma outcome but warrants further investigations in relation to CPP insult.
Genetic factors such as Apolipoprotein E (APO E) genetic polymorphisms may
additionally influence outcome, but it was not known whether genetic factors lessen
the quantity of CPP insult or the cellular response to it.  We demonstrated that the e4
carriers who had unfavourable outcome had 22 times less CPP insult than the non-e4
carriers, while the e3 homozygous who had good recovery had 26 times more CPP
insult than the non-e3 homozygous. This suggests that APO E polymorphisms may
affect the patient’s cerebral ischaemic tolerance differently, indicating especially the
need to prevent CPP insult among e4 carriers.
Cerebral ischaemia may, therefore, be a common pathway through which
physiological and genetic factors modulate outcome after brain trauma.
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CHAPTER 1: OVERVIEW OF CHILDHOOD TRAUMATIC BRAIN INJURY
(TBI)
1.1) INTRODUCTION
Traumatic brain injury (TBI), from either accidental or non-accidental origin, occurs
frequently in children and is responsible for up-to 50% of all A&E attendants less
than 15 years of age [1].  Despite major advances over the recent years in
resuscitation and trauma care, brain trauma remains the commonest cause of trauma
death and long-term disability in children [2, 3] .  For every 100,000 population in
Scotland, there are more than 100 new cases of disability occurring each year as a
result of brain trauma [4] .  The consequences can be profound neurological deficits
[5] including severe developmental delay if the injury is sustained in early childhood,
resulting in an enormous burden of caring for parents, carers, and society.
Intensive care management of critically ill brain injured children remains largely
empirical [6] because the paucity of clinical research in this area has translated into
only limited advances in certain specific areas of monitoring and treatment.  The
majority of animal models for brain injury have been small rodents, whose anatomy
and physiology are very different from those of humans, and these experiments often
fail to consider the effects of neuro-intensive care.  As a result, data from these
models have limited potential for extrapolation to intensive care treatments.
Similarly, most basic animal research has employed adult animal models with few
studies examining animals equivalent to the newborn infant or young child.  Clinical
studies investigating the complex pathophysiological processes initiated by brain
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trauma in critically ill infants and children and experimental studies using immature
animals are, therefore, required urgently before evidence based recommendations
and guidelines can be developed rationally for the intensive care management of the
brain injured infants and children.
An overview of the childhood traumatic brain injury literature is presented and is
followed by formulation of the hypotheses to be investigated in this thesis.
1.1.1) Terminology Definition
Head injury may be defined as injuries to the scalp, skull, or brain caused by an
external force applied to the head from either accidental or non-accidental means i.e.
trauma to the head.  The extent of the structural damage to the head following trauma
depends upon the intensity and severity of the mechanical insult.  It is, therefore,
possible to have sustained a head injury isolated to the scalp without involvement of
the underlying skull or brain.  Head injury is, therefore, not synonymous to brain
injury, which by definition, signifies injuries to the brain.
Brain injury may be the result of congenital or acquired insults.  Acquired brain
injury may be caused by trauma, neoplasm, infections, inflammation, degeneration,
autoimmune reactions, thrombosis, or bleeding.
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The patients studied in this thesis have suffered brain injury from trauma and for
consistency sake they will be referred to as having sustained traumatic brain injury
(TBI) or brain trauma.
1.2) EPIDEMIOLOGY
1.2.1) Epidemiology of Childhood TBI in Scotland
The epidemiology of childhood traumatic brain injury in Scotland has only been
described previously in four reports which are summarised below.
The hospital admission rate for childhood head injury in Scotland between 1984 and
1985 was 4011 per 100 000 children per year which was determined in a
retrospective case review involving all attending children aged 14 years or less with
head injury of all severity among 23 different Scottish A&E departments [7].
Brookes and colleagues then identified those with evidence of brain injury within the
cohorts (i.e. children who had altered consciousness on arrival to hospital or had a
history of altered consciousness and amnesia on arrival to the A&E department) to
calculate the hospital admission rate for childhood traumatic brain injury which was
290 per 100 000 children per year [7].  Majority of these brain injured children had
suffered a mild injury but five to ten percents of the patients had sustained a severe
injury giving the incidence of severe paediatric traumatic brain injury to be between
14.5 and 29 per 100 000 children per year [7].  Road traffic accidents were the cause
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of severe brain injury in 75% of cases and responsible for 71% of brain trauma death
[7].
Jennett and co-workers subsequently investigated the A&E attendants in Scotland
during 1985 [1].  This retrospective study reported similar incidence for childhood
head injury and childhood traumatic brain injury to those reported by Brookes and
co-workers [7] which was not surprising given the same catchment population was
used for both reports and the time lapse between the studies was insufficient to
demonstrate any effect from injury prevention measures.  Childhood brain trauma
mortality rate in Scotland was reported for the first time in this study and was
thought to be 5.3 per 100 000 children per year [1].
Scottish childhood injury mortality rate between the years of 1981 and 1985 was
reported by Morrison’s group in 1999 to be 11.6 per 100 000 children per year [8].
This figure was based upon retrospective data collection from Registrar General and
included infants and children aged between 0 and 14 years [8].  Similar to the two
previous Scottish reports, road traffic accident related mortality rate was high (4.8
per 100 000 children per year) which was eight times more than the mortality rate
related to accidental falls (0.6 per 100 000 children per year) [8].
National mortality data collected by Registrar General in Scotland over a ten-year
period (1986 to 1995) was reviewed by Williamson and colleagues [9].  A total of
290 children died as a result of traumatic brain injury during the study period giving
a mean annual head injury mortality rate of 3 per 100 000 children [9].  This study
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reported a 2.3 times reduction in paediatric head injury mortality rate over ten years
(4.1 per 100 000 children in 1986 vs. 1.8 per 100 000 children in 1995) [9] which
may be the result of the various injury prevention measures introduced during the
study period.  This report also highlighted the existence of significant variations in
childhood brain trauma mortality between socially deprived and affluent areas in
Scotland with the highest paediatric head injury mortality rate (5.1 per 100 000
children) observed in the most deprived area [9].  This was 2.4 times higher than the
childhood head injury mortality rate observed in the most affluent area (2.1 per 100
000 children) [9].  Similar to previous reports, pedestrian accidents were the most
frequent cause of paediatric head injury mortality.
1.2.2) Difficulties in Comparing Childhood TBI Epidemiological Data
The incidence of childhood brain trauma relies upon a few existing epidemiological
studies which often involved different patient populations such as A&E attendants,
patients admitted for neuro-observations, patients with evidence of brain injury, or
critically ill brain trauma patients.  Comparison between studies is, therefore,
difficult.  Attempts to compare the 4 available Scottish childhood brain trauma
epidemiology reports in the literature clearly demonstrate this difficulty.  Hospital
admission rate was used in Brookes and Jennett’s papers [1, 7] while injury mortality
rate and head injury mortality were reported in Morrison and Williamson’s groups
[8, 9] respectively.  Two of the four Scottish studies investigated the mortality data
collected by Registrar General without considering survivors of paediatric brain
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trauma [8, 9], while the authors of the remaining papers reported data drawn from
A&E attendants [1, 7].
Inter-hospital transfers of brain trauma patients create another problem for reliable
prevalence comparison between studies because with the danger of ‘double
counting’, it is difficult to ascertain the accurate number of brain trauma patients and
to define catchment populations.  As a result, many reports of brain trauma patient
numbers and fatalities from trauma units or pathology departments do not usually
provide a population denominator.
Variations in admission and triage polices between hospitals also make comparison
difficult between reports with apparently similar patient groups.  The 9
th
 edition of
the International Classification of Diseases (ICD) is the most widely used coding
system in the UK, but there are 10 non-mutually exclusive codes in the ICD to cover
the diagnosis of head injury.  This makes accurate identification of head injury
patients difficult and may increase the risk of double counting.  Application of these
codes may also be different between hospitals and countries making the validity of
the comparison between reports in the literature doubtful.  In addition, the ICD codes
are not capable of differentiating injury severity and this makes retrospective
identification of severe injury impossible from ICD codes alone without reference to
impairment of conscious levels.  Finally coding errors occur frequently and may not
be easily identifiable.
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1.2.3) Comparisons Between the International And Scottish Childhood
TBI Epidemiology
In America, a steady decline in mild and moderate childhood head injury has been
observed over the past 3 decades but the incidence of severe paediatric brain trauma
was slightly increased.  The mean paediatric brain trauma incidence during the
period between 1930s and 1980s was between 180 and 310 per 100 000 per year [10-
12], with a childhood brain trauma mortality rate of around 8 per 100 000 per year
[10-12].  By the late 1980s and 1990s, the mean incidence of childhood brain trauma
has reduced to between 60 and 160 per 100 000 per year [13-16], and the mortality
rate was between 5 and 6 per 100 000 per year [13-17].  Brain trauma incidence was
consistently higher in the rural areas than metropolitan regions [13-18], and it was 3
times more common in boys than girls [10, 13, 18].  Falls was the main cause of
brain trauma in children aged between 0 and 4 years of age while motor vehicle
related accidents were the commonest cause of brain injury among children older
than 4 years of age [14, 15, 17-21].
Epidemiological data from European countries often only included severe brain
injury and would, therefore, appear less than those reported by US authors since
many US reports included head injury of all severity.  If only severe brain injury was
considered, the incidence was fairly similar between the reported European and
American figures.
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During the 1980s and 1990s, the mean incidence of childhood severe brain trauma in
Northern European countries (Finland, Demark, Iceland, and Sweden) was 12 – 17
per 100 000 per year while the annual mortality rate was 2.6 – 4.8 per 100 000 [3,
22-24].  In 1996, the mean incidence of childhood severe brain trauma in France [25]
was reported to be lower (8.4 per 100 000 per year) than those reported by the
Northern European countries [3, 22-24].  Similarly, the mortality rate was also lower
and was found to be between 1.3 and 2.1 per 100 000 per year [25].  However, the
mean incidence of severe paediatric brain trauma in Switzerland was as high as 15.2
per 100 000 per year and the mortality rate was 6.8 per 100 000 children [26].  Motor
vehicle related accidents were the main cause of childhood brain trauma in Europe
[3, 25, 27].  The European annual incidence of severe childhood brain trauma is,
therefore, between 8 and 18 per 100 000 children with a mortality rate between 2 and
7 per 100 000 children.
Given the aforementioned limitations to the comparability between reports, the
hospital admission rate for head injury in Scotland [1, 7] is similar to those reported
in the literature for the United States of America and other European countries [3,
13-26] which were between 100 to 300 per 100 000 children per year.  Little
difference exists in the reported proportion of severe brain injury in children across
the world [1, 3, 7-9, 13-26] giving an estimated incidence of 10 – 30 per 100 000
children per year for severe brain injury in children.
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1.2.4) Causes of Paediatric TBI
Accidental fall remains the commonest cause of childhood traumatic brain injury
worldwide but when only severe brain injury is considered, motor vehicle accident
related injuries become the commonest cause of brain trauma in developed countries
[1, 3, 7-9, 14, 15, 17-21, 25, 27].  Different road users, for examples pedestrian and
motor vehicle occupants, may become victims of brain injury from motor vehicle
accidents.  Significant variations exist worldwide in whom the commonest brain
injury victims are in motor vehicle related accidents [1, 3, 7-9, 14, 15, 17-21, 25, 27].
Pedestrian is the commonest type of road users to sustain brain injury from motor
vehicle related accidents in Britain [1, 7-9], while motor vehicle occupants constitute
the majority of brain injury sufferers following such accidents in the Untied States of
America [14, 15, 17-21].  This variation reflects the different road and vehicle usage
between countries and needs to be taken into consideration when designing local
accident preventative measures.
Sample statistics of A & E attendants with head injury at Royal Hospital for Sick
Children in Edinburgh over a 1-year period demonstrated a similar pattern with
accidental falls accounting for half (53%) of these attendances and 12% had a history
of significant falls (i.e. more than 1 meter height).  Motor vehicle related accidents
were responsible for 4.6% of attendances and the remainder (42%) were due to
miscellaneous causes including non-accidental head injury.  Similar to other reported
series, toddlers i.e. those between one and two years of age represented the peak age
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group of attendants with a steady decline in attendance thereafter up to 13 years of
age.
1.2.5) Classifications of Brain Injury Severity
Severity of brain injury may be classified using the post resuscitation Glasgow Coma
Scale (GCS) [28], duration of unconsciousness or post-traumatic amnesia, and neuro-
imaging scales reserved for severe injury e.g. Marshall Scale [29, 30].  Coma or loss
of consciousness is caused by primary midbrain injury from rotation of the cerebral
hemispheres on the midbrain.  Since rotational forces are not necessary the cause of
all head trauma, not all head injury are associated with a loss of consciousness (e.g.
some frontal lobe injuries, extradural haematomas and some penetrating and
compression injuries), but conversely, all cases with loss of consciousness indicate
brain injury.  Jennett [1] considers coma to be clinical evidence of damage to the
brain and the most reliable way to recognise that a brain injury has occurred.  Thus,
evidence of brain injury is indicated by an altered consciousness on arrival or a
history of altered consciousness with amnesia on arrival, or abnormal neurological
signs.
1.2.5.1) Coma Scales
The GCS (Table 1.1a) [28], which is essentially a mini neurological examination, is
the most frequently used method to classify injury severity in adult brain trauma.  It
enables comparisons between successive examinations of the consciousness level to
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identify any clinical deterioration.  GCS also remains the most useful clinical index
of brain injury because it provides a gradient of injury severity: a summated score of
13 – 15 is designated mild, a score of 9 – 12 is designated moderate, and a score of 3
– 8 is designated severe injuries.  To minimise the subjectivity of GCS in the
classification of brain injury severity, the British Society of Rehabilitation Medicine
has elected to use a combination of GCS and duration of unconsciousness to classify
head injury severity: mild injury is defined as an injury causing unconsciousness for
less than 15 minutes and a post-resuscitation GCS of 13 to 15; moderate injury is
defined as any injury causing loss of consciousness for more than 15 minutes and a
post-resuscitation GCS of 9 to 12; and severe injury is defined as any injury causing
unconsciousness for more than 6 hours and a post-resuscitation GCS of 3 to 8.
However, the criteria used in this classification system are not mutually exclusive
and may pose difficulty when, for example, a patient presents with a post-
resuscitation GCS of 4 but was only unconscious for 3 hours.
Many of the responses assessed in the GCS require an adult level of neurocognitive
function and cannot be easily graded in children less than 10 years of age [31].
Modifications of the GCS to include age-adjusted verbal and motor responses have
been described and used to assign severity for childhood brain injuries [32-38].  The
inter-observer variability between 6 different coma scales used in children was
assessed and the Paediatric Coma Scale had the highest inter-observer agreement
[12].  In an attempt to standardise the way coma is measured in children, the British
Paediatric Neurology Association (BPNA) has recommended the James adaptation
of the GCS (Table 1.1b) as it takes into account the developmental immaturity in
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small children, uses the same number of points as the standard GCS irrespective of
the child’s age, and is simple to use.
The determination of the GCS may be complicated by endotracheal intubation,
sedation, and pharmacological paralysis [39].  In adults, the full GCS was not
testable in up to 44% of the patients at the time of admission to a neurosurgery
service [39].  Serious implications on the treatment required and prognosis may arise
if the initial GCS is not scored accurately.  In an attempt to overcome this problem,
members of the Traumatic Coma Data Bank have proposed to assign a GCS verbal
score of 1.1 to all adult head injured patients who have been intubated prior to the
first GCS assessment [39].  However, this practice may significantly overestimate
the injury severity.











































Child > 5 yrs Child < 5yrs
Spontaneous As older child 4
To speech As older child 3
To pain As older child 2
None As older child 1
Best Verbal Response
Child > 5 yrs Child < 5 yrs









Inappropriate words Cries to pain 3
Incomprehensible
sounds
Moans to pain 2
None None 1
Best Motor Response
Child > 5 yrs Child < 5 yrs
Obeys command As older child 6
Localises to pain As older child 5
Withdraws from
pain
As older child 4
Abnormal flexion As older child 3
Extensor response As older child 2









Child > 5 yrs Child < 5yrs
Spontaneous As older child 4
To speech As older child 3
To pain As older child 2
None As older child 1
Best Verbal Response
Child > 5 yrs Child < 5 yrs
Orientated Alert, babbles, coos,
words or sentences to
usual ability
5




Inappropriate words Cries to pain 3
Incomprehensible
sounds




Spontaneous normal facial/oromotor activity e.g.
sucks tube, cough
5
Less than usual spontaneous ability or only
response to touch
4
Vigorous grimace to pain 3
Mild grimace or some change in facial
expression to pain
2
No response to pain 1
Best Motor Response
Child > 5 yrs Child < 5 yrs
Obeys command As older child 6
Localises to pain As older child 5
Withdraws from pain As older child 4
Abnormal flexion As older child 3
Extensor response As older child 2
None As older child 1
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A recent report from Britain proposed the use of a grimace score instead of the
verbal component of the GCS while assessing the conscious levels in intubated
children. (Table 1.2) [40].  This modified paediatric coma scale for intensive care
practice has originated from the Sharples’ adaptation of the James’ modification of
the GCS and was formulated on the basis that (i) non-verbal communication and
verbal language are not totally independent, and (ii) both facial expression and
grimace form an important part of non-verbal communication [40].  In a cohort of 73
critically ill children, the inter-observer reliability of this scale was found to be
between moderate to good for all components assessed using the grimace score, and
this was shown to be better than the verbal score in the whole group suggesting that
the grimace score may be more useful in intubated patients [40].  However, this
component requires further evaluations before formal introduction into clinical
practice can take place.
1.2.5.2) Other System Injury Scores
Various other scoring systems, such as the Injury Severity Score (ISS), Revised
Trauma Score (RTS), and Trauma Score-Injury Severity Score (TRISS), have also
been used to classify the severity of head injury and are summarised below.
However, these scoring systems often have very strict and detailed definition criteria
or involve complex calculations limiting their applicability and usage in clinical
practice particularly in the emergency room and the intensive care settings where
prompt management decisions are often required.  Thus, most of these scoring
systems have been restricted to research practice.
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1.2.5.2.1) Injury Severity Score (ISS)
This is an anatomical scoring system which gives an overall score for multiple
injuries.  For each injury present, an abbreviated injury scale (AIS) score is allocated
to one of six body regions.  The three highest AIS scores from the three most
severely injured body regions scores are squared and added to produce an overall
ISS.  The range is between 0 and 75.  The ISS correlates with mortality, morbidity,
hospital stay and other measures of severity [41].
1.2.5.2.2) Revised Trauma Score (RTS)
This is a physiological scoring system and predicts mortality.  It is based on the first
set of examinations of the Glasgow Coma Scale (gcs), the systolic blood pressure
(sbp), and respiratory rate (rr):
RTS = 0.9368 gcs + 0.7326 sbp + 0.2908 rr.
The range is from 0 to 7.8408.  The RTS correlates well with the probability of
survival.
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1.2.5.2.3) Trauma Score  – Injury Severity Score (TRISS)
This determines the probability of survival using the ISS and RTS.  Although the
TRISS indicates the probability of survival for blunt or penetrating injuries, these are
not differentiated in children [42].
1.2.5.2.4) The Paediatric Trauma Score (PTS)
The Paediatric Trauma Score (PTS) summates scores of weight, airway maintenance,
systolic blood pressure, pupil responses, and the presence of an open wound or
skeletal trauma.  It indicates only a significant mortality risk and ranges from +12 to
–6.  A score of ! 8 indicates a significant mortality risk [43].
1.2.6) Outcome
1.2.6.1) Global Outcome Assessment
The Glasgow Outcome Scale (GOS) score has become the most widely used method
to describe the global outcome after head injury in adults since it was first published
in 1974.  Although it is quick to administer and has clinically relevant categories, it
does not take into account the special developmental considerations in the
assessment of outcome in children with traumatic brain injury.  Adelson and co-
workers have modified the GOS for use in infants and children (Table 1.3) [44] but
the modified GOS still does not consider behavioural morbidity which is common
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after childhood brain trauma.  Crouchman and colleagues further modified the five
categories of the modified GOS to produce the eight points King’s Outcome Scale
for Childhood Head Injury (KOSCHI) analogous to the expanded adult GOS (Table
1.4) [45].  The scale places a high emphasis on concentration, behaviour and
disinhibition which are common problems in children.  It is intended to allow
completion by either direct observation or from routine follow-up medical records,
prospectively or retrospectively.  The KOSCHI scale shows comparability with the
GOS allowing comparison with adults as well as facilitating the transition of follow-
up into adulthood.
Table 1.3: Modified Glasgow Outcome Scale
Category Description
1 Dead Dead
2 Vegetative No interaction or cognition of outside stimuli.
3 Severely disabled Significant gross motor or cognitive dysfunction
requiring ongoing therapy, special schooling, or early
intervention; minimal gaining of age-appropriate
milestones.
4 Moderately disabled Notable motor or cognitive dysfunction requiring
ongoing therapy, special education, or early
intervention; occasionally able to independently perform
age-appropriate activities; gaining milestones though
delayed.
5 Good Outcome Good outcome with minimal dysfunction, return to
school, independent age-appropriate activities, or
continuing to achieve age-appropriate milestones.
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Table 1.4: King’s Outcome Scale for Childhood Head Injury (KOSCHI)
Category Definition
1 Death Death
2 Vegetative The child is breathing spontaneously and may have sleep/wake
cycles.  He may have non-purposeful or reflex movements of limbs
or eyes.  There is no evidence of ability to communicate verbally
or to respond to commands.
3 Severe
disability
(a) The child is at least intermittently able to move part of the
body/eyes to command or make purposeful spontaneous
movements; for example, confused child pulling at nasogastric
tube, lashing out at carers, rolling over in bed.  May be fully
conscious and able to communicate but not yet able to carry out
any self care activities such as feeding.
(b) Implies a continuing high level of dependency, but the child
can assist in daily activities; for example, can feed self or walk
with assistance or help to place items of clothing.  Such a child is




(a) The child is mostly independent but needs a degree of
supervision/actual help for physical or behavioural problems.
Such a child has overt problems; for example, 12 year old with
moderate hemiplegia and dyspraxia insecure on stairs or needing
help with dressing.
(b) The child is age-appropriately independent but has residual
problems with learning/behaviour or neurological sequelae
affecting function.  He probably should have special needs
assistance but his special needs may not have been
recognised/met.  Children with symptoms of post-traumatic stress
are likely to fall into this category.
5 Good recovery (a) This should only be assigned if the head injury has resulted in
a new condition which does not interfere with the child’s well
being and/or functioning; for example:
• Minor headaches not interfering with social or school
functioning
• Abnormalities on brain scan without any detectable new
problem
• Prophylactic anticonvulsants in the absence of clinical
seizures
• Unsightly scarring of face/head likely to need cosmetic
surgery at some stage
• Mild neurological asymmetry but no evidence of affect on
function of limb.  Includes isolated change in hand
dominance in young child.
(b) Implies that the information available is that the child has made




TBI is the commonest cause of trauma death in children aged 1-15 years in England
and Wales [46].  The mean mortality rate from childhood head injury calculated from
18 published studies was 5.1 ± 2.39 per 100,000 children per year [1, 3, 8-10, 12, 14-
17, 20, 21, 25, 26, 46-49].  While the incidence of severe traumatic injury (GCS 3 -
8) has been decreasing it remains at 7-10% of all head injuries, and the mortality for
this severely injured group is high at 20-40%.  Although accidental injury mortality
rates have fallen in the United Kingdom, certain population groups, such as children
residing in less affluent areas, remain at greater relative risk [8, 50].  In Scotland,
pedestrian accidents were the leading cause of brain trauma deaths in children [8, 9].
The incidence of severe childhood brain trauma mortality has declined steadily and
significantly over the past two decades.  The reason for this decline is likely to be
multifactorial because of the simultaneous injury prevention efforts from the
governments, parents, health care professionals, engineers and manufacturers of cars
or playgrounds to improve safety and to reduce fatality among childhood accidents.
1.2.6.3) Morbidity
Approximately 3000 children every year acquire new neurological or cognitive
disability as a result of head injury in the UK [51] and in Scotland, there are more
than 100 new cases of disability occurring each year as a result of brain trauma for
every 100,000 population [4].
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Survivors of childhood brain trauma may suffer from a variety of deficits ranging
from physical disabilities to behavioural and cognitive difficulties.  Even mild head
injury may lead to persistent cognitive and behavioural deficits [52, 53].  Morbidity
experienced by different cohorts of childhood head injury survivors is difficult to
compare because outcome assessments in children post brain injury require special
developmental considerations.  Neurodevelopmental processes continue, although
often modified, after injury, measures of outcome must, therefore, relate to age
appropriate expectations.  Physical, behavioural, and cognitive aspects contribute
varying degrees towards the overall morbidity depending upon the age at injury,
interval since injury, injury severity, and injury independent factors.
One long term follow up study of childhood head injury indicated that 1/3 of the
patients reported sequelae from the head injury with 1/3 of the complaints related to
physical disabilities, another 1/3 were intellectual deficits, and the final 1/3 were
emotional complaints [54].  A higher proportion of morbidity was reported in
another study where 55% of patients reported symptoms and physical limitations
were detected among 45% of these patients [55].  The most common neurological
complaint in all reported series was headache, while musculoskeletal symptoms were
the second most frequently documented symptoms.  Learning difficulties occurred
frequently after head injury and were experienced by 22 to 78% of children [54, 55].
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1.3) DETERMINANTS OF OUTCOME AFTER BRAIN TRAUMA
1.3.1) Introducing Primary Brain Injury and Secondary Brain Insults
Brain trauma outcome is determined by the amount of brain injuries sustained during
the moment of trauma and its subsequent clinical course.  When trauma occurs, the
initial mechanical forces applied to the head will cause injuries to the neurons, glial
cells, and surrounding blood vessels.  These are primary brain injuries and may,
therefore, include epidural and subdural haematomas; subarachnoid, intracerebral,
and intraventricular haemorrhages; traumatic axonal injuries; as well as brain
contusions and lacerations.  Additional brain injury occurs as a result of the
pathophysiological response to the primary brain injuries, and these are called
secondary brain insults which will also modulate neurological outcome.
The concept of secondary brain insults was first introduced in the late 1970s when
one third of the brain trauma patients who died after admission to neurosurgical units
were reported to have talked at some point after the initial trauma [31, 56, 57].  The
primary brain injury in these patients was judged to be not severe enough to cause
death, but subsequent events resulted in fatal or disabling cerebral injury [31, 56, 57].
At the same time, evidence from post-mortem studies showed that over 80% of
adults with fatal brain trauma had ischaemic brain damage despite the introduction of
intensive care treatment regimes [58].  Secondary brain damage has also been shown
to occur in children following brain trauma.  Sharples’ group reported the present of
‘avoidable’ secondary brain insults in children with head injury [59], and hypoxic
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brain damage has been shown to occur frequently in fatal accidental and non-
accidental brain injury in infants and children [60-62].
Accident preventative measures have dramatically reduced the number of fatal
childhood brain trauma but accidents continue to occur and little can be done to alter
the extent of primary brain injuries once sustained.  For patients who survive the
initial brain trauma to reach hospital and subsequent neuro-intensive care, outcome
is, therefore, related to the amount of secondary brain insults experienced [31, 56, 57,
59, 60].
1.3.2) Secondary Brain Insults
1.3.2.1) Secondary Physiological Derangements
In response to the initial brain trauma, serious systemic and intracranial physiological
complications occur which include hypoxia, hypotension, raised intracranial pressure
(ICP), reduced cerebral perfusion pressure (CPP), pyrexia and disturbances of global
brain oxygen extraction (SjvO2) [63].  These secondary physiological derangements
may arise at any stage following the initial trauma and cause further brain damage
through secondary brain injuring mechanisms.  Deranged physiology is easily
detectable clinically and prompt treatment may, therefore, reduce secondary brain
insult and alter the outcome of brain trauma patients.
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1.3.2.1.1) Frequency of Secondary Physiological Derangement after
Brain Trauma
Prior to implementation of advance trauma care and active resuscitation at the scene
of accidents, hypoxemia occurred in up to 30% of brain injured patients and arterial
hypotension was found in 15% of patients on arrival to the Accident & Emergency
Department [64-69].  Deranged physiology may also occur later in the clinical course
of brain trauma in the Intensive Care Unit and during transfers.  Miller and
colleagues reported a high incidence (53%) of raised ICP (levels > 20 mmHg) among
brain injured adults requiring intensive care in the late 1970s and early 1980s [65,
70] but data from the Traumatic Coma Data Bank (TCDB) indicated subsequently
that an even higher proportion (72%) of intensive care patients suffered from
intracranial hypertension following head injury [71].
In a prospective study involving 124 critically ill head injured adults, Jones and her
colleagues examined up to 14 different physiological variables (such as ICP, arterial
blood pressure, CPP, heart rate, oxygen saturation, core and peripheral temperature)
recorded in minute resolutions during the patients’ intensive care management [72].
They found that the majority (91%) of the brain trauma patients had deranged
physiology regardless of the initial brain trauma severity, their age, or the admission
Injury Severity Score (ISS) [72].  Andrews and co-workers demonstrated that 50% of
brain trauma patients developed deranged physiology during intra-hospital transfers
(mostly between the ICU and CT scanning suites) [73].  In addition, more than 65%
also had physiological derangements in the ICU during the subsequent 4 hours of
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continuous monitoring following the transfer [73].  These studies have highlighted
that intracranial and systemic physiological complications occur frequently after
brain trauma and the importance to continuously monitor and normalise brain trauma
patients’ physiology throughout their early clinical course.
1.3.2.1.2) Secondary Physiological Derangement and Brain Trauma
Outcome
Brain trauma mortality and morbidity were increased significantly in patients who
suffered from early hypoxia or hypotension following the initial trauma [63].
Similarly, the duration of hypotension, pyrexia, and hypoxemia that occurred in the
intensive care were the most significant predictors of mortality [72].  One possible
explanation is that deranged physiology affect oxygen and substrates (particularly
glucose) delivery to the brain.  When the physiological response to brain trauma
becomes so severely impaired that brain perfusion and oxygenation is no longer
sufficient to meet its metabolic need i.e. below the critical ischaemic thresholds,
brain ischaemia occurs and causes further damage to the already injured brain,
thereby worsening the prognosis.
1.3.2.2) Critical Care Neuro-trauma Management
Modern critical care brain trauma management aims to normalise cerebral and
systemic homeostasis to prevent additional brain insults [74, 75].  This concept was
first introduced by the late Professor JD Miller in Edinburgh during the 1970s.
26
Standardised treatment guidelines were developed locally to ensure rapid diagnosis
and treatment of intracranial mass lesions, prevention of hypoxia, hypercapnea, fluid
and electrolytes imbalance, anaemia, and arterial hypotension [76] among brain
trauma patients.  Its effectiveness in reducing head injury related mortality by as
much as 20% quickly became apparent [76] with worldwide adoption of the practice
which evolved into the basis of modern adult and paediatric neuro-trauma care.
The original critical care brain trauma management emphasized on the treatment of
raised ICP [76], because intracranial hypertension was associated with poor outcome
after brain trauma and was responsible for up to half of the brain trauma fatalities
[70] and ischaemic brain damage [77-79].  Vigilant clinical examination and prompt
access to neuro-imaging allow early identification and evacuation of intracranial
haematomas [74, 76].  Introduction of neuro-intensive care and advancement in
physiological monitoring technology enable prevention, early detection and
treatment of cerebral oedema and intracranial hypertension with controlled
mechanical ventilation, maintenance of adequate sedation and the use of muscle
relaxants, osmotic diuresis, treatment of seizures and pyrexia, and pharmacologically
induced coma with barbiturate [74, 76].
Despite vigorous treatment of intracranial hypertension, a significant proportion of
fatal brain trauma patients in the 1980s continued to demonstrate the presence of
ischaemic brain damage [58, 79].  At the same time, poorer brain trauma outcome
was increasingly linked with longer duration of low cerebral perfusion pressure [63,
72].  The emphasis of brain trauma management was, therefore, shifted towards
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maintenance of an adequate CPP while preventing and minimising other
physiological derangements including raised ICP and hypoxia [74].
Although intensivists agree that it is important to normalise cerebral and systemic
physiology after brain trauma, alarming differences have been reported in the
intensive care management of brain injured patients in Europe and the USA during
the 1990s [80-82].  This finding highlighted the need to develop standardised
management guidelines for brain trauma.  The Brain Trauma Foundation [74],
European Brain Injury Consortium [83], and Scottish Intercollegiate Guidelines
Network [84] have independently published intensive care management guidelines
for adult traumatic brain injury with a general aim to normalise cerebral homeostasis.
Treatment thresholds for ICP and CPP have been proposed in these guidelines [74,
83] which have became widely accepted in clinical practice across the world even
though they have not been validated.  Lack of threshold validation may be due to
limitations in current methodology to determine and summarise abnormal physiology
which only allows one dimensional derangement assessment at any one time e.g. the
duration or magnitude of physiological derangement.
Much of the current literature on prevention, detection, and correction of secondary
physiological derangements after brain trauma comprised of adult brain trauma
studies.  Very little research investigates the clinical aspects and pathophysiology in
children with brain trauma apart from a few specialised studies [85, 86] which
primarily examined cerebral blood flow, cerebral hyperaemia, CMRO2, and
AjDvO2.  Brain trauma treatment principles from adult practice have been projected
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and applied to manage infants and children after brain trauma without considering
the age-maturation effect on intracranial haemodynamics.  Because of this lack of
sufficient data available in the paediatric head injury literature, considerable
variations exist among different paediatric intensive care units across the UK and
worldwide [6].
1.3.2.2.1) Lack of Normative Age-Related Intracranial Physiological Data
Normal systemic and intracranial physiology changes with age from birth through
childhood and adolescence to the final adult values and may partly explain the
difficulties in conducting research on this vitally important topic.  Previous
population studies have acquired normal acceptable ranges for heart rate and blood
pressure among children of different ages [87] but normative data for ICP in children
are more difficult to establish because of the ethical difficulties to measure it
accurately through invasive means in healthy children.  As a result, no information is
available on the normal age-specific childhood cerebral perfusion pressure (CPP)
values, which is calculated as the difference between mean arterial blood pressure
(MAP) and ICP.  This vital lack of knowledge on normative data has hindered
clinical research progress and development of age appropriate brain trauma treatment
guidelines.  This difficulty was highlighted in the Pediatric Head Injury Guideline
[75] endorsed by the following medical associations and societies: American
Association for the Surgery of Trauma, the Child Neurology Society, the
International Trauma Anesthesia and Critical Care Society, Society of Critical Care
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Medicine, and the World Federation of Pediatric Intensive and Critical Care
Societies.
Because of the significant gaps in normative age-related intracranial physiological
data, almost all previous childhood TBI studies have grouped children of all ages
together and applied a unified adult derangement definition to identify ‘abnormal’
intracranial physiology [88-91].  To use a standard definition of abnormal physiology
for all ages without taking into account of the natural age-related physiological
changes would be too simplistic and the transferability and usefulness of these results
to clinical settings are questionable.  A pilot study was, therefore, carried out by the
Edinburgh Paediatric Traumatic Brian Injury Study Group to demonstrate the
important associations between age-specific CPP derangement and outcome using
pre-defined theoretical age-specific thresholds [92].  This study introduced a novel
way to compare abnormal physiology among children of different ages [92].
However, like other studies of secondary physiological derangements, this study only
assessed the relationships between the durations of the mean CPP values and
neurological recovery without considering the effects of the derangement severity or
the total burden of derangement on outcome [92].
1.3.2.2.2) Limitation in Research Methodology to Quantify Physiological
Derangements
A measure that takes into account both the severity and duration of deranged
physiology should provide a better reflection of the total burden of the potential
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insult and allow better prediction of the outcome.  Furthermore, an accurate
measurement of the total quantity of derangements would allow testing of the
theoretical age-specific thresholds to define the critical thresholds that differentiate
normal and abnormal physiologies throughout different ages.  Once these critical
insult thresholds are identified, the amount of deranged physiology may then be
refined as insults and validation of current therapies and other future novel treatment
will then become possible.
1.3.2.3) Cellular and Molecular Pathophysiological Response to Brain
Trauma
In addition to causing abnormal physiology, brain trauma also initiates a complex
cascade of pathophysiological processes at cellular and molecular levels which
include hypoxic ischaemic injury, oxidative stress response, excitotoxicity, neuro-
inflammation, gliosis, and apoptosis.  The current understanding of the precise roles
and interactions of these pathophysiological processes is very limited but it is clear
that some of these processes aid the repair of the injured brain while others cause
further insults i.e. secondary brain injuring mechanisms.  When trauma induced
deranged physiology becomes insufficient to sustain cerebral metabolism, they
become insults to the already injured brain and will also trigger these cellular and
molecular pathophysiological brain injuring mechanisms.
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1.3.2.3.1) Secondary Brain Injuring Mechanisms
1.3.2.3.1.1) Hypoxic / Ischaemic Injury
After brain trauma, hypoxic ischaemic damage occurs when the brain’s oxygen and
nutrient supplies become inadequate to meet its metabolic demands and may be the
result of (i) primary brain injury when apnoea occurs following medullary injury
[93], or (ii) secondary deranged physiological response to the initial brain trauma
such as hypotensive shock, raised ICP, decreased cerebral perfusion pressure, and
decompensated prolonged seizures.  In cases of non-accidental head injuries, hypoxic
ischaemic brain injury may rarely additionally be the result of suffocation which may
have occurred to quell the infant’s crying.  The “big black brain” indicates
particularly severe hypoxic ischaemic damage which is followed by death or the
rapid development of cerebral atrophy.  Hypoxic ischaemia is almost always an
agonal event in most infant and childhood deaths as demonstrated by post-mortem
evidence of severe hypoxic ischaemic brain damage found in 80% of fatal childhood
accidental head injuries [60] and 77% of fatal non-accidental head injuries [61, 62].
Adequate perfusion is required to provide energy substrates and oxygen to meet the
metabolic demands of the brain and to remove the metabolic waste products to
prevent biochemical toxicity.  Brain infarction, therefore, occurs following impaired
perfusion which may be the result of hypotension, raised intracranial pressure, brain
shifts with associated vascular occlusions, vascular spasm/obstructions, seizure or
other causes of increased cerebral metabolism.
32
Hypotension does not result in uniform infarction of the whole brain [94] as
ischaemia may occur in any major vessel from low perfusion pressure.  The unique
design of the Circle of Willis with its four feeding arteries means that there are areas
within the brain where the pressures are equal, resulting in “no flow”.  When the
cerebral blood flow is severely impaired, these watershed zones between adjacent
vascular territories are most susceptible to ischaemic damage because the cerebral
arterioles are ‘end arteries’ without anastomosis.  In the newborn, this is between
centrifugal and centripetal arteries causing periventricular leucomalacia.  In the older
child it is between the middle and posterior cerebral arteries, causing infarcts in the
pericentral white matter of the optic radiations and posterior temporal lobe, or
between the anterior and middle cerebral arteries causing a wedge shaped infarct in
the ‘leg area’.
Cerebral infarction as a result of brain herniations such as pericallosal or subfalcine
shifts may follow specific patterns due to compression of the specific vital cerebral
arteries.  For examples, tentorial herniation may be associated with infarct in the
areas supplied by the posterior cerebral artery and coning into the Foramen Magnum
can cause compression of the posterior inferior cerebellar artery (PICA).
The main energy source for the brain is glucose which would produce 38 molecules
of adenosine triphosphate (ATP) under aerobic conditions but only 2 under anaerobic
conditions.  Under anaerobic conditions the supply of glucose and removal of lactic
acid becomes more essential since ATP is required for essential processes such as
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neuro-transmitter formation, transport mechanisms, maintenance of membrane
pumps and polarisation of membranes.  Ischaemia is, therefore, far more dangerous
than hypoxia because there is no supply of substrates (glucose or ketones) for ATP
production, nor any way of removing lactic acid which results in the rapid
development of neuronal necrosis.
Ischaemia initially causes swelling of the mitochondria within the neurons and
astrocytes as a result of water retention.  The neurons release potassium which is
collected by the astrocytes and together with accumulation of glycogen within the
astrocytes further swelling occurs [95].  Blood-brain barrier damage will result in
leakage of proteins and blood, as in cases of haemorrhagic infarct, into the
extracellular space through the endothelial cells.  Finally, liposome rupture and
neuronal cell death occur and coupled with the biochemical breakdown of tissue
proteins result in (i) swelling of the infarct which further compresses capillaries, (ii)
breakdown of blood-brain barrier, (iii) loss of cerebral auto-regulation, (iv)
thromboplastin release causing sludging, and (v) liquefaction of the tissues.
The necrotic tissue may then be absorbed by macrophages leaving a cyst, as in
periventricular leucomalacia, or may cause an astrocytic reaction replacing the dead
tissue with the formation of a glial scar and capillary proliferation i.e. reactive
astrogliosis.
Acute hypoxic ischaemia activates cellular production of adenosine and ACTH in an
attempt to slow down cerebral metabolism to minimise the degree of cerebral
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metabolic perfusion mismatch.  Thus, a potential therapeutic window may exist to
allow reduction of brain damage after hypoxic ischaemia.  Additionally, a
biochemical cascade is initiated which includes excitotoxicity, oxidative stress,
neuroinflammation and pathways leading to programmed neuronal cell death
(apoptosis) which may also be the targets of other neuroprotective measures.
1.3.2.3.1.2) Excitotoxicity
The main excitatory amino acid in the brain is glutamate [96].  Under normal
circumstances, glutamate stimulation of the post-synaptic ligand-gated ion channel
receptors (NMDA, AMPA, and kainite) is only transient.  Excitotoxicity occurs
when this stimulation is prolonged.
Glutamate concentration in the interstitial tissue is normally lower than the blood or
intracellular glutamate levels, and its concentration is regulated by trans-membrane
up-take of glutamate using the energy dependent sodium (Na
+
) ion pump.  Damaged
neurons release glutamate into the interstitial fluid where it will accumulate to toxic
levels if the blood-brain barrier is disrupted.  The glutamate transport is impaired
during ischaemia causing further increase in the interstitial glutamate level.  When
all energy supply is exhausted, membrane pumps fail and cause further sodium and
water influx into the neurons.  This results in cell swelling and subsequent release of
glutamate [97].  In addition, there is excessive calcium influx [98] which may trigger
activation of protein C, calpain I, phospholipase, xantine oxidase, nitric oxide, and
oxygen free radials [99, 100].  All these processes may cause further brain insults.
35
1.3.2.3.1.3) Oxidative Stress
Reactive oxygen species and reactive nitrogen species are produced in small amounts
during oxidative metabolism in the mitochondria.  After brain trauma, their
production is enhanced with excitotoxicity [101].  Metabolic acidosis from reduced
perfusion and anaerobic metabolisms may also induce oxidative stress.  This may be
the result of iron release from transferrin and ferritin caused by the low pH.  The
released iron may then act as a catalyst for the production of oxygen free radials
[102].  Neuro-inflammation has also been demonstrated to cause oxygen free radial
productions [103].
Oxygen free radials cause lipid peroxidation and affect the integrity of cell
membranes [104].  This may cause damage to the blood-brain barrier [105] resulting
in worsening of cerebral oedema.  Free radials may also oxidise proteins and DNA
[106-108] resulting in either apoptosis or necrosis.
1.3.2.3.1.4) Neuro-inflammation
Inflammation is the reaction of vascularized living tissue to any form of local injury
with the ultimate aim of achieving healing and repair.  Intracranial inflammation
(neuro-inflammation) initiated by brain trauma has become the focus of many
clinical research studies and animal brain trauma models over the past few decades
but the understanding of this complex pathophysiological cascade remains limited.
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Cerebral ischaemia induced cellular energy failure causes pathological membrane
depolarization and leads to cellular release of excitatory amino acids (EAA) [97]
such as glutamate and aspartate.  In addition, massive influx of calcium and sodium
ions into injured cells [98] which will cause activation of various enzymes such as
proteases, phospholipases, inducible nitric oxide synthase and xanthine oxidase.  As
a result, the arachidonic acid cascade is initiated with the formation of nitrogen- and
oxygen-derived free radicals [99, 100].  Lipid peroxidation follows further damaging
cell membrane and ultimately results in neuronal cell death [104, 106-108].
In addition to neuronal cell death, damage to endothelial cells and astrocytes can
cause a disturbance of the blood-brain barrier (BBB) integrity, consequently leading
to passive leakage of serum proteins into the intracranial compartment.  The post-
traumatic intracranial production and release of pro-inflammatory cytokines such as
tumour necrosis factor (TNF)-" and interleukin 1#  (IL-1#) further contribute to
BBB dysfunction [109].  These inflammatory mediators have been linked with BBB
damage and intracranial inflammation in a variety of experimental models [110,
111].  Vasogenic cerebral oedema occurs as a result of the increased BBB
permeability leading to increased ICP and decreased CPP, thus aggravating cerebral
ischaemia and the concomitant pathophysiological events.
Blood derived leukocytes are attracted across the disrupted BBB into subarachnoid
space by endothelial and leukocyte adhesion molecules, all have been demonstrated
to be up-regulated during the acute post-brain injury period.  Locally released
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chemo-attractant mediators such as " and # chemokines, brain derived chemotactic
factor, arachidonic acid derived leukotrienes and activated complement fragments all
contribute towards leukocyte recruitment into the intracranial compartment.  The
recruited leukocytes are likely to contribute towards further brain damage by release
of proteolytic enzymes and reactive oxygen intermediates since several experimental
studies [111-114] have reported an increased accumulation of neutrophils in the
brain and their association with increased secondary brain damage and adverse
outcome.
Constitutive complement expression in the normal CNS is low because of the intact
BBB separating the vascular and brain compartments [115].  Elevated serum and
CSF complement levels have been demonstrated following brain trauma [116, 117].
This may be the result of ‘acute phase response’ following trauma with hepatocytes
producing complement proteins which subsequently leak into the intracranial
compartment through the dysfunctional BBB [118-120].  IL-6 is a potent stimulator
of acute phase response and its increased production following brain trauma is well
documented [118, 119].  Synthesis of complement proteins by resident cells such as
astrocytes and microglia within the CNS is also likely to occur post trauma and
increased intracranial production of pro-inflammatory cytokines (TNF-", IL-1#, IL-
6, and IL-8) have been demonstrated in many clinical studies [109, 121-126] and
these mediators are known to induce the biosynthesis of complement proteins by
CNS resident cells.  Activation of the complement system within the CNS [127-129]
is likely to contribute further to the local inflammatory response and thereby
influencing outcome after brain trauma.
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Anaphylatoxins such as C3a and C5a are generated through activation of the
complement system and are potent mediators of inflammation.  Their actions include
(i) increasing vascular permeability via induction of BBB damage, (ii) chemotaxis
(via up-regulation of cellular adhesion molecules expressions), and (iii) activation of
blood derived inflammatory cells [130-132].  This results in further local tissue
damages via release of protease and free radicals [133, 134].  The intracerebral
activations of the terminal complement pathways result in the production of C5b-9
(MAC) which may contribute towards host cell death by inducing cell lysis
(necrosis) [135].
Recent evidence suggests that C5a may contribute towards astrogliosis and scar
formation as well as neuronal apoptosis by binding to the C5aR expressed by glial
cells and neurons [136].  It has also been suggested that the recruited leukocytes may
also play a role in the induction of apoptosis or programmed cell death.
1.3.2.3.1.5) Apoptosis
Apoptosis or programmed cell death has been demonstrated to occur after brain
trauma in animal models [137, 138] and has generated intense search for its
occurrence in human after brain injuries.  Ng and co-workers in Singapore examined
brain tissue from head injured patients excised during emergency craniotomy for
evacuation of cerebral contusions with mass effect and found that variable
expression of apoptosis related genes p53, bax, and bcl-2 [139].  They also
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demonstrated the expression of the anti-apoptotic gene (bcl-2 gene) was associated
with a positive correlation with survival [139].  In another study using the in situ nick
translation (ISNF) technique, apoptotic neuronal cells had been detected in cortical
contusion within 45 minutes of sustaining a blunt head injury with a peak incidence
occurring at around 24 hours post injury [140].  This study also showed that the
presence of apoptotic neuronal cells was detectable for up to 2 weeks after the initial
injury [140].
Some authors suggested apoptosis inhibitors might be used to limit secondary
neuronal cell death and may, therefore, potentially improve neurological recovery
after various brain injuries.  However, apoptosis is only one of the secondary brain
injuring pathways and is in delicate balance with necrosis.  Inhibition of one pathway
may merely enhance the others.
1.3.3) Genetic Factors
Variation in brain trauma outcome despite introduction of neuro-intensive care
suggests that other factors such as genetic makeup may influence outcome following
brain injury.  Over the past decade, the polymorphic Apolipoprotein E (APO E) gene
has been suggested to affect outcome after brain trauma in adults because the
possession of the APO E e4 allele has been associated with poorer outcome [141-
143].  Furthermore, its gene product, apolipoprotein E (apoE) is involved in the lipid
transport system within the central nervous system [144] which is thought to be
particularly important to the repair process following neuronal injury.  However, the
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precise mechanisms through which APO E genotypes influence outcome after brain
injury remain unknown.
Despite the independently growing brain trauma literature on secondary
physiological derangement and genetic influence on outcome, no previous study in
adults or children have investigated whether brain trauma patients in possession of
the different APO E alleles suffer different burden of secondary deranged
physiology.  Clinical studies are urgently required to determine the relationship
among APO E genotypes, secondary physiological insults, and outcome.
1.4) NEUROPATHOLGY IN FATAL TBI IN CHILDREN
Between 5 to 20% of acute childhood brain trauma requiring hospital admission have
a fatal outcome [1, 145, 146].  Only a few large cohort studies of fatal TBI in
children are available in the literature.  Graham and colleagues [60] examined
fatalities from accidental childhood brain trauma and found that the pathology
distribution was similar to those seen in adults.  They also found that hypoxic
ischaemic brain damage was a frequent finding among their exclusive child cohort
and its prevalence was higher than that previously reported in adult fatal brain
trauma [60].  Neuropathology from non-accidental brain trauma differs significantly
from accidental brain trauma.  Geddes and co-worker examined the neuropathology
of fatal non-accidental head injury and found statistically significant different
patterns of age-related damages [61, 62].  They found that infants aged 2-3 months
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have craniocervical axonal damage with global hypoxia, while children >1 year of
age have severe extracranial injuries, and neuropathology similar to adults [61, 62].
Although brain trauma is the commonest cause of death in children, no studies have
investigated whether implementation of modern trauma care has reduced the
frequency of hypoxic ischaemic brain damage in childhood brain trauma.
1.5) OUTCOME PREDICTION DURING THE ACUTE PHASE POST BRAIN
TRAUMA
Parents of critically ill brain trauma patients will want to know if their injured
children will survive the injury, how well they will recover, and any long term
disability to expect after recovery from the injury.  They often ask clinicians to
predict outcome soon after the occurrence of brain trauma.  Accurate outcome
prediction needs to be based upon accurate facts, which would require the patient to
display pathognomonic features that only occur in a specific outcome.  Irreversible
brain stem damage is currently the only circumstance where clinicians can accurately
and confidently advise the patient’s family of a definite outcome i.e. death [147].
Difficulties to accurately predict brain trauma outcome during the acute phase post
injury are expected because determinants of brain trauma outcome are multiple and
heterogeneous.  In addition, current understanding of the interaction between these
brain injuring mechanisms remains very limited.  Attempts have been made to use
clinical features such as post-resuscitation GCS, duration of coma, length of ICU
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stay, neuro-imaging findings, and physiological derangement thresholds to predict
unfavourable outcome after brain trauma [148-159], but none of these measures offer
prediction accurate enough for use in clinical practice.
Despite the vast quantity of literature available on the pressure signals of ICP, MAP
and CPP, only a few describe their variability after traumatic brain injury.  Early
attempts to assess the variability using paper recordings were made [160-162] but
proven difficult by the many technical difficulties which included lengthy traces,
chart speed variations, and a lack of objectivity in the quantification and analysis of
the data.  Computerised physiological monitoring is the established norm in modern
neuro-intensive care, but there have been few attempts to re-examine these early
findings.  It is possible that the variability of these pressure signals recorded over
time after brain trauma in children may be important for outcome prediction.
Injured neuron and astroglial cells release brain specific proteins such as S100B
protein, and neuron specific enolase which may be detected in the CSF and blood
during acute phase of brain trauma [163-168].  In addition, cellular and molecular
pathophysiological responses to brain trauma are modulated by biochemical
mediators which are also measurable in the CSF and blood after brain trauma [122,
123, 125, 126, 169-176].  Clinicians have hoped to utilise these biomarkers to
provide objective assessment of brain trauma severity and to predict outcome during
the acute phase after brain trauma.  As a result, increasing numbers of potential brain
trauma biomarkers have been added to the literature describing their associations
with injury severity or brain trauma outcome, but none have been translated into
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clinically effective tools.  This may be because most researchers have only
investigated individual markers or small number of biomarkers of the same family at
any one time.  In addition, not all proposed biomarkers have been evenly
investigated.  Significant variations in sample type used, sampling time points, and
data analytical methodologies exist between studies making comparisons difficult
within the current literature.  As a result, it is unknown whether some biomarkers
may offer better injury quantification while others have more superior outcome
predictive values.
1.6) SUMMARY
Brain trauma is the commonest cause of death and disability in children [46, 177].
Hypoxic ischaemic brain damage is a frequent finding in fatal childhood brain
trauma [60-62] indicating that its prevention may improve traumatic brain injury
outcome.
Attempts to translate promising novel neuro-protective strategies from the laboratory
into clinically effective therapies have been disappointing.  For those who survive
the initial brain trauma to reach hospital, the current best treatment option is to
prevent secondary cerebral ischaemia by normalising cerebral and systemic
haemodynamics [74, 75].  Because bedside measurement of cerebral metabolisms is
not possible, clinicians use cerebral perfusion pressure as a guide of the driving
pressure for cerebral blood flow.  Treatment thresholds for raised ICP and low CPP
have been proposed and become widely accepted in adult brain trauma management
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[74] despite the lack of threshold validation.  Current methodology to quantify
deranged physiology is limited to a single dimensional assessment (e.g. duration or
magnitude) at any one time, and may be the reason why threshold validation has not
been possible.
Management of childhood brain trauma is further complicated by the lack of
normative data on the age-related changes in intracranial physiology.  As a result,
some paediatric intensivists apply the well accepted but non-validated adult ICP and
CPP treatment thresholds to treat brain injured infants and children, while others
anecdotally adjust the thresholds to levels they feel appropriate to the patient’s age.
The Edinburgh Paediatric Traumatic Brain Injury Study Group has hypothesized
age-related minimum CPP levels [92] which require validation before they may be
developed into clinically meaningful treatment thresholds.
Secondary brain injuring mechanisms at cellular and molecular levels are complex
and it is unclear whether a particular pathway has higher modulating effect on brain
trauma outcome than others.  They are modulated by biochemical mediators which
may be detectable in systemic circulation and may, therefore, be potential objective
indictors of brain trauma severity and predictors of outcome.  The number of
potential brain trauma biomarker has increased over the past decade but none has
been translated into clinically useful tools.  Difference in research methodology
including sample types, sampling time points, biomarker studied, and data analysis
may explain the difficulty to develop brain trauma biomarker usage.  Identifying the
biomarkers that best predict unfavourable outcome may highlight more influential
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secondary brain injuring pathway and re-direct future research focus which may then
enable identification of potential novel treatment points.
Genetic polymorphisms may be a determinant of brain trauma outcome.  Possession
of the APO E e4 allele has been associated with poorer outcome after brain injury in
adults [141-143] and its gene product is involved in the CNS lipid transport system
[144] which is thought to be particularly important in neuronal repair.  It is unknown
whether brain trauma patients with the different APO E genotypes respond
differently to deranged physiology after brain trauma.
1.7) HYPOTHESES & AIMS
We hypothesize that:
1. Accurate quantification of the total burden of CPP derangement (i.e.
assessing both duration and magnitude simultaneously) after brain trauma has
better correlations with unfavourable outcome than using a single
dimensional assessment of deranged CPP, and allows critical age-related
minimum (insult) CPP thresholds to be defined.
2. APO E genetic polymorphisms modulate brain trauma outcome by affecting
the different allelic carriers’ response to brain trauma and the amount of CPP
insult they experienced with carriers of the APO E e4 allele experiencing the
largest amount of CPP derangement.
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3. Reduction of CPP insult during critical care management will reduce cerebral
ischaemia and improve outcome after childhood brain trauma.
4. Acute serum inflammatory marker levels have more superior prognostic
values for unfavourable outcome after childhood brain trauma than those of
brain specific proteins.
In order to test the above hypothesis in this thesis, we aim to:
1. Develop a method that quantifies the total burden (i.e. duration and
magnitude) of CPP derangement and to assess its relationship with outcome
after childhood brain trauma.
2. Validate the hypothetical age-related minimum CPP thresholds and to define
the critical age-related CPP thresholds.
3. Determine whether children with different APO E genotypes experience
different burden of physiological derangements, and their relationships with
outcome.
4. Assess the predictability of 8 different serum biomarkers levels for
unfavourable outcome after brain trauma.
5. Determine whether using 2 biomarker levels have more superior outcome
prediction than using individual biomarker level.
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6. Determine the relationship between the pre-morbid burden of CPP
derangement and the amount of hypoxic ischaemic brain damage in fatal
brain trauma.
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CHAPTER 2: CRITICAL AGE-RELATED CEREBRAL PERFUSION
PRESSURE THRESHOLDS AND QUANTIFICATION OF THE TOTAL
BURDEN OF CPP INSULT
2.1) INTRODUCTION
Normalising cerebral and systemic homeostasis after brain trauma improves outcome
[63, 65] and remains the principle management aim of modern neuro-intensive care
[74] since its introduction over three decades ago [76].  It is unclear from the
literature whether intracranial hypertension or low cerebral perfusion pressure best
predict outcome after brain trauma.  For management of adult brain trauma,
treatment thresholds for raised intracranial pressure (ICP) and low cerebral perfusion
pressure (CPP) have been proposed and become widely accepted in clinical practice
without formal validations [74, 84].
The intensive care management of childhood brain trauma is based upon the same
principle as adult neuro-intensive care but there is no agreement on the optimal
treatment thresholds for raised ICP and low CPP for children of different ages [75].
This is because of the insufficient knowledge on the normal intracranial
physiological variations with age maturation as previously discussed in Chapter 1.
Currently, many paediatric centres merely apply adult treatment thresholds without
considering the age-maturation effect on the intracranial physiology, while others
anecdotally adjust their treatment thresholds with ill defined age groups.  There is,
therefore, a pressing need to define critical thresholds that enable identification of
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secondary ischaemic brain insults, and to develop age–related treatment thresholds
for raised ICP and low CPP so that outcome of childhood brain trauma may be
improved.
The importance to consider age-related intracranial dynamics and systemic
physiology in childhood brain injury is highlighted over the past decade.  Jackson
and colleagues used three different CPP (70, 60, and 50 mmHg) and ICP (12, 14, and
24 mmHg) thresholds to determine CPP and ICP insults in ten head injured children
aged less than 16 years and demonstrated that ICP increased significantly between
the CPP < 60 and CPP < 50 mmHg analyses [90].  This pilot work did not correlate
with outcome assessment and their chosen thresholds had no physiological basis.  In
another report, based upon a single point on a Receiver Operator Characteristic
(ROC) curve that had been created using a minimum of a rolling mean CPP in 84
children aged 3 months to 16 years, Chambers suggested absolute levels of 45
mmHg in children and 55 mmHg in adults for clinical CPP management [91].
Although this report attempted to introduce a different threshold for childhood
management, it failed to consider the age-maturation effect throughout infancy and
childhood and suggested only one threshold for the entire childhood which would
range from toddlers as young as 2 year olds to adolescence of 16 years of age who
will have adult physiology [91].
Jones and co-workers from the Edinburgh Paediatric TBI Research Group
demonstrated that the duration of age-specific abnormal CPP predicted unfavourable
outcome (p=0.004) and mortality (p=0.003) [92].  They proposed using pre-defined
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theoretical age-specific minimum CPP levels to define abnormal CPP in a series of
critically ill brain injured children aged less than 15 years of age [92].  As discussed
previously in Chapter 1, detailed age-specific normative data for blood pressure exist
in the literature but there is only incomplete age-related information on ICP causing
difficulties in defining the normative values of CPP throughout childhood.  Minns
had tabulated the normal values of ICP as described by earlier workers, and had
calculated the mean upper normal limits for specific age groups by plotting a graph
of best fit [178].  However, these theoretical normative values for ICP are still not
sufficient for calculation of theoretical age-specific minimum CPP thresholds.  Given
that ICP should be low and contribute very little towards the normal CPP in healthy
infants and children, the Edinburgh Paediatric TBI Study Group hypothesizes that
the theoretical lowest acceptable age-specific thresholds for CPP should be the same
values as the lowest acceptable MAP by age [92].  This is because assuming ICP is
zero, the lowest possible driving pressure for cerebral blood flow that may perfuse
the brain must be the same as the lowest acceptable MAP.  This study was the first to
demonstrate the significant predictive value of age-specific abnormal CPP as defined
by these theoretical age-specific thresholds on outcome after paediatric head injury
and also provided a novel approach to study childhood brain trauma [92].  However,
the thresholds used were purely theoretical and would require validation.
Many methods exist in the current literature to quantify the amount of ICP and CPP
derangement reflecting the lack of standardised method to assess pressure insult.
However, all these preceding studies relating ICP / CPP to outcome in traumatic and
non-traumatic encephalopathies have focussed on individual excursions of pressure
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beyond the currently accepted thresholds in clinical practice or the duration of the
derangements.  These levels lack a secure evidence base.  In addition, these
approaches concentrate on a single summary measurement, for examples means over
hourly recordings or other time-frames, maximum or minimum values, percentage
duration of derangement, and do not combine both severity and duration of
derangement.  Furthermore, these are pragmatic and loose much of the detail by
virtue of averaging the peaks and troughs of the pressure recording.  Lack of suitable
methods to accurately quantify the total burden of secondary physiological
derangements has hindered any attempts to determine age-related thresholds, validate
current treatment regimes, and to develop novel therapies.  A measure incorporating
both degree and duration would theoretically be a better reflection of the total
potential insult and allow for determination of thresholds as well as validation of
current treatment regimes, thereby injecting evidence base approach into critical care
medicine.
2.2) HYPOTHESES & AIMS
We hypothesize that inadequate cerebral perfusion pressure affects outcome after
childhood brain trauma more than raised intracranial pressure.  In addition, we
hypothesize that unfavourable outcome prediction after childhood brain trauma is
better achieved with assessment of the total burden of CPP insult (i.e. both duration
and magnitude) than any of the traditional single dimensional assessment of CPP
insult.  Finally, we hypothesize that our theoretical age-specific minimum CPP levels
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are critical thresholds which define CPP insults and provide the best predictability
for outcome.
The aims of this chapter are to test the above hypotheses and will be achieved
through (i) determination of the predictability of outcome of the various routinely
monitored physiological parameters in the intensive care settings, (ii) the
development a novel index that summarises both time and depth of derangement for
ICP and CPP using detailed physiological data in minute resolutions; (iii)
determining the sensitivity and specificity of the index to outcome; and (iv) applying
this index to determine the age-related critical CPP thresholds in relation to
childhood traumatic brain injury.
2.3) PATIENTS AND METHODS
2.3.1) Design of the Study
A prospective observational study was conducted to determine the relationship
between secondary physiological derangement and outcome after childhood brain
trauma.  Children aged less than 16 years who had sustained traumatic brain injury
and required intensive care management were included in the study with the
exception of those who had a previous history of brain trauma.  Local ethical and
hospital management committees approved the study protocol.  Parental consents
were obtained prior to inclusion in the study.
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2.3.2) Patients
A total of 128 brain trauma children were enrolled in the study and they were
recruited from the regional paediatric neuro-surgical and intensive care centres based
in Edinburgh and Newcastle up-on Tyne.  Of the whole cohort, 52 patients originated
from the pilot study [92], 34 patients were recruited from the Royal Hospital for Sick
Children (RHSC) in Edinburgh, 36 were recruited from Newcastle General Hospital
(NGH), and 6 were from Western General Hospital (WGH) in Edinburgh.  The
original pilot group fulfilled the same inclusion criteria as our current cohort.  81
children were aged between 2 and 16 years and had continuous ICP monitoring.
Detailed analyses of ICP and CPP (including the development and validation of the
novel Cumulative Pressure-Time Index) were, therefore, conducted on these 81
children.
Patients were classified according to the post-resuscitation summated GCS into
severe brain trauma (GCS ! 8 with no eye opening i.e. E1), moderate brain trauma
(GCS 9 – 12), and mild brain trauma (GCS 13 – 15) associated with other significant
injuries sufficient to give an ISS of at least 16.  The ISS score was chosen to ensure
that patients with epidural haematomas of less than 100 ml were included.
All the recruitment units including that of the pilot group were specialist paediatric
and adolescence intensive care units and the patients were managed by experienced
neurosurgeons, paediatric intensivists and specialist critical care nurses.  Mechanical
ventilation and ICP monitoring were employed (i) after evacuation of an intracranial
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haematoma where the patients’ GCS was ! 8; (ii) where there was a diffuse cerebral
injury and GCS ! 6; (iii) where there was CT or operative evidence of brain
swelling; and (iv) where other injuries dictated the need for ventilation.  Invasive
monitoring was employed as clinically indicated.  Physiological data was, therefore,
only collected for those parameters judged by clinical staff to be applicable.  The
management guidelines for all Units were similar including therapeutic goals for
maintaining CPP $ 50 mmHg, and ICP ! 15 mmHg for children aged 0 – 13 years,
and for those aged 14 – 15, CPP and ICP were maintained $ 60 mmHg and ! 20
mmHg respectively.  These guidelines were set for all children and had been in use
prior to the commencement of the study.
Physiological data was collected until clinical monitoring ceased, even when this was
for several weeks, once the patient was enrolled into the study.  Clinical notes and
nursing charts were reviewed.  Admission and clinical details were recorded
prospectively which included data on the cause and nature of the injury, age, GCS on
admission and after acute non-surgical resuscitation, pupil responses, the results of
X-rays and neuro-imaging such CT and MRI scans, operative and treatment details,
and inter-hospital transfer details.
55
2.3.3) Data Collections and Analyses
2.3.3.1) Physiological Data
2.3.3.1.1) Original Data Collection Plan
Mobile computer data collection (CDC) systems were to be connected to ICU
bedside monitors with RS232 card pre-installed.  We initially planned to use a data
acquisition software called Edinburgh Monitor© to download and store the
continuous real-time physiological data in minute resolutions.  Although the
Edinburgh Monitor© Software was designed to read physiological data from a wide
variety of bedside monitors, it was unable to detect pressure signals from the stand-
alone (i.e. non-networked) Hewitt Packard Merlin monitors that were used in the
ICU at the Edinburgh RHSC.  The only parameters downloadable from these
monitors were heart rate, oxygen saturation and temperature recording.
The creator and programmer of Edinburgh Monitor© (Dr. Tim Howells) attempted
to create a software patch to read the pressure signals from the Hewitt Package
Merlin monitors but was not successful.  Networking all the bedside monitors in the
RHSC site to a central terminal was an alternative approach and would enable
storage of physiological data in minute resolutions.  The stored data could then be
exported using the Hewitt Packard network software into a format compatible with
the Edinburgh Browser© software for analyses.  However, this option would incur
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expenses in excess of £20000.  With a limited financial resource for the project, this
option was excluded as a realistic solution.
ICUPilot™ software, produced by CMA Microdialysis, had the ability to download
and store all physiological signals including pressure signals from Hewitt Packard
Merlin monitors.  In addition, it was able to export the stored data in .csv format
which was a computer file format known to be compatible with the Edinburgh
Browser© programme.  Dr. Magnus Hedberg, the Head of Development of CMA
Microdialysis, kindly offered to provide a free complimentary licence for our
Paediatric TBI Research Group to use the software throughout the duration of our
study.
2.3.3.1.2) Actual Data Collection Methods
Detailed methods for data download, storage and exportation on the three
recruitment sites are summarised below.
Two mobile CDC systems with ICUPilot™ software installed were available at the
RHSC site for connection to the stand-alone bedside monitors to download and store
the routine continuous real-time minute-by-minute physiological recordings.  Four of
the six bedside monitors had the required RS-232 cards installed and were correctly
configured (band width 19200) to communicate with the ICUPilot™ software.  This
set up did potentially limit the number of patients that could be monitored
spontaneously and had a theoretical risk for the need to exclude a suitable patient if
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both of the CDC systems were in used.  However, in reality no patient was excluded
as a result of this arrangement.  ICUPilot™ exported the stored data for off-line
analyses using the Edinburgh Browser© programme.
The bedside monitors in the ICU at the Edinburgh Western General Hospital (WGH)
and the PICU at Newcastle General Hospital (NGH) were networked to a central
terminal for storage of the minute-by-minute physiological data and therefore, posed
no restriction to the number of suitable patients that could be monitored
spontaneously.  The stored physiological data were then exported using the
WardWatch© software in the Edinburgh WGH site and the Critical Care Physics©
(Regional Medical Physics Department Reporting) Software in Newcastle for
analyses using the Edinburgh Browser© programme.
2.3.3.1.2) Physiological Parameters Measured




• mean ICP (measured by fibre-optic intracranial pressure monitor),
• systolic, diastolic and mean arterial blood pressure (measured with a standard
intra-arterial line with the pressure transducer zeroed at the level of the
external auditory meatus),
• CPP (the calculated difference between MAP and ICP),
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• oxygen saturation (measured by a pulse oximeter), and
• core and peripheral temperature.
In addition, interventions (e.g. drug therapy, ventilation changes, nursing procedures
or other textual notations) and observations (GCS and pupil responses) were
recorded and stored in real time.
2.3.3.2) Outcome Data Collection
Global outcome of the survivors was assessed at 6 months post injury using a
structured parents / carer questionnaire and was categorized using the Modified
Glasgow Outcome Score (GOS) and King’s Outcome Score for Children with Head
Injury (KOSCHI).  Fatal cases were assigned GOS or KOSCHI 1 for analyses.  Two
independent investigators blinded to the physiological and demographic data
conducted outcome scoring for all patients.
Patients were dichotomised into the following groups for analyses:
(1) Alive vs Mortality (i.e. dead)
(2) Independent (GOS 4 and 5) vs Poor outcome (GOS 1 –3)
(3) Best (GOS 5) vs Rest (GOS 1 – 4)
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2.3.3.3) Data Analyses
2.3.3.3.1) Choosing Age-Specific Thresholds (Age Index)
The interpretation of the recorded data relied upon comparisons with accepted
normal ranges.  Age-specific threshold for each physiological parameter was,
therefore, defined prior to data validation and analyses.
A literature review was undertaken to identify previously published data describing
the normal values by age for each of the specific physiological parameters of interest
namely heart rate, arterial blood pressure (systolic and mean), ICP, CPP, oxygen
saturation, and core temperature [92].  A table of thresholds for physiological
derangements for children by age was then constructed (Appendix I).
2.3.3.3.1.1) Heart Rate
Previously published normal ranges of heart rate in neonates and children of different
ages have showed that after an initial rise in heart rate between birth and about 3
months, resting heart rate slows as the child grows.  These values have been adopted
as the pre-defined age-specific heart rate thresholds for this study and no gender
difference has been applied to this study.
60
2.3.3.3.1.2) Hypoxia
Hypoxia is defined as having an arterial PaO2 of 60 mmHg or less which is the
equivalent of having an oxygen saturation of less than or equal to 90% as measured
by pulse oximeter [179].  For the purpose of this study, hypoxia threshold for all age
group was defined as having an oxygen saturation of 90% or less.
2.3.3.3.1.3) Pyrexia





C [180].  The threshold for pyrexia in this study was taken as 38
0
C.
2.3.3.3.1.4) Arterial Blood Pressure
Normative data on arterial blood pressure in children had been acquired in several
major studies [87, 181-183].  The largest and most comprehensive data originated
from the US Second Task Force of 1987 which measured blood pressure in over 72
000 children aged between newborn and 20 years old in the sitting position using a
standard clinical sphygmomanometer [87].  The published results included age and
gender specific data for systolic and diastolic blood pressure.  MAP was not given in
either of the Task Force publications, and those described by Shann’s group in
Australia, although commonly used, were not year-specific.  MAP, was, therefore,
calculated from the Task Force values, having first identified the ranges for diastolic
BP (mean ± 2 SD).  Mean pressure is usually given as the diastolic pressure (D) plus
61
one-third of the pulse pressure, where pulse pressure is the difference between the
systolic (S) and diastolic (D) pressures: thus, MAP = [D+(S-D)/3].
Because there is no comparable data available for UK children, we have adopted
values from this American Study as our blood pressure thresholds.  Data were
summarised for our study for each age group, and are detailed below: using the Task
Force tables of boys’ and girls’ data, the normal ranges (calculated from the mean ±
2SD) were found.  Where there were differences between the genders, the lowest and
highest were used to give the widest possibility range for this study since it was not
our intention to consider sex and height differences.  In practice, this made a
potential difference of approximately 1 mmHg at each end of the systolic BP range,
so only fractionally affected the mean blood pressure (MAP), which was rounded to
the nearest integer.
2.3.3.3.1.5) Intracranial Pressure (ICP)
Accurate measurement of intracranial pressure requires invasive monitoring and
given the ethical difficulties of measuring it in healthy normal subjects, normative
data for ICP in infants and children is sparse.  Much of the available information on
childhood ICP has originated from the neurology literature i.e. measurements taken
from infants and children who had already presented to the medical service with a
variety of symptoms.  These patients did not necessary have a neurological
condition, but their clinical presentations warranted investigations for raised ICP.
Comparisons between studies were made difficult because these cohorts often
62
included infants and children of different ages i.e. some continued to have open
fontanelles while others’ cranial sutures had already fused which might influence the
ICP recordings.  Furthermore, ICP measurement sites and technique varied between
studies further complicating comparisons between studies.
Despite these potential difficulties in comparing existing childhood ICP data in the
literature, fairly similar ranges of ICP values have been quoted by these studies as
being normal ranges for infants, children and adults.  Moront’s group considered
normal ICP for children and adults as being less than 15 mmHg and a recording of
less than 8 – 10 mmHg for infants [184].  Mann and Punt stated that ICP increases
with age and reported a value of 8 mmHg to be normal in the older child [185] while
Welch found normal CSF pressure in young children to be between 2 – 10 mmHg
[186].  Lam recently gave adult normal ICP values as 8 – 18 mmHg, and for children
between 2 and 4 mmHg without specifying the age but stressed the need for further
evaluation [187].
Previously published normal ICP values were tabulated by Minns who had also
calculated the mean upper normal limits for specific age groups [178].  Most authors
agree that mean ICP in children rises with age, but remains less than adults.  We used
the figures given by Minns [178] as our thresholds, which were rounded to the
nearest whole number, as required by our data analyses system.  Plotting those
values with a line of best fit provided the missing yearly increments.
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2.3.3.3.1.6) Cerebral Perfusion Pressure (CPP)
Cerebral perfusion pressure (CPP) has been used as a way of assessing the
intravascular pressure gradient across the brain.  CPP is calculated as the difference
between MAP and ICP.  Under ideal circumstances, CPP can act as a useful
guideline to ensure that systemic blood pressure is adequate to perfuse the brain in
the face of increasing ICP.
No composite charts or tables of CPP were found to suggest normal lower limits in
children of different ages, although some authors have given values of between 40
and 50 mmHg under normal conditions, without specifying age [184, 188-190].  A
few notable studies of CPP have included children [90, 91, 191], but these have used
the previously accepted adult value of 60 mmHg, or more recently 70 mmHg [192].
In adults, the lowest normal limit of CPP in brain trauma patients is usually
empirically considered to be the same numeric value as the lowest acceptable limit
for MAP [192-195].  For example, if 70 mmHg was the lowest limit of acceptable
MAP, then 70 mmHg was also the lowest acceptable CPP in adults.  While the range
of normative data for blood pressure is quite precise (allowing calculation of the
mean of MAP), the normative data on children’s ICP is thin with only maximum
values suggested by the literature for a few age groups.  The values we have used
have been deducted from references to normal children’s ICP and are, therefore,
hypothetical.  We have used the lowest acceptable mean MAP value as the lowest
acceptable CPP value, which is likely to be numerically as accurate as an estimation
of the range of ICP.  Accordingly, CPP was considered normal if > 45 mmHg in 1
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year-olds increasing to > 58 mmHg at 15 years of age.  It should be noted that to
maintain a normal CPP, ICP and MAP need not both be in the normal range at the
same time, i.e. CPP could still be normal if ICP rises above normal, but MAP is
maintained at a sufficiently high level.
2.3.3.3.2) Physiological Data Validation and Analyses
Edinburgh Browser©, a specially developed minute-by-minute data analysing
programme, was used to analyse the recorded data ‘off-line’ [72, 92, 159].  It was
able to scrutinise and validate the data to exclude invalid recordings or artefacts such
as probes detachment during patient care procedures, arterial line being flushed
during blood sampling, calibration errors, or computer disconnections.  These invalid
data or artefacts were discarded.  Any data recorded during the last 4 hours before
death i.e. premorbid data were also excluded from the analysis if the patient
underwent brain stem death tests.
Using predefined thresholds for each parameter by age, Edinburgh Browser© could
then identify the validated physiological data which was out-with these preset norms
i.e. abnormal physiology [72, 92].  Abnormal but valid physiology such as those
associated with nursing care procedures or physiotherapy etc was retained.
Physiological derangements were deemed to have occurred only when the abnormal
recordings persisted for at least five consecutive minutes.  This rule applied to all
physiological parameters with the exception of temperature as it had a much slower
rate of change.  For a temperature derangement to be identified, the recording must
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be outside the preset normal ranges for at least one hour.  Where the derangement
persisted beyond 5 minutes and judged to be ‘real’, the total derangement time
recorded would include this initial 5 minutes.  The derangement was deemed to have
ceased when the recording returned to values within the preset normative values for
5 uninterrupted minutes or 1 hour in the case of pyrexia.
After validation and application of the age index for each child, Edinburgh
Browser© was used to calculate (i) the overall start and stop dates and times of
monitoring and the total number of minutes of monitoring time; and (ii) for each
physiological variable, the duration (in minutes) of the invalid times, and the number
of episodes and total duration of derangements.  Total monitoring time was defined
as the longest duration of any monitored modality.  The cumulated deranged
physiology time (DPT), both the absolute value and as a proportion of total
monitoring time, was then calculated for each variable, for each child.
2.3.3.3.3) Logistic Regression Modelling & Discrimination Assessments
- Misclassification Rate & Receiver Operator Characteristic (ROC)
Curves
Since the clinical course of each patient could be different, the cases used for logistic
regression analyses were restricted to those who had ICP monitoring available, and
the data limited to those collected while an ICP monitor was in situ (i.e. the acute
monitoring time).  ICP monitoring was continued as long as required for clinical
management of raised ICP.  The likelihood of later derangements was then felt to be
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reduced.  This was referred to as the acute monitoring time, i.e. the ICP monitoring
time excluding the pre-terminal 4 hours in those cases that underwent brain stem
death testing.  Only cumulated duration of derangements (absolute and percentage)
were studied as there were insufficient patients in each year group to attempt to
categorize the physiological data to reflect the magnitude of the derangement, or to
use epochs since injury.
Logistic regression modelling was used to assess the prognostic significance of the
demographic variables in a method similar to that described by Signorini and
colleagues [159].  Each variable was initially fitted in a univariate model to assess
the functional relation with outcome.  For categorical variables, categories were
merged as necessary to give fewer and simplified variables.  Similarly, the duration
and percentage duration of physiological derangements occurring during the acute
monitoring time were assessed using a univariate model.  The next step used
multivariate modelling of the variables, using functional relations developed in the
univariate models in a multivariate setting.  The Hosmer & Lemeshow (HL)
goodness of fit test statistic was used to assess calibration [196].  The discrimination
was assessed by calculating both the misclassification rate and the area under the
ROC curves for each model.
2.3.3.3.4) Derivation of the Cumulative Pressure-Time Index (PTI)
For each patient recording, the total area between the continuous threshold and the
recorded CPP tracing was calculated.  For the duration of each CPP insult detected
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by the Edinburgh Browser© program the difference between the age threshold and
the recorded CPP value was determined for each minute value.  These were then
summed to produce what we have termed the Cumulative Pressure-Time Index
(PTI).  Thus, PTIc is defined as the area below the pre-defined age-related threshold
limits and the plot of CPP against time as shown in grey areas in Figure 2.1, and can
be mathematically described by:
%(CPPthreshold – CPP) x tsample interval
Figure 2.1:
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2.3.3.3.4.1) Calculation of the PTI for CPP (PTIc)
2.3.3.3.4.1.1) Allocation of Age Groups
As the normal ranges for physiological parameters such as blood pressure,
intracranial pressure, and cerebral perfusion pressure vary with age from birth until
about mid teenage years, it was necessary to factor this into the analysis.  The values
change rapidly during the first 12 months of life but insufficient cases with brain
injuries in these early years were available, and to use annual increment would
likewise have required more subjects.  Our patients were divided into three groups
using the following age bands: those aged 2 – 6 years, 7 – 10 years, and 11 – 16
years for the purpose of this analysis.  Using our pre-set age-specific CPP thresholds,
a theoretical mean CPP threshold was calculated for each age band and they are
summarized as follows:
AGE Mean CPP Threshold
2-6 years ! 48mmHg
7-10 years ! 54mmHg
11-15 years ! 58mmHg
PTIc was used as a test level of outcome prediction by making comparisons of the
PTIc values between children with different recovery.  Taking all the patients with
independent outcome, a PTIc level could vary from 0 to its maximum value and the
sensitivity and specificity of the index were calculated.  The sensitivity of PTIc
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would fall as the PTIc level was raised (fewer independent outcomes with greater
insult severity), whilst the specificity would rise with an increasing level of PTIc
(greater number of poor outcomes with increasing insult severity).
Using the values of specificity and sensitivity calculated at each threshold level,
receiver operator characteristic (ROC) curves were plotted for independent outcome
versus poor outcome, mortality (dead versus the rest) and morbidity (good recovery
versus all other outcomes).
2.3.3.3.4.1.2) Determination of the Age Band Related Critical CPP
Thresholds
In order to investigate the effect of different threshold levels for insult detection and
whether these might better differentiate outcome, each age band threshold was
reduced first by 10% and then by 20% and the PTIc recalculated.  The age thresholds
were then increased by 10% and the PTIc calculated again.  Using the independent
versus poor outcome dichotomy ROC curves were plotted for each of the new
threshold test levels and the area under each curve determined.
2.3.3.3.4.2) Calculation of the PTI for ICP (PTIi)
Using the same methodology, a similar index was calculated for ICP by calculating
the total area above the age threshold and the recorded ICP tracing.  Again the effect
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of altering the thresholds was investigated by reducing the thresholds by 10% and
then increasing them by 10% and then 20%.
2.4) RESULTS
Details of the current cohort and the pilot group are presented separately before the
results of the final analyses to demonstrate the comparability between these two
groups.
2.4.1) Current Cohort
All brain trauma children (n = 76; Edinburgh n = 40; Newcastle, n=36) admitted
enrolled between October 2000 to March 2003 were enrolled into the study.  74 of
the cases were as a result of accidental traumatic brain injury, and 2 were suspected
non-accidental head injury (one from each centre).  Basic demographic data is
tabulated below (Table 2.1).
Table 2.1:







Severe (GCS ! 8)
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              Motor Cycle driver
              Bicycle
              Pedestrian
              Short Fall <3’
              Fall from Height
              Struck on head
              Assault
              Sport (rugby)
              Penetrating Injury














Since the clinical needs of the patient dictated which physiological parameters were
monitored during the intensive care admission, not all possible variables were
monitored in every child.  All time-series data that were monitored were collected
and downloaded for analysis.  For the 76 children, arterial blood pressure monitoring
was collected in 74 cases, intracranial pressure monitoring in 52, heart rate in 75,
core temperature in 63 and oxygen saturation via a pulse oximeter in all 76 children.
As CPP = MAP-ICP, CPP values were available for 51 cases.
The mean time from injury to commencement of physiological monitoring was 10.7
hours, and the mean duration of monitoring was 124.28 hours (i.e. more than 5 days).
2.4.1.2) Comparison with Pilot Group
There were no statistical differences between the current and pilot groups for the
following: gender, severity of injury, mode of injury, time to start of monitoring,
percentage duration of derangement: for raised ICP, hypotension, hypertension,
cerebral perfusion pressure, hypoxia, pyrexia and brady- and tachy-cardia.
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2.4.2) Combined Current and Pilot Groups Data Set
For the total 128 children in this combined cohort, the descriptive statistics are
provided below (Table 2.2) showing the numbers with and without derangements,
the total monitored time, total derangement durations (minutes) and number of








































Raised ICP 96/99 493241 391466
(79.4%)
97 - 17779 3954.2 2645 4117.8 0 - 17364 10
Hypotension 38/123 698911 4926 (0.7%) 44 - 42662 40.05 0.00 127.39 0 – 868 0
Hypertension 111/123 699710 307697
(43.9%)
44 - 42662 2501.6 1261.0 3207.91 0 - 18815 12
Low CPP 77/98 472136 72910 (15.4%) 0 - 17556 736.46 247.0 1296.5 0 - 9045 6
Hypoxia 23/124 769467 1951 (0.25%) 21 - 42909 15.73 0.0 94.17 0 - 1010 0
Pyrexia 75/109 461885 121209 (26.2) 120 - 29638 1112.01 475.0 1844.65 0 - 10159 1
Tachycardia 99/125 769627 164208
(21.3%)
97 - 42845 1313.66 265.0 2854.97 0 - 22284 4
Bradycardia 54/125 769431 53099 (6.9%) 97 - 42845 424.79 0.0 1078.19 0 - 5520 0
Overall, more than 5 million minutes (5 134 408) of data were collected.
Derangements were found in every physiological variable, and every child was found
to have some age-specific derangement in at least one physiological variable.  The
most commonly identified abnormality was raised intracranial pressure (in 97% of
children), followed by hypertension (90%), low cerebral perfusion pressure (79%)
and tachycardia (79%), pyrexia (69%), bradycardia (43%), hypotension (31%) and
hypoxic derangements (19%).
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The percentage duration of age-specific derangement per variable ranged from
almost 80% for raised ICP to as little as 0.25% for hypoxia.  The total duration of
low cerebral perfusion pressure, which occurred in 15% of the valid monitoring time
was clearly predominantly due to ICP being above threshold levels, rather than
arterial hypotension which was recorded for just 0.25% total duration derangement.
2.4.3) Determining the Best Predictors of Outcome
Univariate logistic regression was carried out from the total of 128 patients, for both
outcome groups: ISS, pupil reactions, presence of coma, GCS sumscore, RTS,
TRISS, percentage duration of ICP and CPP were all significant for both dead/alive
and poor vs. independent outcome.  Tachycardia was found to predict mortality i.e.
dead/alive (p=0.047) while hypertension predicted poor vs. independent outcome
(p=0.045).
2.4.3.1) Those with ICP/CPP Monitoring
99 children had intracranial pressure monitoring but in 12 patients, the ICP
monitoring commenced 24 hours after the initial injury (range from 26.0 – 107.3
hours post injury) and they were, therefore, excluded from analyses.  Additionally,
one child had only non-invasive blood pressure monitoring, which could not be used
to calculate CPP, so this case also had to be excluded from this analysis.  86 children,
all with 6 months outcome data available, were, therefore, included in the final
logistic regression modelling.
74
This final group comprised of 25 girls and 61 boys.  Two children suffered a mild
injury with ISS>16, 19 had moderate injury severity, and 65 with severe injuries on
admission.  At 6 months post-injury, 11 had died, there were no children who
remained in a persistent vegetative state, 6 suffered severe disability, 33 were
moderately disabled, and 36 made good recovery.  Outcome groups were therefore
Alive (75) vs. dead (11), and Independent outcome (69) vs. poor outcome (17).
2.4.3.1.1) Alive vs. Dead
Significant (univariate logistic regression) demographic features for outcome (Alive




p Value Details Odds Ratio 95% C.I.





GCS sumscore 0.024 Linear 1.53 (1.06 – 2.20)
Motor Score 0.012 Linear 1.97 (1.16 – 3.33)
RTS 0.004 Linear 2.66 (1.37 – 5.18)
Similarly, significant (univariate logistic regression) physiological derangement
calculated as a percentage of the ‘acute monitoring time’ and outcomes (alive vs.




 p   Value Odds ratio 95% CI Area under the ROC
Raised ICP 0.044 0.91 (0.84 – 0.99) 0.818
Low CPP <0.0001* 0.94 (0.92 – 0.97) 0.890
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With the data truncated to ‘acute monitoring time’ (i.e. duration of monitoring with
ICP monitor in situ), tachycardia was no longer significant in the dead vs. alive
comparison, and was therefore not included in the final model.  The final model
(Logistic Regression, Forward step method) for duration as a percentage of ‘acute
monitoring time’ found the following for the alive vs. dead comparison (Table 2.5):
Table 2.5:
Variables  p - Value Odds ratio 95% CI




2.4.3.1.2) Poor vs. Independent Outcome
Significant (univariate logistic regression) (n=86) demographic features for outcome




p Value Details Odds
Ratio
95% C.I.






GCS sumscore 0.002** Linear 1.77 (1.24 – 2.52)
Motor Score 0.000** Linear 2.51 (1.51 – 4.15)
RTS 0.000** Linear 3.09 (1.65– 5.80)
Similarly, significant (univariate logistic regression, n=86) physiological
derangements calculated as a percentage of the ‘acute monitoring time’ and
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p   Value Odds ratio 95% CI Area under the ROC
Raised ICP 0.017 0.96 (0.92 – 0.99) 0.738
Low CPP 0.001* 0.96 (0.94 – 0.98) 0.793
With the data truncated to ‘acute monitoring time’, hypertension was no longer
significant in the independent vs. poor comparison, and was therefore not included in
the final model.
Final Model:  Independent vs. Poor outcome, Logistic Regression. Forward step
method for duration as a percentage of ‘acute monitoring time’.  From total of n=86,
85 cases were in the final model (one with no MAP). (Table 2.8)
Table 2.8:
Variables p   Value Odds ratio 95% CI
RTS 0.005* 2.65 (1.35 – 5.22)




Of the 86 children with ICP monitoring, five were excluded from CPP quantification
using the cumulative pressure time index because some CPP data were lost during
the first 24 hours post injury due to computer downtime.  Based upon the post
resuscitation summated Glasgow Coma Score (GCS), sixty-three children of the 81
77
were considered to have suffered a severe head injury (GCS 3-8, E1, V!2, and M!5)
and 16 children suffered a moderate head injury (GCS 9-12).  There were two with a
mild head injury (GCS13-15, with ISS $16).  The mean Injury Severity Scores was
20 (range 9 – 38).
From the 81 children, 35 made a good recovery, 30 suffered from moderate disability
(i.e. 65 had an independent outcome), 5 had severe disability at six months post
injury and 11 died (i.e. 16 had a poor outcome).  None remained in a persistent
vegetative state.
2.4.4.1) PTI for CPP (PTIc)
Using the initial age-specific threshold values, the PTIc ranged from 0 – 1959
mmHg-hrs. The median PTI values varied significantly with Glasgow Outcome
Score (good recovery 4.2; moderate disability 16.5; severe disability 73.6 and dead
769.1 mmHg-hrs, Kruskall-Wallis p < 0.001).  There was no significant difference in
the mean values of PTIc between the three age groups taken as a whole (not
subdivided by outcome) i.e. comparable amounts of insult were found in all
childhood age groups.
For both independent and poor outcome, there were no significant differences in the
magnitude of PTIc across the 3 age bands (Figure 2.2, p = 0.3).  However there was a
very significant difference between the PTIc values in the poor vs. independent
outcome categories (p < 0.001).
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Figure 2.2:
The PTIc values associated with an 80% sensitivity for independent outcome was
73.1 mmHg-hrs.  The corresponding values for mortality and morbidity were 331
and 1.4 mmHg-hrs respectively (Figure 2.3).
Figure 2.3:
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When the threshold levels were changed (increased by 10% and lowered by 10% and
20%), the sensitivity fell more rapidly with lower threshold values, but there
remained a clear delineation between each of the curves of sensitivity (Figures 2.4).
For a specificity of 80%, the PTIc values for each of the outcome groups were poorly
separated at 99.5, 96.9 and 101.4 mmHg-Hrs for mortality, independence, and




The ROC curves for PTIc created using the initial CPP threshold values for the three
different outcome dichotomies are shown in Figure 2.5 and the areas under the
curves (AUCs) for all the ROC curves, along with their standard errors, are tabulated
in Table 2.9.  The PTIc index has a very high predictive value for mortality (AUC =
0.957) and for independent outcome it is only slightly lower (AUC = 0.890).  The
predictive power is the lowest for separating the ‘best’ recovery (i.e. GOS 5) from all








ROC area Std. Error
Independent versus poor
CPP + 10% 0.858 0.054
CPP 0.890 0.044
CPP - 10% 0.883 0.053
CPP - 20% 0.886 0.051
‘Best’ versus rest
CPP + 10% 0.652 0.062
CPP 0.662 0.061
CPP - 10% 0.645 0.061
CPP - 20% 0.667 0.060
Mortality versus alive
CPP + 10% 0.931 0.046
CPP 0.957 0.034
CPP - 10% 0.968 0.027
CPP - 20% 0.966 0.026
When the threshold levels were altered by the previously described amounts, the
resultant ROC curves for each of the three different outcome comparisons had
smaller AUC values than that of our original threshold, indicating our original
thresholds were better predictive values (Table 2.9).
For independent outcome, the original CPP threshold remained the best predictor of
outcome, but for both mortality and morbidity the predictive value increased very
slightly (without reaching statistical significance) as the threshold level was
decreased (Table 2.9).
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2.4.4.2) PTI for ICP (PTIi)
The results for PTIi were similar but not identical when compared to those for PTIc.
The range of PTIi values was 0 - 5887 mmHg-Hrs, with a significant difference of
median values of 232.8, 134.1, 776.3, and 1763.6 mmHg-Hrs in those who had good
recovery (GOS 5), were moderately disabled (GOS 4), severely disabled (GOS 3), or
died (GOS 1) respectively (Kruskall-Wallis, p < 0.001).  There was a greater
variation in the index across the two older age groups for both independent and poor
outcome groups than for PTIc (p = 0.026 and p<0.001) (Figure 2.6).  There was a
significant difference in the mean PTIi for independent vs poor outcome (p < 0.001).
Figure 2.6:
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The rate of change of specificity was very similar to that of the CPP index for the 3
outcome comparisons.  Although the shapes of the sensitivity curves were similar to
those of PTIc, they were spread over a much wider range of values (Figure 2.7).  For
each of the 3 outcome dichotomies, the different threshold levels produced very
similar sensitivity and specificity curves with little difference between mortality,
independence and morbidity values, unlike those for CPP.
Figure 2.7:
The areas under the ROC curves for the PTIi for mortality, independent outcome,
and morbidity were smaller than the respective PTIc values (Figure 2.8 and Table
2.10).  The PTIi index has a very high predictive value for mortality (AUC = 0.871)
and a slightly lower value for independent outcome (AUC= 0.819).  For morbidity,




The final ICP values (i.e. ICP values before ICP monitoring was discontinued) for
children aged 2-6 were 12 mmHg, for 7-10, 18mmHg, and 11-15 years, 16 mmHg,
corresponding final CPP values (i.e. CPP values before ICP monitoring was
discontinued) of 78, 74 and 79 mmHg respectively.  Although 42 children had final
ICP values that were a mean of 11 mmHg above their age-specific thresholds, this
was obviously compensated because there was a negligible amount of corresponding
final CPP insult, with only 5 children having had final CPP values of a mean of 3
mmHg below threshold levels.  Even if this level of insult in these 5 patients
continued for the next 1 hour, the PTI would still have estimated 98.6% of all CPP
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insult.  It can be seen, therefore, that the pressure recordings has been discontinued






ROC area Std. Error
Independent versus poor
ICP - 10% 0.816 0.050
ICP 0.819 0.050
ICP + 10% 0.823 0.050
ICP + 20% 0.825 0.052
‘Best’ recovery versus rest
ICP - 10% 0.555 0.065
ICP 0.550 0.065
ICP + 10% 0.548 0.064
ICP + 20% 0.545 0.064
Mortality versus alive
ICP - 10% 0.864 0.042
ICP 0.871 0.041
ICP + 10% 0.882 0.039
ICP + 20% 0.887 0.038
The duration of ICP monitoring bore no relation to the severity of the primary injury
as assessed by the initial GCS motor score level (p = 0.572), nor to the Injury
Severity Score (p = 0.237).  In addition, there was no significant difference between
the two participating children’s neuro-intensive care units in the duration of ICP
monitoring (p = 0.749).
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2.5) DISCUSSIONS
This study examined the relationships between different age-specific physiological
derangements and outcome in critically ill children following traumatic brain injury.
Inadequate cerebral perfusion pressure by age was demonstrated to be the best
physiological parameter routinely monitored in the ICU to predict outcome.
Furthermore, successful development of a bi-dimensional index to summarise the
total burden (i.e. duration and magnitude) of age-related cerebral perfusion pressure
insult has enabled critical age-related cerebral perfusion pressure thresholds to be
defined.
2.5.1) Physiological Derangements
Intensive search for effective neuroprotective strategies to improve outcome after
brain trauma has been disappointing.  The current best treatment option available for
these critically ill patients remains the detection and prevention of secondary brain
insults from physiological derangements.  Avoidable secondary physiological
derangements may occur at any stage after brain trauma [64-69] and those that are
known to correlate with poorer outcome include hypoxia, hypotension, raised ICP,
low CPP, or pyrexia [72, 92].  However, it is unclear from the literature which of
these abnormal physiologies best correlate and predict outcome.
Detection and prevention of physiological derangement rely heavily upon accurate
monitoring.  Continuous physiological monitoring in minute resolution has become
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the expected routine practice in modern neuro-intensive care for nearly three
decades.  However, data collection from previous brain trauma studies of critically ill
patients rarely utilise recording with this degree of accuracy despite development of
research computer systems that are capable of capturing, recording, and analysing
the continuous physiological data to identify and quantify potential insults.  Majority
of these studies used end-of-hour data to assess the relationships between potential
physiological insults and outcome.  However, physiological derangements may occur
at any time during the intensive care management and may not have been present
during the collection of the end-of-hour data.  Using end-of-hour data, therefore,
poses a great danger in omitting potential insults and the true relationship between
physiological insults and outcome cannot be determined.  Using real time
physiological data, all potential insults would be included in the analyses thereby
increasing the accuracy of insult quantification and a more valid conclusion may then
be drawn on their relationships with outcome.
In this current study of the critically ill brain injured children, more than 5 million
minutes of data were collected.  Physiological derangements were identified in all
children but not all parameters were necessarily deranged in every child.  Given the
composition of our cohort is similar to other previously published British and
European childhood TBI case series with respect to the type, cause and severity of
injury as well as outcome [4, 7, 48, 197, 198], our findings have highlighted that
secondary physiological derangements occur extremely frequently in children after
TBI during the intensive care management.  The accuracy of data collection and the
amount of data available in this current study have also enabled us to confirm that
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age-specific cerebral perfusion pressure derangement was the best predictor of
outcome in childhood brain trauma.
2.5.1.1) CPP and ICP Derangement
2.5.1.1.1) CPP Derangement
2.5.1.1.1.1) Incidence and Duration
Comparison of the incidence and duration of CPP derangement in children after TBI
within the literature remains difficult partly because of the lack of normative data by
age making definition of derangement variable between studies, and ICP monitoring
is not a uniform practice in neuro-intensive care worldwide.  Chambers and
colleagues examined a total of 4373 hours of CPP monitoring collected prospectively
from 84 children during their intensive care treatment following TBI and found that
CPP derangement (i.e. recording below their single pre defined threshold of 70
mmHg) was present in 2083.7 hours of the monitoring time (47.6%) [91].  This
figure was 3.2 times higher than the previously reported overall duration of CPP
derangement of a group of adult brain trauma patients from Edinburgh using the
same single intervention threshold [72].  Injury severity of the cohort reported by
Chamber and co-workers [91] was not more severe than other previously reported
childhood brain trauma cohorts and therefore, could not account for the longer
duration of CPP derangement identified.  Despite having apparently longer CPP
derangement, 75% of their cohort had recovered with a good recovery and the
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mortality rate was 13% [91] which was similar to the expected mortality for brain
injured children in the UK and other European countries [1, 3, 8-10, 12, 14-16, 20,
21, 25, 26, 46-49].  The threshold for CPP derangement in Chambers’ report [91]
was the same as the widely accepted adult CPP threshold [74] and, therefore, may
not accurately identify the true frequency of CPP derangement in children after brain
trauma given that the CPP thresholds in normal children have been generally agreed
to be below 70 mmHg [184, 188-190].
Jackson and co-workers determined the incidence and duration of CPP derangement
in a cohort of 18 brain injured children aged less than 16 years of age by applying
three arbitrary chosen CPP thresholds: CPP < 70 mmHg, CPP < 60 mmHg, and CPP
< 50 mmHg [90].  They found that 30% of the CPP monitoring time of these children
were between 60 and 70 mmHg [90], which was similar to the figure from the much
larger cohort reported by Chamber and colleagues [91].  However, Jackson’s group
found that as the CPP threshold was reduced arbitrary to less than 60 and 50 mmHg
respectively, lesser duration of the CPP recording was identified as being potential
derangement (21% and 8% of the monitoring time were respectively detected as
potential derangement with a threshold of > 60 mmHg and > 50 mmHg) [90].  This
has confirmed the speculation that more false positive CPP derangement would be
identified in children after brain trauma by using super-normal CPP thresholds than
using thresholds closer to the physiological norm since most authors agreed that
normal CPP in infants and children should be between 40 and 60 mmHg [184, 188-
190].  The CPP thresholds chosen by Jackson and co-workers were, however,
without physiological basis and they applied these thresholds to the whole group
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without considering any age maturation effect on the normal CPP physiology [90].
Thus, age related CPP thresholds are required to determine the true incidence and
duration of CPP derangement in children.
A previous report of our pilot data by Jones and colleagues indicated that 77% of
brain injured children had age specific CPP derangement during intensive care
treatment and 11.8% of the total duration of CPP monitoring was lower than the pre
defined age specific thresholds i.e. potential derangements [92].  Using the same
theoretical age specific levels to define CPP derangement, our current study which
included the original pilot data identified 1215.2 hours of CPP derangement out of a
total of 7868.9 hours of CPP monitoring (i.e. 15.4%).  Thus, 42% less potential
derangement was found in our current study when compared to those identified by
Chamber’s group [91] despite having more prolonged period of monitoring and
using narrower but age-specific thresholds to define abnormal physiology in our
current study.  Given the different thresholds used throughout childhood, the overall
duration of CPP derangement identified in our cohort was also comparable to those
previously reported in adults after brain trauma [72].
2.5.1.1.1.2) Causes of CPP Derangement
CPP derangement may be the direct results of raised ICP alone, arterial hypotension
alone, or a combination of the two since CPP is calculated through the formula:
CPP = MAP - ICP
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Cortbus and colleagues reported on the causes of episodes of reduced cerebral
perfusion pressure in a group of 74 adults with traumatic brain injury [199].  Two
clusters of reduced CPP were found with one cluster occurring during the first 24
hours of monitoring and the other at 5 or 6 days after injury [199].  The causes of
reduced CPP between these two clusters were very different, with arterial
hypotension being the predominant cause for the first cluster while intracranial
hypertension was responsible for majority of the reduced CPP during day 5 or 6 post
injury [199].  The latter finding did not raise any surprises because raised ICP had
been demonstrated to occur frequently after brain trauma [63, 70] and cerebral
oedema usually worsen over the first few days after the initial primary brain injury.
However, arterial hypotension related reduced CPP during the acute management of
these patients would suggest that resuscitative measures for these patients were less
than optimal.
Chambers and colleagues also investigated the causes of secondary insults in 84
children and 291 adults after brain trauma and found that secondary insults occurred
regardless of the outcome [91].  Using adult threshold values for ICP, CPP and
arterial blood pressures (MAP and systolic blood pressure), they demonstrated that
majority of the CPP insults in children were caused by decreased arterial blood
pressure and as the thresholds used to define low CPP is reduced from 70 mmHg to
60 and then 50 mmHg, the number of insults caused by a combination of reduced
arterial blood pressure and raised ICP were increased [91].  Furthermore, almost all
insults were due to a combination of reduced arterial pressure and raised ICP when
CPP were less than 50 mmHg in their paediatric cohort [91].  These findings differ
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significantly from those of our current study since the predominant cause of low CPP
in our patients was raised ICP rather than arterial hypotension which only occurred
in 0.25% of the total monitoring time throughout the study.  This highlights the
importance and the need to consider the age-maturation effects on the intracranial
and systemic pathophysiology when conducting paediatric brain injury studies and
appropriate age related thresholds should be used to define secondary physiological
insults in childhood brain trauma.
2.5.1.1.2) ICP Derangement
Raised ICP was the most frequently identified derangement in our study and was
found in virtually all cases (97%).  Mayer and Walker had previously reported in
1985 that intracranial hypertension, which was defined as having a raised ICP of
more than 20 mmHg, occurred in 80% of the 200 children they investigated after
brain trauma [200].  The incidence of intracranial hypertension was 1.2 times higher
in our current cohort recruited 15 years later than those described by Mayer and
Walker [200].  Treatment of raised ICP has changed little over the years, but
continuous computerised physiological monitoring is now the norm in modern
neuro-intensive care and the accuracy of data collection used in our study may
explain the increased detection of intracranial hypertension in our cohort.  Different
thresholds were used to define intracranial hypertension between our current study
and that of Mayer and Walker’s [200].  The thresholds used in our study to define
raised ICP were theoretical age-specific norms and were much lower than thresholds
definition of intracranial hypertension that were used by Mayer and Walker [200]
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and may explain the discrepancies between the frequencies of raised ICP reported by
these two studies.
Mayer and Walker were not the only investigators to apply an adult ICP threshold to
define raised ICP in brain injured children because of the lack of normative ICP
values by age.  Brain trauma children with ICP more than the widely accepted adult
threshold of 20 or 25 mmHg were associated with poorer outcome or death.
Pfenninger and co-workers retrospectively reviewed 24 children after brain trauma
who were managed with a treatment goal of maintaining ICP of less than 20 mmHg
and to abolish persistent ICP rises of more than 25 mmHg for 3 minutes [201].  They
found that persistently raised ICP of more than 40 mmHg was significantly
associated with death [201].  In another retrospective review of 56 children with
severe TBI, Esparza and colleagues similarly found a significantly higher mortality
among brain injured children whose ICP were more than 40 mmHg which was 3.6
times higher than those who had ICP between 20 and 40 mmHg (100% vs. 28%)
[202].  Both of these studies [201, 202] were conducted retrospectively and although
they had highlighted the obvious association between prolonged periods of raised
ICP and poor outcome after brain trauma, no attempts was made to address ICP
treatment thresholds or to define the physiological changes in ICP with age.
The relationship between intracranial hypertension and cerebral blood flow post
brain trauma among 21 severely brain injured children was assessed prospectively by
Sharples’ group [89] who also defined intracranial hypertension as having an ICP
elevation of more than 20 mmHg for 10 consecutive minutes.  This important report
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suggested for the first time that cerebral hyperaemia was an uncommon cause of
intracranial hypertension in paediatric TBI because cerebral hyperaemia occurred
only in 2 out of 21 children they examined [89].  However, like other paediatric brain
injury studies, the definition of intracranial hypertension was not age adjusted.
Given that majority of authors agreed that the normal ICP for children would be
much lower than the traditional thresholds of 20 mmHg, it is possible that by
applying adult ICP thresholds to child cohorts, the frequency and duration of true
age-related intracranial hypertensive insult is under-estimated.  Our study has,
therefore, highlighted the importance of applying age-related thresholds when
investigating childhood brain trauma.
Despite the possibility of underestimating the frequency and duration of true
intracranial hypertensive insults, these previous reports have led to the general
acceptance of raised ICP being a secondary physiological insult that adversely
affects outcome after paediatric brain trauma.  Treatment of raised ICP of more than
20 mmHg after TBI has been recommended as a treatment option for intracranial
hypertension in the recently published first edition of the Guidelines for the Acute
Medical Management of Severe Traumatic Brain Injury in Infants, Children and
Adolescents [75].  This guideline has emphasized the insufficient evidence in the
current literature to allow formulation of treatment standards or even guidelines.  It
was, therefore, not possible to recommend specific thresholds for treatment of
intracranial hypertension in infants and children after TBI.  It is, therefore, of
paramount importance to direct future research focus in defining critical age related
treatment thresholds.  Using theoretical physiological norms for ICP adjusted with
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age as thresholds, the predictive value of the age adjusted ICP derangement (as a
percentage of the acute monitoring time) on the mortality and morbidity after
childhood brain trauma was demonstrated for the first time by our current study.  We
have, therefore, presented a novel approach to define ICP derangement by age.
However, as the thresholds used in our study were only theoretical physiological
norms and may not necessary represent insult thresholds, there is an urgent need to
define age-specific ICP insult thresholds so that treatment thresholds may be
developed.
2.5.1.1.3) Quantification of the Total Burden of Secondary Intracranial
Physiological Insults
Development of computerised data collection and analysis systems have progressed
dramatically over the past decade enabling better identification of potential
secondary physiological insults.  However, previous studies of the relationships
between CPP and outcome in both adult and childhood brain trauma had focused on
using a single measurement of CPP derangement values (either mean, minimum,
absolute, or percentage duration) but all failed to incorporate the effect of both the
duration and severity in the total burden of CPP insults.  The failure to accurately
quantify the totality of CPP derangement may have limited the determination of
critical ICP and CPP treatment thresholds, and development of novel therapies.  This
study is the first to address this problem by successfully creating a novel pressure
time index that simultaneously measure both the duration and intensity of CPP
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derangement (i.e. quantifying the total burden of abnormal physiology) using
detailed physiological data [203, 204].
The pressure time index was a measure solely of secondary brain insult and allowed
comparability of insults at any age [203, 204].  Insult comparability across different
ages is of particular importance in the progress of future paediatric TBI studies given
the urgent needs to investigate the age maturation intracranial physiological
variations between infants and children of different ages.  With the development of
the pressure time index, this study has also derived critical CPP insult thresholds in
three paediatric age groups and confirmed the importance of CPP as a determinant of
outcome in childhood traumatic brain injury [204].
2.5.1.1.3.1) Cumulative Pressure-Time Index for CPP (PTIc)
The PTIc values were significantly related to each of the GOS outcome categories or
the combinations we had used (independent vs. poor, mortality, morbidity) [204].
Other studies had shown a similar relationship of ‘single dimension’ CPP
derangement to outcome [91, 92].  The similar PTIc values across our three different
age bands indicated that this novel index was independent of age thereby allowing
comparability of CPP insults at any age [204].
The sensitivity of the PTIc (i.e. proportion of those who made an independent
outcome reduced with increasing PTIc) – separated the three outcome comparisons
showing that the largest insult burden occurred in those who died, and the least insult
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was found among those who made a good recovery [204].  Specificity, on the other
hand (i.e. the proportion of poor outcome patients increased with increasing values of
the PTIc) proved to be less discriminating for our outcome categories, and remained
so when the theoretical thresholds were applied [204].
Receiver Operator Characteristic (ROC) curve is a plot of sensitivity against 1 –
specificity.  It is a powerful tool for evaluating a process that has a binary outcome
without the need to define one single arbitary cut-off level [205].  It provides a
simple and easily interpretable graphical display of the trade-off between sensitivity
and specificity at each decision threshold [205].  Furthermore, the area under the
ROC curve (AUC) gives a measure of the predictive value of a test and can be used
to compare different variables [206], with an AUC of 1.0 equating to perfect
prediction while that of 0.5 indicating random chance.
The threshold levels that were chosen were based upon hypothetical minimum
physiological norms, (48 mmHg for those aged 2 – 6 years; 54 mmHg for those aged
7 – 10 years; and 58 mmHg for those aged 11 – 15 years) and were not known at the
outset to be insult thresholds.  We reduced the CPP thresholds arbitrarily by a factor
of 10 and 20% and similarly increased it by 10% (theoretical values), and compared
these sensitivities and specificities.  Our ROC analysis had clearly demonstrated that
the PTIc values for CPP calculated using our original theoretical CPP threshold
values at different ages most accurately separated the outcome categories [204].
Altering these theoretical threshold levels failed to improve the predictive value
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indicating that the original physiologically based theoretical thresholds were in fact
critical insult thresholds for CPP [204].
2.5.1.1.3.2) Cumulative Pressure Time Index for ICP (PTIi)
Although it is generally accepted that raised intracranial pressure can promote
deleterious events that can be related to outcome, previous studies of ICP and
outcome in the brain trauma literature have failed to demonstrate any statistic
significance.  For ICP, the high ROC area under the curve values for mortality and
for independent vs. poor outcome using our new index indicated for the first time
such a considerable relationship to outcome [204].  However, its predictive value
remained less than that of the PTI for CPP highlighting once again the importance of
maintaining an adequate CPP during the acute management of these patients [204].
Children who were severely disabled or died in our cohort had progressively larger
amounts of ICP insults than those who had moderate disabilities or good recovery as
would be expected.  However, children with good recovery appeared to have
suffered more ICP insult than those with moderate disabilities.  The duration of
monitoring did not differ significantly between patients with good recovery and
those with moderate disabilities.  One possible explanation of this anomalous finding
is that the pre-defined theoretical age-related ICP thresholds were not critical insult
thresholds.  Alternatively, other factors, such as the genetic constitutions of the
patients, might have different influence on how they responded and recovered from
raised ICP, thereby affecting outcome differently.  Another possible explanation is
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that cerebral autoregulation remained intact in patients with good recovery and as a
result, they were able to compensate the higher burden of ICP insult by maintaining
an adequate cerebral perfusion pressure.  This highlighted the importance of
examining cerebral autoregulation in brain trauma patients in future studies.
Increasing or decreasing the ICP threshold did not significantly change the
sensitivity or specificity and hence did not improve the predictive value in relation to
outcome – i.e. it is the CPP at our age-specific thresholds that is the more influential
factor in the outcome of paediatric brain trauma [204].
2.5.1.1.3.3) Critical Thresholds
We divided our patients into three age groups to allow calculation of the PTI and
determination of critical physiological thresholds but these age bands have
subsequently been described in another report which used the hourly measurements
of the first 6 hours of acute monitoring data from over 200 head injured children
[207].  The ROC curves from our current study demonstrated differences in the
specificity of CPP and ICP with outcome for the various age groups where at 50%
specificity, the CPP values for the three age groups (age 2 - 6 years, 7 – 10 years, and
11 – 16 years) separated at 53, 58, and 67 mmHg; and those for ICP separated at 24,
19, and 18 mmHg respectively for the three different groups [204].  Although these
bands could be refined, in practice the rate of development of the physiology of
children can vary quite markedly and therefore the banding provides a measure of
spread.  We are conscious that we have not addressed ages between 0 and 2 years,
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because the rapidly changing physiology at this stage of development would require
a large cohort of patients and may only be possibly with a large multi-centre study.
There are three different types of thresholds: (1) brain insult thresholds are threshold
values where irreversible brain damage will occur if CPP is persistently below the
critical CPP insult threshold or ICP is persistently above the critical ICP insult
threshold; (2) physiological thresholds are threshold values where physiology is
deranged but not necessary causing irreversible tissue damage; and (3) treatment
thresholds are thresholds where clinicians act and instigate treatment for raised ICP
or low CPP.  It is logical to think that brain insult thresholds are likely to be less than
physiological thresholds and would require measurement of brain metabolism to
define these insult thresholds.  For treatment thresholds to be effective in improving
outcome by preventing brain insults and physiological derangements, they would
need to be above the physiological thresholds.  We have tested our proposed age-
related theoretical physiological thresholds for CPP and proved that they are in fact
critical thresholds since lowering them further did not improve the predictive value
of outcome [204].  Each of these needs to be precisely defined and understood, but
we believe that for children, the CPP physiological thresholds are in fact, identical to
the brain insult thresholds.
Current critical care guidelines for adult and childhood brain trauma have
emphasized the usefulness of ICP monitoring in selected patient groups but, because
of insufficient evidence, have failed to recommend universal ICP monitoring in all
brain trauma patients requiring intensive care.  With the newly defined age-related
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critical CPP thresholds, the argument for using ICP monitoring should now be
strengthened.  Furthermore, this novel Cumulative Pressure-time Index is essential
for future studies because the ability to quantify the totality of secondary
physiological insults will enable ICP and CPP physiological / insult thresholds in
adults to be defined.  In addition, current intensive care treatment regimes may be
validated, and critical care management options may be explored.
2.5.1.2) Other Derangement
2.5.1.2.1) Blood Pressure Derangement
2.5.1.2.1.1) Hypotension
Normative data on age related changes in arterial blood pressure is well documented
in the literature [87, 181-183].  Unlike the definition of intracranial hypertension,
majority of the studies in the literature assessing the relationship between
hypotension and outcome in paediatric brain trauma have employed age related
thresholds to define hypotension, with many studies adopting the widely accepted
definition of having a systolic arterial blood pressure below the 5
th
 percentile for age
for 5 consecutive minutes.
The incidence of age adjusted hypotension in childhood TBI has been reported to be
between 29 and 39%.  In 1985, Mayer and Walker reported that 29% of patients
among the 200 severely brain injured children they investigated had low arterial
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blood pressure for their age [200].  Despite its less frequent occurrence in
comparison to raised ICP in their cohort, hypotension was associated with a 2.5
times increased in mortality when present [200].  The significant influence of
hypotension on the mortality after childhood TBI was confirmed by a later
prospective study involving 1906 children and 6908 adults with severe brain trauma
where the mortality of brain injured children aged less than 15 years with
hypotension was 2.8 times higher than that of brain injured adults with hypotension
[208].
Levin and colleagues investigated physiological data recorded prospectively from a
cohort of 103 children with severe brain trauma who were recruited as part of the
Traumatic Coma Data Bank study and found that younger children, aged 0 to 4
years, had higher incidence of hypotension and the poorest outcome [18].  Another
review of the prospectively collected data of 75 children with severe brain trauma by
the Trauma Registry confirmed that the presence of hypotension in the field or the
emergency department were associated with higher mortality [209].  The importance
of early hypotension (i.e. on the scene of the accident or in the Emergency
Department) on brain trauma outcome was confirmed by another retrospective study
of 93 brain trauma children attended a Level I Trauma Centre in the United State of
America [210].  In 1993, Pigula and colleagues reported a 2.8 times increased in
mortality in the presence of hypotension on arrival to the emergency department
among a cohort of 58 severely brain injured children recruited prospectively over a 5
year period [179].  Kokoska and co-workers retrospectively reviewed medical charts
of 72 brain injured children with moderate severity and found that 39% of patients
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had hypotension while being resuscitated in the emergency department, and a similar
proportion (37%) suffered hypotensive insults during intensive care management
[211].  Patients in this cohort with moderate and severe disability had significantly
more episodes of hypotension recorded than those who recovered with good
outcomes [211].
Hypotensive derangement was found in 31% of the children in our current study but
was only detectable in 0.7% (82.7 hours) of the total duration of monitoring time
(over 11648 hours or 485 days).  The incidence of hypotensive insults identified in
our cohort is, therefore, similar to those previously reported suggesting that despite
significant development in advance trauma care and acute resuscitation technique
over the past decade, considerable proportion of children continued to suffer from
hypotensive insults after traumatic brain injury.  However, the duration of
hypotensive derangement in our cohort was very low and was not statistically
predictive of mortality or morbidity.  This would suggest that although modern acute
trauma and neuro-intensive care have made little impact on the incidence of
hypotension over the last three decades among critically ill brain injured children,
they have successfully reduce the duration of hypotension in these patients to break
the association of hypotension with mortality as previously reported.
2.5.1.2.1.2) Hypertension
Arterial hypertension after brain trauma has not been as extensively investigated as
other physiological derangements like intracranial hypertension, hypotension,
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hypoxia or reduced CPP.  The literature’s definition of hypertension post paediatric
TBI is not well defined and a conflicting relationship between arterial hypertenion
and outcome following childhood TBI has been reported by the few studies in the
literature.
Kanter and colleagues examined the relationship between persistent arterial
hypertension and outcome of 42 comatose children caused by brain trauma, Reye’s
syndrome, anoxia, and CNS infection [212].  They found that 74% of patients with
high blood pressure persisting until ICU discharge had poor outcome [212].  It is
possible that children included in this study had lost cerebral autoregulation, as a
result, an increased in the arterial blood pressure would be transmitted intracranially
resulting in a mirroring rise in the ICP thereby failing to improve the CPP which
resulted in the poorer outcome.  Alternatively, ‘false cerebral autoregulation’ may
explain the inverse relationship between arterial hypertension and outcome.  ‘False
cerebral autoregulation’ is a concept described by a recent cerebral blood flow study
in adults where the cerebral blood flow remained constant or even reduced during a
clinically apparent improvement in the CPP with induced arterial hypertension
despite a simultaneous rise in the ICP [213].
However, more recent studies have described a favourable association between
arterial hypertension and outcome in paediatric TBI.  Luerseen and colleagues
reported that the lowest mortality was observed among brain injured children with
severe hypertension which was defined as having a systolic blood pressure > 135
mmHg [208].  Similarly in another retrospective study which tried to determine
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predictors of outcome among severely brain injured children, White and co-workers
found that the odds of survival was increased by 19 folds with the present of a
maximum systolic blood pressure of more than 135 mmHg [214].  It is unclear
whether the reported super-normal blood pressure observed in children within these
studies were artificially raised with inotropes or whether it was the result of the
cerebral autoregulatory response.  Nevertheless, it is easy to understand the
association of an improved outcome with arterial hypertension because having a
higher systolic blood pressure would result in a higher than normal mean arterial
blood pressure which would in turn improve cerebral perfusion pressure in the
presence of an intact cerebral autoregulation, thereby improving outcome.  Thus, the
association between super-normal arterial blood pressure and an improved outcome
following childhood brain trauma should not pose any surprises.
Age adjusted arterial hypertension was detected in majority (90%) of our patients
and had significant predictive value on good outcome.  It is likely to be a reflection
of the management guidelines used and their emphasis on the importance to maintain
an adequate CPP after childhood brain trauma by raising the systemic arterial
pressure with the use of inotropes.  This finding once again highlighted the
importance of maintaining an adequate cerebral perfusion pressure.
2.5.1.2.2) Hypoxia
Correlation between hypoxia and unfavourable outcome after brain trauma was first
reported in 1958 when McIver and co-workers described the role of respiratory
106
insufficiency in the mortality of severely brain injured adults.  Definitions of hypoxia
varied between reports in the literature with older studies adopting cyanosis as a
clinical diagnosis of hypoxia, while studies after the development of arterial blood
gas analyses in 1966 using various thresholds between 60 and 80 mmHg to define
hypoxia.  Since it has been shown that an oxygen saturation of less than 90%
generally equates to an arterial partial oxygen concentration of less than 60 mmHg,
some investigators have opted to use the non-invasive pulse oximetry monitoring to
define hypoxia with the thresholds varying between 90 and 92%.
Correlation between poorer outcome and hypoxia sustained at different stages of the
management of adult TBI, such as at presentation to emergency departments, on
admission to or while in intensive care or neurosurgical units, has encouraged the
Brain Trauma Foundation to recommend vigilant prevention and prompt treatment of
hypoxia after brain trauma as a ‘treatment guideline’ in their latest Guidelines in the
Acute Management of TBI [74].
Paediatric evidence linking hypoxia and poor outcome after brain trauma is scanty
with most of the reports concentrating only on the effect of hypoxia documented in
the emergency department following brain trauma and the results between reports are
often contradicting.  Mayer and Walker first suggested hypoxia causing increased
mortality in childhood brain trauma in 1985 when they prospectively examined 200
children with severe brain trauma and the determinants of poor outcome [200].  They
found that patients with systemic complications such as hypoxia, hypercarbia, or
hypotension identified in their emergency department had a mortality rate that was
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seven times higher than those who did not experience any of these systemic
complications [200].  However, they did not investigate the individual effect of these
systemic complications on outcome.  Hypercarbia is the single most potent inducer
of intracranial hypertension while hypoxia and hypotension contribute to ischaemia,
it was therefore, not possible to differentiate the individual contribution of these
systemic complications to poor outcome from this report.
Subsequent reports describing the correlation between hypoxia and poor outcome
after brain trauma have also grouped hypoxia with other systemic complications such
as hypotension when assessing their effects on outcome.  Sharple and co-workers
reported a four fold increased in mortality from brain trauma caused by hypoxia
among children with evidence of hypotension when they were examining potentially
avoidable factors among fatal cases of paediatric brain trauma [59].  In a recent
Italian prospective study assessing the pre-intensive care complications and their
impact on outcome of brain injured children, Chiaretti and colleagues similarly found
that early complications such as hypoxia and hypotension significantly related to
poorer outcome regardless of the severity of the primary brain injury as measured by
the GCS [215].  Chiaretti and co-workers conducted another study to retrospectively
determine prognostic factors of childhood TBI and similarly reported a 5 fold
increased in poor outcome after brain trauma in the presence of early complications
(i.e. hypoxia or hypotension) occurring in the emergency departments [216].
However, only the combined effect of hypoxia and hypotension on outcome was
assessed without determining the specific contribution from each of these early
complications.
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The lone effect of oxygenation on childhood brain trauma outcome were described
by 3 groups of investigators.  Ong and colleagues reported hypoxia being solely
responsible for an increase in poor outcome after severe paediatric head injury [153].
They evaluated the prognostic value of hypoxia, hypotension, and measures of
primary brain injury such as the GCS and the initial brain CT findings on outcome
after paediatric head injury in Kuala Lumpur using a data set collected prospectively
from 151 consecutive children admitted with head injury including those without
evidence of brain trauma [153].  The 2 to 4 folds increased in poor outcome observed
in the presence of hypoxia occurred independent of hypotension and other systemic
complications [153].
Pigula and co-workers, however, reported that hypoxia on its own did not alter
mortality after paediatric brain trauma [179].  They analysed single point data
collected on admission to the emergency department from 509 brain injured children
of which 58 were recruited from a single trauma centre in Vermont while the rest
were data provided by the National Trauma Registry [179].  Hypotension was found
to significantly increase mortality after brain trauma in children but combined
hypoxia and hypotension only slightly increased mortality over the effect of
hypotension on its own [179].  They concluded that hypotension was the more
critical factor in oxygen delivery post brain trauma and hypothesized that the brain
had significant oxygen extraction capacity to prevent ischaemia even in the presence
of hypoxia but hypotension would impair oxygen delivery to the brain even in the
presence of normal PaO2 causing damaging ischaemic insults [179].  The difference
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in findings between Ong’s group and Pigula’s might be explained by the different
inclusion criteria and study end points.  Ong’s group examined the effect of hypoxia
on outcome among head injured children of all severity regardless whether there was
evidence of brain injury [153], while Pigula’s group investigated mortality among
children who had evidence of severe brain injury [179].
It is possible that hypoxia has more influence on morbidity than mortality.  In a
retrospective analysis of Trauma Registry data collected prospectively on 75 brain
injured children, Michuad and colleagues found that hyperoxygenation was related to
better outcome [217].  In their series, brain injured children with a PaO2 of more than
350 mmHg in the emergency department had better outcome than those with a PaO2
of 105 to 350 mmHg [217].  The arterial partial pressure of oxygenation quoted in
their cohort even at the lowest level of 105 mmHg was still well above any
recognised thresholds of hypoxia (60 to 80 mmHg).  It is, therefore, impossible to
stipulate whether hypoxia has a detrimental influence on outcome after paediatric
brain trauma.  But the findings did suggest that hyperoxygenation during
resuscitation might confer a beneficial effect on outcome in childhood TBI.  Modern
trauma resuscitation and emergency care emphasizes on the priority to control and
maintain the airway and breathing with the provision of high flow oxygen therapy
and mechanical ventilation to prevent hypoxia and hypercapnea respectively while
hypotension is promptly identified and being corrected.
Little information is available in the literature on the frequency of hypoxia in the
intensive care setting following paediatric brain trauma.  Hypoxia was extremely
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uncommon among our patients during their intensive care management reflecting the
success of modern trauma care.
2.6) MONITORING OF BRAIN OXYGEN AND SUBSTRATE DELIVERY &
CONSUMPTION
Assessment of brain oxygen and substrate delivery and consumption has gained
considerable interests in adult brain trauma research and their translation into clinical
management.  Their usefulness in paediatric brain trauma remains unclear because of
the lack of previous studies.  An overview of the development in this area of
monitoring is presented in the following sections.
2.6.1) Brain Tissue Oxygen Delivery and CO2 Removal Monitoring
Over the past few years, the use of a fiberoptic sensor that is capable of measuring
oxygen tension, CO2 tension, pH, and temperature in the blood has gained
considerable interests and has been adapted for use in adult brain tissue [218].  The
multi-parameter sensor may be inserted into brain tissue together with the standard
ventriculostomy catheter and a microdialysis probe through a triple lumen
intracranial bolt.  Evidence from animal studies suggested a potential clinical role for
this multi-parameter sensor [218, 219], and several adult studies have been carried
out to investigate its clinical usefulness in brain trauma [220, 221].  In one study of
20 brain trauma adults, those with severe injury had low brain oxygen tension in the
first few hours following the initial insult [220].  A slow increase in brain oxygen
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tension and a decline in the brain CO2 tension to normal values was observed in
those patient who recovered with a favourable outcome while a further decrease in
brain oxygen tension to anaerobic levels was seen among those with bad outcome
[220].  Furthermore, the brain CO2 levels of 90 – 150 mmHg were seen consistently
after brain death [220].  Continuous monitoring of the brain oxygen tension, CO2
levels, pH and temperature may, therefore, provide additional information to aid the
management of the comatose patients but require detail evaluations in larger cohorts.
Transferability of its use in paediatric brain trauma is yet to be investigated.
2.6.2) Monitoring of Cerebral Blood Flow and Metabolisms in the Injured
Brain
Although maintaining an adequate CPP is important as it provides a pressure
gradient governing the cerebral blood flow, the ultimate determinants of the cerebral
metabolism are cerebral blood flow (CBF) and the oxygen content in the blood.
Monitoring of the ICP and CPP alone, therefore, offer no information on the brain’s
oxygen delivery and usage with some investigators of adult brain trauma considering
this conventional practice ‘un-physiological’.  Cerebral blood flow targeted treatment
may, therefore, be more ‘physiological’ and beneficial to neuronal recovery.  At
present, methods to measure cerebral blood flow such as Positron Emission
Tomography (PET), Xenon clearance or Single Positron Emission Computed
Tomography (SPECT) are too cumbersome for use at the bedside in the ICU.
Jugular venous bulb oximetry and transcranial doppler ultrasound may be performed
112
in the ICU and may, therefore, provide a better bedside understanding of the state of
the cerebral circulation and oxygen consumption.
2.6.2.1) Jugular Venous Bulb Oximetry
Arterio-jugular venous oxygen saturation differences (AVDO2) allow assessments of
the balance of the brain’s metabolism and blood flow.  Mixed venous oxygen
saturation (SjvO2) of blood leaving the brain can be measured from blood samples
drawn from the jugular venous bulb situated at the base of the brain.  This involves
placement of a catheter directed upward in the internal jugular vein so that the tip of
the catheter rests in the jugular venous bulb.  Continuous SjvO2 monitoring is
possible by using a fibreoptic catheter.
In adults, the SjvO2 is normally between 50 and 75 %.  When the blood supply to the
brain exceeds its demand for oxygen (hyperemia), an increase in SjvO2 to more than
85% will occur.  This may be the result of an increase in the cerebral blood flow i.e.
cerebral hyperemia, or a relative hyperemia due to a decrease in cerebral metabolic
rate associated with impending cell death/brain death.  Up-to 55% of adults have
been shown to develop hyperemia after brain trauma and there is a highly significant
association between hyperemia and the occurrence of intracranial hypertension .  As
the cerebral blood flow responses to hyperventilation are generally preserved, brain
trauma patient with hyperemia is more CO2 reactive .  Hyperventilation may be used
to treat intracranial hypertension in these patients with the guidance of SjvO2
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monitoring to ensure cerebral ischemia does not occur as the brain’s demand for
oxygen changes during recovery.
Inadequate cerebral blood flow from an increased cerebral vascular resistance (CVR)
will result in a reduction of SjvO2 below 50% in the absence of a fall in arterial
oxygen saturation (SaO2).  Elevation of cerebral vascular resistance occurs
frequently after brain trauma and is made worse by hypocapnea .  An increase in the
cerebral metabolic rate would also cause a fall in the SjvO2.  Thus, in patients with
persistent intracranial hypertension unresponsive to standard therapies and in the
absence of evidence for cerebral hyperemia, barbiturates may be used to produce
intermittent burst suppression to reduce the cerebral metabolic rate for oxygen
(CMRO2).  The occurrence of jugular venous desaturation was demonstrated to be
strongly associated with a poorer neurological outcome in adult brain trauma [222].
90% of patients with multiple episodes of desaturation and 74% of those with one
desaturation had a poorer neurological outcome compared to 55% of those with no
episodes of desaturation [222].
The normal SjvO2 values in infants and children remain unknown.  Practical
difficulties in siting the sizeable jugular bulb catheter in small children have limited
its use in the paediatric population to selective cases of older children and
adolescents with intracranial hypertension unresponsive to conventional first line
therapies.  None of our cohort had SjvO2 measured during their ICU management.
Further studies are needed to ascertain the clinical usefulness of SjvO2 in childhood
brain trauma and its relationship with outcome.
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2.6.2.2) Transcranial Doppler Ultrasound (TCD)
Transcranial Doppler ultrasound (TCD) is a non-invasive method to assess flow
velocities of the intracranial cerebral arteries and was first described in the early
1980s [223].  Flow velocities can be measured in the middle, anterior and posterior
arteries by placing a probe in the temporal area just above the zygomatic arch.  As
the cross-sectional area of the arteries cannot be measured directly, flow cannot be
measured from velocity, but the doppler shift measured is inversely proportional to
the diameter of the vessel.  Thus, provided all other factors remain constant,
vasospasm will result in an increase in flow velocity.
Using transcranial doppler, middle cerebral artery spasm was identified in 40% of
patients after traumatic brain injury and could begin as early as 48 hours post injury
[224].  Maximal MCA spasm was found between 5 to 7 days after the initial trauma
[224].  In another study of brain trauma adults, severe MCA spasm identified on the
transcranial doppler was confirmed by angiography [225].
Daily measurements of the MCA velocity from 121 patients with varying severity of
brain trauma showed an inverse correlation between the injury severity and the MCA
velocity [226].  In addition, a significantly lower MCA velocity on admission was
demonstrated among the brain injured patients when compared to those of normal
controls [226].  High ICP and low cerebral blood flow were responsible for the low
velocities in the intracranial circulation after brain trauma.  Furthermore, an
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admission MCA velocity of less than 28 cm/s correctly predicted 80% of the early
deaths [226].
Currently, TCD remains a research tool and is not used in the clinical management of
the brain trauma children.  Furthermore, it only offers intermittent measurements of
cerebral blood flow and its usefulness and accuracy in determining cerebral
vasospasm is operator dependent.  Its role in outcome prediction and in identifying
brain trauma children at risks of developing vasospasm requires further
investigations.
2.6.2.3) Microdialysis
As the composition of the cerebral interstitial fluid reflects the biochemistry of the
neurons and glial cells in the brain, attempts have been made over the past decade to
develop the use of cerebral microdialysis to monitor neurotransmitter release and
energy metabolism in the animal and human brain.  By mimicking the function of a
blood capillary, the microdialysis catheter enable monitoring of the chemical
changes in the interstitial fluid [227].  Because of a concentration gradient across the
semi-permeable microdialysis membrane, chemical substances within the interstitial
fluid diffuse across the dialysis membrane and into the perfusion fluid inside the
catheter [227].  Samples are collected in microvials and brought to a bedside analyser
as often as necessary [227].
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The dialysate lactate, lactate/pyruvate ratio, glycerol, glutamate, glucose and
adenosine levels have been investigated in the brain trauma adults [228-234].  The
lactate/pyruvate ratio has been shown to be a better marker of ischaemia than lactate
alone as an increase in lactate may be the result of hypoxia, ischaemia, or hyper-
metabolism [228, 229].  But during ischaemia, neurons become dependent upon
anaerobic metabolism to produce ATP from glucose.  This will cause an increased in
lactate production while pyruvate production decreases.  As a result, there is an
increase in the lactate/pyruvate ratio during ischaemia [228, 229].  Glycerol is an
integral component of the cell membrane and has, therefore, been used as a marker
of cell membrane damage [230, 231].  Although glutamate has been proposed as an
indirect marker of cell damage, it is often hard to interpret the dialysate level as the
neuronally released glutamate is mixed with the large metabolic pool of glutamate.
A reduction in the dialysate glucose is often associated with a decrease in brain
oxygen tension suggestive of reduced cerebral perfusion [232].  A mark increase in
the cerebral interstitial fluid adenosine level has been shown to occur during jugular
venous oxygen desaturations suggesting a potential role for adenosine during the
periods of secondary insults after brain trauma [235].
As microdialysis samples from surrounding interstitial fluid, it, therefore, only offers
monitoring of the local neurochemistry.  The interpretation of microdialysis data
depends upon the position of the catheter in relation to the existing pathology and its
use in children requires investigations.
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2.7) LIMITATIONS
This study has several limitations.  Power calculation of sample size was not possible
at the onset of the study because the main aim was to develop and validate a novel
bi-dimensional index for quantification of pressure insult so that critical age-related
CPP and thresholds may be defined.  The original study proposal planned to recruit
140 brain trauma children over a two-and-a-half year period starting on 1 October
2000.  This proposed sample size was based upon the estimated number of available
patients calculated from the best available ICU admission figures in 1997.  The
prevalence of paediatric brain trauma had fallen sharply since the calculation of our
sample size, which possibly reflected the success of the many accident preventative
measures introduced.  Re-organisation of the Scottish Paediatric ICU services had
not increased the number of brain trauma admissions to the Edinburgh RHSC as
expected.  Despite successful recruitment of all available brain trauma patients into
the study from all 3 sites, only half of the proposed number was enrolled by the end
of the study period.  The number (n = 76) was insufficient for meaningful statistical
analyses.  As a result, patients recruited from a prospective pilot study carried out in
the late 1980s in the regional paediatric neuro-intensive care centre in Edinburgh
[92] were included for analyses.  This was only possible because their inclusion
criteria and treatment protocol were the same as our current study and they did not
differ statistically from our current cohort.
Despite inclusion of the pilot group to give our final cohort of 128 patients, not all
patients had ICP monitoring.  Once excluding patients aged less than 2 years and
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those with ICP monitoring commencing after 24 hours of injury, the sample size
reduced to 81, which is smaller than our original anticipated number.  Although the
sample size was smaller than intended, we were able to develop and validate our
novel index for pressure insult quantification.
Majority of our patients had GOS 4 and 5 (i.e. independent outcome), with very few
patients had severe disability or a fatal outcome.  This uneven spread of outcome
made it necessary to assess the influence of physiological derangement and CPP
insult on outcome using dichotomies which included patients with severe disabilities
(GOS 3) and fatal outcome in the same category.  Despite this limitation, we have
demonstrated that CPP insult predicted death and those with poor outcome (GOS 1-
3).
Our study included children of different ages up-to 16 years.  Like other paediatric
brain trauma cohort, patients are not evenly distributed across the different age
ranges.  Because of the diverse and uneven patient distribution across age ranges, our
cohort was divided into 3 age bands for analyses.  As a result, we have only managed
to propose critical CPP thresholds for 3 different age bands.  A much larger cohort in
each year of age with physiological recordings in minute resolutions will be required
to define critical CPP thresholds for each age group, but our current study has
provided the necessary information to calculate sample size for future studies.
CPP data was calculated from continuous recordings of arterial blood pressure and
intracranial pressure.  Variations in the positions of the pressure transducer across
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recruitment units or under-damping of fluid-filled catheter-transducer system may
influence the accuracy of the recorded arterial blood pressure value with the potential
to introduce error into data analysis.  This was minimised in our study because the
pressure transducers were zeroed to the external auditory meatus in all recruitment
sites.
Our study did not examine cerebral autoregulation when it is an important
determinant of brain trauma outcome.  We chose not to include cerebral
autoregulation assessment in our study because there is no gold standard for cerebral
autoregulation assessment and continuous assessment of cerebral autoregulation is
not yet available with all currently available methods only offering intermittent
evaluation of cerebral autoregulation.  Despite this limitation, CPP insult
quantification was achieved and its high outcome predictive value was demonstrated.
Our novel cumulative pressure time index (PTI) is a powerful tool for summarising
the total burden of CPP or ICP insult bi-dimensionally.  Because it is calculated post
hoc, it is a research tool and is, therefore, not useful for clinical management of brain
trauma patients at the bedside.  However, its development and validation has added
significant values to the brain trauma literature by providing a novel method to
quantify the total burden of pressure insult.  In addition, it enables definition of 3
age-related critical CPP thresholds which has not been possible previously with the
various exiting methods to quantify pressure derangement in single dimension.
Furthermore, with PTI, we may now investigate whether ICP/CPP values measured
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in minute resolutions offer more accurate insult summary and outcome prediction
than may be achieved using pressure recordings at hourly intervals.
2.8) CONCLUSIONS
A novel index combining the degree and duration of physiological derangement has
been developed.  This is the first method to include more than one dimension in the
analyses of ICP and CPP data from brain trauma patients.  Using pre-defined age-
specific theoretical physiological threshold values for ICP and CPP, we have
demonstrated that the index is robust and relates extremely well to both morbidity
and independent outcome.  This novel index has opened up future brain trauma
research opportunities in critical care medicine particularly in relation to (i)
determination of the total burden of secondary physiological insults, (ii) definition of
critical ICP and CPP physiological thresholds, (iii) validation of current treatments,
and (iv) development of novel therapies.
Our pre-determined age-related physiological based theoretical CPP thresholds have
been proven to be the critical minimum CPP thresholds since altering these original
threshold levels failed to improve the predictive value of the PTIc on outcome.  We
believe that for children age-related critical physiological CPP thresholds are in fact
identical to the insult thresholds.
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CHAPTER 3: VARIABILITY AND INTER-RELATIONSHIPS OF ICP, CPP,
AND MAP SIGNALS AND THEIR RELATIONSHIPS WITH OUTCOME
AFTER CHILDHOOD TBI
3.1) INTRODUCTION
Prompt detections and corrections of secondary physiological derangement after
brain trauma are the basis of modern neuro-surgical and neuro-intensive care and
may improve outcome.  The success of modern neuro-intensive care, therefore, relies
heavily upon simultaneous monitoring of multiple biosignals continuously.  Rapid
development in computing technology over the past three decades means that it is
now the expected norm to use computerised monitoring in intensive care settings.
Large quantity of raw data is generated as a result which could be analysed in detail
off-line at a later stage and the findings of these analyses, in turn, contribute towards
improving neuro-intensive care treatments.
Despite the endless research interests in the pressure signals of intracranial and
cerebral perfusion pressure and the vast quantity of literature generated, relatively
few described their variability after traumatic brain injury.  These early studies
describing variability of pressure signals used data from paper recordings [160-162],
but were hindered by the many technical difficulties.  These difficulties included
lengthy traces, chart speed variations, and a lack of objectivity in the quantification
and analysis of the data.  Despite the already established norm to employ
computerised monitoring in modern intensive care, there have been little attempts to
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re-examine the relationships between the variability of pressure signals and outcome
after brain trauma.
3.2) AIMS
This chapter aims to test the hypothesis that the variability of the pressure signals
over time after childhood brain trauma may be important in relation to outcome.
3.3) PATIENTS AND METHODS
3.3.1) Design of the Study
A prospective observational study of critically ill brain injured children with global
outcome assessment at 6 and 12 months post injury was conducted to view time-
series data (artefact-excluded) over extended time periods, to investigate the
significance of the observed variability and to identify other practical but simple
visual displays available at the bedside.
3.3.2) Patients
Forty-three children admitted to the Regional Head Injury Unit in the South-East of
Scotland between 1 January 1989 to 16 June 1996 were included in the study if the
following criteria were fulfilled:
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a) There was a post-resuscitation pre-intubation Glasgow Coma Score [28]
sumscore (GCSs) of 12 or less.  The Pediatric Glasgow Coma Score [236] was
used for children aged 5 years and under;
b)  The GCSs was >12 in association with an Injury Severity Score (ISS) [237]
of 16 or more;
c)  There were clinical indications for monitoring the patients in the Intensive
Care Unit and continuous ICP monitoring was available;
d)  There was a Computerized Data Collection (CDC) system available for use
within 24 hours of injury.
Children were excluded from the study if they had previously sustained a brain
injury.  Ethical approval for this study was granted through the local ethics
committee as part of a larger study of secondary insults, and assent were obtained
from parent or guardian prior to entry into the study.  These children were managed
using a standardised TBI management guideline which had been described
previously in Chapter 2.
3.3.3) Data Collections
3.3.3.1) Demographic Data
Demographic and clinical data collection had been described in details previously in
Chapter 2 and included the cause and nature of injury, age, Glasgow Coma Score on
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admission and, after acute non-surgical resuscitation, pupil responses, X-ray and
Computerised Tomography (CT), operative and treatment details.
3.3.3.2) Physiological Data
Details on the acquisition of the physiological data could be found in Chapter 2.
Data were collected every minute until clinical monitoring ceased.  They were then
manually validated using the Edinburgh Browser® software and any artefact or
unreliable data were excluded.  For this study, the pressure signals (ICP, MAP and
CPP) data used were restricted to the duration of the ICP monitoring, and from
quantitative statistics the mean, range and standard deviations were calculated, using
all valid data for each of the parameters.
In addition the data were divided into epochs of 48-hour, taken from the time of
injury, and the same descriptors recorded for each epoch.  Up to 6 epochs were
recorded for each patient.  The first epoch, taken from the time of injury always had
less than 48 hours of data, as this epoch necessarily included the transfer time,
admission time and “set up” time.  Similarly, the last epoch for each child could be
less than 48 hours, as this depended on a clinical decision as to when the ICP
monitor was removed.
For each patient time series plots were prepared for each epoch, where the 3 pressure
signals were displayed using the same vertical axis of mmHg.  Each 48-hour epoch
was then assigned a ‘pattern type’, by consensus among 3 researchers.
125
3.3.3.3) Outcome Data
Global outcome assessment was performed at 6 and 12 months post injury and the
details of the questionnaire used could be found in Chapter 2.  Outcome was
dichotomised into ‘recovered’, i.e. good recovery and moderate disability (GOS 4-5)
and ‘not recovered’ i.e. severe disability, vegetative state or death (GOS 1-3).
3.3.4) Analyses
Microsoft& Excel 97 and SPSS& for Windows (Release 9.0.0) packages were used to
analyse the data, employing Mann-Whitney U, Kruskal-Wallis and Chi Square tests,
and the significance level of p<0.01 to ensure non-chance relationships.
3.4) RESULTS
3.4.1) Demographic Results
All 43 children had intracranial pressure (ICP) monitoring, with complete data for
arterial pressure and cerebral perfusion pressure (among other parameters).  The
demographic features of the group, including age, sex, and outcome at 12 months
post-injury, are summarised in Table 3.1.
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Table 3.1:













Grade Severe (GCS ! 8)
Moderate (GCS 9 – 12)
















Outcome at 12 months by Grade on admission
Severe Moderate Minor Total
GOS 1 8 1 - 9
GOS 2 - - - -
GOS 3 2 - - 2
GOS 4 6 3 - 9
GOS 5 16 5 2 23
Total 32 9 2 43
Monitoring times ranged from 97 – 17 778 minutes (mean = 6319; median = 3446), a
total number of 221 291 data points were, therefore, available for analysis.  There
were a total of 104 epochs (of 48-hour) available for analysis.  Epochs 1 through 6
had data from 42, 28, 19, 10, 4 and 1 patient respectively.  The mean number of
epochs per patient was 2.4.  In one case, computer data were lost during the first
epoch and therefore excluded from the analysis.
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3.4.2) Variability
Table 3.2 shows results for the total duration of acute monitoring i.e. ICP monitoring
time and the first 3 consecutive epochs (i.e. admission to 48 hr post injury [epoch 1];
48-96 hrs [epoch 2] & 96-144 hrs post injury [epoch 3]).  There were insufficient




 EPOCH     INJURY TO 48 HOURS        p VALUES
Alive vs. Dead Recovered vs. Not recovered
Test     (n) Mann Whitney U (42) Mann Whitney U (42)
ICP Mean <0.001* 0.001*
S.D. 0.011 0.008*
MAP Mean 0.053 0.021
S.D. 0.193 0.191




 EPOCH    48 – 96 HOURS POST INJURY  p VALUES
Alive vs. Dead Recovered vs. Not recovered
Test     (n) Mann Whitney U (28) Mann Whitney U (28)
ICP Mean <0.001* 0.006*
S.D. 0.365 1.000
MAP Mean 0.806 0.709
S.D. 0.682 0.784




 EPOCH   96 – 144 HOURS POST INJURY  p VALUES
Alive vs. Dead Recovered vs. Not recovered
Test     (n) Mann Whitney U (17) Mann Whitney U  (17)
ICP Mean 0.006* 0.279
S.D. 0.953 0.879
MAP Mean 0.300 0.442
S.D. 0.953 0.721
CPP Mean 0.244 0.646
S.D. 0.859 0.959
TOTAL DURATION OF ICP MONITORING       p VALUES
Alive vs. Dead Recovered vs. Not recovered
Test      (n) Mann Whitney U (43) Mann Whitney U (43)
ICP Mean <0.001* <0.001*
S.D. <0.001* <0.001*
MAP Mean 0.067 0.036
S.D. 0.003* 0.017
CPP Mean <0.001* 0.003
S.D. 0.005 0.021
* Sig at p <0.01
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3.4.2.1) Total Duration
The variability of ICP, MAP and CPP (as measured by the standard deviation) over
the whole time that the patients had an ICP monitor in place, was significantly
different between those who died and survived.  Variability of ICP significantly
related to outcome (GOS at 12 months post-injury), and was also significantly
greater in those who did not recover compared to those who recovered.
Mean ICP and mean CPP for total duration of ICP monitoring were significantly
related to outcome in the 3 outcome tests.
3.4.2.2) 1st Epoch (First 48 Hours from the Time of Injury)
The variability of ICP was significantly greater during the first 48 hours of injury in
those who recovered compared to not recovered.  However, the variability of MAP
and CPP during the first epoch did not appear to be related to outcome in this study.
3.4.2.3) 2nd Epoch (48 – 96 Hours from the Time of Injury)
By this time frame, the variability of neither ICP, MAP nor CPP were shown to be
significantly related to outcome, however, all the mean values of mean ICP and CPP
were related to outcome at the 1% level.
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3.4.2.4) 3rd Epoch (96 – 144 Hours from the Time of Injury)
During this epoch, there was no relationship between the variability of any test signal
and outcome and only the mean value of mean ICP was related to survival
(p=0.006).
3.4.3) Patterns
When 3 variables are displayed on the same graph using a common vertical axis,
there are necessarily 6 permutations, in terms of the order of magnitude in which the
variables could theoretically be presented.  However, because of the mathematical
relationship, CPP = MAP-ICP, only 3 physiological ordered combinations are
possible.
3.4.3.1) Descriptions of Patterns (see Figure 3.1)
Type I – where MAP was greater than CPP, which was greater than ICP (this would
be considered the ‘normal’ and desirable relationship between the variables.
Type II – where MAP was greater than ICP, which was greater than CPP. The ICP is
so high that there is insufficient compensation in systemic pressure to maintain
adequate CPP.
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Type III – where ICP was greater than MAP, which was greater than CPP. With
grossly elevated ICP there is total failure of compensation by systemic pressure and
CPP is absent.
Type II / I Cross-over – where MAP remains greatest, but CPP changes from being
lower than ICP to greater than ICP (i.e. an improving pattern, and is actually a
changing pattern from Type II to Type I).
Type I / II Cross-over – where MAP was greatest, but CPP changes from being
greater than ICP to less than ICP (i.e. a deteriorating pattern, or changing from Type
I to Type II).
Type I / II / III Cross-over – generally where MAP remains the highest of the three
variables, but ICP and CPP repeatedly reverse their relative positions, i.e. fluctuating
between type I and Type II. The multiple changes could also be a pattern that






3.4.3.2) Patterns in Relation to Outcome Scores
104 epochs (of 48 hours) were identified from the data of 43 patients.  We found no
instances of Type III reverting to Type I.  There was only 1 epoch (in 1 patient) with
an improving cross-over pattern (Type II / I), and this epoch has been included with
the Type I group for analysis.  Overall 93 (89.4%) epochs displayed Type I pattern.
GOS scores at 12 months were highly significant in relation to pattern type (Chi Sq.
test p = <0.0001, Fisher’s exact Test).
3.4.3.3) Patterns in Relation to Fatal Cases
Nine children died, presenting a total of 20 epochs.  9 of these epochs were described
as Type I.  Four patients who died only displayed cross-over patterns and at no time
had a Type I.  Of the remaining 5, 4 had episodes of Type I (9 epochs) that
subsequently changed to Type II, III or Cross-over.  No patient survived if they
displayed at any time epoch any of the following patterns: Type II, Type III, Cross-
over Types I / II or Type I / II / III.
The one patient, who did not survive but displayed just one epoch of Type I pattern,
eventually died after all monitoring was withdrawn, some 2 days later.
Unfortunately data were lost for all the subsequent epochs.
134
3.5) DISCUSSIONS
Modern computerised monitors allow multiple clinical parameters to be displayed
simultaneously providing trends in the clinical conditions.  Their ultimate aim is to
alert clinicians to any significant changes in the patient’s condition so that
appropriate treatment may be instigated.  However, with the rapid advances in
monitoring techniques, clinicians face the danger of having data overload while
interpreting and responding to a great number of increasingly complex clinical
parameters.  There is, therefore, an urgent need to summarise these data for
meaningful interpretation.
Prior to the development of computerised data storage and usage of the more
elaborate analyses such as artificial intelligence techniques [238] and decision-tree
induction [239], the only way to obtain a permanent copy of the physiological
monitoring and to condense the data into a manageable format for interpretation was
by manually transcribing data displayed on the ICU monitors onto specially designed
charts at specific time points, e.g. hourly creating a snapshot in time.  The advantage
of this method included the ability to view trends over longer time periods than as
seen on the monitor screen, but it was disadvantaged by excluding almost all the data
made available with the new continuous monitoring technology.  Furthermore, it
utilized valuable specialist ICU nursing time.
Most modern ICP research still uses these hourly data transcribed by nurses onto
observation charts.  Some researchers have used specific time points such as overall
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time taken from commencement of monitoring [72, 91] which gives no indication of
how long between injury and arrival in ICU.  Others have truncated the data to
particular time durations, for examples, 24, 48 and 72 hours from the point of impact
[240], or averaged the data over 24 hours [71] or 12 hours periods [241].  Because
on-line data produces lengthy files we conducted our analysis in 48-hour epochs as
well as for the total time.
Each of these methods has disadvantages as the length of ICP monitoring continues
to be determined by clinical conditions.  Monitoring may be removed early in those
who recovery quickly or after physiological stability is achieved.  Cortbus [199],
describing the "stages" in the pathophysiology of TBI, found that the majority of
hypotensive insults occurred with the first 24 hours, and ICP derangements clustered
around days 5 and 6, although insults were detected up to 12 days.  Therefore, by
choosing 48 hours as our standard epoch, we compromised between a duration long
enough to show variations (the cross-over patterns generally take more than 12 hours
to develop), but not so long that there were overwhelming amounts of data to handle.
Epochs were well represented with patient deaths occurring in each epoch, and
withdrawal of ICP in each epoch.
We have not recorded the presence of abnormal ICP wave forms, such as plateau and
B waves, which may influence the standard deviation of these relatively short-
duration waves forms but their effect would be relatively minimal when compared to
all ICP data points over a 48-hour epoch.  Additionally, pre-morbid data i.e. any data
136
that were recorded within the last 4 hours before death was excluded in this analysis
as is common practice, since pre-morbid data by definition can only predict death.
Many methods of analysing pressure signal data have been described previously,
including using the maximum [69, 76] or mean ICP [71]; durations of secondary
insults [72]; mean CPP [91, 242]; times above and below specific thresholds [243];
“mean average”, and “mean worst” ICP or CPP (in 12-hour epochs) [241] and using
rolling two-minute averages [244], and each method highlighted a relationship with
outcome.  However, each paper described a different methodology to summarise the
data, suggesting that there is no universally accepted standard analysis.  More
elaborate analysis has included artificial intelligence techniques [238] and decision-
tree induction [239].  Our method described here adds another method to the
literature, but is simple to perform and aids the understanding the plethora of data
presented at the bedside [245].
3.5.1) Variability
Similar to findings of previous ICP studies in the brain trauma literature, the mean
values of ICP and CPP in this study were highly significant in most of the epochs in
relation to outcome [245].  However, the standard deviation of ICP was the only
significant predictor (at "= 0.01) of non-recovery, and only then in the 1st 48-hours
from injury [245].
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Signorini and colleagues examined 'insults added to injury' at 24, 48 and 72 hours
post injury in a population of head injured adults [240].  Various summary measures
were examined including the presence or absence of any grade of insult, the total
time (and proportion of time) spent in insult of grade 1 or worse, and a weighted sum
or proportion of monitoring time at specific grades of insult [240].  Importantly, they
concluded that raised ICP however summarised was independently predictive of
mortality at each of these times [240].  Our findings add another simple summary
measure to the list mentioned previously, at a clinically useful time (48 hours after
injury) which is predictive of morbidity [245].  No other test of variability in any
other epoch was significant at this stringent 1% level.
A different picture was seen however, when considering the 3 pressure signals over
the total duration of ‘acute’ monitoring time (i.e. time that ICP monitoring was in
situ).  In this case, the variability of all three traces was highly significant in those
who died, and the variability of ICP was significantly related to outcome in the other
two comparisons, reflecting the cumulated changes over time [245].  Practically,
however, the standard deviation (i.e. the variability) over the whole trace (if more
than 48 hours) is not a useful predictor during the acute care of these children, as the
variability only becomes significant in retrospect (when it is already evident that the
child has survived, or has died).  It may be useful for counselling grieving parents
and families because the displayed trends may summarise information in such a way
that may be readily understood by individuals without medical knowledge.
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Two other groups of investigators (Marmarou from the Traumatic Coma Data Bank
group [246] and Gaab [162]) have used standard deviation as an index of ICP
variability.  Marmarou used ICP ‘variance’ (standard deviation squared), which was
considered to be an indirect measure of the pressure stability, but found that it was
only poorly related to outcome [246].  This may be because only ‘end hour’ readings
were used which were considered to be an average estimate of the whole hour,
giving only 24 data points per day, compared to our 1440 per day for each variable.
Clearly, the fewer the data points used, the less variability there is to measure.  Gaab
[162] studied a group of 16 head injury patients (including both adults and children)
out of a total group of 72 with ICP monitoring ranging from 24-280 hours duration.
While these study durations are comparable to those in ours, he found the mean ICP
ranged from 20-50 mmHg, and the standard deviation ranged from 4-21 mmHg, both
parameters showed less variability than found in our study of 43 children (mean
range 2.56-99.36 mmHg; S.D. range 1.53-32.21 mmHg) after artefactual data were
removed.
3.5.2) Pattern Types
By creating time-series plots using the data of the three pressure signals (ICP, MAP,
and CPP) along the same vertical axis, the pattern of the plot may be readily
categorized using ‘the order of magnitude’.  We demonstrated that the pattern type
displayed were predictive of survival or death since (i) all patients who exhibited
patterns of Type II, Type III, multiple cross-over (type I/II/III) or simple cross-over
(Type I/II) died; and (ii) all patients with Type II / I (changing from a ‘poor’ to
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‘better’ type of pattern) survived, indicating a response to treatment [245].
Furthermore, the pattern type identified has unanimous agreement among different
researchers indicating the classification was robust and easily applicable in clinical
practice.  This could, therefore, be a simple but yet useful addition to the traditional
nurse transcribed observation charts, where generally numerical values for ICP and
CPP are recorded on a separate section of the chart, thus obscuring the information.
It was noted that it would be possible to further subdivide Type I patterns depending
on the amount of variability seen in the ICP trace, for example by identifying those
with only 10 mmHg within-trace variation, or 20, 30, 40 or >40 mmHg within-trace
variability.  We were unable to relate these sub-group patterns to outcome in this
sample group of patients as examples were found in all outcome groups.
Amalgamating Type I sub-categories into !30 mmHg or >30 mmHg of variability
revealed 14% (7/43) of those with less variability had a poor outcome while 21%
(9/43) of those with greater variability of Type I pattern had a poor outcome.  While
not statistically significant in this small patient group, the method may be useful in
larger groups with Type I patterns, to identify a threshold variability which predicts a
less desirable pattern type.
By viewing these patterns over 48-hour time frame, it appeared in some cases as if
there was a rhythmical character to the slow wave forms seen.  The evident
rhythmicity made us consider if there were some other underlying wave forms, but
on close analysis these were 4 hour treatment-related events and not an inherent
hydro- or haemo- dynamic pulse.
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3.6) CONCLUSIONS
The standard deviation (or variability) of ICP signals frequently recorded during ICU
care of paediatric TBI patients only gives useful predictive information about
outcome during the first 48 hours after injury.
The “time series patterns” generated from traces of three variables (ICP, MAP and
CPP) when plotted on the same vertical axis, show clearly which patients are likely
to survive or die, and these are useful throughout the whole acute monitoring time.
If these values were plotted on standard ICU nursing charts, it could form a simple
but useful visual adjunct to other methods already available in the management of
TBI in the Intensive Care Unit.
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CHAPTER 4: MODULATING EFFECT OF APOLIPOPROTEIN E
POLYMORPHISMS ON SECONDARY INSULT AND OUTCOME AFTER
CHILDHOOD BRAIN TRAUMA
4.1) BACKGROUND
Recovery from childhood brain trauma remains diverse and sometimes appears out
of proportion to the severity of primary brain injury and the amount of secondary
insult experienced.  This suggests that there may be other influences, for example
genetic make-up, which may be an additional determinant of outcome after brain
trauma.
Potential genetic influence on outcome after brain injury has increasingly been
investigated over the past decade.  The Apolipoprotein E (APO E) gene has secured
a central role in this research area because this 5083-nucleotides gene is polymorphic
in human with 3 allelic forms (e2, e3, and e4) [247] and its gene product,
apolipoprotein E (apo E), is a major lipoprotein involved in lipid transport and
metabolism within the central nervous system (CNS) [144], which is thought to be
particularly important for the repair process after CNS damage.
The influence of the APO E polymorphisms on neurological recovery may be related
to the presence of the e4 allele because its possession has been associated with
increased risk of developing Alzheimer’s Disease [248, 249] and poorer outcome
following various acute brain injury [141, 142, 250].  Furthermore, the number of e4
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allele present appears to govern its allelic effect on the risk of developing
Alzheimer’s Disease where the e4 homozygous conferred the highest risk, while e4
heterozygotic subjects had an intermediate risk, and individuals without the e4 allele
possessed the least risk [249].  Teasdale’s group speculated a similar gene dose effect
on brain trauma recovery since all their e4 homozygotic patients (n=4) suffered
severe disability after brain trauma, 8 (31%) of their 26 heterozygous e4 recovered
with a poor outcome, but only 11 (17%) of the 63 patients without the e4 allele had
an unfavourable outcome [141].  However, no other clinical brain injury study in
adults or children has confirmed this potential gene dose effect.
Animal studies suggest that the absence of the e4 allele may affect recovery after
brain injury.  Following closed head injury, the APOE e3 transgenic mice recovered
more rapidly than the controls, APOE deficient, and APOE e4 transgenic mice in
both neurological and histological analysis [251].  Furthermore, adult transgenic
mice expressing the human APOE e4 allele are shown to be more susceptible to
fatality from closed head injury than those expressing the e3 allele [251].  Buttini and
colleagues found that hemizygous and homozygous transgenic mice with human
APOE e3 allele were protected against age-related and excitotoxin-induced
neurodegeneration (by injection with kainic acid which is a glutamate antagonist)
while those expressing APOE e4 were not [252].  Apolipoprotein E e3/e4 bigenic
mice were as susceptible to neurodegeneration as APOE e4 singly-transgenic mice
[252].  Although the translation and transferability of these findings into clinical
setting remain unclear, these animal data, in addition to confirming the association
143
between APO E e4 allele and poorer neurological recovery, has suggested that the
absence of the e4 allele may offer neuro-protection.
Precisely how APO E polymorphisms affect neurological recovery in human remains
unknown.  Postulated mechanisms have originated mostly from animal or in-vitro
investigations and include potential allelic-related differential influence on the host’s
response to oxidative stress [253] or excitotoxicity [254, 255], and the rate of
conversion of the neuroprotective # amyloid precursor protein (#APP) to the
neurotoxic # amyloid (#A4) [256] but the clinical relevance of these mechanisms
remains unclear.  Despite the vast literature supporting the predictive value of CPP
insult on brain trauma outcome in adults and children, the relationships between
APO E genotypes and CPP insult following brain trauma has not been investigated
previously.
4.2) AIMS
This chapter aims to test the hypothesis that Apolipoprotein E genetic
polymorphisms differentially affect the burden of CPP insult and outcome after
childhood brain trauma.
144
4.3) PATIENTS AND METHODS
4.3.1) Design of the Study
A prospective case-controlled study was carried out over a two and a half year period
(1 April 2001 to 30 September 2003).  Local ethics and hospital research
management committees approved the study.  Parental consent was obtained for
inclusion in the study.
4.3.2) Patients
Brain injured children admitted to the ICU at the Edinburgh RHSC and Newcastle
General Hospital during the study period and had already been enrolled into the
secondary physiological derangement study were eligible for inclusion in this study.
Sixty-five of the 70 eligible children were recruited successfully into the study.
4.3.3) Controls
160 healthy active age and sex matched children were recruited from the Accident &
Emergency Department at the Edinburgh RHSC as control subjects.  They all
attended the A&E Department with minor injuries and had no previous history of
head injury.
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4.3.4) Sample & Data Collections
All participants had buccal smears collected for DNA extractions and subsequent
Apolipoprotein E genotyping.  Demographic and clinical details of the brain trauma
cohort were collected prospectively as described previously in Chapter 2.  In
addition, their routinely monitored physiological parameters in minute resolutions
were prospectively downloaded from the PICU bedside monitors for detection of
age-specific physiological derangements as described previously in Chapter 2 using
the Edinburgh Browser programme [92].  The total burden of CPP insult was
quantified using the cumulative pressure time index for CPP (PTIc) [204] in patients
with ICP monitoring.  Forty-five children had continuous ICP monitoring but 7 were
excluded from this subgroup analyses because significant amounts of ICP data were
lost during the first 24 hours post injury from computer downtime.
4.3.5) Outcome Assessment
Conscious level was determined at PICU discharge which equated to the end of
neuro-intensive care when the brain injured children no longer required airway
protection, ventilatory and circulatory support.  The modified Glasgow Coma Scale
(GCS) [236] was used for this assessment.  In addition, global outcome was assessed
at 6 months post injury using the modified Glasgow Outcome Score (GOS).
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4.3.6) Laboratory Methodology
I collected all buccal smear samples, developed and conducted all DNA extraction
and APO E genotyping.
4.3.6.1) APO E Genotyping
4.3.6.1.1) DNA Extraction From One Buccal Brush
The PUREGENE DNA Buccal Smear Isolation Kit™ (produced by Gentra Systems)
was used for collection of buccal smear and DNA extraction.
4.3.6.1.1.1) Buccal Smear Sample Collection
A sterile nylon bristle cytology brush (provided as part of the PUREGENE DNA
Buccal Cell Isolation Kit™) was used to scrape the inside of the mouth (cheek) for
10 strokes.  The brush was then dipped up and down 10 times in a 1.5 ml microfuge
tube containing 300 µl of Cell Lysis Solution.  When the brush was removed from
the Cell Lysis Solution, care was taken to ensure minimal amount of solution was
lost.  Buccal smear was confirmed to be floating in the Cell Lysis Solution under
direct vision.  The sample was then stored at room temperature until sufficient
number of samples (at least 10 but no more than 20 samples) had been collected to
allow for batch DNA extraction.  The buccal cells were stable in the Cell Lysis
Solution at room temperature for 18 months.
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4.3.6.1.1.2) Cell Lysis
1.5 µ l of Proteinase K Solution (20 µg/ml) was added to each sample.  Each
microfuge tube was then inverted 25 times before overnight incubation at 55
0
C.  This
allowed for maximal cell lysis to achieve maximum DNA yield.  The samples were
then taken out of the oven and cooled for 35 minutes in room temperature before
proceeding to RNase treatment.
4.3.6.1.1.3) RNase Treatment
1.5 µl of RNase A Solution was added to the cell lysate which was then inverted 25
times.  The cell lysate was incubated at 37
0
C for 60 minutes.  The samples were then
cooled to room temperature which usually took 35 minutes before proceeding to
protein precipitation.  This ensured maximum final DNA yield and minimised the
risk of protein contamination.
4.3.6.1.1.4) Protein Precipitation
100 µl of Protein Precipitation Solution was added to each of the cell lysate.  Each
microfuge tube was then vortexed at high speed for 20 seconds to ensure uniform
mixing of the Protein Precipitation Solution with the cell lysate.  The mixed cell
lysate was placed immediately in an ice bath and remained in the ice bath for 5
minutes.  The microfuge tubes were then centrifuged at 12 000 x g for 3 minutes.
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The precipitated proteins should form a loose white pellet after the first
centrifugation.
To ensure complete protein precipitation, the following steps were repeated: (i) high
speed vortex (20 seconds), (ii) ice bath incubation (5 minutes), and (iii)
centrifugation at 12 000 x g (3 minutes) until the formation of a tight white pellet.
This was usually achieved within 2 – 4 cycles.
4.3.6.1.1.5) DNA Precipitation
The supernatant containing the DNA was poured into a clean 1.5 ml microfuge tube
containing 300 µl 100% Isopropanol (2-Propanol, molecular biology grade) and 0.5
µl Gentra Glycogen Solution (20 µg/ml) leaving behind the precipitated protein
pellet.  The solution and supernatant was gently mixed by inverting the microfuge
tube 50 times.  The microfuge tubes were left in room temperature for 10 minutes
before centrifugation at 12 000 x g for 5 minutes.  The extracted DNA was usually
visible as a small white pellet.
The supernatant was poured off and the tubes were drained on a clean absorbent
paper.  300 µl of 70% Ethanol was then added to each tube.  The tubes were then
gently inverted 10 times to wash the DNA pellet.  The tubes were then centrifuged at
12 000 x g for 1 minute.  The ethanol was carefully poured off while ensuring the
pellet remained in the tube.  Each of the tubes was then inverted and drained on a
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clean absorbent paper and allowed to air dry for 15 minutes.  The DNA pellet was
then hydrated within 20 minutes.
4.3.6.1.1.6) DNA Hydration
20 µl of the DNA Hydration Solution was added to each tube containing the DNA
pellet.  Immediately upon adding the DNA hydration solution, each tube was tapped
10 times and then incubated at 65
0
C for 1 hour.  The tubes were left in room
temperature overnight with periodic tapping of each tube to aid dispersal the DNA.
The DNA was then stored in –70
0
C until genotyping.
4.3.6.1.2) Polymerase Chain Reaction (PCR)
Stored DNA samples were thawed in room temperature, which usually took 30
minutes, and the samples were vortexed briefly (for up to 8 seconds) at 12 000 x g.  5
µl of the DNA was then added to a 0.6 ml microfuge tube containing 45 µl of the
PCR mastermix made up with the following components:
• 24.55 µl of deionised water
• 5 µl of x10 PCR buffer (MgCl2 free)
• 8 µl of dNTPs
• 1.8 µl of MgCl2
• 5 µl of betaine
• 0.2 µl of R3
• 0.2 µl of L3
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• 0.25 µl of Taq polymerase
4.3.6.1.2.1) PCR Mastermix Components
Components of the PCR mastermix are detailed below:
• x10 PCR buffer (MgCL2 free) and MgCl2 were available as part of the Taq
Polymerase Pack produced by Invitrogen (Cat. Number 18038-067).
• dNTPs used were produced by Amersham Pharmacia (Cat. Number 27-2035-02)
which consisted of the following components: (i) Deoxyadenosine triphosphate
(dATP) (100mM), (ii) Deoxycytosine triphosphate (dCTP) (100 mM), (iii)
Deoxyguanidine triphosphate (dGTP) (100 mM), and (iv) Deoxythymidine
triphosphate (dTTP) (100 mM).  The dNTPs was reconstituted as follows: 12.5 µl
of dATP, dCTP, dCTP and dTTP were thoroughly mixed with 950 µl of de-
ionised distilled water (molecular biology grade).  The re-constituted dNTPs were
divided into 100 µl aliquots for storage at – 20
0
C until use.
• Betaine (1.7mM) which assisted the breakage of G-C bonds during PCR was
available as dry powder through Sigma (Cat. Number B-2629).  5.86 g of betaine
powder was dissolved in 10 ml of de-ionised distilled water (molecular biology




• Two 100pM/µl custom oligo primers (R3 and L3) were available through MWG-
Biotech.  The sequences of these primers are shown as follows:
R3 = 5’ - ACA GAA TTC GCC CCG GCC TGG TAC ACT GCC A – 3’
L3 = 5’ – TCC AAG GAG CTG CAG GCG GCG CA – 3’
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PCR was carried out in PCR machines with the following PCR programme settings:
1. Pre-heat the lid for 2 minutes at 1050C
2. 95oC for 2 minutes (Prerun)
3. 94oC for 30 seconds (Denaturation)
4. 62oC for 30 seconds (Annealing)
5. 72oC for 1 minutes (Extension)
6. Repeat steps 2 – 4 for 35 cycles
7. 72oC for 5 minutes (Delay)
4.3.6.1.2.3) Detection of PCR Product Using Gel Electrophoresis
3% agarose gels were used to detect PCR products.  2 µl of the gel loading buffer
was mixed with 10 µl of the PCR product before loading into the well.  5 µl of the 1
Kb ladder marker was used.  After electrophoresis at 120V for 30 minutes, the gel
was then read under UV light.
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4.3.6.1.2.3.1) 3% Agarose Gel
The following steps were carried out to make one 3% agarose gel tray with 32 wells
(maximum 104 wells).
1. 100 ml 1xTBE was added to a flask.
2. 3g of agarose powder was added slowly to the TBE while shaking the flask
gently to avoid forming clumps.
3. A stir bar was placed into the flask and then heated on a hot stir plate (speed
was set at 7-8, and the temperature was set at 6).  3 ml of ethidium bromide
was added to the mixture.  The solution was heated until all the agarose had
dissolved (i.e. the clear liquid phase), which usually took 25 – 30 minutes.
4. The gel solution was cooled for 10 minutes before pouring into the gel tray in
a cold room, and the combs were inserted with particular care to ensure they
lined up straight.
5. The gel was left in room temperature until it solidified, which usually took 25
– 30 minutes.
4.3.6.1.2.3.2) TBE BUFFER
Concentrated TBE (x 10) stock was made by dissolving 108 g of Tris base, 55 g of
Boric Acid and 7.44 g of EDTA in 700 ml of de-ionised distilled water and then
made up to 1 litre with de-ionised distilled water.  This was then stored at room
temperature until use.  To re-constitute the 1x TBE, 10 ml of the TBE
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hyperconcentrate (x 10 stock) was mixed with 90 ml of de-ionised distilled water
immediately prior to use.
4.3.6.1.2.3.3) Gel Loading Buffer (Blue) For Agarose Gels
50 ml of bromophenol blue (5 mg/ml) was mixed with 400 mg of sucrose and 950 ml




4.3.6.1.2.3.4) 1 kb Ladder Marker
50 ml of the 1 Kb ladder, which is available through Invitrogen (Cat. Number 15615-
016), was dissolved in 100 ml bromophenol blue and 350 ml of de-ionised distilled
water.  The solution was thoroughly mixed together before being separated into
aliquot and stored at – 20
0
C.
4.3.6.1.3) Restriction Enzyme Digest On PCR Products
1 µl of the restriction enzyme Hha1 (available through New England Biolabs Inc,
Cat. Number R0139L) was added to each of the positive PCR product and the
mixture was incubated overnight at 37
0
C using a vibrating water bath.
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4.3.6.1.4) APO E Genotype Identification Using Gel Electrophoresis
Gel electrophoresis of the digested PCR product was performed to identify the
different APO E genotypes.  Fine separation was required for this gel electrophoresis
and 4% metaphor agarose gel was used.  8 µl of the gel loading buffer was mixed
with the PCR digested product (40 µl) before loading into the wells.  8 µl of the 25
Kb ladder marker was used.  The gel was allowed to run for one and a half hours
using 120V.  It was then read under UV light.  Figure 4.1 shows a reference gel with
the characteristic bands for the 6 APO E genotypes.
Figure 4.1:
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4.3.6.1.4.1) 4% Metaphor Agarose Gel
To prepare one 4% metaphor agarose gel tray with 30 wells, the following processes
were carried out:
1. 125 ml of 1x TBE was added to a flask.
2. 5g of metaphor agarose powder was added slowly in small portions while
shaking the flask gently to prevent formation of clumps.
3. The flask was shaken until all metaphor agarose powder had dissolved into a
thick solution.
4. A stir bar was added to the flask.  The flask was then placed on a heated stir
plate (the speed was set at 7-8, and temperature of the plate was set at 6).  4
ml of ethidium bromide was added to the mixture after 30 minutes.  The
solution was heated until bubbling and the clear liquid phase was achieved
i.e. all the metaphor agarose powder had completely dissolved and this
usually took 35 to 40 minutes.  Care was taken to ensure the solution was not
heated for too long because of the flux.
5. The gel solution was cooled off for 10 minutes before pouring (in a cold
room) onto the gel tray with care while ensuring the combs were lined up
straight.
6. The gel was left in room temperature until it solidified, which usually took 25
– 30 minutes.  It was then placed in the fridge (+ 4
o
C) for 30 minutes before
use to achieve a firmer consistency.
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4.3.6.1.4.2) Gel Loading Buffer (Orange) For Metaphor Agarose Gel
50 ml of the Orange G (5 mg/ml) was mixed with 400 mg of sucrose and 950 ml of
de-ionised distilled water.  The solution was vortexed at high speed before being
separated into aliquot and stored at 4
0
C until use.
4.3.6.1.4.3) 25 Kb Ladder Marker
40 ml of the 25 Kb DNA ladder marker (available through Invitrogen Cat. Number
10597-011) was mixed with 220 ml of bromophenol blue (5 mg/ml) and 500 ml of





4.3.7.1) APO E Allelic Distributions
The frequency of the six APO E genotypes was determined for the brain injured
children and their controls.  The distribution ratios of the three APO E alleles were
then calculated for these two groups of children.  Comparisons of the APO E allelic
distribution ratios were made among the brain injured children, their controls, and a
previously reported cohort of healthy Scottish adults (n = 400) [257].  Chi square
tests were employed to assess any statistical difference.
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4.3.7.2) Allelic Dichotomies & Outcome Groups
The brain-injured children were divided into the following allelic dichotomies for
analyses:
(i) Patients possessing the APE e2 allele vs. those without the APO E e2
allele
(ii) Patients carrying the APO E e4 allele vs. those without the APO E e4
allele
(iii) Patients who were APO E e3 homozygous vs. those who were not e3
homozygous.
The PICU discharge conscious states of the patients were dichotomised into those
who had ‘regained consciousness’ (GCS > 8) and those with ‘delayed return of
consciousness’ (GCS 8 or less).  For the 6-month outcome, patients were grouped
into ‘good recovery’ when GOS 4 and 5 was achieved, and ‘poor outcome’ when
GOS was between 1 and 3.
4.3.7.3) APO E Alleles and Outcome
To assess the effects of the different APO E alleles on PICU discharge conscious
state and outcome after childhood brain trauma, two-by-two tables were constructed
between the different allelic dichotomies and outcome groups described above.
Fisher’s Exact Tests were employed to detect statistical significance (p < 0.05).
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4.3.7.4) APO E Alleles, Demographic Details, Injury Severity, and
Secondary Insults
Statistical differences of demographic details, injury severity and secondary
physiological derangement between the different allelic groups were assessed using
Mann Whitney U tests (for continuous variables) or Fisher’s Exact Tests (for
nominal variables).
4.3.7.4.1) APO E Alleles and Age-Related CPP Insult
The relationship between of the total burden of CPP insult as measured by the
cumulative pressure-time index and the different APO E alleles was determined
using the Mann Whitney U test for the different allelic dichotomies.
4.3.7.5) APO E Alleles, Demographic Details, Age-related Physiological
Derangements, and Outcome
Mann Whitney U tests were employed to detect difference in the frequency and
duration of age-related physiological derangements, the total burden of CPP insult
for the following APO E genotype and outcome dichotomies:
• Children in possession of the APO E e2 allele with ‘Good recovery’ vs. those
in possession of the APO E e2 allele with ‘Poor recovery’
• Children in possession of the APO E e4 allele with ‘Good recovery’ vs. those
in possession of the APO E e4 allele with ‘Poor recovery’
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• Children in possession of the APO E e3 allele alone with ‘Good recovery’ vs.
those in possession of the APO E e3 allele alone with ‘Poor recovery’
Logistic regression analyses were performed to determine the associations between
the different APO E alleles on PICU discharge conscious state and outcome
controlling for age, sex, post-resuscitation/pre-intubation GCS, initial brain CT
findings, the duration of ICU stay and ICP monitoring, and age-related CPP insult as
measured by PTIc.  Post-resuscitation/pre-intubation GCS, initial brain CT findings
and duration of ICU stay were included in the analyses because they are generally
accepted as indicative of primary brain injury while CPP insult was the most
significant and influential secondary insult on outcome.  These key prognostic
factors were agreed in advance.  Age, duration of ICU stay, duration of ICP
monitoring and PTIc were included in the regression model as continuous variables
while the post-resuscitation GCS was categorised into severe injury where the GCS
was 8 or less, and non-severe injury when the modified GCS was more than 8.
Initial brain CT findings were classified into either diffuse or focal injuries for the




Of the sixty-five brain injured children (46 boys and 19 girls with a median age of
9.3 years), 2 suffered a mild injury (GCS 13 – 15), 25 suffered a moderate injury
(GCS 9 – 12), while 38 had a severe injury (GCS ! 8).
The subgroup of children with CPP insult measurement had more severe brain injury
and longer duration of stay in ICU than those of the whole cohort but other
demographic details such as age, sex distribution, and initial brain CT findings did
not otherwise differ significantly (Table 4.1).
Table 4.1




























































































4.4.2) APO E Allelic Distributions
APO E genotyping was successful in all participants.  The APO E allelic
distributions for brain injured children and their controls are summarised in Table
4.2.  The distribution ratios of the three APO E alleles were similar between the brain
injured children and their controls, but when compared with healthy adults from a
previously reported Scottish population [257], the e2 allele was significantly over-
represented (p = 0.04) among our participants (Table 4.2).
Table 4.2:
APO E Alleles
e2 e3 e4 Total
TBI Children (whole cohort n = 65) 18 (0.14) 96 (0.74) 16 (0.12) 130
Control Children (n = 160) 36 (0.11) 238 (0.74) 46 (0.15) 320
(
2
 for trend: e2 p = 0.44; e3 p = 0.91; e4 p = 0.86
APO E Alleles
e2 e3 e4 Total
TBI Children (Whole cohort n = 65) 18 (0.14) 96 (0.74) 16 (0.12) 130
TBI Children (CPP insult Measured n =
38)
13 (0.15) 53 (0.73) 10 (0.12) 76
(
2
 for trend: e2 p = 0.53; e3 p = 0.53; e4 p = 0.86
APO E Alleles
e2 e3 e4 Total
TBI Children (Whole cohort n = 65) 18 (0.14) 96 (0.74) 16 (0.12) 130
Healthy Adults (n = 400)
*
66 (0.08) 616 (0.77) 118 (0.15) 800
(
2
 for trend: e2 p = 0.04; e3 p = 0.43; e4 p = 0.46
APO E Genotypes
e2/e2 e2/e3 e2/e4 e3/e3 e3/e4 e4/e4
TBI Children (whole cohort n = 65) 2 11 3 38 9 2
TBI Children (CPP insult Measured n =
38)
1 8 3 20 5 1
Control Children (n = 160) 3 26 4 90 32 4
Healthy Adults (n = 400)
*
2 51 11 233 99 4
*[239]
4.4.3) APO E Alleles and Outcome
Of the whole brain trauma cohort, 46 children ‘regained consciousness’ while 19
remained in a coma at the time of PICU discharge.  At 6 months post injury, 8
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children had ‘poor outcome’ of whom only 1 had ‘regained consciousness’ at PICU
discharge (p < 0.001, Fisher’s Exact Test).
Table 4.3 summarises the relationships between the different allelic dichotomies and
outcome at PICU discharge and 6 months post injury.  Only 3 of the 38 e3
homozygous (8%) had ‘poor outcome’ at 6 months post injury while 3 of the 16 e2
carriers (19%) and 3 of the 14 e4 possessors (21%) had ‘poor outcome’.  There was a
trend for the e2 allele possessors to remain in a coma at PICU discharge (p = 0.05,











e2 allele present 8 8
No e2 allele present 38 11
p = 0.05
e3 homozygous 30 8
Non-e3 homozygous 16 11
p = 0.10
e4 allele present 8 6









e2 allele present 13 3
No e2 allele present 44 5
p = 0.40
e3 homozygous 35 3
Non-e3 homozygous 22 5
p = 0.26
e4 allele present 11 3
No e4 allele present 46 5
p = 0.35
163
4.4.4) APO E Alleles and Secondary Derangement
The frequency and duration of secondary age-related physiological derangements did
not differ between children of the different allelic groups.
4.4.4.1) APO E Alleles and The Total Burden of CPP Insult
Children with various APO E alleles experienced differential amounts of CPP insult
with the e3 homozygous experiencing the most while the e4 carriers had the least
CPP insult.  Children carrying the e4 alleles had significantly less (13.3 times) CPP
insult than those without the e4 allele (p = 0.04, Mann Whitney U Test) (Figure 4.2).
E3 homozygous suffered 9.2 times more CPP insult than the non-e3 homozygous (p
= 0.03, Mann Whitney U Test) (Figure 4.2).  In general, children in possession of the
e2 allele experienced 2.2 times less CPP insult than the non-e2 carriers but this did
not reach statistical significance (p = 0.58, Mann Whitney U Test) (Figure 4.2).
164
Figure 4.2:
4.4.5) APO E Alleles, CPP Insult and Outcome
4.4.5.1) At PICU Discharge
Children with delayed recovery of consciousness at PICU discharge tended to have
experienced more CPP insult than those who regained consciousness early with the
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When considering children who regained consciousness (GCS > 8) at PICU
discharge, e3 homozygous had suffered significantly more CPP insult than the non
e3 homozygous (p < 0.01, Mann Whitney U Test) while children with the e4 allele
experienced significantly less CPP insult than those without the e4 allele (p = 0.03,
Mann Whitney U Test) (Table 4.5).  There was a trend to suggest that the e2 carriers
who had ‘regained consciousness’ had suffered less CPP insult than those without
the e2 allele (p = 0.05, Mann Whitney U Test).  (Table 4.5)
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4.4.5.2) 6 Months Post Injury
At 6 months post injury, regardless of the APO E genotypes, brain injured children
with a good recovery had suffered less CPP insult than those who had poor outcome
(Table 4.4).  When considering children with a good recovery, e3 homozygotic
patients recovered well despite having suffered significantly (nearly 26 times) more
CPP insult during their ICU management than those who were not e3 homozygous (p
= 0.02, Mann Whitney U Test) (Table 4.5).  Children possessing the e4 allele with a
poor outcome experienced significantly less CPP insult than those without the e4
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allele (p = 0.03, Mann Whitney U Test) (Table 4.5).  Furthermore, the median PTIc
for the e4 carriers with poor outcome was 22.8 mmHg.hr which should have
conferred good recovery given that the median PTIc for the whole cohort with good
recovery was 32.3 mmHg.hr (Table 4.4).
4.4.6) Determinants of Outcome after Childhood Brain Trauma
4.4.6.1) Delayed Return of Consciousness at PICU Discharge
Different APO E alleles had different associations with the PICU discharge
conscious status (Table 4.6).  The presence of the e2 allele was associated with
‘delayed return of consciousness’ at PICU discharge (p = 0.0146, 95% CI 0.001 –
0.472).  A negative association was found with the e3 homozygous (p = 0.0253, 95%
CI 1.629 – 1616.765) but the possession of the e4 allele had no association with
PICU discharge GCS of 8 or less.
Age was associated with delayed returned of consciousness at PICU discharge in
children who were e3 homozygous (p = 0.0337, 95% CI 1.015 – 1.441) and those
possessing the e4 allele (p = 0.0336, 95% CI 1.019 – 1.458), but it did not appear to
have any association with the PICU discharge conscious state in the e2 allele
carriers.  No correlation was demonstrated between CPP insult and the coma status at
PICU discharge.
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4.4.6.2) Poor Outcome at 6 Months Post Injury
Poor outcome at 6 months after childhood brain trauma was significantly related to
the amount of CPP insults experienced during neuro-intensive care regardless of the
child’s APO E genetic composition (Table 4.7).  Possession of the e4 allele had a
positive association (p = 0.0325, 95% CI 1.471 – 1782.500) with poor outcome while
being an e3 homozygous had a negative correlation (p = 0.0010, 95% CI 1.376 –
1.609) with poor outcome (Table 4.7).  No significant association was demonstrated
between poor outcome at 6 months post injury and the possession of the e2 allele.
Table 4.6
Factors Associated with Delayed Return of Consciousness at PICU Discharge
Coefficiency Significance (p value) 95% Confidence Intervals
e2 allele present 3.807 p = 0.0146 0.001 – 0.472
Sex (Boys) - 5.905 p = 0.0381 1.381 – 97469.601
Age 0.301 p = 0.1409 0.495 – 1.105
Severe injury 1.056 p = 0.4439 0.023 – 5.194
Initial brain CT
(focal injury)
2.457 p = 0.1059 0.004 – 1.685
Duration of PICU
stay
1.198 p = 0.0304 1.009 – 1.667
CPP insult (PTIc) 0.003 p = 0.4142 0.990 – 1.004
e3 homozygous - 3.938 p = 0.0253 1.629 – 1616.765
Sex (Boys) - 5.478 p = 0.0287 1.766 – 32464.56
Age 1.402 p = 0.0337 1.015 – 1.441
Severe injury 1.561 p = 0.2594 0.014 – 3.164
Initial brain CT
(focal injury)
2.356 p = 0.0997 0.006 – 1.567
Duration of PICU
stay
0.249 p = 0.0384 0.616 – 0.987
CPP insult (PTIc) 0.005 p = 0.1603 0.987 – 1.002
e4 allele present 1.946 p = 0.1298 0.012 – 1.771
Sex (Boys) - 4.776 p = 0.0045 1.932 – 7289.863
Age 0.382 p = 0.0336 1.019 – 1.458
Severe injury 1.112 p = 0.4165 0.022 – 4.812
Initial brain CT
(focal injury)
0.837 p = 0.4650 0.046 – 4.092
Duration of PICU
stay
0.147 p = 0.0631 0.730 – 1.019
CPP insult (PTIc) 0.003 p = 0.4334 0.991 – 1.004
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Table 4.7:
Factors Associated with Poor Outcome at 6 month Post Injury
Coefficiency Significance (p value) 95% Confidence Intervals
e2 allele present 2.156 p = 0.2024 0.213 – 350.605
Sex (Boys) -1.379 p = 0.3093 0.018 – 3.595
Age 0.139 p = 0.4937 0.772 – 1.711
Severe injury 0.952 p = 0.6105 0.009 – 15.722
Initial brain CT
(focal injury)
2.945 p = 0.0952 0.343 – 105.104
Duration of PICU
stay
0.184 p = 0.0893 0.949 – 1.523
CPP insult (PTIc) 1.009 p = 0.0184 1.019 – 1.999
e3 homozygous -9.06 p = 0.0010 1.376 – 1.609
Sex (Boys) -0.745 p = 0.6925 0.012 – 19.055
Age 0.739 p = 0.1216 0.821 – 5.341
Severe injury 0.565 p = 0.8358 0.003 – 118.928
Initial brain CT
(focal injury)
6.930 p = 0.0776 0.464 – 225.499
Duration of PICU
stay
0.407 p = 0.0797 0.953 – 2.369
CPP insult (PTIc) 1.029 p = 0.0003 1.059 – 1.999
e4 allele present 3.366 p = 0.0325 1.471 – 1782.500
Sex (Boys) -0.918 p = 0.5837 0.015 – 10.649
Age 0.266 p = 0.2646 0.817 – 2.083
Severe injury 0.106 p = 0.9615 0.015 – 84.717
Initial brain CT
(focal injury)
1.984 p = 0.9615 0.360 – 146.939
Duration of PICU
stay
0.138 p = 0.214 0.911 – 1.447
CPP insult (PTIc) 1.010 p = 0.0046 1.102 – 1.999
4.5) DISCUSSIONS
Potential genetic influence on neurological recovery after brain trauma was first
described in 1995.  Since then, many clinical studies have emerged in the literature
linking the APO E e4 allele possession with poorer outcome after brain trauma in
adults.
Teasdale and co-workers prospectively examined the associations between APO E
genotypes and the 6-month global outcome score of 93 head injured patients, who
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were predominantly adults, and found that twice as many in possession of the e4
allele made a poor recovery as those without this particular allele [141].
Friedman and colleagues investigated the predictive value of the APO E genotypes
on the duration of unconsciousness and functional outcome in 69 adults after head
injury, but took no account of the genetic influence on non-survivors [143].  Carriers
of at least one APO E e4 allele in their cohort were more likely to remain
unconscious for more than 7 days [143].  In addition, only 3% of the e4 carriers had
a good functional recovery at 6 – 8 months post injury whereas 10 times as many
non-e4 carriers recovered with a good function outcome [143].  Duration of
unconsciousness is likely to be largely reflective of the primary brain injury and not a
measure of secondary brain insults, but yet these investigators found that the
possession of the APO E e4 allele were associated with longer duration of
unconsciousness and poorer outcome.  This is suggestive that APO E genetic
polymorphisms may differentially affect patients’ response to primary brain injury,
which has contributed to the length of coma.
In a further study which excluded fatal brain trauma, Lichtman’s group reported on
the functional recovery in 31 surviving adults of brain trauma and found poorer
outcome among the APO E e4 carriers [142].  APO E e4 allele might also have a
negative influence on late outcome of brain trauma as described in a recent study
evaluating the specific outcome measure (neuropsychological outcome) of 396
survivors of head injury [258].  They found 1.3 times more non-e4 carriers had a
good long-term neuropsychological outcome than the e4 possessors [258].
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4.5.1) Over-Representation of the e2 Allele in Active Children With or
Without Brain Injury
The patients in the previously reported APO E brain trauma studies consisted of
either exclusively or predominantly adults with very few paediatric cases.  Although
the APOE allelic distribution ratios from all these cohorts [141, 259, 260] were
reported to be similar to previously published population data, none have actually
included appropriate population controls for their injured cohorts.  Our study
evaluated the associations between the child’s APO E genotype, the measured
secondary physiological derangements after brain injury, and outcome classification
at ICU discharge and 6 months post injury [261].  To the best of my knowledge, this
is the first clinical study within the APO E-brain trauma literature to investigate APO
E genotypes’ influence on secondary insult and outcome after brain trauma in an
exclusive child cohort which includes an appropriate same population control group.
Our control subjects were comprised of healthy active children who had sustained
minor injuries from their normal life styles and were age and sex matched to the
brain-injured group.  They were chosen to ensure as similar a risk for sustaining
brain injury as possible to allow accurate comparison of the APO E allelic
distribution frequency which we found to be similar between the groups [261].  Our
decision to include a separate paediatric population control group was further
justified by the finding of a significant e2 allelic over-representation among our
participants when compared to that of a previously reported group of healthy adults
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who were born in North-East Scotland [257].  This adult cohort was chosen for
comparison because it represented the largest reported healthy Scottish adult cohort
to have their APO E genotyped and its allelic distribution ratio (0.08 for e2, 0.77 for
e3, and 0.15 for e4) was similar to those described in other adult brain trauma
cohorts [141, 259, 260], and general populations worldwide [247, 262] including
different regions of Scotland, Germany, Taiwan, and the United States of America.
Geographic variation of the APO E allelic distribution is, therefore, unlikely to
explain our observed over-representation of the e2 allele.
The frequency of the e2 allele among a previously reported healthy Scottish newborn
population [263] recruited from the same geographic area as our cohort, was similar
to the e2 allele frequency of the above adult reports rather than to our study.  Our
participants, children with minor injuries and critically ill children post brain trauma,
may, therefore, represent a different population to brain injured adults and the
general (adult and neonatal) populations.  Paediatric injuries tend to occur more
frequently because of the level of activity among normal young children, while adult
injuries (include the elderly population) may occur regardless of their activity levels.
Further investigation is required to determine whether APO E e2 allele relates to a
heightened physical activity level.
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4.5.2) Different Amount of CPP insult between the Carriers of the
Different APO E Alleles
Almost all previous clinical studies of APO E polymorphisms and brain trauma have
focused on its influence on neurological recovery and using it as a potential
prognostic indicator without making any serious attempts to determine how APO E
genotypes may affect outcome.  Although genetic constitution cannot be altered,
understanding how genetic polymorphisms differentially modulate recovery after
brain trauma may allow suggestions for novel therapies to be directed specifically to
patients with or without a particular allele.  This would be particularly useful in brain
trauma management especially when no novel treatment has been introduced for the
past 20 years despite extensive attempts to translate basic science research data into
effective and novel treatment suitable for clinical use.
CPP insult is a proven determinant of outcome after brain trauma [63, 66, 204] and
its prevention remains the main emphasis of all modern neuro-intensive care
management strategies worldwide [74, 75].  Although CPP insult and APO E
polymorphisms have independently been described to affect brain trauma outcome,
the relationships between APO E genotypes and CPP insult following brain trauma
has not been evaluated previously.
Our study confirms the importance of CPP insult on outcome after childhood brain
trauma regardless of the patient’s APO E status [261].  Additionally, this study was
the first to report children carrying the e4 allele to have experienced the least amount
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of CPP insult, while the e3 homozygotic patients suffered the most after brain trauma
despite having sustained primary brain injury of similar severity and being treated
with standardised intensive care management [261].  This suggests that APOE E
genetic polymorphisms may potentially affect the body’s response to primary brain
injury or its management differently.
Our patients possessing the e4 allele with poor outcome had experienced a lesser
burden of CPP insult than non-e4 carriers and the amount of CPP insult was at a
level that should have conferred good recovery [261].  Carriers of the e4 allele may
be less tolerant of CPP insult and develop more cerebral ischaemic damage than
children without this allele so that even with the small amount of CPP insult they
suffered, which should have conferred good recovery, the e4 carriers had poor
outcome.  This interpretation would support the observed trend of an increased
incidence of severe ischaemic brain damage among the e4 carriers from a recent
report of a post-mortem study evaluating brain specimens from 239 fatal cases of
TBI aged between 2 months and 84 years [264] although the burden of secondary
CPP insult suffered by these patients were unknown.
Cerebral ischaemia may be caused by an imbalance of the cerebral metabolic
demand and substrate delivery.  Lesser amount of CPP insult found in our e4 carriers
would imply the presence of age-appropriate cerebral perfusion.  It is known that
cerebral metabolic rate in severely brain injured children was normal in 81% and this
subsequently fell between the first and third day following brain trauma [89].  One
may, therefore, postulate that the e4 allele increases its carriers’ cerebral metabolic
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demand after brain trauma and thereby increasing their susceptibility to cerebral
ischaemia.  To assess this postulate, continuous measurements of cerebral
metabolism and cerebral substrate supply would be required.
Recent animal studies have suggested that brain trauma causes an increased neuro-
inflammation in transgenic animals carrying the human e4 allele when compared
with those with the e3 allele [265, 266].  It is unknown whether humans with
different APO E alleles experience a different degree of neuro-inflammation and
further studies are required to ascertain whether this may explain our observation on
outcome which appeared out of proportion to the allelic-related variations in CPP
insult post brain trauma.  Another possible explanation for this observation is that the
APO E e4 allele adversely affects outcome through mechanisms independent of the
amount of CPP insult.
Almost all previous reports in the literature have suggested the adverse effect of the
APO E gene on outcome was related to the possession of the e4 allele.  However,
despite transgenic animal data suggesting a potentially more superior neurological
repair offered by the e3 allele [251], no study has investigated whether APO E allelic
influence on neurological recovery may be related to the absence of the e4 allele.
The e3 homozygotic children in our cohort experienced more CPP insult than those
in the other allelic groups which by conventional evidence on the positive correlation
between CPP insult and poor outcome [63, 66, 204], more of the e3 homozygous
would have been expected to have an unfavourable outcome.  However, we found
fewer e3 homozygotic patients among the brain injured children with a poor
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outcome.  Additionally, children possessing only the e3 allele with ‘good recovery’
in our cohort had achieved that despite having suffered nearly 26 times more CPP
insult than non-e3 homozygous [261].  This would suggest the e3 homozygous
potentially enjoys a protective effect from ischaemic insult.  This benefit may be due
to the lack of the e4 or e2 alleles and warrants further investigations.
4.5.3) APO E Polymorphisms Influence Recovery at Different Time Point
Post Injury
Most studies in the APO E genetic polymorphisms – brain trauma literature assessed
outcome at a single time point post-injury.  In a recent adult study where the e4
allelic influence on the speed of recovery after brain trauma was evaluated,
Alexander and colleagues reported individuals possessing the e4 allele recovered at a
significantly slower rate than those without the allele [260].  They additionally found
that the e4 carriers who survived the initial injury and early recovery phase had
poorer long-term outcome at 24 months post injury than those without the e4 allele
[260].  Effect of the other APO E alleles on the recovery rate was, however, not
assessed in their report.
We found that different APO E alleles had different associations with the PICU
discharge conscious state and the 6-month global outcome.  Although the presence of
the e4 allele had no association with the PICU discharge coma status, it was
associated with poor outcome at 6 months post injury.  This suggests that the e4
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allele may have more influence on longer term recovery, which is consistent with the
findings reported by Alexander and co-workers [260] as described above.
Possession of the e2 allele was significantly associated with the delayed return of
consciousness at PICU discharge in our cohort, but it was not associated with poor
outcome at 6 months post injury.  One possible interpretation of this finding is that
the e2 allele may have a negative influence on the early recovery from brain trauma.
However, one previous family study of Alzheimer’s disease suggested the possession
of the e2 allele lowered the risk of developing Alzheimer’s Disease [249].  If the
APO E e2 allele potentially offers protection against neuro-degenerative disease, it
is, therefore, possible to suggest that it may have a similar protective effect on
neurological recovery after brain trauma but its protective effect does not take place
until later in the recovery process.  Given the rarity of this allele among the general
population and the absence of a transgenic APOE e2 animal model, a large multi-
centre study with appropriate controls from each centre would be necessary to assess
the true effect of APOE e2 allele on neurological recovery after brain trauma.
Being an e3 homozygous had a negative association with both delayed returned of
consciousness at PICU discharge and poor outcome at 6 months post injury in our
study.  This supports the postulation that the e3 allele offers a more superior recovery
from brain trauma as observed in transgenic animal studies [251].  Alternatively, the
beneficial effect on recovery may be the result of the lack of either e4 or e2 allele.
This highlights the need to assess the effects of all APO E alleles on the recovery
178
after brain trauma at various time points without restricting the investigation to only
the e4 allele.
4.5.4) Limitation of the Study
Although we have demonstrated carriers of the various APO E alleles experienced a
differential burden of CPP insult, the small cohort size has limited any possibility of
ascertaining whether the presence or absence of any particular allele has caused this
observation.
The proportion of patients with poor outcome was unexpectedly low in our cohort,
and was a third less than the projected figure from previous reports [141].  Our
original power calculation was based upon figures available from these previously
published adult studies with a similar projected proportion of unfavourable outcome.
Successful recruitment of 65 patients should have produced a 5% significance value
when assessing the influence of the different APOE alleles on outcome.  Given a
more than 50% reduction in the number of patients with unfavourable outcome, to
achieve a 5% significance would require twice the number of patients recruited
which was not possible within the planned time frame since all suitable patients had
been included.  Fewer unfavourable outcomes following childhood brain trauma,
although a welcome finding, makes our study insufficiently powered to assess
whether there is any allelic influence on neurological recovery after childhood brain
trauma.
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Despite these limitations, we demonstrated that unfavourable outcome at 6 months
was 2.6 times more common among the e4 carriers than the e3 homozygotic patients,
although 58% of the cohort were e3 homozygous and only 22% were e4 carriers,
who suffered the least amount of CPP insult.  We additionally demonstrated that
different APO E alleles potentially exert their influence on recovery at different
phases after brain trauma.  The e3 homozygous appeared to enjoy a sustained
positive influence on recovery starting at the PICU discharge to 6 months post injury,
while the potential negative influence of the e4 allele only appeared to occur to late
recovery.  The paucity of our cohort size was again reflected in the wide confidence
intervals for the e4 allelic association with poor outcome.  Our findings highlighted
the need to further investigate the influence of APO E alleles on childhood brain
trauma.  Additionally, our observed over-representation of the e2 allele in active
children reaffirmed the importance to include an appropriate control population in
any future studies.
4.6) CONCLUSIONS
After childhood brain trauma, carriers of the APO E e4 allele may tolerate CPP insult
less well than those with other allelic possession.  APO E e3 homozygotic patients
may enjoy a relative protective effect, mitigating CPP insult.
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CHAPTER 5: BRAIN TRAUMA SERUM BIOMARKERS AND THEIR
PROGNOSTIC VALUES FOR UNFAVOURABLE OUTCOME AFTER
BRAIN TRAUMA
5.1) BACKGROUND
Current methods to classify brain injury severity and to predict outcome during the
acute management of brain injured patients remain limited.  The most frequently
used clinical method to classify brain injury severity continues to be the Glasgow
Coma Scale (GCS) [28].  Although its inter-observer reliability is high among adult
patients, GCS may be difficult to assign accurately in brain injured children, who are
often frightened and uncooperative, especially if this is attempted by clinicians
inexperienced in assessing the immature nervous system and may result in either
over or under estimation of injury severity.  Inaccurate classification of brain injury
severity has serious consequence to the provision of the appropriate treatment
required and may therefore, potentially affects recovery.
A number of biochemical mediators are produced after brain trauma when there is
irreversible damage to the glial and neuronal cells [163-168].  Other biochemical
mediators are produced to modulate the complex cascade of brain trauma induced
secondary brain insult and pathophysiological repair processes [122, 123, 125, 126,
169-176].  Some of these mediators are measurable in blood or CSF, and their acute
blood or CSF concentrations may, therefore, potentially be used to classify injury
severity, to monitor recovery, or to predict outcome.  Many potential brain
181
biochemical markers have been studied so far and may be classified into three major
groups: (i) brain specific proteins; (ii) inflammatory mediators; and (iii)
vasoconstrictors.
5.1.1) Brain Specific Proteins
Brain specific proteins are synthesized by the astroglial cells or neurons, and have
been proposed as potential markers of glial and neuronal cell damage or disruption of
the blood-brain barrier integrity following documentation of their detections in the
CSF and the systemic circulation after central nervous system disorders or insults
[163, 164, 267-270].  Numerous brain specific proteins have been investigated in
brain injury but those that have attracted most research attentions included S-100B
protein, neuron specific enolase (NSE), and creatine kinase (CK).
The S-100 protein is a small dimeric calcium binding protein found in the cytosol
with a molecular weight of 22kD [271].  Depending on its alpha or beta chain
structure, several forms exist.  The ##-form or the S-100B protein is found in high
concentration in glial cells and Schwann cells, while the S-100A protein ("#-form) is
present in glial cells only [272].  The S-100A0 or the ""-form of the protein is found
exclusively in neurons [272].  The S-100 protein can be found in much smaller
concentration in non-nervous tissues such as adipose tissue, melanocytes and T-
lymphocytes [273-276].  It is metabolised in the kidneys and excreted in the urine
with a biological half-life of around 2 hours [277].
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Neuron specific enolase (NSE) (defined as )-subunit of enolase) is a soluble
cytoplasmic protein localised principally in neurons and neuroendocrine cells [278-
281].  Although its precise role in the nervous system remains unclear, recent
evidence suggests it may have important interaction with the neuroinflammatory
cascade [282, 283].
CSF and serum concentrations of these brain specific proteins are usually very low in
normal individuals but become elevated following primary neurological disorders
such as TBI [163, 164, 168, 284], stroke [283, 285, 286], seizures [287, 288], and
secondary neurological complications after circulatory arrest [269, 289] and
cardiopulmonary bypass [290].  After brain trauma, the concentration of the brain
specific proteins in the CSF and serum rise steadily reaching a maximal level at the
second day post injury and decline to undetectable values within 7 days.
The precise mechanisms by which these brain specific proteins are released into the
CSF and bloodstream remain unclear but direct release into the CSF from damaged
astrocytes and neurons followed by diffusion into the systemic circulation through a
disrupted blood-brain barrier seems a likely mechanism given the positive correlation
between the serum concentrations of these proteins and the size of the brain lesions
[291-293].  This theory was supported by the findings of Pleines’ group who
demonstrated that the CSF concentrations of S100B and NSE in brain trauma
patients were ten times higher than those detected in the serum samples collected
simultaneously [294].  Thus, the blood or CSF concentrations of these brain specific
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proteins measured during the acute management of brain trauma patients may be
used as a marker of the severity of astroglial damage.
Elting and co-workers demonstrated the serum S-100B levels after strokes peaked 3
to 4 days later than those after brain trauma suggesting alternate release mechanisms
existed following different brain insults [268].  In vitro studies have demonstrated
that S-100B protein can be released into the extracellular space by (i) activation of
A1 adenosine or mGlu3 metabotropic glutamate receptors [295], (ii) stimulation of
astroglial 5-HT1A receptors [296-298], (iii) adrenocorticotropic hormone (ACTH)
and corticotrophin-like intermediate-lobe peptide [299], and (iv) secretion from
proliferating astrocytes [300].  The extracellular adenosine level rises soon after
experimental TBI [301, 302] and stroke [303] and is thought to be due to rapid
intracellular ATP depletion resulting in an immediate secretion of S-100B.  This
mechanism offers a likely explanation to the acute rise in serum and CSF S-100B
levels in human TBI patients but does not fit with the clinical observation in stroke.
It has been suggested that following stroke high level of adenosine can be found
within the core of the infarct, which is an area not perfused with blood resulting in
accumulation of S-100B protein in the region without being released into the
bloodstream.  The delayed release of S-100B may then be explained by reactive
astrogliosis which is observed to be at its maximal intensity on
immunohistochemical staining approximately 3 to 4 days after induction of
experimental TBI [304-306] and stroke [307, 308].  Most clinical studies have shown
the serum and CSF S-100B levels begin to drop 2 days after brain trauma [166, 309,
310] indicating a lesser degree of reactive astrogliosis than those observed in stroke.
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However, reactive astrogliosis is likely to play a role in brain trauma as well because
a secondary excessive rise in serum S-100B levels had been observed in three
severely brain injured adults, all with fatal outcome despite normal CPP, SaO2,
PaCO2 and controlled ICP [311].
The mechanisms by which brain injury is sustained may also affect the temporal
release pattern of S-100B and NSE [312].  Berger’s group examined CSF samples
collected from infants with an inflicted head injury and showed a peak level for both
S-100B and NSE at a median of 63 hours after admission while those collected from
children with accidental head injury showed a peak level at a median of 11 hours
following trauma [312].  Furthermore, a second peak in NSE concentration was only
observed in patients with inflicted head injury [312].  This is consistent with recent
findings from experimental TBI animal models and clinical studies showing an
increase in markers of delayed neuronal death in abuse victims [313-315].
Acute serum or CSF brain specific protein concentrations may provide an objective
indication of the initial brain trauma severity [168, 293, 294, 310] but the predictive
values of these proteins in outcome is less clear.  Rothoerl and colleague examined
41 head injured adults with varying degree of severity and found that the mean serum
S-100B levels were significantly higher in those with unfavourable outcome [168].
Another recent study suggested that only the admission serum S-100B correlated
with outcome [316].  Among 84 severe brain trauma patients, the peak serum S-
100B levels obtained from patients with favourable outcome was significantly lower
than those with unfavourable outcome, but the serum NSE levels did not differ
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between the two groups [317].  Others investigators had also failed to demonstrate a
correlation between the serum or CSF NSE concentrations and recovery [166, 310].
Very little information is available in the literature on brain specific proteins and
children with traumatic brain injury.  Berger’s group reported the CSF concentrations
of these proteins in head injured children to be much higher than their adult
counterparts suggesting a potential increased in susceptibility of the developing brain
to neuronal or glial cell death after traumatic injury [312].  However, further studies
are required to clarify the role of brain specific proteins as a marker of injury severity
and predictor of outcome in children after brain trauma.
5.1.2) Inflammatory Mediators
5.1.2.1) Cytokines in Acute Brain Injury
Cytokines are low molecular weight polypeptides with a primary action to mediate
inflammation and growth process.  Brain injury stimulates microglia and astrocytes
to produce and release cytokines such as interleukins (predominantly IL-6, IL-8, and
IL-10) which are thought to be responsible for many of the clinical signs of
inflammation observed after acute brain injury namely pyrexia, neutrophilia, and
brain swelling.  They are also thought to play a vital role in the production and
release of other mediators in the secondary brain injury cascade such as oxygen-
derived free radicals, neuropeptides and arachidonic acid derivatives, and up-
regulation of adhesion molecules activities.
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5.1.2.1.1) Interleukin 6 (IL-6)
IL-6 is an important mediator capable of causing and inhibiting inflammation
following brain injury [109, 318].  In additional, its ability to increase endothelial
permeability [319] suggests its potential involvement in the evolution of the blood-
brain barrier disruption.  Its presence in the brain following experimental traumatic
brain injury was first reported in the early 1990s [320-323] with peak concentration
found around 8 hours following the brain insult [322].  In vitro study using culture
human astrocyte has also shown an increased IL-6 production following fluid
percussion injury [324].
Several clinical studies have investigated the role of IL-6 as a monitor of recovery
following brain injury.  McClain’s group found an increased serum IL-6
concentration in 30 brain injured patients with the highest level observed on the first
day after the injury [121].  The decline in serum IL-6 level correlated with clinical
improvement and the rate of reduction in patients with an admission GCS 8-10 was
faster than those with an admission GCS <8 [121].  This release of IL-6 soon after
brain trauma has also been confirmed to occur in children.  Bell and co-workers
studied paired CSF and serum IL-6 levels in severely brain injured children with
GCS ! 8 and found raised IL-6 concentration in both fluid with a peak level
demonstrated within the first day of injury [122].  In another study of 45 children
with TBI, Kalabalikis and colleague have demonstrated the peak serum IL-6 level
occurred 4 hours post injury and declined steadily over the next three days [123].
187
The IL-6 level of head injured children at 72 hours post injury remained higher than
those of healthy controls [123].  Although the IL-6 concentration was significantly
higher in the severely injured children (GCS < 8), they did not demonstrate any
correlation with clinical outcome [123].
Experimental studies have suggested that IL-6 detected after brain trauma is likely to
have originated intracranially.  Elevated IL-6 concentration in ventricular fluid had
been documented to occur after brain trauma in both adults [121, 124] and children
[122].  McKeating and co-workers from Edinburgh investigated the arterial and
jugular venous IL-6 levels in 32 adults with either TBI or spontaneous subarachnoid
haemorrhage (SAH) [171].  They demonstrated a marked jugular venous-arterial
difference in the elevated IL-6 concentration supporting the possibility of intracranial
IL-6 production following brain injury [171].
5.1.2.1.2) Interleukin 8 (IL-8)
Interleukin 8 (IL-8) is a pro-inflammatory cytokine belonging to the cysteine-x-
cysteine family with potent chemotactic and activating properties on neutrophils
[109].  It is synthesised by various cell types including moncytes/macrophages,
endothelial cells, astrocytes and glia, in response to stimulation by other cytokines
like IL-1 and TNF " [325-328].  In vitro and in vivo studies have demonstrated the
ability of IL-8 to increase vascular permeability in the presence of inflammatory
leukocytes [327, 328] suggesting a potential role in the development of blood-brain
barrier dysfunction.
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Brain trauma induced IL-8 production was first described in 1994 by Ott’s group
when they demonstrated a rise in the serum IL-8 concentration soon after severe
brain trauma [109].  In another study of 14 adults with severe TBI, Kossmann and
colleague found that both the CSF and serum IL-8 levels were significantly elevated
in the brain injured patients for up-to 21 days post injury, and the CSF IL-8
concentrations were significantly higher than those measured in the serum suggesting
an intracranial production of IL-8 [125].  A positive association was demonstrated
between the IL-8 levels and severe blood-brain barrier dysfunction, but IL-8
concentrations had no associations with the initial injury severity or neurological
recovery [125].  Other investigators have also confirmed rises in serum and CSF IL-8
after brain trauma [126, 329], and the CSF IL-8 concentration may be associated
with mortality of severe childhood brain injury [126].
5.1.2.1.3) Interleukin 10 (IL-10)
Interleukin 10 (IL-10) is a potent anti-inflammatory mediator with
immunosuppressive actions.  It has the ability to inhibit the synthesis of pro-
inflammatory cytokines such as IL-1, TNF and adhesion molecules by macrophages
[330-334], while at the same time, it promotes the production and secretion of their
endogenous antagonists [335, 336].  In addition, IL-10 directly reverses the
stimulating effects of these pro-inflammatory cytokines on glia [337, 338],
macrophages and neutrophils [339].
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Clinical studies of children and adults after traumatic brain injury have confirmed the
presence of high level of IL-10 in both CSF and peripheral blood [122, 172, 175,
340].  The ventricular IL-10 concentration was first reported to be increased in 15
severely brain injured children in 1997 [122].  The elevated IL-10 level was noted to
persist for 3 days following the initial injury and children less than 4 years of age
appeared to have a higher concentration of IL-10 in the CSF [122].  This suggested
an age dependent IL-10 production response following brain trauma.  Furthermore,
this study was also the first and only to report an association between the increased
CSF IL-10 concentration and mortality [122].
Csuka’s group confirmed elevation of IL-10 CSF concentrations after severe isolated
brain injury among 28 adults [172].  They measured the paired CSF and serum IL-10
levels daily and found that the peak CSF IL-10 levels occurred on the first day post
injury [172].  A smaller secondary rise was observed in the second week following
trauma.  The CSF level was higher than the corresponding serum concentration
suggesting after brain damage IL-10 was produced intrathecally [172].  Neither the
CSF nor serum IL-10 levels correlated to the functionality of the blood-brain barrier
[172].  In another study of 29 adults with isolated TBI, Maier and co-workers
similarly found no correlation between the blood-brain barrier dysfunction and IL-10
concentrations in plasma and CSF [175].
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5.1.2.2) Adhesion Molecules
Soluble adhesion molecules belong to a family of less well investigated
inflammatory mediators that have been found in high concentrations in the CSF
following brain trauma.  They include intercellular adhesion molecules (ICAM),
vascular cellular adhesion molecules (VCAM), neural cell adhesion molecules
(NCAM), E-selectin, L-selectin and P-selectin.  The selectins are glycoproteins that
mediate the initial rolling and early adhesion of leukocytes to the vessel wall by
binding to endothelial receptors at the site of inflammation [341].  Deficiency of the
selectins or their ligands would, therefore, result in failure of the leukocyte migration
process and recurrent infections.  Cellular adhesion molecules belong to the
immunoglobulin superfamily.  ICAM and VCAM are present on the endothelial
surface while their counterreceptors, the integrins are found on the leukocyte surface.
Through binding of the cellular adhesion molecules to their respective integrins, the
process of strong adhesion and migration of leukocytes across the endothelium into
tissue is mediated [341].  The selectins and cellular adhesion molecules are found in
soluble active forms in the blood of normal humans but their precise function in
healthy individuals remain unknown [342].
McKeating and colleagues from Edinburgh studied the systemic and jugular venous
serum concentrations of SICAM-1 and sL-selectin, and their relationships with
injury severity and outcome after adult TBI [169].  They found that although the
admission serum SICAM-1 levels in head injured patients were similar to those
measured in the controls, significant production of SICAM-1 was observed among
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head injured patients within 96 hours of injury [169].  Furthermore, the serum
SICAM-1 level was significantly related to both neurological recovery and injury
severity as classified by the GCS [169].  The concentrations of sL-selectin in head
injured patients, on the other hand, were consistently lower than those without brain
trauma [169].  No transcranial gradient was found for either of the adhesion
molecules suggesting that the changes in intracranial adhesion molecule activity may
be the result of a systemic inflammatory response in addition to that produced
intracranially [169].
An American study investigated the CSF concentrations of P-selectin, SICAM-1, E-
selectin, L-selectin, and VCAM-1 in children with brain trauma or meningitis but
found a heterogenous expression pattern of the adhesion molecules among head
injured children [170].  Some head injured children had increased CSF
concentrations of the adhesion molecules similar to levels observed in children with
meningitis while others did not show any increase CSF adhesion molecules post
injury [170].  They also found that P-selectin was the only adhesion molecule that
was modestly increased in the CSF at later times after TBI (12-24 hours and 24-48
hours) [170].  No previous study has examined the production of adhesion molecules
beyond 3 days after brain trauma and their relationships with outcome prediction.
5.1.3) Vasoconstrictor (Endothelins)
Endothelins are peptides with potent vasoconstriction properties and have been
reported to be present in higher concentration after various brain insults such as
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spontaneous subarachnoid haemorrhage [343], brain trauma [343, 344], and
neurosurgical procedures for epilepsy [344].  These case series suggested a potential
correlation with neurological deterioration in patients with high CSF endothelin
concentrations.  A recent Chinese study investigated the clinical significance of early
changes (within 24 hours of injury) in plasma endothelin (ET), nitric oxide (NO),
and arginine-vasopressin (AVP) in adult brain injured patients [345].  They found
that the plasma levels of these markers correlated with injury severity and patients
with subdural haematoma had significantly higher concentration of ET, NO and AVP
than those who had epidural haemorrhage [345].  Larger studies would be required to
ascertain the role of endothelins and other vasoconstrictors following brain trauma
and their relationships with outcome and injury severity prediction.
5.1.4) Difficulties in the Development of Neurochemical Monitoring
Although growing number of potential biomarkers of brain trauma continue to
emerge in the literature, little progress has been made to successfully translate these
research findings into clinically useful monitoring and prognostic technique.  As
demonstrated in the above section, some mediators have been investigated more
extensively than others as potential markers of brain injury severity, recovery, and
prognosticators.  This is because majority of the research interests in the brain trauma
– biomarker literature has so far concentrated on investigating individual mediators
or a small number of mediators within the same biochemical family.  It is unclear
from the existing literature whether certain mediators better differentiate severe
injury while others better predict outcome.
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In medicine, combining several clinical features and tests results often provide more
accurate diagnosis and prognostication than may be achieved with using the
individual features or tests alone.  It remains unknown whether this is also true for
brain trauma outcome prediction using serum biomarkers.
5.2) AIMS
This chapter aims to determine and compare the predictive values of 8 different
biochemical mediators’ serum levels on injury severity and outcome after childhood
brain trauma.  We also aim to determine which mediator better identifies severe brain
injury and predict poor outcome.  Additionally, we aim to determine whether
prognostic rules using 2 biomarker levels are better at predicting unfavourable
outcome after childhood brain trauma than using individual marker level.
5.3) PATIENTS AND METHODS
Twenty-eight consecutive children (21 boys and 7 girls) requiring neuro-intensive
care after isolated brain trauma were enrolled into a single-centre (Edinburgh RHSC)
prospective observational study.
Clinical and demographic details were collected prospectively using a pre-designed
proforma.  Primary brain injury severity was assessed using the post-
resuscitation/pre-intubation Glasgow Coma Scale (GCS), and was classified into
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‘severe injury’ where GCS was 8 or less and ‘non-severe injury’ where GCS was
more than 8.
Conscious level was assessed using the modified GCS at PICU discharge which
equated to the end of neuro-intensive care when the brain injured children no longer
required airway protection, ventilatory and circulatory supports.  The children were
dichotomised into those who had ‘regained consciousness’ (GCS > 8) and those with
‘delayed return of consciousness’ (GCS 8 or less).
Global outcome was assessed at 6 months post injury using the modified Glasgow
Outcome Score (GOS) and divided into ‘good recovery’ when GOS 4 and 5 were
achieved, and ‘unfavourable outcome’ when GOS were between 1 and 3.
5.3.1) Sample Collections
All patients had an arterial blood sample collected at 24 hours (day 1) post injury.
Eighteen patients whose clinical condition required PICU stay beyond 5 days had an
additional blood sample collected at 120 hours (day 5) post injury.  The blood
samples were collected in pyrogen-free plastic tubes and centrifuged at 1200 g for 10
minutes.  The serum was removed immediately and stored in pyrogen-free plastic





Commercially available enzyme linked immunoassays (ELISA) were used to
quantify the following serum biomarker concentrations:
• Glial Protein:
o S-100B (Nexus Dx™ S-100 Test Kit, Synx Pharma Inc)
• Neuronal Protein:
o NSE (Nexus Dx™ NSE Test Kit, Synx Pharma Inc)
• Interleukins:
o IL-6 (IL-6 ELISA Kit, Diaclone Research)
o IL-8 (IL-8 ELISA kit, Diaclone Research)
o IL-10 (IL-10 ELISA Kit, Diaclone Research)
• Adhesion Molecules:
o L-selectin (human sL-Selectin Immunoassay, R&D Systems)
o SICAM (sICAM-1 ELISA Kit, Diaclone Research)
• Vasoconstrictor:
o Endothelin (Endothelin 1-21 Test Kit, Biomedica)
Samples were analysed in duplicate and averaged to provide the marker
concentration.  I performed all biomarker ELISA for this study.  There are many
similarities between the different ELISA kits.  To avoid being repetitive, the basic
principles of ELISA is presented in the following section and details of the
commercially available ELISA kits used in this study may be found in Appendix II.
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5.3.2.1) Basic Principles of Sandwich Enzyme Linked Immuno-Sorbent
Assays
Enzyme Linked Immuno-sorbent Assays (ELISA) are immunochemical methods for
determination of substrates such as peptides, proteins, antibodies, and hormone, in
which a crucial element of the detection is an antigen-antibody interaction.  These
assays utilize antibodies that are covalently linked to an enzyme which can catalyse
an easily visualised reaction, such as colour change, when a substrate is added.
Biological samples containing the mediator to be tested are exposed to specific
antibody to that particular mediator so that an antibody-antigen complex is formed.
This antibody-antigen complex is detected by treating the test system with a
conjugate i.e. another antibody linked to an enzyme to ensure formation of another
antibody enzyme complex.  This antibody enzyme complex serves as a marker and
attaches only to a specific substrate.  When a substrate for the enzyme is added to the
assay, a reaction between the substrate and the conjugate is usually indicated by a
colour change.  If no mediator was present in the test sample to bind with the specific
antibody, no conjugate interaction would take place and no colour change will occur
at the time of detection.
Sandwich method ELISA forms the basic principle of the commercially available
ELISA kits used in this study.  As the name implies, the molecule tested is held
between two different antibodies in this technique.  Monoclonal antibody specific to
the test molecule has been coated onto the wells of the microtiter strips provided in
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the kit.  Test samples, the supplied standardised amount of the test molecule, or
control specimens are added to the wells and allowed to react with the bound
antibody.  After washing, a known amount of enzyme-labelled antibody is added and
allowed to react with the bound test molecule.  Any excess unbound enzyme-linked
antibody is washed away after the reaction.  The substrate is added and the reaction
between the substrate and the enzyme produces a colour change.  The amount of
visual colour change is a direct measurement of the specific enzyme-conjugated
bound antibody, and is proportional to the concentration of the test molecule present
in the samples.  The colour change is assessed using a fibre-optic multichannel
spectrometer.
5.3.3) Statistical Analysis
Non-parametric statistical tests were used and data were given as median and
interquartile range because the observed mediator levels did not follow a normal
distribution.  Mann Whitney U tests were employed to detect statistical difference in
mediator concentrations between dichotomies for injury severity, PICU discharge
coma status, and outcome at 6 months.  For each mediator that had significantly
different levels between each assessment dichotomies, sensitivity and specificity of
incremental values as predictor of severe injury, coma at PICU discharge, and
unfavourable outcome at 6 months were calculated.
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5.3.3.1) Receiver-Operator Characteristic (ROC) Curve Analysis
Receiver Operator Characteristic (ROC) curves were then plotted and the optimal
cut-off value for each mediator, which was defined as the point closest to the left
upper corner of the ROC curve, was identified.  Areas under the ROC curves were
measured to compare the predictive values between mediators.
5.3.3.2) Multivariate Receiver-Operator Characteristic (MultiROC) Curve
Analyses
Multivariate Receiver-Operator Characteristic (MultiROC) curves analysis was used
to assess the outcome predictability of the pre-defined prognostic rules that had
specific criteria for the serum levels of 2 biomarkers.  One of the 2 biomarkers within
each prognostic rule acted as ‘the screening marker’ and was fixed at the prognostic
threshold while the other biomarker acted as the ‘varying marker’ so that
corresponding sensitivities and specificities at incremental values were calculated to
plot the MultiROC curve.
5.3.3.2.1) Defining Prognostic Thresholds for Screening Markers within
the Prognostic Rules
To define the prognostic threshold for each of the ‘screening marker’ within the
prognostic rules, each marker level was plotted against the outcome dichotomies and
the level which identified the most patients with good recovery without including
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any patient with unfavourable outcome was used as the prognostic threshold for that
particular marker.  The prognostic thresholds for each of the 8 biomarkers were




















Endothelin Level did not differentiate outcome
5.3.3.2.2) Defining Prognostic Rules for MultiROC Analyses
Because IL-10 and endothelin levels did not differentiate between the outcome
dichotomies, they were excluded from MultiROC analyses.  There were, therefore, 6
possible screening markers, and each screening marker was paired in turn with the
remaining 5 biomarkers to form 30 different prognostic rules which were
summarised in Table 5.2.
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Table 5.2:
Prognostic Rules for MultiROC Analyses
IL-6 $ 30 pg/ml as the screening marker:
• IL-6 $ 30 pg/ml AND IL-8 at varying incremental cutpoints
• IL-6 $ 30 pg/ml AND S100B at varying incremental cutpoints
• IL-6 $ 30 pg/ml AND NSE at varying incremental cutpoints
• IL-6 $ 30 pg/ml AND SICAM at varying incremental cutpoints
• IL-6 $ 30 pg/ml AND L-Selectin at varying incremental cutpoints
IL-8 $ 20 pg/ml as the screening marker:
• IL-8 $ 20 pg/ml AND IL-6 at varying incremental cutpoints
• IL-8 $ 20 pg/ml AND S100B at varying incremental cutpoints
• IL-8 $ 20 pg/ml AND NSE at varying incremental cutpoints
• IL-8 $ 20 pg/ml AND SICAM at varying incremental cutpoints
• IL-8 $ 20 pg/ml AND L-Selectin at varying incremental cutpoints
L-Selectin $ 700 ng/ml as the screening marker:
• L-Selectin $ 700 ng/ml AND IL-6 at varying incremental cutpoints
• L-Selectin $ 700 ng/ml AND IL-8 at varying incremental cutpoints
• L-Selectin $ 700 ng/ml AND S-100B at varying incremental cutpoints
• L-Selectin $ 700 ng/ml AND NSE at varying incremental cutpoints
• L-Selectin $ 700 ng/ml AND SICAM at varying incremental cutpoints
SICAM $ 700 ng/ml as the screening marker:
• SICAM $ 700 ng/ml AND IL-6 at varying incremental cutpoints
• SICAM $ 700 ng/ml AND IL-8 at varying incremental cutpoints
• SICAM $ 700 ng/ml AND S100B at varying incremental cutpoints
• SICAM $ 700 ng/ml AND NSE at varying incremental cutpoints
• SICAM $ 700 ng/ml AND L-Selectin at varying incremental cutpoints
S100B $ 0.04 ng/ml as the screening marker:
• S100B $ 0.04 ng/ml AND IL-6 at varying incremental cutpoints
• S100B $ 0.04 ng/ml AND IL-8 at varying incremental cutpoints
• S100B $ 0.04 ng/ml AND NSE at varying incremental cutpoints
• S100B $ 0.04 ng/ml AND SICAM at varying incremental cutpoints
• S100B $ 0.04 ng/ml AND L-Selectin at varying incremental cutpoints
NSE $ 12 ng/ml as the screening marker:
• NSE $ 12 ng/ml AND IL-6 at varying incremental cutpoints
• NSE $ 12 ng/ml AND IL-8 at varying incremental cutpoints
• NSE $ 12 ng/ml AND S100B at varying incremental cutpoints
• NSE $ 12 ng/ml AND SICAM at varying incremental cutpoints
• NSE $ 12 ng/ml AND L-Selectin at varying incremental cutpoints
5.3.3.2.3) Assessment of the Predictive Values of the Prognostic Rules
Areas under the MultiROC curves (AUC) were measured to compare the predictive
values between the different prognostic rules.  The predictive values of the
prognostic rules were also compared with the predictive value of each individual
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mediator of the same cohort to determine whether combining 2 biomarker levels had
a more superior outcome prognostic value.  The optimal cut-off value for each of the
varying mediator within the prognostic rules, which was defined as the point closest
to the left upper corner of the MultiROC curve, was also identified.
5.4) RESULTS
5.4.1) Injury severity and Outcome
Of the 28 children included in the study, 17 had severe injury while 11 had non-
severe injury.  19 patients had diffuse brain injury demonstrated on the initial CT
brain scan.  At PICU discharge, 23 patients regained consciousness while 5 remained
in a coma.  At 6 months post injury, 24 patients made a good recovery while 4
children had an unfavourable outcome of whom only 1 had regained consciousness
at PICU discharge (p = 0.01, Fisher’s Exact Test).
In the subgroup of 18 patients with day 5 mediator concentrations measured, 14 had
severe injury.  13 regained consciousness and 5 remained in a coma at PICU
discharge.  4 children had unfavourable outcome at 6 months of whom 3 had
remained in a coma at PICU discharge (p = 0.04, Fisher’s Exact Test).
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5.4.2) Mediator Concentrations and Injury Severity
Children with severe injury had significantly higher day 1 serum concentrations of
SICAM (p = 0.002) and IL-6 (p = 0.018) than those with non-severe injury (Figure
5.1). The area under the ROC curve (AUC) for SICAM was 0.834 while that for IL-6
was 0.791 indicating that SICAM was more superior in the diagnosis of severe injury
than IL-6 (Table 5.3).  No difference was found in any of the day 5 serum marker
concentrations between patients with different injury severity.
Figure 5.1:
5.4.3) Mediator Concentrations and Initial Brain CT Findings
NSE day 1 serum level was the only mediator level that was significantly raised in
children with diffuse injury demonstrated on the initial brain CT scan when
compared to those with focal injury (median levels for diffuse and focal injury were
15.21 and 7.31 ng/ml respectively, p = 0.01, Mann Whitney U test; AUC = 0.792).
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5.4.4) Mediator Concentrations and Outcome
5.4.4.1) At PICU Discharge
The day 1 IL-6 and L-selectin serum levels were significantly higher among patients
who remained comatose at PICU discharge than those who had regained
consciousness (Figure 5.2).  This was true for the day 5 serum level of S100B, NSE
and L-selectin (Figure 5.2).  Although day 1 L-selectin level had a better predictive
value than IL-6 for coma status at PICU discharge (Table 5.3), S100B day 5 level
had the best predictability of the PICU discharge coma status with a sensitivity of








SICAM Day 1 Level 800 ng/ml 76% 73% 0.83
IL-6 Day 1 Level 40 pg/ml 61% 91% 0.79




S100B Day 5 Level 0.025 ng/ml 80% 85% 0.88
NSE Day 5 Level 10 ng/ml 80% 77% 0.87
L-selectin Day 5
Level
800 ng/ml 100% 77% 0.86
L-selectin Day 1
Level
1000 ng/ml 80% 70% 0.86
IL-6 Day 1 Level 40 pg/ml 80% 61% 0.78






1200 ng/ml 75% 88% 0.92
L-selectin Day 5
Level
800 ng/ml 100% 71% 0.89
IL-8 Day 1 Level 30 pg/ml 75% 92% 0.88
NSE Day 1 Level 25 ng/ml 75% 83% 0.83
S100B Day 1 Level 0.05 ng/ml 75% 79% 0.83
IL-6 Day 1 Level 60 pg/ml 75% 71% 0.83
NSE Day 5 Level 10 ng/ml 75% 71% 0.82
5.4.4.2) 6 Months Post Injury
Patients with unfavourable outcome had significantly higher day 1 serum
concentrations of S-100B, NSE, L-selectin, IL-6, and IL-8 than those with good
recovery (Figure 5.3).  When considering the day 5 marker serum levels, only L-
selectin and NSE levels were significantly higher in children with unfavourable
outcome than those with good recovery (Figure 5.3).  Day 1 L-selectin level had the
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best predictive value for unfavourable outcome at 6 months after brain trauma with a




5.4.5) Comparisons of the Outcome Prediction Performance Between
the Different Prognostic Rules and Individual Marker Levels
When using individual marker level to predict unfavourable outcome, only the day 1
L-selectin level had an AUC > 0.9.  Of the 30 prognostic rules examined using
combination of 2 biomarker levels, 17 had AUC > 0.9 for prediction of unfavourable
outcome after brain trauma (Figure 5.4).  Prognostic rules using S100B > 0.04 ng/ml
as the screening markers had better predictive values for unfavourable outcome than
rules using other markers as the screening marker (Figure 5.4).  L-selectin when used
as the varying marker within the prognostic rules had better predictive values for




As described above, Day 1 L-Selectin level of 1200ng/ml was 75% sensitive and
88% specific for predicting poor outcome after brain trauma.  When considering the
prognostic rule that used the same L-Selectin level cut point (i.e. at 75% sensitivity)
but combined with S100B as the screening marker, the specificity increased to 96%
for prediction of unfavourable outcome (Figure 5.5).  Similarly if NSE > 12 ng/ml
was used as the screening marker with L-selectin day 1 level of 1200 ng/ml in the
prognostic rule, the sensitivity was 75% and specificity was 96% for predicting
unfavourable outcome (Figure 5.5).  The improvement in specificity was less if L-
selectin was paired with an inflammatory marker in the prognostic rule and only
increased to 92% when paired with IL-6 as the screening marker (Figure 5.5).
Figure 5.5
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The following prognostic rules were 100% sensitivity and 96% specific for
predicting unfavourable outcome after childhood brain trauma in our cohort (Figure
5.6):
1. Day 1 serum S100B level > 0.04 ng/ml AND Day 1 L-selectin level of 1000
ng/ml or more. (AUC 0.98)
2. Day 1 serum S100B level > 0.04 ng/ml AND Day 1 IL-6 serum level of 40




This study simultaneously evaluated the serum concentrations of multiple
biomarkers of different mediator families and their predictive values for severe
injury and unfavourable outcome in an exclusive child cohort measured at two
distinct time points after brain trauma.  We found that adhesion molecules had better
predictive values for severe injury and poor outcome after brain trauma than glial or
neuronal proteins, while glial protein had the best predictive value for PICU
discharge coma status.  In addition, we demonstrated prognostic rules combining 2
biomarker levels had more superior outcome prediction than could be achieved using
individual marker levels.
5.5.1) Investigating the Diagnostic and Predictive Values of Multiple
Biomarkers of Different Mediator Families
Majority of the reports in the current brain trauma biomarker literature have focused
on investigating individual mediators or a small number of mediators of the same
biochemical family [119, 121-123, 125, 126, 163-167, 169-172, 267, 309, 317, 346-
348].  Furthermore, they used different sample types and sampling time points after
injury making comparisons between study results difficult.  Our study, in contrast,
simultaneously evaluated the serum levels of 8 biomarkers which were chosen from
the main mediator families of previously reported potential brain trauma markers
namely: (i) glial proteins (S100B), (ii) neuronal proteins (NSE); (iii) interleukins (IL-
6, IL-8, and IL-10), (iv) adhesion molecules (SICAM and L-selectin); and (v)
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vasoconstrictors (endothelins).  This allowed us to investigate the diagnostic and
prognostic abilities of some of the previously lesser investigated biomarkers such as
adhesion molecules in addition to the more frequently studied biomarkers like S100B
and NSE.
Receiver-Operator Characteristic (ROC) curve analysis was used to compare these
markers’ diagnostic and outcome predictive values because it is a powerful tool for
evaluating a medical test’s validity without the need to define one single arbitrary
cut-off level [205].  It provides a simple and easily interpretable graphical display of
the trade-off between sensitivity and specificity at each decision thresholds [205].
Furthermore, calculating and comparing the area under the ROC curves (AUC) of
the different tests assess predictive discrimination with an AUC of 1.0 equating to
perfect prediction while that of 0.5 indicating random guessing [349].  Using this
simple but powerful tool, we were, therefore, able to report for the first time that out
of the 8 biomarkers evaluated, SICAM was the best severe brain injury indicator
while L-selectin had the best predictability of unfavourable outcome after childhood
brain trauma.
5.5.2) Biomarkers and Indication of Injury Severity
IL-6 [123, 350-352], SICAM [169], S100B [353, 354], and NSE [163] have
independently been associated with severe brain injury in previous adult and
paediatric brain trauma studies.  IL-6 is able to cause and inhibit inflammation after
brain injury.  Its serum and CSF levels measured at various time points up to 12
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hours after brain trauma have been extensively reported to differentiate injury
severity in adults and children [123, 350, 352, 355, 356].  Our finding is consistent
with these previous reports [123, 350, 352, 355, 356] and suggested that IL-6 level
measured at 24 hours post injury was still useful in identifying severe brain trauma in
children.
SICAM is present in soluble active forms in the blood of normal humans but its
precise function in healthy individuals remains unknown.  Although it is less well
investigated previously, CSF and arterial serum SICAM levels have been shown to
correlate with injury severity in adults when measured at 24 hours after brain trauma
[169, 347].  Our finding is, therefore, consistent with these previous reports.  Given
the limited knowledge on the function of SICAM post brain trauma, it is difficult to
ascertain why it is potentially more superior in diagnosing severe brain injury than
other markers in our cohort and warrants further investigations.
L-selectin is another adhesion molecule that has been previously reported to
differentiate injury severity after brain trauma.  Similar to SICAM, little information
is available on its function in humans.  Its serum level measured after brain trauma
has been found to be persistently below those detectable in normal healthy adults
[169].  McKeating and colleague additionally found that when considering its
concentrations in brain trauma adults, those who sustained severe brain trauma had
significantly higher serum L-selectin levels than those with non-severe injury [169].
We did not demonstrate any association between L-selectin level and injury severity
212
in our exclusive child cohort.  Further studies are necessary to ascertain its
relationship with injury severity after brain trauma.
S100B is a calcium binding protein in astrocytes and NSE is a soluble cytoplasmic
protein localised principally in neurons and neuroendocrine cells.  Although raised
serum levels of these glial and neuronal proteins indicate irreversible astrocyte and
neuronal injury, their ability to quantify brain injury severity remains controversial
with only limited reports describing an association between severe injury and early
serum levels measured in the emergency department or on admission to ICU [163,
353, 354].  In our cohort, S100B and NSE serum levels did not differentiate injury
severity.  This was consistent with previous reports where serum measurement of
these markers at 24 hours post injury failed to relate to severe brain trauma [270,
357].  This suggested that the timing of the assay after the initial injury was
particularly important if glial or neuronal proteins were used to diagnose severe brain
trauma and this may be related to their relatively short serum half-life.
5.5.3) Biomarkers and Prediction of PICU Discharge Coma Status
In our cohort, only 1 of the 23 patients who regained consciousness at PICU
discharge had unfavourable outcome at 6 months after brain trauma.  This reaffirmed
the relationship between conscious state and outcome after brain trauma.  We found
that brain specific proteins measured on the fifth day post injury had the best
predictive value for PICU discharge coma status even though their levels on day 1
had no association with the conscious state at the completion of neuro-intensive care.
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It is possible that day 5 marker levels represent the total burden of brain damage
from both primary brain injury and second insults and may, therefore, better
differentiate patients who are likely to remain comatose from those who will regain
consciousness at PICU discharge.  Reactive astrogliosis has previously been reported
to associate with a secondary rise in S100B levels after brain trauma [311] and this
may explain our finding.  Alternatively, the rate of recovery in conscious levels may
vary with the speed of decline in the serum levels of glial or neuronal proteins.
Further studies are required to assess this postulate and to determine whether the
decline rate of these markers’ serum levels may potentially be used as a monitor of
clinical recovery.
5.5.4) Biomarkers and Outcome Prediction
5.5.4.1) Brain Trauma Outcome Prediction with Glial and Neuronal
Proteins
Brain specific proteins are the most frequently investigated potential brain trauma
biomarkers, and many studies have reported an association between poor outcome
and elevated serum levels of glial and neuronal proteins in adults and children.  In a
study of 41 head injured adults with varying degree of severity, Rothoerl and
colleague found that the mean serum S-100B levels were significantly higher in
those with unfavourable outcome [168].  Jackson and co-workers examined the
admission and 4-hour post injury serum S100B levels of 30 severely brain injured
adults and found that only the admission serum level correlated with outcome [316].
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In another study involving 84 patients with an admission GCS ! 8, the peak serum S-
100B levels were significantly higher among patients with unfavourable outcome
when compared to those with favourable recovery, but the serum NSE levels did not
differ between the two groups [317].  Evaluation of the serum S100B levels of 27
children measured within 12 hours of sustaining brain trauma showed that children
with poor outcome (Pediatric Cerebral Performance Category score of less than 4) at
6 months post injury had significantly higher S100B concentrations than those with
good recovery [358].  In another childhood brain trauma study, the emergency
department admission serum NSE levels of the 86 patients predicted poor outcome at
the time of hospital discharge with 74% specificity and 86% sensitivity using a cut-
off value of 21.2ng/ml [359].  However, others investigators had also failed to
demonstrate any correlation between the serum or CSF NSE concentrations and
neurological recovery [166, 310].  Our finding with S100B and NSE day 1 levels and
poor outcome was, therefore, consistent with these previous reports.
5.5.4.2) Brain Trauma Outcome Prediction with Interleukins
Inflammatory mediators have similarly been reported to have potential outcome
predictive value after brain trauma.  In a study of 94 head injured adults, the
maximum IL-6 plasma levels in fatal cases were 8 times higher than those measured
in the survivors [360].  In another study of 22 patients with severe brain trauma,
serum IL-6 and IL-8 levels measured after 72 hours post injury were significantly
higher in the fatal group [176].  Minambres and colleagues assessed paired arterial
and venous serum IL-6 levels in 62 adults requiring intensive care after brain trauma
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and found that elevated transcranial gradient of IL-6 was associated with poor
outcome at 6 month post injury [352].  Our study confirmed that serum IL-6 and IL-8
levels were predictive of unfavourable outcome after childhood brain trauma.  The
outcome predictive value of IL-6 in our cohort was inferior to that of IL-8, while IL-
10 had no association with outcome.  This indicated that mediators from the same
biochemical family may have very different outcome predictability after brain
trauma and highlighted the need to study multiple markers even if they belonged to
the same biochemical family.
5.5.4.3) Brain Trauma Outcome Prediction with Adhesion Molecules
In addition to IL-6 and IL-8, we found L-selectin serum levels to be highly predictive
of unfavourable outcome after childhood brain trauma.  It is one of the least
investigated potential biomarkers of brain trauma and, to the best of my knowledge,
our study is the first to describe its association with poor outcome after brain trauma.
Further studies are, therefore, warranted to investigate this promising brain trauma
biomarker.
5.5.4.4) L-Selectin and IL-8 Serum Levels had the Highest Outcome
Predictive Values
It is unclear from the exiting literature whether acute serum levels of brain specific
proteins or inflammatory mediators have more accurate brain trauma outcome
prediction.  This is because majority of these previous studies concentrated on
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evaluating a single mediator or limited numbers of mediators from the same
biomarker family.  Additionally, the reports in the literature often use different
specimen types, sample collection time points, and data analyses making
comparisons between studies difficult.  Our study demonstrated that some
inflammatory markers (L-selectin and IL-8) had better predictability of unfavourable
outcome after brain trauma than glial or neuronal proteins when measured on day 1
and 5 post injury.  The relatively short serum half-life of glial and neuronal proteins
may explain this observation and serum levels of these proteins measured sooner
after brain trauma may offer more superior outcome prediction.  Another possible
interpretation is that although serum levels of glial and neuronal proteins estimate
astrocyte and neuronal damage, they are unable to accurately quantify the degree of
damage.  Serum inflammatory marker levels may, on the other hand, have better
associations with the actual burden of neuro-inflammation.  Alternatively, neuro-
inflammation may have greater influence on outcome after brain trauma than
previously expected.
We also demonstrated that the day 1 L-selectin level had a higher predictive value
for unfavourable outcome than its level measured on the fifth day post injury, and
neither IL-6 nor IL-8 day 5 levels were associated with poor outcome.  Different
marker’s decline time course may explain this observation.  Neuro-inflammation is a
heterogeneous process with different pathways operating and subsiding at various
time points after brain trauma.  It is, therefore, important to further evaluate the
pathways involved in neuro-inflammation and their time course after brain trauma.
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5.5.4.5) Brain Trauma Outcome Prediction with Prognostic Rules
Combining 2 Biomarker Levels
Brain trauma outcome is dependent upon many factors, and to expect successful and
accurate prognostication with a single serum biomarker is unrealistic.  However,
most previous studies of serum biomarkers for brain trauma only investigated the
relationships between individual markers and outcome.  Other investigators who
simultaneously assessed a small number of mediators from the same biomarker
family compared each marker’s outcome predictive values without considering
combined markers’ predictability.  To the best of my knowledge, this study is the
first to report the usefulness of prognostic rules combining 2 biomarker levels on
outcome prediction after brain trauma.
5.5.4.5.1) Multivariate Receiver-Operator Characteristic (MultiROC)
Curve Analysis
Powerful statistical techniques such as linear discriminate analysis and logistic
regression are able to combine the results of multiple tests to form decision trees, but
require expert statistical assistance.  In addition, the derived diagnostic or prognostic
rules are often too complex to apply to day-to-day clinical practice and are, therefore,
restricted to research use only.  Although ROC curves are simple to interpret and
allowed robust assessment of a medical test’s validity, they are limited to the display
of a single test’s performance, or the comparison of different single tests.  Shultz
described a novel multivariate extension to ROC curve analysis that allowed
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comparisons between the performances of multivariate rules while retaining the
simplicity of interpretation of the traditional ROC curves [361].
To construct a multivariate ROC (MultiROC) curve, a pre-defined diagnostic rule
using two or more test results is required [361].  The pre-defined diagnostic rule will
typically consist of a Boolean expression (i.e. containing ‘and’, ‘or’, ‘not’) of
different tests related by algebraic operators (addition, subtraction, multiplication,
division, equivalence, less than, or greater than) [361].  Each component of the rule
is fixed at a specific diagnostic threshold with the exception of one component which
is varied over all of its possible values, and the corresponding sensitivity and
specificity are calculated to create the curve [361].  Interpretation of the MultiROC
curve is the same as the traditional ROC curve [361].  MultiROC curves may,
therefore, be created for different diagnostic rules to compare their diagnostic
accuracy using the graphical displays [361].  Alternatively, the diagnostic
performance between different rules may be assessed using the calculated areas
under the MultiROC curves [361].
5.5.4.5.2) Screening and Varying Markers in Prognostic Rules and Their
Effects on the Rules’ Prognostic Performance
Utilising the MultiROC curve analysis, we demonstrated that prognostic rules
combining 2 biomarkers had a higher prognostic accuracy for outcome prediction
than using individual marker’s levels after brain trauma.  In addition, we found that
the rules’ performance varied greatly with the choice of the screening and varying
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markers within the prognostic rule.  Prognostic rules that used a glial or neuronal
protein as the screening marker had better predictability than rules that used either of
these proteins as the varying marker.  On the other hand, prognostic rules that used
L-selectin as the varying marker offered more superior outcome prediction than
those using it as the screening marker.  One possible explanation to these
observations was that the screening marker thresholds we chose for the glial or
neuronal markers were more sensitive in screening for patients with unfavourable
outcome than that chosen for L-selectin.  Alternatively, although elevated glial and
neuronal proteins signalled irreversible glial and neuronal damages, their relatively
short serum half lives meant that their serum levels at the time of sampling in our
cohort were better served as a screening tool for patients with unfavourable outcome.
We also found that outcome prediction with prognostic rules that used 2 biomarkers
from the same mediator family was inferior to rules that utilized 2 markers from
different mediator families.  The most superior prediction of unfavourable outcome
was achieved with rules that utilised S100B as the screening marker and either L-
selectin (an adhesion molecule) or IL-6 (an interleukin) as the varying marker.
These rules were 100% sensitive and 96% specific in their prognostic accuracy.  The
enhanced performance observed with these rules may be because of their ability to
draw information from the degree of glial damage and neuroinflammation.  This may
also explain why prognostic rules that combined interleukins and SICAM had very
inferior predictive values as they only assessed the degree of inflammation without
considering glial or neuronal damage.
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5.5.5) Limitations of the Study
The major limitation of our study is the small cohort size and paucity of patients with
unfavourable outcome resulting in the need to assess outcome in dichotomies.  In
addition, because of the small cohort size, we were not able to validate the proposed
prognostic rules.
Brain trauma induced cellular and molecular pathophysiological processes are
modulated by many more mediators than the 8 biomarkers we chose for evaluation in
this study.  Although it is a step forward from investigating individual markers, we
have only investigated the outcome predictive values of 8 different biomarkers and
prognostic rules that combined 2 of these chosen biomarkers at any one time.
Predictability of mediators not studied in this study requires further investigation and
may have more superior outcome prediction than our chosen biomarkers.
5.6) CONCLUSIONS
Adhesion molecules may be more useful in diagnosing severe injury and predicting
poor outcome after childhood brain trauma than brain specific proteins.
Combining 2 biomarker levels in prognostic rules offered more superior outcome
prediction than using the individual marker’s levels.  Prognostic rules that utilize the
day 1 serum levels of 2 biomarkers from different mediator families may predict
unfavourable outcome after brain trauma with 100% sensitivity and 96% specificity.
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A larger clinical study is required to validate these proposed prognostic rules and to
assess their relationships with CPP insult.
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CHAPTER 6: NEUROPATHOLOGICAL FEATURES OF FATAL
PAEDIATRIC TBI
6.1) BACKGROUND
Brain trauma remains the commonest cause of childhood death in Britain despite
significant advances in resuscitation skills and trauma care over the past two
decades.  It has been estimated that fatal outcome occurs between 5 to 20% of all
acute childhood brain trauma requiring hospital admissions [1, 145, 146].  In spite of
its frequent occurrence, only a few studies in the literature have detailed the
pathological findings of fatal childhood brain trauma.
Between the 1960s and 1980s, a number of historic reports described the types of
brain damage encountered among fatal non-missile head injury in adults and children
[362-368].  However, comparisons of these studies were difficult because their
findings relied upon data originating from two distinct types of studies: some studies
consisted of only macroscopic examinations of large number of brain trauma
fatalities but failed to recognise many important brain damage features, while the
others consisted of small series of detailed neuropathological studies which were too
selective to be of much general value.
In 1980, Adams and colleagues utilized a unique systematic post-mortem reporting
method to document the detailed neuropathological features of 151 cases of fatal
non-missile brain injury [369].  They demonstrated that important severe brain
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damage features might be missed at necropsy unless various lesions were looked for
specifically [369].  In addition, they introduced a novel quantitative contusion index
which allowed for the first time a statistical approach to the assessment of contusions
[369].  Both the systematic post-mortem reporting method and the quantitative
contusion index have since been adopted by other investigators to summarise
neuropathological features of fatal brain trauma in both adult and childhood
populations.
Adams’ cohort included both adult and childhood brain trauma fatalities.  The first
comprehensive report of detailed neuropathological features of fatal paediatric brain
trauma appeared in the literature in 1989 when Graham and co-workers used the
same systematic reporting system as Adams’ report to document necropsy features of
87 fatal childhood accidental brain trauma from the west of Scotland [60].  Their
cohort comprised of fatal brain trauma patients aged between 2 and 15 years
identified from their main cohort of 635 cases of accidental brain trauma occurring
between 1968 and 1982 [60].  They found that the pattern of brain damage observed
in fatal paediatric brain trauma was generally similar to those identified in adult brain
trauma fatalities [60].  This was not a surprising finding given their cohort excluded
infants and children younger than 2 years of age based upon the known
developmental difference in the skull base and calvaria in this age group compared
with those of adults.  The only significant difference they found between paediatric
and adult brain trauma fatalities was the prevalence of diffuse brain swelling which
occurred 4 times more frequently in children than in adults [60].  This finding
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supported other neuroimaging reports where acute brain swelling was a frequent
finding among comatose children following brain trauma [370].
Hypoxic ischaemic brain damage is another frequent post-mortem finding of fatal
brain trauma and was identified in 61% of the paediatric brain trauma fatalities
reported by Graham’s group [60] when resuscitation skills and trauma care were not
as vigilant as the current system in place in Scotland.  It is unknown whether the
improvement in acute trauma care training and provision over the past 2 decades has
any effect on the prevalence of hypoxic ischaemic brain damage identified at post
mortem examinations.  Furthermore, no previous study has investigated the
correlation between the amount of cerebral perfusion pressure insult experienced by
paediatric brain trauma patients prior to death and the degree of hypoxic ischaemic
brain damage identified at post-mortem.
Advancement in neuro-imaging and histopathological examination techniques
enables white matter damage or axonal injuries to be identified more frequently in
brain trauma patients.  The introduction and routine application of
immunohistochemical staining for #-APP have greatly facilitated the assessment of
axonal damage in fatal brain trauma [371-373].  This antibody can be used to
identify areas of disrupted axonal flow.  Although it is only a marker of axonal
damage and is not specific for trauma, it is still useful in the assessment of diffuse
traumatic axonal injury (TAI).  Damageed axons in adults have been identified
among those who survived for as little as 35 minutes following the initial brain
trauma using this technique [374], and the immunoreactivity is maximal at about 24
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hours post-injury [373].  However, the time course and distribution of traumatic
axonal pathology in infants and children has never been adequately studied, and
there are good reasons to anticipate differences due to the varying degree of
myelination with age and the vulnerability of the developing brain to metabolic
insults such as hypoxia [375] and hypoglycaemia [376] which have been postulated
as an important mechanism of secondary axonal injury.
Many advances have been introduced into modern trauma care over the past twenty
years.  These changes included improvement in resuscitation training and its
provision, early transfer of brain trauma patients to trauma centres, and early
instigation of neuro-intensive care.  However, little is known on how these clinical
management changes have affected neuropathological features of fatal childhood
brain trauma.
Some neuropathological features of fatal brain trauma such as diffuse axonal injury
and hypoxic ischaemic brain damage have been accepted to require time to evolve
clinically and most published neuropathological series of fatal brain trauma have
only examined fatalities that have survived long enough to reach neurosurgical
centres and excluded instantaneous brain trauma deaths.  This latter group of patients
are unique given their primary mechanical brain injury was so severe that death
occurred instantaneously or very shortly after the injury was sustained, and therefore,
secondary brain damage should contribute very little towards its brain damage
pattern seen at post mortem.  It remains unknown whether diffuse traumatic axonal
injury or hypoxic ischaemic brain damage is also found in instantaneous deaths.
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6.2) HYPOTHESES AND AIMS
We hypothesize that (i) advances in modern trauma care over the past twenty years
to minimise secondary insults have reduced the incidence of hypoxic ischaemic brain
damage in fatal childhood brain trauma.  In addition, (ii) the amount of hypoxic
ischaemic brain damage identified at the post mortem of paediatric brain trauma
fatalities correlates proportionately to the total burden of secondary cerebral
perfusion pressure insult experience by these patients in the PICU prior to death.
In this chapter, we aim to determine whether the neuropathological features of
paediatric brain trauma fatalities differ between cases of different survival duration,
and different mode of primary injury mechanisms.  In addition, we aim to assess
whether the amount of hypoxic ischaemic brain damage identified at post mortem
correlated to the total burden of pre-morbid CPP insult in childhood brain trauma.
6.3) METHODS
6.3.1) Original Proposed Methods
All fatal cases already enrolled into the secondary insult study were to be recruited
into the neuropathological study.  As required by law, all brain trauma fatalities are
referred to the Procurator Fiscal in Scotland and the Coroner in England.  Permission
from the family to perform further detailed research neuropathological investigations
227
on the samples obtained and retained by the Fiscal or Coroner post-mortem
examination would need to be sought before conducting post-mortem examinations.
We had planned to ask the Procurator Fiscal or Coroner for access to the post-
mortem examination report (including the detailed neuropathological report) after the
Fiscal or Coroner post-mortem examination had been carried out.
Laboratory based investigation was to be conducted at the Department of Pathology,
Neuropathology Section, Western General Hospital, Edinburgh.  A pre-designed
proforma was to be used for each case to collect standardised information relating to
the detailed pathological features as described previously by Adams and co-workers
[369].  Histology was to be examined from the cerebrum, cerebellum, and spinal
cord, using both haematoxylin and eosin (H&E) and #-APP immunohistochemistry.
In addition, clinical and demographic details, and physiological recordings in minute
resolution collected during their intensive care stay prior to death were to be
correlated with the recorded pathological findings.  Local ethics and hospital
management committees approved the study.
6.3.1.1) Problems Encountered During Recruitment
Since the highest anticipated fatality rate of childhood brain trauma is up to 20% [1,
145, 146], the maximum possible number to be recruited for detailed neuropathology
investigations from the two centres over a two-and-a-half-year period would still be
small.  Fatality rate was lower than expected and there were only 5 deaths among the
participants of the secondary physiological insult study during the first year of
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recruitment.  This period also coincided with the height of the public and media
attentions on the Alder Hey organ retention scandals.  Despite our attentions to
research details and forward planning, recruitment into the neuropathological study
suffered greatly.  Fiscal or Coronial post-mortem examinations were ordered in four
of the five fatal cases from our study.  All of these families were approached to seek
their permissions to use the specimens collected for research by the principal
investigator who was also a senior paediatrician.  Following verbal explanation of
the neuropathology study protocol, written study information sheet was also given to
the families.  Only two of these four families (50%) gave their consent for the
autopsy specimens to be used in research.  One family refused consent to a hospital
post-mortem following the Fiscals’ decision on not ordering a fiscal autopsy.  This
participation rate is significantly less than the projected figures based on previous
data [377] and in contrast to the views of a significant proportion of families
involved in the Alder Hey Inquiry where they had indicated their willingness to grant
consent for organs that had been kept for research had they been asked [378].
6.3.2) Actual Study Methods
Once the difficulty in prospectively recruiting fatal brain trauma cases with detailed
physiological data into the study was realised, the methodology was modified so that
most of our hypotheses could be tested using an archival collection of post-mortem
information and specimens collected from 50 childhood brain trauma fatalities held
within the Neuropathology Section of the Department of Pathology at Western
General Hospital over a thirteen-year period between 1990 and 2003.  Utilising the
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same pre-designed proforma, standardised information relating to the principal
pathological features was collected.  The previously proposed histological
examination was conducted from the cerebrum, cerebellum, and spinal cord, using
both haematoxylin and eosin (H&E) and #-APP immunohistochemistry.  Non-
parametric statistical analyses were conducted because the distribution of data did
not follow normal distribution.  Mann Whitney U Test was used for continuous
variables while Fisher’s Exact Test was used for nominal data examined in
dichotomies.
I acknowledge that this modified methodology does not allow determination of the
relationships between neuropathological findings and pre-morbid physiological
insults in fatal childhood brain trauma.
The position on conducting research on archival necropsy materials i.e. organs and
tissue retained before December 2000 has been clarified by reports and guidelines
published by the Independent Review Group on the Retention of Organs at Post-
mortem in Scotland (The McLean Review) [379] and the Medical Research Councils
[380].  They acknowledge the difficulties to seek retrospective consents from
families for the use of archival tissues for ethically legitimate research or teaching
purposes.  As a result, they recommended that these material may be used for
research provided that ethical approval has been granted by the local ethical
committee for the proposed project and the specimens are used in an anonymous and
unlinked manner [379, 380].  Following the guidance from these publications, ethical
approval for the modified aims and methodology of the study was obtained prior to
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commencing data collection and analyses.  The study was in accordance with the
Human Tissue (Scotland) Act 2006.
6.4) RESULTS
6.4.1) Mode of Brain Trauma and Survival Durations
Mode of brain trauma and survival duration were known in all 50 cases, of which 7
were due to falls, 31 were the result of road traffic accidents, 9 cases were sustained
from non-accidental injuries, and 3 were due to other trauma (such as sporting
injury).  31 of the 50 cases survived less than 24 hours, of which 19 suffered an
instantaneous death.
6.4.2) Distributions of the Different Pathological Findings
49 cases had detailed documentation of all neuropathological features and table 6.1
summarised the distribution of the pathological findings.  Brain swelling was the
commonest finding as demonstrated in 46 of the 49 cases (94%).  The most frequent
signs of intracranial hypertension were tentorial and tonsillar hernia.  None of the 49
cases demonstrated any infarct without evidence of raised ICP.  Supertentorial
subarachnoid haemorrhage were the most frequently identified intracranial bleeding
site occurring in 73% of cases.  31 of 47 cases had evidence of hypoxic ischaemic
brain damage of which 7 were mild, 8 were moderate, and 16 were severe.
231
Information regarding skull fracture was available in only 34 cases of which half had
skull fracture identified.
Table 6.1:
Pathological Features Numbers (%)
Brain Swelling 46 (94%)
Supertentorial Haematoma 40 (82%)
Evidence of Raised ICP 33 (67%)
Hypoxic Ischaemic Brain Damage
(Documented in 47 cases only)
31 (66%)
Brain Contusion 30 (61%)
Infratentorial Haematoma / Burst Lobe 19 (39%)
Intracerebral Haematoma 16 (33%)
Diffuse Axonal Injury 12 (24%)
Supertentorial Burst Lobe 11 (22%)
Gliosis 3 (6%)
Acute Vascular Injury 2 (4%)
Microglial Activation 1 (2%)
Boundary Zone Infarct 1 (2%)
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6.4.3) Comparisons of the Neuropathological Features Between
Different Survival Durations
6.4.3.1) Survival Less than 24 Hours vs. Survival of 24 Hours or More
Post Injury
31 of the 49 cases examined survived less than 24 hours following brain trauma.
Table 6.2 detailed the important and statistical significant pathological feature
comparisons.
Table 6.2:
Survival < 24 hours Survived 24 hrs or
more
Significance
Age (months) 90.6 69.6 p = 0.160
(Mann Whitney U)
Boys 17 / 31 12 / 18 p = 0.768
(Fisher’s Exact)
RTA 24 / 31 7 / 18 p = 0.011
(Fisher’s Exact)





11 / 30 9 / 17 p = 0.229
(Fisher’s Exact)




11.23 14.74 p = 0.680
(Mann Whitney U)
























1 / 31 4 / 18 p = 0.054
(Fisher’s Exact)
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Evidence of raised ICP was found in 55% of cases surviving less than 24 hours post
injury but it was evident in 89% of cases surviving more than 24 hours (p = 0.025).
16 of the 18 cases (89%) surviving more than 24 hours had evidence of tonsillar
herniation bilaterally while it was found in only 29% of cases surviving less than 24
hours (p < 0.001).  Left sided tentorial hernia was identified more frequently among
cases surviving more than 24 hours post injury (p = 0.04).
6.4.3.2) Instantaneous Deaths vs. Non-Instantaneous Deaths
19 of the 49 cases examined suffered an instantaneous death.  Table 6.3 summarised






Age (months) 74.5 57.5 p = 0.159
(Mann Whitney U)
Boys 12 / 19 17 / 31 p = 0.769
(Fisher’s Exact)
RTA 16 / 19 15 / 30 p = 0.012
(Fisher’s Exact)





4 / 18 16 / 28 p = 0.032
(Fisher’s Exact)




12.58 12.55 p = 0.834
(Mann Whitney U)












2 / 18 15 / 30 p = 0.011
(Fisher’s Exact)
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Fewer cases of instantaneous deaths had diffuse hypoxic ischaemic brain damage
than those among non-instantaneous deaths (Table 6.3).  Significantly more
instantaneous deaths (72%) had either no evidence or only mild degree of hypoxic
ischaemic brain damage when compared with cases from non-instantaneous deaths
(34%) (p = 0.02, Fisher’s Exact Test).  Diffuse traumatic axonal injury was not found
in any of the instantaneous deaths but was identified in 67% of non-instantaneous
deaths (p < 0.01, Fisher’s Exact Test).
Evidence of raised ICP did not differ significantly between the two dichotomies
(Table 6.3).  Significantly fewer instantaneous deaths demonstrated evidence of
tentorial and tonsillar hernia when compared with non-instantaneous deaths (22% vs.
63% for left sided tentorial hernia, p < 0.01; 26% vs. 63% for right sided tentorial
hernia, p = 0.02; 22% vs. 70% for tonsillar hernia bilaterally, p < 0.01).
6.4.4) Comparisons of the Neuropathological Features Between
Different Modes of Brain Injury
6.4.4.1) Road Traffic Accidents (RTA) vs. Non-RTA
31 cases sustained their brain trauma from road traffic accidents (RTA).  RTA
fatalities were significantly older than those from non-RTA (median age 105.2
months vs. 32.9 months respectively, p < 0.01, Mann Whitney U Test).
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Significantly more instantaneous deaths were the result of RTA (52%) when
compared with non-RTA (13%) (p < 0.01, Fisher’s Exact Test).  Similarly, there
were significantly more RTA fatalities who survived less than 24 hours post injury
than non-RTA fatalities (77% vs. 38%, p < 0.01).
There was also a trend to suggest that RTA fatalities tend to have more moderate or
severe contusion than the non-RTA deaths (32% found in RTA fatalities vs. 7 % in
non-RTA fatalities, p = 0.07).  The mean total contusion index was 13.2 and 12.8 in
RTA and non-RTA deaths respectively and did not show any statistical significance
(p = 0.36).  Brain trauma deaths from RTA and non-RTA had similar evidence of
raised ICP.  No significant difference was found in the incidence of haematomata
and burst lobes of all intracranial locations between RTA and non-RTA fatalities.
6.4.4.2) Accidental Head Injuries vs. Non-Accidental Head Injuries
(NAHI)
9 cases sustained their brain trauma from non-accidental head injuries (NAHI).  They
were significantly younger than those cases with brain trauma from accidental causes
(median age of 3.6 weeks in NAHI cases compared to 107.2 weeks in accidental
head injuries, p < 0.001, Mann Whitney U Test).
None of the NAHI suffered an instantaneous death while 46% of the accidental head
injuries suffered an instantaneous death (p < 0.01, Fisher’s Exact Test).  There was a
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trend to suggest more accidental head injuries cases surviving less than 24 hours than
the NAHI cases (68% in accidental head injuries vs. 33% in NAHI, p = 0.06).
Contusion was found significantly more frequently among accidental brain trauma
fatalities than NAHI (71% in accidental brain trauma fatalities vs. 13% in NAHI, p <
0.01, Fisher’s Exact Test).  No significant difference was found in the evidence of
raised ICP between the two causes of brain trauma fatalities.
Apart from the highest frequency of left sided supratentorial subdural haematomata
found among NAHI fatalities (75% in NAHI vs. 33% in accidental head injury, p =
0.04, Fisher’s Exact Test), no significant difference was found in the incidence of
haematomata, and burst lobes of other intracranial locations within the dichotomy.
6.4.4.3) Falls vs. Non-Falls
Fall was the cause of brain trauma in 7 cases.  The median age, sex distribution, and
survival duration did not differ between fatalities due to falls and non-falls.
Death from falls and non-falls had similar incidence of signs of raised ICP.
Significantly more fatalities from falls had left sided supratentorial extradural
haematomata when compared with brain trauma death caused by non-fall mechanism
(57% in falls vs. 10% in non-falls, p < 0.01 Fisher’s Exact Test).  Right sided
supratentorial subarachnoid haematomata were found among all falls related
fatalities but demonstrated in only 56% of non-fall related death (p = 0.04, Fisher’s
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Exact Test).  No significant difference was found in the incidence of haematomata
and burst lobe in other intracranial locations between the 2 groups.
6.5) DISCUSSIONS
Detail neuropathological examination of fatal childhood brain trauma provides an
ideal opportunity to understand how different injuring mechanisms, survival
durations, brain maturity, and clinical management affect the distribution of
neuropathological patterns.  To the best of my knowledge, there is no other
systematic neuropathological report of fatal paediatric traumatic brain injury which
included accidental injuries since Graham’s report [60] in the literature until our
current study.  Our current series differ from Graham’s cohort [60] in several ways.
Our series collected necropsy data from fatal childhood brain trauma which included
younger infants and those who died of non-accidental brain trauma.  In addition, our
cohort had shorter survival duration (62% of the current series survived less than 24
hours while the median survival period was 48 hours in Graham’s cohort [60]),
originated from a different geographic area (Eastern vs. Western Scotland), and the
fatalities had occurred at least 10 years later than those cases from Graham’s group
[60].  Despite these differences, important information on both primary brain injury
and secondary brain insults can be obtained from data comparisons between these
studies.  Furthermore, the composition of our current series allowed important
comparison to be made between cases of different survival durations and mode of
brain trauma and allowed the difference in the neuropathological pattern among
these groups to be highlighted.
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6.5.1) Diffuse Brain Swelling
Diffuse brain swelling is the commonest pathological finding of fatal brain trauma at
post mortem and it is identified more frequently among childhood brain trauma than
adult TBI.  Graham and co-workers previously reported finding brain swelling
among 70% of the cases of fatal paediatric brain trauma [60] which was 4 times
more frequent than the figure reported from their main adult brain trauma fatality
cohort [369].  Brain swelling was found in 94% of our current cohort which was
even higher than that found in Graham’s series [60] which excluded patients who did
not survive long enough to reach neuro-surgical care.  This finding confirmed that
the immature brains of infants and children were prone to developing brain swelling
following trauma, and brain swelling may occur any time after trauma regardless of
the survival period.
Different duration of survival and mode of brain trauma did not have any differential
effect on the prevalence of brain swelling among our current series.  This was not an
unexpected finding given that cerebral oedema is a generic clinical manifestation of
various pathological processes initiated by brain trauma.
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6.5.2) Hypoxic Ischaemic Damage
Ischaemic brain damage is a common post mortem finding of adults and children
who died from brain trauma.  Despite advancement in resuscitation and treatment of
brain trauma, Graham and colleagues reported that ischaemic brain damage
identified at post mortem was as common in the early 1980s as it was in the late
1960s and early 1970s in the West of Scotland [58].  The prevalence of ischaemic
brain damage in our current series (66%) is lower than that previously reported by
Graham’s paediatric group (80%) [60] but majority of the ischaemic brain damage
identified in both series were of moderate to severe severity (51% in our series vs.
61% in Graham’s group [60]).
The difference in prevalence of ischaemic brain damage between our current series
and that of Graham’s paediatric group may be a mere reflection of the improvement
of resuscitation measures and brain trauma treatment with time.  However, the
similarity in the prevalence of moderate to severe ischaemic brain damage identified
in both series would suggest that the changes in resuscitation training and provision,
and neuro-intensive care treatment of brain trauma patients over the past two decades
had failed to prevent ischaemic brain damage of this severity.
The difference in survival durations between our current series and that of Graham’s
cohort [60] may better explain the difference observed in the overall ischaemic brain
damage prevalence.  The survival time composition of our cohort enabled us to
confirm that hypoxic ischaemic brain damage requires time to evolve.  In our current
240
cohort, we found that although hypoxic ischaemic brain damage was identifiable in
cases of instantaneous death, significantly fewer cases of instantaneous death had
evidence of diffuse hypoxic ischaemic brain damage when compared to those of non-
instantaneous deaths (p = 0.03).  Instantaneous death from fatal brain trauma
represented the most severe brain trauma when the primary brain injury was too
severe to survive and these cases did not have sufficient time for secondary brain
insult to evolve.  Secondary brain insult should, therefore, contribute little towards
the pathological findings in this group.  Graham’s cohort did not include any
instantaneous deaths [60].  All their cases had, therefore, survived long enough to
allow ischaemic brain damage to evolve and be identified at post mortem which may
explain the higher prevalence of ischaemic brain damage described in Graham's
report.
We also demonstrated that survival beyond 24 hours did not increase the ischaemic
brain damage prevalence when compared with those surviving less than 24 hours (p
= 0.23).  Patients surviving less than 24 hours represented a group of patients whose
primary brain injury was not severe enough to cause death instantaneously, and
although their survival time was short, it was long enough for secondary hypoxic
ischaemic brain damage to develop.  It also reflected that any patients who survived
the initial brain trauma were as susceptible to ischaemic brain damage as those who
survived longer than 24 hours and highlighted the importance of diligent acute
trauma care (including pre-hospital care) to normalise the systemic and cerebral
homeostasis early following brain trauma.
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We were unable to correlate the amount of ischaemic damage present at post mortem
with the patients’ pre-morbid CPP insult because they were archival cases and their
pre-morbid physiological insult data were not available.
6.5.3) Diffuse Traumatic Axonal Injury
Diffuse traumatic axonal injury is defined as widespread damage to axons in the
white matter of the brain and is a well recognised sequela of traumatic brain injury
[381-385].  The first clinical description of primary shearing injury of the axons was
reported by Strich from a series of demented patients following severe brain trauma
in the 1950s [383], but her concept was actually hypothesized earlier in the 1940s by
a physicist called Holbourn who predicted the brain’s peculiar vulnerability to
shearing injuries given the extremely low modulus of neural tissue to shearing
deformation and a very high modulus of compressibility [386, 387].  Experimental
evidence over the years supported Holbourn’s theory of ‘swirling’ motion of the
brain within the skull during impact.  Furthermore, evidence indicated that the
shearing injury to the brainstem would only occur in more severe injuries than those
required to initiate shear strains within the cerebral white matter [388].  Thus,
primary brainstem injury usually occurs in concomitant with shearing injuries of the
cerebrum except in rare circumstances where a rapidly fatal tear occurs in the
pontomedullary junction [367].
The prevalence of diffuse traumatic axonal injury in our study (24%) was similar to
that of Graham’s paediatric report (22%) from Western Scotland [60] but was almost
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double the prevalence (13%) reported in Scottish adult brain trauma fatality [369].
This difference in diffuse traumatic axonal injury prevalence between paediatric and
adult brain trauma fatalities may be explained by the progressive increase in
myelination of the immature nervous system through development.  The increase in
brain weight over the first 4 years of life is mainly due to an increase in white matter
myelin.  Grey matter is firm and cellular whilst poorly myelinated white matter is
more gelatinous and of slightly different density and so with acceleration-
deceleration injury they swirl at different velocities giving rise to tears in the
parenchyma between the grey and white matter [389].  With this tendency of the
infants axons to stretch more than the fully myelinated adult fibres [390], it is easy to
understand why white matter injuries are also observed more frequently in infants
sustaining non-accidental brain injury as demonstrated by neuroimaging.
White matter shearing injuries are particularly seen in corpus callosum, superior
cerebellar peduncle, and in the midbrain.  Shearing injury of the midbrain results in
loss of consciousness from the moment of impact because sudden rotation of the
cerebral hemispheres upon the more anchored midbrain causes a primary stem injury
ensuring the occurrence of sudden coma [388].  The clinical picture consists of loss
of consciousness, dilated pupils, decorticate posture, and abnormalities of blood
pressure, pulse and respiration.
When comparing the prevalence of diffuse traumatic axonal injury among cases of
different survival durations, we found that none of the instantaneous deaths had
evidence of diffuse traumatic axonal injury but it was more frequently identified in
243
deaths with a survival period longer than 24 hours.  This was consistent with the
findings of an earlier Scottish study where only 4% of diffuse traumatic axonal
injury was found in patients surviving less than 24 hours after brain trauma [391].
Similar preponderance of longer survival duration in cases with diffuse traumatic
axonal injury was also described in a later Australian study where 82% of the brain
trauma cases with evidence of diffuse axonal injury survived more than 24 hours
[392].  Thus, diffuse traumatic axonal injury requires time to evolve and it is evident
that diffuse traumatic axonal injury has several different microscopic appearances
dependent upon the survival interval [93].  Axonal retraction balls are typically
found in fatal brain trauma of short survival durations (in terms of days) and are
formed by exuded axoplasm from shearing of axons by traction forces.  They may be
detected among brain trauma fatalities who had survived for as short as 35 minutes
[374].  The appearance of diffuse traumatic axonal injury of intermediate survival
duration of several days to weeks post brain trauma is characterised by microglial
scars while fibre tracts degeneration in the white matter is only evident in patients
who had survived for many weeks to months following brain trauma.
The relationship between early feature of diffuse traumatic axonal injury (axonal
swelling) and survival time after brain trauma has been previously investigated.
Wilkinson and colleagues demonstrated that axonal swelling size was directly
proportionate to survival time until 85 hours post injury when the size of axonal
swelling plateaued in a cohort of 66 fatal brain trauma [393].  This positive
correlation between axonal swelling size and survival time was also confirmed by
another British group who examined brain sections from 63 (adult and childhood)
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brain trauma fatalities [394], and Gorries’ group from Sydney who investigated the
characteristics of axonal injury among 32 children dying from motor-vehicle related
brain trauma [395].  Developmental difference in myelination between the immature
and adult brains did not appear to influence the relationship between axonal size and
survival time because Gorries’ group also compared axonal sizes from various
survival times between paediatric and adult brain trauma fatalities and found no
difference in the sizes of axonal swelling between the two groups [395].
Majority (67%) of our cases with evidence of diffuse traumatic axonal injury
sustained their injury from road traffic accidents while falls infrequently resulted in
diffuse axonal injury.  This finding was consistent with figures described by previous
reports [385, 391, 392].  Denny-Brown and Russell reported that in experimental
brain trauma, greater force was required to initiate shearing injury in the fixed head
than when the head was free to move [396].  Angular acceleration of the head is,
therefore, more likely to occur during road traffic accidents with the potentials for
whiplash and similar injuries than during a fall when the head is relatively stationary
at the moment of impact.
Genarelli’s group confirmed the importance of angular acceleration of the head in the
production of diffuse axonal injury [397, 398].  They utilised angular acceleration of
the head in subhuman primate and reproduced diffuse axonal injury that was
pathologically identical to those observed in human brain trauma [397, 398].
Duration of angular acceleration differs significantly between RTA and falls, and it
is thought to be important to the production of diffuse traumatic axonal injury.
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Genarelli’s earlier experiments only reproduced contusions in the frontal and
temporal lobes as well as the occasional intracerebral haematoma from using short
acceleration pulse.  However, with increasing the acceleration, they were able to
reproduce torn bridging veins and the formation of rapidly fatal subdural haematoma
while increasing the duration of the applied acceleration pulse resulted in the
reproduction of prolonged unconsciousness and diffuse axonal injury [398].  They
also found that subdural haematoma occurred less frequently with increasing angular
acceleration durations [398] which was consistent with the clinical observations
made by Adams’ group where significantly lower incidence of intracranial
haematoma was found among patients with diffuse traumatic axonal injury [391].
The precise mechanisms responsible for the production of diffuse traumatic axonal
injury in brain trauma have been the subject of intense investigations since its first
clinical description in the 1950s.  Although the time course of pathological changes
in diffuse traumatic axonal injury has been defined by Adams [381] and many
clinico-pathological studies supported the concept of primary mechanical shearing
injury to the axon [93, 381, 391], many other authors argued that primary axotomy
only represented one possible mechanism and suggested that secondary insults such
as hypoxia, cerebral oedema, vascular disruption from raised intracranial pressure
and subsequent tentorial herniation, and other metabolic disturbances like
hypoglycaemia and seizures were causes of delayed secondary axotomy [376, 399].
Adams and colleagues evaluated 45 cases of non-missile head injury in the early
1980s but found no difference in the incidence of ischaemia or cerebral oedema
between cases with or without diffuse traumatic axonal injuries [391].  In addition,
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they found significantly fewer cases with diffuse traumatic axonal injury had
evidence of intracranial hypertension than those without diffuse axonal injury [391].
The concept of secondary axotomy has regained research interests over the past
decade when Kaur and Oehmichen independently described hypoxia induced axonal
injury without brain trauma [375, 400], and Dolinak and co-workers demonstrated
axonal injury among 13 fatal non-traumatic coma attributed to hypoglycaemia [376].
Although both Kaur and Oehmichen’s series described hypoxia induced axonal
injury without brain trauma [375, 400], they did not explore the contributory effects
of confounding factors such as cerebral oedema, raised ICP, and internal herniation
[401, 402].  Dolinak and colleagues addressed these issues in their investigations of
the brains from 44 fatalities due to cardiac arrests, status epilepticus, carbon
monoxide poising, and controls cases who died from extracranial causes [376].  They
found that patients with evidence of axonal injury also had evidence of raised
intracranial pressure suggesting that hypoxia per se was an unusual cause of axonal
injury [376].  These studies have highlighted that not all post traumatic axonal injury
is caused by the primary mechanical trauma but secondary insult also contributes to
the evolution of diffuse axonal injury.  Thus, the analysis of fatal brain trauma must
include a full assessment of both primary injury and secondary insults which requires
the full clinico-pathological details including injuring mechanisms, survival
durations, physiological insult measurement, and detailed neuropathological studies.
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6.5.4) Limitations
Data used in our study originated from an archival collection of post-mortem reports
and specimens obtained from fatal childhood brain trauma over a thirteen-year
period.  A number of different pathologists would have been involved in the post-
mortem of these cases, and although standardised post-mortem examinations were
conducted, invariably some findings were not recorded in the post-mortem report
resulting in missing data and potentially introducing some bias into the data analyses.
From our data set, one case had incomplete documentation of pathological features
and was excluded from the analyses.  Evidence of skull fracture was not documented
in 32% of cases, as a result, we were unable to investigate the relationship between
skull fracture and other pathological features of childhood brain trauma, and to
compare its prevalence to previous reports in the literature.  This has not affected
testing of our hypotheses but skull fracture is an important pathological feature of
impact injury and its presence is often associated with other significant intracranial
injury such as intracranial haematomata.  Thus, the knowledge of its prevalence and
correlation with other brain damage features are still important in any detailed
neuropathological study of brain trauma fatalities.
Another limitation is the small cohort size.  Our cohort consisted of 50 cases of
paediatric brain trauma with different modes of injuring mechanisms, age, and
survival duration.  Once the cohort was subdivided into dichotomies, each sample
size became fairly small making it difficult to obtain statistically meaningful findings
for certain comparisons.  We have however, been able to demonstrate a number of
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important and statistic significant differences in the observed pathological features
between different survival durations.  This was particularly useful given majority of
the reports in the literature were from patients surviving long enough to reach neuro-
surgical centres and excluded instantaneous deaths.
6.6) CONCLUSIONS
Very few detailed reports of neuropathological features of fatal childhood brain
trauma exit in the literature even though brain trauma remains the commonest cause
of paediatric deaths.  Brain swelling, moderate to severe hypoxic ischaemic brain
damage, and diffuse traumatic axonal injury continue to be common findings in fatal
childhood brain trauma and they all occur as frequently in the 1990 and early 2000s
as they were in the 1960s and early 1980s despite significant changes to the clinical
management of these patients over the past 2 decades including advances in
resuscitation and trauma care with an increased emphasis on minimising secondary
insults.  Children dying from brain trauma are more susceptible to brain swelling
than adults, but it is unclear whether there is any age related difference in the
susceptibility to the development of brain swelling throughout childhood.
We confirmed that hypoxic ischaemic brain damage and diffuse traumatic axonal
injury required time to evolve and rarely found among instantaneous deaths.
Survival period beyond 24 hours did not increased the prevalence of hypoxic
ischaemic brain damage indicated that brain injured children who survived the initial
brain trauma would be susceptible to ischaemic brain damage and highlighted the
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importance of diligent acute trauma care (including pre-hospital care) to normalise
the systemic and cerebral homeostasis following brain trauma.  The prevalence of
diffuse traumatic axonal injury was highest among deaths with survival period
beyond 24 hours following the initial injury but it remains unclear whether secondary
axonal injury contributed towards this finding.
Further study is required to determine the relationships between secondary CPP
insults and hypoxic ischaemic brain damage in fatal childhood brain trauma, and
how maturational difference in the nervous system throughout childhood influences
the susceptibility of developing different neuropathological features such as brain
swelling, hypoxic ischaemic brain damage and diffuse traumatic axonal injury after
brain trauma.
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CHAPTER 7: MODULATING EFFECTS OF PHYSIOLOGICAL, GENETIC,
AND BIOCHEMICAL FACTORS ON THE SEQUELAE OF CHILDHOOD
BRAIN TRAUMA
7.1) INTRODUCTION
Brain trauma occurs frequently, and remains the commonest cause of death and
disability in children over 1 years of age [46, 177].  Many survivors of paediatric
brain trauma suffer from significant physical, emotional, and psychological
morbidities [52-55].  Although injury prevention has dramatically reduced the
number of trauma deaths, accidents will continue to occur.  It is, therefore, essential
to optimise brain trauma management and to develop new therapies so that when
brain trauma occurs, the potentially devastating outcome may be improved.
Basic principles of neuro-intensive care for both adults and children remain
unchanged since its introduction in the late 1970s [76] with an emphasis on
minimisation and prevention of secondary ischaemic insults [74, 75].  Search for
novel neuro-protective strategies have been extensive but disappointing mostly
because of the difficulty to translate animal research and in-vitro study results into
clinically relevant therapies.  One possible explanation for the bench-to-bedside
translational difficulty is that these promising laboratory neuro-protective strategies
mostly target grey matter damage without affecting white matter injuries which may
be more important to neurological recovery after brain trauma.  Furthermore, most of
these potential therapies have targeted a single pathway among the complex cascade
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of brain trauma induced pathophysiological responses.  Reduction in one injuring
pathway may only exacerbate other brain injuring mechanisms which will not
improve the overall recovery.
This thesis utilizes clinical studies to investigate multiple outcome determinants of
childhood brain trauma.  This chapter aims to address how physiological, genetic,
and biochemical factors modulate the sequelae of childhood brain trauma.
7.2) CEREBRAL ISCHAEMIA AND BRAIN TRAUMA RECOVERY
Prevention and minimisation of cerebral ischaemia are the treatment goals of modern
neuro-intensive care [74, 75].  However, cerebral ischaemia is difficult to quantify at
the bedside.  Clinicians, therefore, use cerebral perfusion pressure (CPP)
derangement as an indirect measure of cerebral ischaemia and the critical care
management of brain trauma patients emphasizes the importance to maintain an
adequate CPP.  Treatment thresholds for CPP and ICP have been proposed and
become widely accepted in adult practice [74] but they have not been validated.  This
is possibly because of the previous lack of suitable quantification methods to
measure the total burden of CPP or ICP insult.
Methodology to quantify deranged CPP has previously been limited to assessing one
dimension of the insult (for example, duration or magnitude) at any one time.
Despite the limited assessment methods available, the relationships between CPP
derangement and brain trauma outcome in adults and children have been well
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described [63, 90-92, 207].  Some researchers, therefore, questioned the need to
develop more robust quantification methods that enable assessment of the total
burden of CPP insult i.e. measuring both the insult duration and magnitude
spontaneously.
The importance to quantify the total burden of CPP insult after brain trauma was
apparent when we assessed brain trauma children’s APO E genotypes and their
relationships with CPP insult and outcome [261].  The duration or frequency of CPP
derangement (i.e. one dimensional insult assessment) did not differ between children
carrying the different APO E alleles.  However, when the total burden (i.e. duration
and magnitude) of CPP insult was quantified using the novel cumulative pressure
time index (PTI), the APO E genetic polymorphisms were clearly associated with
different burden of CPP insult with the e4 carriers having the least amount while the
e3 homozygotic children experiencing the largest insult burden [261].
Our novel PTI is the first described method to measure the total burden of CPP insult
by taking into account both the duration and magnitude of the insult [203, 204].  It is
easy to calculate and allows comparison of insult between different age groups [204],
which is particularly important in paediatric brain trauma research.  With the PTI, we
confirmed the importance of cerebral ischaemia on brain trauma recovery.  Brain
trauma children with unfavourable outcome had suffered significantly more CPP
insult than those who had good recovery [204].  This was true regardless of the
patients’ APO E genotypes [261].  Furthermore, PTI has enabled us to define age-
related critical CPP thresholds [204].
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Unlike adult practice, there are no accepted CPP treatment thresholds for infants and
children because of the lack of information on the normal age-related intracranial
haemodynamics.  The desired CPP treatment thresholds in childhood brain trauma
are often extrapolated from the non-validated adult threshold or have been age-
adjusted anecdotally by individual clinicians.
Our proposed age-related theoretical minimum levels for CPP were based upon
normal physiology where ICP should have minimal contribution to the CPP, which
must, therefore, equate to the minimum age-related mean arterial blood pressure [92,
192-195].  In brain trauma, if the cerebral autoregulation remains intact, the body
should, theoretically, be able to regulate the mean arterial blood pressure to
compensate for any rises in the ICP and to ensure this minimum CPP level is
maintained.  Brain trauma critical care management aims to ensure an adequate CPP
is maintained in addition to treating intracranial hypertension [74, 75].  In patients
with impaired cerebral autoregulation, intensivists use vasopressors to artificially
drive mean arterial blood pressure to super-physiological levels to maintain the target
CPP [74, 75].
Using the PTI, we demonstrated that insult measured using these theoretical age-
related CPP thresholds correlated best with unfavourable outcome and altering these
thresholds did not improve the outcome prediction performance of the calculated
insult [204].  CPP levels lower than these critical thresholds will, therefore, cause
ischemic insult thereby affecting recovery.  This proved that our theoretical age-
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related thresholds were the minimum CPP levels by age where cerebral perfusion
may be achieved [204].  CPP treatment thresholds in the paediatric population must,
therefore, be higher than these critical thresholds to avoid cerebral ischaemia, but
further studies are required to define the best age-related therapeutic CPP thresholds.
Age-related CPP insult was found to occur very frequently in our cohort indicating
that existing brain trauma management was ineffective in its prevention.  The urgent
need to define CPP treatment thresholds was also confirmed by our post-mortem
study.  We found that despite diligent efforts to improve paediatric trauma
resuscitation and neuro-intensive care provision in Scotland, hypoxic ischaemic brain
damage continued to be a frequent finding in paediatric brain trauma fatalities with
little change in the prevalence over the past 20 years [60].  Since none of the
potential novel neuro-protective strategies are likely to be translated successfully into
clinically effective therapies overnight, the best chance to improve brain trauma
outcome in the foreseeable future relies upon optimisation of the CPP treatment
thresholds to prevent cerebral ischaemia.  The development of PTI will not only
benefit paediatric brain trauma research but also enable validation of the well-
accepted adult CPP treatment threshold and to assist development of a threshold that
best prevent cerebral ischaemia which may then improve outcome.
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7.3) Potential Modulating Mechanisms of APO E Genetic
Polymorphisms on Brain Trauma Outcome
The human genome project suggests that genetic factors do not only predispose
individuals to certain pathological conditions such as various cancers or emphyzema
but also govern the body’s response to injuries or disease processes and medical
treatments [403].  Understanding how genetic polymorphisms affect the host’s
response to brain trauma and its treatment may enable potential novel treatment
points to be identified.  Most previous clinical studies of the APO E genetic
polymorphisms had concentrated on assessing the association between poorer
outcome and the possession of the APO E e4 allele [141-143]. Majority of the
potential mechanisms of action have only been assessed using animal models and in-
vitro cell cultures.  Only a few clinical and post-mortem studies have attempted to
investigate potential mechanisms of action.
7.3.1) Potential Mechanisms Assessed by Clinical or Post Mortem
Studies in the Literature
7.3.1.1) Apolipoprotein E Polymorphisms and Coagulation
Apolipoprotein E genetic polymorphisms have varying influence on blood
coagulation.  Vitamin K concentrations vary between dialysis dependent renal failure
patients possessing the different APO E alleles with the highest concentration found
among the APO E e2 carriers, intermediate amount found in the e3 carriers, and the
256
least amount found in the e4 carriers [404].  The APO E genotypes have also been
reported to affect the prothrombin times in patients with alcoholic cirrhosis [405].
Significant prolongation of both the international normalised ratio (INR) and the
ratio of the partial thromboplastin times were found among APO E e4 carriers of
stroke patients when compared to patients without this allele in a recent retrospective
study involving 578 adult stroke sufferers [406].
Since coagulopathy post brain trauma is an independent predictor of vascular
complication and poor outcome [407-409], the influence of APO E genetic
polymorphisms on neurological recovery after brain injury may potentially be
mediated through allelic specific effects on coagulation.  Liaquat and co-workers
assessed the effects of APO E genotypes on the size of acute intracranial
haematomas among 129 brain trauma patients and reported that larger sized
haematomas (3.1 cm vs. 2.5 cm, p = 0.0039) were found among those in possession
of one or more APO E e4 allele [410].  Coagulation status will influence the size of
intracranial haematomas after brain trauma, but the mechanisms of primary injury
will also determine the size of the haematomas in these patients.  It may be possible
that the mechanisms of injury were more severe among those possessing APO E e4
allele resulting in larger haematomas in these patients.
Traumatic coagulopathy has been proven to be a form of disseminated intravascular
coagulation (DIC) triggered by the release of tissue thromboplastin by injured brain
tissue [411, 412].  Tissue thromboplastin may also stimulate intravascular
microthrombosis which has also been confirmed recently to be an important
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secondary insult following non-fatal brain trauma and appears to correlate with post-
traumatic ischaemic neuronal death [413-415].  Thus, traumatic coagulopathy is not
limited to regions of initial mechanical injury in brain trauma but may induce a series
of secondary insult distant to the original injury site.  Despite previous reports of the
relationship between APO E genetic polymorphisms and coagulation, only recently
the influence of the APO E genotype on the intravascular coagulation, and in
particular intravascular microthrombosis (IMT) following brain trauma have been
investigated.
Stein and colleagues conducted detailed neuropathological investigations on 19 post-
mortem materials from fatal brain trauma and 18 surgical specimens obtained from
contused brain removed during surgical decompression for closed traumatic brain
injury [416].  They found that e4 carriers were more likely to have a lower IMT
density.  Despite having slightly longer prothrombin times and higher coagulation
indices, no association was found between this particular allele and the degree of
coagulopathy [416].  Stein and colleagues believed that these findings had disproved
their postulation of a predisposition to developing DIC and IMT after brain trauma in
patients possessing the APO E e4 allele [416].  However, the sample size of their
study was small and the sampling sites of both the surgical and autopsy groups were
heterogenous limiting the validity of the findings.  Further study employing larger
sample size and unified sampling site is required to define the true relationship
between APO E genotypes and the development of DIC following brain trauma.
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7.3.1.2) APO E Genotypes and Post-Traumatic Cerebral Swelling
APO E genotypes have been suggested to affect the degree of post-traumatic cerebral
swelling differently because APO E e4 carriers have been found to have greater
degree of cerebral swelling related to focal traumatic contusions than the non-e4
carriers [410].  The potential influence of apolipoprotien E on cerebral oedema
development has also been demonstrated in animal experiments where APO E
knockout mice develop more marked cerebral oedema after experimental trauma
than wild-type mice [417].  Diffuse brain swelling was found more frequently in fatal
paediatric brain trauma than in adult TBI [60].  A recent paediatric post-mortem
study was, therefore, conducted to assess the effect of APO E genotypes on unilateral
or bilateral hemispheric swelling in fatal paediatric head injury [418].  No
association was found between the APO E e4 allele and post-traumatic brain
swelling in this archival post-mortem study of 106 cases [418].  The sample size of
this study should have been sufficient to detect a difference of 30% in the proportion
with swelling with 80% power, but the actual difference observed was 1% [418].  In
a study of 102 adults suffering from intracerebral haemorrhage, McCarron and
colleagues demonstrated that although higher mortality rate was found among the
APO E e4 carriers than the non-e4 carriers, and larger volume of cerebral oedema
was found among the non-survivors, the size of cerebral oedema was not related to
the e4 allele [419].  APO E genotypes are, therefore, unlikely to have any genuine
influence on the development of cerebral oedema post brain injury.
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7.3.1.3) APO E Genotypes and the Conversion of # amyloid Precursor
Protein to # Amyloid
The influence of APO E genotypes on the conversion of the neuroprotective #
amyloid precursor protein to # amyloid has considerable evidential support over the
last decade and has been tested in several post-mortem studies.  #APP is expressed
constitutively in neurons.  Its up-regulation following neuronal injury is observed in
perikarya and axons [256].  In certain circumstances and predisposed individuals,
#APP may give rise to deposits of # amyloid (#A4), which is known to be toxic to
neurons [256].  #A4 deposition have been found in up-to one third of patients who
die from brain trauma and a higher frequency of APO E e4 allele is found among
those who has #A4 deposition after head injury [420].  The density of #A4 plaques
found in fatal head injured patients was associated with the APO E e4 allele in a
dose-dependent manner [421].  In a further study comparing #A4 deposition in long-
term survivors of head injury with that found in a group of age and APO E genotype
matched controls, MacFarlene and colleagues found that #A4 deposits were not more
common among those who had survived a previous TBI although #A4 deposits were
more common among those possessing APO E e4 allele [422].
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7.3.1.4) Limitation of Post-mortem Studies for Assessing Potential
Mechanisms of Action
Post-mortem studies limit the investigations of the postulate because clearly, the
patient cohort has been selected by death and a bias towards the worst outcome has
been introduced.
7.3.2) Potential Mechanisms Assessed by Animal or In-Vitro Studies
Most postulated mechanisms of the APO E genetic influence on neurological
outcome after CNS insults have been related to the functions of its gene product, the
apolipoprotein E (apoE), which is a major lipoprotein in the CNS [144].  It is
involved in the CNS lipid transportation and metabolism [144].  Because the
presence of apoE within the cytoplasm of neurons [423], it has also been postulated
to interact and regulate the integrity of cytoskeletal proteins [424-426].
In vitro studies have demonstrated that the E3 isoform of apoE binds the
microtubule-associated proteins (MAPs) tau, and MAP-2c to form apoE/MAP
complex [425, 426].  The region of tau where apoE3 binds to is thought to be
responsible for causing self-assembly into the paired helical filament, which is the
basic structural component of the neurofibrillary tangles [427, 428].  The E4 isoform
on the other hand does not bind with MAPs tau [425].  Apolipoprotein E isoform
specific interaction with MAPs tau may, therefore, regulate the rate of formation of
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the paired helical filaments and neurofibrillary tangles which are important in the
maintenance of the cytoskeletal integrity.
Apolipoprotein E may also protect against oxidative and excitotoxicity injury
because experiments involving apoE deficient mice indicate that the lack of apoE
increases oxidative injury [429, 430].  Plasma lipoproteins from these mice were
more susceptible to in-vitro oxidation than those of wild-type mice, and they have an
increased expression of autoantibodies against oxidized lipids when compared to
control animals [429, 430].  Furthermore, different isoforms of apoE offered a
neuronal cell line different protection against hydrogen peroxide toxicity with the E2
isoform offering the highest degree of protection, while the least protection was
observed with the E4 isoform [431].  As a result, APO E genetic polymorphisms
have been postulated to modulate brain injury recovery by offering isoform-specific
protection against oxidative injury.
In vitro neurite extension of a central nervous system-derived neuronal cell line was
increased with apoE3 but not apoE4 [432].  In addition to this potential direct
neurotrophic effects on injured neurons, apoE has been shown to enhance the
neurotrophic effects of growth factors such as ciliary neurotrophic factor [433].
Laminin is an extracellular matrix protein that affects neuronal adhesion, spreading,
differentiation, and growth by binding integrin-type cell surface receptors.  It has
been shown to interact with apoE in vitro.  Furthermore, the laminin-apoE substrate
produced higher number of live, attached hippocampal neurons in cell culture than
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laminin alone.  This suggests that apoE may be important in the development and
maintenance of neurons in the CNS by regulating interactions between the neuron
and the extracellular matrix [434].
Apolipoprotein E may modulate neuro-inflammation. Its in-vitro immunomodulatory
effect suppressed lymphocyte proliferation and immunoglobulin synthesis after
mitogenic stimulation [435, 436].  It has also been shown to suppress glial secretion
of inflammatory cytokines in an isoform specific and dose-dependent fashion [437].
Recent transgenic animal studies suggested that an enhanced neuro-inflammation
was found in the APOE4 transgenic animals when compared to the E3 transgenics
[265, 266].  APO E genetic polymorphisms may, therefore, modulate brain injury
recovery through different allelic influence on neuro-inflammation.
All these postulates may have important modulating effects on brain trauma outcome
but none have been assessed in the clinical setting.  Their clinical relevance is,
therefore, unclear.
7.3.3) APO E Genetic Polymorphisms And Cerebral Ischaemic
Tolerance: Evidence from Bench and Bedside Studies
No previous studies have assessed whether carriers of the different APO E alleles
would have different burden of CPP insult after brain trauma.  Given the significance
of CPP insult on brain trauma outcome and the growing evidence to suggest an APO
E e4 allelic association with poorer outcome, we postulated that the e4 carriers
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recovered less favourable after brain trauma because the e4 allele affects the host’s
response to brain trauma and its management causing more CPP insult than patients
without this allele.  This postulate was disproved when we demonstrated that brain
trauma children possessing the e4 allele had experienced the least amount of CPP
insult, which were 13.3 times less than the non-e4 carriers [261].  We also observed
that the e3 homozygotic children with good outcome did so despite having had
nearly 26 times more CPP insult than those who were non-e3 homozygous [261].  In
addition, the CPP insult level experienced by the APO E e4 carriers with
unfavourable outcome was 22 times less than the non-e4 carriers and it was at a level
that should have conferred good recovery [261].
The observed relationships between APO E genotypes, CPP insult and outcome
suggests that APO E genetic polymorphisms may affect the host’s cerebral ischemic
tolerance differently and the prevention of cerebral ischaemia may be even more
important in the APO E e4 carriers after brain trauma.  This postulate supports a
recent observation from transgenic animal research which showed an increased risk
of brain damage from ischemic injury in the APO E e4 transgenic mice when
compared to the e3 transgenic animals [248].
7.4) BRAIN TRAUMA BIOMARKERS AND OUTCOME
Because the complex cascade of biochemical and molecular pathophysiological
processes initiated by brain trauma are regulated and modulated through
biomediators, many intensivists hope to utilize these biomarkers for objective
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quantification of injury severity and accurate outcome prediction during acute care of
the brain trauma patients.  Identifying brain trauma biomarkers with strong
prognostic values may highlight the pathophysiological pathways that best modulate
neurological recovery and, therefore, enable researchers to focus their efforts into
understanding these particular processes which may in turn allow identification of
potential treatment points.
In reality, none of the proposed brain trauma biomarkers have been translated
successfully into clinically useful prognostic tools despite growing number has been
added to the literature over the last decade.  These potential biomarkers are not
evenly investigated, and the variations in methodology with sample types, sampling
time points, and data analyses between different studies made it difficult to conclude
from the exiting literature whether a particular biomarker is more superior at
predicting brain trauma outcome.
By investigating multiple biomarkers simultaneously, we found that serum L-selectin
level measured at day 1 post injury had the highest predictive value for unfavourable
outcome after brain trauma.  Its prognostic value was better than other inflammatory
mediators such as interleukins and SICAM which is also an adhesion molecule.  This
finding highlights that although neuro-inflammation contributes toward neurological
recovery after brain trauma, it is a heterogeneous process with different pathways
commencing and subsiding at different time points after the initial brain trauma.
Meaningful comparison and interpretation of the different biomarkers’ outcome
prognostic values will, therefore, need to be time defined to the initial injury.
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The high outcome predictive value of serum L-selectin suggests that inflammatory
processes involving L-selectin may be of particular importance to the modulation of
neurological recovery following brain trauma.  A recent adult stroke study has
described patients with larger infarct volume to have significantly higher
concentrations of plasma IL-6 and ICAM-1 than those with smaller infarct size
[438].  In two other adult stroke studies, patients with different infarct sizes also have
different concentrations of adhesion molecules [439, 440].  It is unclear whether the
larger infarct size is caused by additional brain injury induced by the higher
circulating cytokine concentrations post ischaemia, or it is the direct result of more
severe initial ischaemia and the higher plasma cytokine levels are merely a reflection
of the severity of the initial ischaemia.
Cellular adhesion molecules mediate leukocyte-endothelial interaction at the site of
tissue injury which is vital for directing leukocytes into areas of acute inflammation.
It has been shown that leukocytes and macrophages exacerbate brain injury
following cerebral ischaemia by physically obstructing capillaries and reducing the
blood flow (i.e. causing more ischaemic damage) to the injured brain [441, 442].  In
addition, they also produce cytotoxic products once extravasated into the brain
parenchyma [441, 442] which potentially may induce further brain insult.  These
may be mechanisms through which adhesion molecules modulate brain trauma
outcome.
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If the adhesion molecule mediated inflammatory response modulates brain trauma
outcome by causing more brain insult from secondary ischaemic damage and
cytotoxicity, its serum level should have no correlations with the burden of primary
brain injury and secondary CPP insult.  In addition, it may be out of proportion to
these brain trauma outcome determinants.  Of the 28 children with biomarker levels
quantified, only 13 had CPP insult measured.  The number of patients was, therefore,
too small for further analysis to ascertain the relationships between adhesion
molecule levels and CPP insult, which would warrant further investigations.
We additionally demonstrated for the first time that prognostic rules combining 2
biomarkers’ serum levels had more superior prognostic value than individual
markers when measured on day 1 post injury.  This was not a surprising finding
given the heterogenic nature of brain trauma pathophysiology.  Importantly, we
demonstrated that the choice of biomarkers within the prognostic rules influenced
their prognostic values.  Combining 2 biomarkers from the same mediator family
was not as useful as using biomarkers from different mediator families for outcome
prediction.  We also demonstrated that although brain specific proteins measured on
day 1 post injury were not as useful for outcome prognosis as the L-selectin, they
dramatically improved a prognostic rule’s outcome predictive value if either S100B
or NSE was used as the screening marker component of the rule.
Assessing 8 biomarkers simultaneously after brain trauma provide more information
than investigating individual markers.  However, there are many more biomediators
that regulate the cellular and molecular pathophysiological processes initiated by
267
brain trauma.  Biomarkers that are not investigated in our current study may have
higher modulating effects on brain trauma outcome than those of our chosen
markers.  Proteomic techniques allow simultaneous assessment of large number of
molecules in bloody fluids and tissue specimens and may offer better understanding
of the pathophysiological pathways after brain trauma.
7.5) ETHICAL CONSIDERATIONS
Clinical research is a vital link between basic science at the bench and clinical
practice by the bedside but its success relies heavily upon patient availability and
their participations.  Conducting paediatric research is fought with difficulties since
children are a vulnerable group of patients who may not have sufficient
understanding to make an informed decision for themselves in research participation.
Furthermore, the law relating to consenting in this area has never been clarified.
When seeking consent for medical treatment and procedures, children are the only
people in British Law whereby consent may be given by an adult with parental
responsibility who is usually the mother.  The issue is more complex and confusing
when teenagers are involved.  At 16 years of age, every person is presumed able to
give his/her own consent to treatment.  However, before the age of 18 years, the
courts or others with parental responsibility can override the refusal of a ‘minor’,
even if this young person is deemed to be competent.  In 1985, the House of Lords
established that a person under the age of 16 who has sufficient understandings and
intelligence may be competent to give consent to treatment by a clinician [443].
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Similar principles have, therefore, been projected to consenting for research
involving children which are detailed in the Principles of Paediatric Research as
recommended by the Ethics Advisory Committee of the Royal College of Paediatrics
and Child Health [444].  Unlike consenting for medical treatments, it is generally
accepted that if a child can give a reasoned refusal to be involved in research, it is
clear that this young person has sufficient understanding and it would be unwise to
rely on parental consent alone in this situation.  However, is it wise to include a child
of sufficient understandings i.e. Gillick Competent who has given consent to take
part in a research study but the parent refuses consent?  Most paediatric research
depends heavily upon parental co-operation, for example collection of follow-up
data, and the research subjects often will not benefit from participating.  Inclusion of
such a child could possibly damage the trust of a parent and the future working
relationship with the family without benefiting research development in medicine.  It
may, therefore, be best to respect the parent’s wishes and to exclude the child’s
participation.
7.5.1) Consent to Participate in Research and Critically Ill Children
For research projects which aim to investigate emergency or critical care treatments,
special considerations are required for consenting.  This thesis relies completely on
studies of critically ill brain injured children, most of whom were in a coma and
were, therefore, incapable of giving consent to participate in the study.  Most of their
families were in great distress from the shock of learning that their beloved children
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had sustained life threatening injuries, while others were involved in the same
accident themselves and required ongoing treatment.  Informed consent in these
situations would, therefore, be impracticable or meaningless [445].  Recent evidence
from Edinburgh demonstrated that at 18 months after enrolment into a clinical
neonatal study, 12% of parents had no recollection of granting consent for their
babies to participate in the study when the babies were critically ill, however, 83% of
the parents from this study expressed their objections to the suggestion of abolishing
the current consent process for trials approved by the local ethical committees [446].
In these situations, it is, therefore, paramount to conduct the consenting process as an
ongoing phenomenon throughout the study.
For our study, initial consent was sought from the families with particular emphases
on (i) the ability to change their minds regarding their participations in the study
without affecting their children’s treatment, and (ii) the reassurance that supports
from the researchers would continue to help them better understand the study
protocol and their involvements.  This concept of obtaining continuing permission
was particularly important because it removed some of the pressure from these
families that were already in great distress and made the consent more valid.  As a
result of this approach, all suitable brain injured children have been recruited into the
study and no family withdrew their involvements from the study.  Furthermore, this
improved the working relationship between the research team and the families
facilitating the follow-up process which was a vital endpoint of this study.
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7.5.2) Ethical Considerations in Research Involving Human Tissues
Thorough post-mortem examinations are crucial to clinical research by determining
the cause of death in patients enrolled in clinical studies [447].  For brain trauma
studies, researching post-mortem specimens is complicated by the fact that all brain
trauma fatalities are required by law to be referred to the Procurator Fiscal in
Scotland or the coroner in England and Wales who will then decide whether a Fiscal
or Coronial post-mortem examination is required.  The specimens collected at Fiscal
or Coronial post-mortems are retained as part of the medical records and are purely
for diagnostic purposes.  In order to use these samples for research or teaching
purposes, prior consent must be sought from the families.  Furthermore, the organs,
particularly the brain and spinal cords, at autopsy are often not in an ideal state for
detail examination because they are too soft especially if they are immature or
affected by pathology such as haemorrhage or ischaemia.  To avoid losing vital
information from examining these organs too early, retention usually occurs to allow
fixation in formalin for 3 – 6 weeks which hardens the tissue to enable detail
examinations.  This also allows a second expert opinion to be obtained.
7.5.2.1) Organ Retention Scandals – The Alder Hey Inquiry
Public enquiries into the cardiac service at Bristol Royal Infirmary and the pathology
service at the Royal Liverpool Children’s Hospital has disclosed organ retention
which has attracted much media and public attentions.  The enquiry to investigate the
removal, retention, and disposal of human organs and tissue following post-mortem
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examinations at the Royal Liverpool Children’s Hospital began in December 1999.
The enquiry report was published in January 2001 highlighting several failures
within the NHS Trust, the University of Liverpool, and the Liverpool Coroner’s
Office which resulted in the systematic removal of organs between 1988 and 1995
[378].  Coupled with the highly fuelled media furore, this report shocked the nation
especially when disclosing the fact that in many of these cases (i) the organs were
removed without consent, (ii) histological examinations were not subsequently
carried out leaving preliminary post-mortem reports unfinished, and (iii) the organs
and tissues were not used for education or research purposes [378].
The necessity to retain organs for further histological examinations after formalin
fixation resulted in the development of archived diagnostic blocks and slides in many
pathology departments across the country.  These materials have been regarded as
part of the medical records and it was understood that there was an obligation to keep
the tissue for possible review.  Their value in advancing medical teaching and
research should not be underestimated.  The long-term retention of organs has been
more variable.  In most centres, organs were disposed of following diagnostic
examination.  Occasionally organs of specific educational value were kept for
teaching and research including displays in medical school museums, although the
latter has decreased significantly in recent years.
The Human Tissue Act 1961 [448] has been used as a guideline to this practice and
stated that informed consent is not required and one must merely established a ‘lack
of objection’.  The Alder Hey Inquiry has demonstrated that this past practice is
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overly paternalistic [378].  New guideline has been issued by the Royal College of
Pathologists in 2000 [449].  Included in this document was a sample consent form
for post-mortem examination which specifically seeks to establish not only a lack of
objection to the necropsy, but also to the retention, disposal, and use of the materials
removed at autopsy for medical research or teaching [449].
7.5.2.2) Impact of the Alder Hey Inquiry On Post-Mortem Rate,
Manpower and Training in Histopathology
Post-mortem rate has fallen in general for many years [378, 447, 450, 451].  This
may be partly explained by the well-recognised nationwide manpower crisis in
histopathology and in particular academic histopathology [452, 453].  Worsening of
this shortage has been observed since the eruption of the hostile media climate
surrounding the Alder Hey inquiry which resulted in several pathologists, in
particular paediatric pathologists leaving the specialty [454, 455] .
The negative publicity from these inquiries is likely to reduce the willingness of
clinicians to seek consent for post-mortem examinations, and the readiness of the
general public to grant consents which would further exacerbate the decline in
autopsy numbers.  Furthermore, fiscals and coroners have requested fewer necropsy
over the recent years.  The true impact of this rapid fall in autopsy rate may not be
known for quite some time, but negative effects can be foretold in the determination
of accurate statistics regarding causes of death, and training of post-graduate doctors
in pathology and other specialty as well as undergraduate medical students.  If the
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present rate of decline continues, both clinical autopsies and pathologists sufficiently
trained to perform them face extinction [456].  In addition, inadequate training in
histopathology will have a knock on effect on the diagnostic services for other
clinical specialties such as surgical oncology.
7.5.2.3) Impact of the Alder Hey Inquiry On Research
It is worrying that many published studies in modern medicine cited death as an
endpoint of the studies but the cause of death in these cases were not confirmed by
necropsy [457].  The impact of the decline in autopsy rates on academic medicine is
already reflected in the significant reduction in the number of scientific papers
presented from the UK to the European Paediatric Pathology Society in successive
years since 1997 (57% in 1997, through 37%, 22%, 9% to 2% in 2001) [458].
Following the Alder Hey Inquiry era, it is apparent that the families of patients
involved in clinical research are reluctant to give consent for post-mortem
examinations and to use the necropsy materials for research as observed from our
study.  This is a particularly alarming trend because without research, medicine will
stagnate and put the future patient care in jeopardy.  Thus, for clinical research
involving human tissue to continue, a programme of continuing education for the
public is urgently required.
Several recently published reports and guidelines such as those produced by the
Independent Review Group on the Retention of Organs at Post-mortem in Scotland
(The McLean Review) [379] and the Medical Research Councils [380] are
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attempting to clarify the position on conducting research on archival necropsy
materials i.e. organs and tissue retained before December 2000.  These reports and
guidelines acknowledge the difficulties to seek retrospective consents from families
for the use of archival tissues for ethically legitimate research or teaching purposes
and recommend these material may be used for research provided that ethical
approval has been granted by the local ethical committee for the proposed project
and the specimens are used in an anonymous and unlinked manner [379, 380].  This
has opened up an opportunity for our pathology study to adopt a modified aim and
methods to investigate and classify the neuropathological patterns of fatal childhood
TBI.
7.5.2.4) Post-Mortem and Research in the Future
The only way to ensure the survival of autopsy practice and research involving
human tissue is by assisting bereaved families to reach an informed decision on post-
mortem examinations, organ and tissue retention, and the use of these materials for
research.  This involves provision of information on what tissue samples may be
taken at autopsies, why they are taken, and what would happen to them after the
diagnostic procedure is completed.  Equally important is the emphasis on what long-
term information may be lost by not having a full post-mortem examination.  Thus,
paediatric clinicians, pathologists and neuropathologists must work together to
ensure clinically relevant research will continue and to prevent stagnation and
decline of academic medicine.
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7.6) Limitations
This thesis has several limitations.  Reduction in brain trauma cases is a welcome
finding clinically, but limits the cohort size for research despite successful
recruitment of all suitable patients during the study period.  The small cohort size
made it necessary to analyse APO E genetic polymorphisms’ influence on CPP insult
and outcome in dichotomies.
We had assessed the effect of a single gene polymorphism on CPP insult and
outcome after brain trauma.  With the complexity of the human genome, it would be
important to investigate the effects of multiple genetic polymorphisms on brain
trauma sequelae simultaneously.
Important prognostic rules using serum biomarker levels were formulated in this
thesis to predict childhood brain trauma outcome but validation of these rules were
not possible due to the paucity of the cohort size.  The complex nature of secondary
brain insult processes meant that potentially important prognostic information could
be missed through investigations of multiple but selective biomarkers after brain
trauma although it is still better than studying an individual marker at any one time.
7.7) Summary
This thesis has demonstrated that (1) cerebral ischaemia may be the common
modulating pathway through which physiological factor and APO E genetic
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polymorphisms affect brain trauma outcome; (2) neuro-inflammation may affect
brain trauma recovery more than previously realised; and (3) combined
quantification of neuro-inflammation and glial-neuronal damage provide better
outcome prognostication than quantification of either of these components on their
own.
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CHAPTER 8: THESIS CONCLUSIONS AND FUTURE RESEARCH
PROPOSAL
8.1) THESIS CONCLUSIONS
8.1.1) Summary of Significant Findings
Almost all previous childhood brain trauma studies failed to consider age-maturation
effects of the intracranial haemodynamics and only measured individual excursion of
pressure, or the duration of derangement.  The novel cumulative pressure time index
(PTI) quantifies the total burden of CPP insult by taking both the duration and
magnitude of the insult into considerations [203, 204].  This quantification method is
robust and allows insult comparison between different age groups [203, 204].  With
PTI and grouping children into three age bands (aged 2 – 6 years, 7 – 10 years, and
11 – 15 years), age-related cerebral perfusion pressure (CPP) thresholds have been
defined as 48, 54, and 58 mmHg for these age groups respectively [204].  We have
also proven that the total burden of CPP insult (i.e. both the duration and magnitude)
affects outcome after childhood brain trauma [204].
In addition, we demonstrated that children carrying the Apolipoprotein E (APO E) e4
allele with unfavourable outcome had 22 times less CPP insult than the non-e4
carriers after brain trauma, while the e3 homozygous with good recovery had 26
times more insult than the non-e3 homozygous [261].  This suggests that the APO E
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genetic polymorphisms may differentially affect brain trauma patients’ cerebral
ischaemic tolerance [261].
Adhesion molecules may be more useful in diagnosing severe injury and predicting
poor outcome after childhood brain trauma than brain specific proteins.  Combining
2 serum biomarker levels in prognostic rules offered more superior outcome
prediction than using the individual marker’s levels.  Prognostic rules that utilize the
first day serum levels of 2 biomarkers from different mediator families may predict
unfavourable outcome after brain trauma with 100% sensitivity and 96% specificity .
8.1.2) Conclusions
Cerebral ischaemia is an important determinant of childhood brain trauma which
may be the common modulating pathway through which physiological and genetic
factors affect brain trauma outcome.  Neuro-inflammatory pathways involving
adhesion molecules may be particularly important to neuronal recovery after brain
trauma in children and their relationships with CPP insult warrants further
investigation.  Combined measurement of neuro-inflammation and glial-neuronal
damage provide more superior outcome prognostication than quantification of either
of these components on their own.
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8.2) FUTURE RESEARCH PROPOSAL
8.2.1) Future Research Proposal Introduction
Associations between cerebral ischaemia and white matter damage are well
established in adult brain trauma [373, 459-461] and stroke [462-464], and MRI
imaging has demonstrated clearly that white matter damage occurs in childhood
brain trauma and contributes significantly to outcome [465, 466].  The APO E
genetic polymorphism may be important to white matter repair after brain trauma
and cerebral ischaemia because of its potential allelic specific influence on the host’s
cerebral ischaemic tolerance [248, 261] and the involvement of its gene product in
the brain’s lipid transportation [144].  It is unknown whether the burden of CPP
insult or APO E genotypes affect the degree of white matter damage differently after
childhood brain trauma.  In addition to its influence in the acute phase, APO E
genotype also plays a major role in post-injury repair and recovery both in children
and young adults after head injury [467] and in transgenic animals [468].
Neuroimaging is used to identify white matter damage but is limited by cost, access
and provides only one time-point in a dynamic pathophysiology.  Attempts to
quantify brain damage using easily measurable and inexpensive individual serum
biomarkers have been unsuccessful.  We recently demonstrated that prognostic rules
combining 2 biomarker serum levels measured on the first day after childhood brain
trauma had more superior outcome predictive values than could be achieved using
individual marker levels, and may be 100% sensitive and 96% specific for
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unfavourable outcome at 6 month after the initial brain injury.  A recent report
described the utility of gel-free proteomics in identifying peripheral serum
biomarkers of brain trauma [469].  It demonstrated that proteomics technique may be
used to yield novel combinations of peripheral biomarkers with potentially higher
informative value about disease characteristics than a single biomarker [469].  No
study has investigated whether combination of proteins and their pattern behaviour
have any correlation with the degree of white matter damage, the burden of CPP
insult, and APO E genetic polymorphisms in childhood brain trauma.
The search for effective neuroprotective strategies has so far yielded only
disappointing results in part because majority of the proposed novel strategies aim to
modify grey matter damage [470].  Mild hypothermia (32 - 36
o
C) is a promising
neuroprotectant in the laboratory, and recent evidence indicates that it may provide
more effective neuro-protection than other proposed strategies by offering protection
to both white matters and the grey matter after experimental non-impact brain
injuries [471-474].  However, the precise mechanisms through which mild
hypothermia affects brain trauma recovery remain unknown.  Some investigators
believe mild hypothermia confers its benefits solely by blocking all changes in
signalling events that are detrimental to the ischaemic brain [475].  But others have
demonstrated an increased neuroprotective protein synthesis with mild hypothermia
after ischaemia [475-478].  If mild hypothermia is to be successfully translated into
clinically effective therapy, understanding its effect on brain injuring mechanisms
and white matter damage, and whether its actions differ in hosts with APO E and
other genetic polymorphisms are essential.
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Mild hypothermia has been demonstrated to be safe in clinical settings without life
threatening complications that are associated with the historic use of prolonged deep
hypothermia (30
o
C or less) [479-482].  Three recent independent clinical studies
demonstrated an improved outcome among adults surviving cardio-pulmonary
resuscitation [483-485].  In addition, reduced risks of death or disability were
associated with selective head cooling [486] and whole body hypothermia [487] in
neonatal hypoxic-ischaemic encephalopathy.  Animal studies have suggested that a
brief period of mild hypothermia is able to limit the extent of brain injury, improves
mortality and morbidity after experimental brain trauma and cerebral ischaemia
[488-491].  It is, however, unclear whether mild hypothermia alters brain trauma
outcome in the clinical setting.
The reported benefits of mild hypothermia were associated with varying durations of
hypothermia ranging from a few hours to 14 days [489-493].  The optimal
hypothermia therapeutic duration is, however, unknown in both human and animal
brain injury.  It is also unclear whether mild hypothermia continues to offer its
potential benefits if initiated several hours after the occurrence of brain trauma.  This
is a particularly important consideration when currently it may take up to 5 hours




1. APO E e4 allelic children suffer more white matter damage after brain trauma
than the non-e4 carriers because of their relative intolerance of cerebral
ischaemia.
2. Pattern behaviour of proteins detected by gel-free proteomics are different in
brain trauma children with varying degree of white matter damage, different
burden of CPP insult, and different APO E genotypes.
3. Longer duration of mild hypothermia therapy, even if commenced after some
delays, is more effective in reducing white matter damage than shorter
treatment period in experimental brain trauma.
4. Animals expressing the different human APO E alleles respond differently to
mild hypothermia therapy, have different patterns of white matter proteins,
and different degree of white matter damage after brain injury.
8.2.3) Aims and Objectives
We aim to determine:
1. How APO E genetic polymorphisms and CPP insult influence white matter
damage and outcome after childhood brain trauma.
2. The optimal therapeutic window and duration of mild hypothermia in
experimental brain trauma.
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3. Whether the APO E genetic polymorphisms affect the host’s response to
mild hypothermia and its mechanisms of action in experimental brain
trauma.
8.2.4) Proposed Methodology
A 5-year project is proposed and will consist of a clinical study component, and a
pre-clinical animal study component that will take place in Toronto, Canada, and
Edinburgh, UK.
The clinical study will assess the influence of APO E genotypes and the total burden
of CPP insult on the amount of white matter damage and outcome after brain trauma.
In addition, serum proteomics will be investigated in these patients.
The pre-clinical animal study will be conducted in two stages over the five-year
period.  Phase 1 (2 of the 5 years) will be conducted at the Hospital for Sick Children
(HSC), Toronto, Canada under the collaboration and supervision of Prof. James
Hutchison.  Phase 2 (3 of the 5 years) will be conducted at the University of
Edinburgh, UK, under the supervision of Prof. James McCulloch and in
collaboration with Dr. Karen Horsburgh.  This part of the study will assess the effect
of mild hypothermia on white matter damage after experimental brain trauma in wild
type and APO E transgenic mice.
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The unique hypothermia-brain trauma model in Toronto is not available in the UK.
This collaboration is essential to the proposed project and will add significantly to
the paediatric brain trauma literature.  In addition, this collaboration will enable us to
bring the hypothermia-brain trauma model back to Edinburgh.  We then hope to
optimize the model for application to APO E transgenic mice by capitalizing the
expertise available in Edinburgh Neuroscience.
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LIST OF ABBREVIATIONS
A&E Accident and Emergency Department
APO E Apolipoprotein E gene
apo E Apolipoprotein E (Gene product of the Apolipoprotein E gene)
AIS Abbreviated Injury Scale
ATP Adenosine triphosphate
AUC Area under the curve
BBB Blood-brain barrier
CDC Computerized Data Collection
CMRO2 Cerebral metabolic rate of oxygen
CNS Central nervous system
CPP Cerebral perfusion pressure
GCS Glasgow Coma Scale
GOS Glasgow Outcome Scale score
ICP Intracranial pressure
ICU Intensive Care Unit




ISS Injury Severity Score
MAP Mean arterial blood pressure




NAHI Non-accidental head injury
NGH Newcastle General Hospital
NHS National Health Service
PCR Polymerase chain reaction
PICU Paediatric Intensive Care Unit
PTI Cumulative pressure-time index
PTIc Cumulative pressure-time index for cerebral perfusion pressure
PTIi Cumulative pressure-time index for intracranial pressure
PTS Paediatric Trauma Score
RHSC Royal Hospital for Sick Children, Edinburgh
ROC Receiver Operator Characteristic curve
RTA Road traffic accident
RTS Revised Trauma Score
SICAM Soluble Intracellular Adhesion Molecule
SjO2 Global brain oxygen extraction
TBI Traumatic brain injury
TCDB Traumatic Coma Data Bank
TNF-" tumour necrosis factor alpha
TRISS Trauma Score-Injury Severity Score
WGH Western General Hospital, Edinburgh
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Neurochemical Marker Assay Procedures
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Nexus Dx™ NSE Test Kit (Synx Pharma Inc.)
Reagent Supplied
(1) 96 microtitration wells (arranged as twelve 8-well strips held in a stripholder)
coated with monoclonal anti-NSE antibody
(2) Five vials of Neuron Specific Enolase standards (0, 6.25, 25, 50, and 100
ng/ml)
(3) One vial of Incubation Buffer
(4) Three vials of NSE protein controls (low, medium and high level)
(5) One vial of monoclonal anti-NSE immunoglobulin labelled as Horseradish
Peroxidase (HRP) – Antibody Conjugate
(6) One vial of Chromogen (TMB) Solution, which is tetramethylbenzidine
(TMB) in citrate/phosphate buffer with hydrogen peroxide
(7) One vial of concentrated Wash Solution which contains phosphate buffered
saline with non-ionic detergent
(8) One bottle of Stopping Solution which contains 1N sulphuric acid
Assay Procedure
(1) All samples (sera only) and reagents are bought to room temperature which
usually takes 35 minutes and mixed well by vortexing.  The Wash Solution is
diluted by adding 1500 ml of distilled de-ionized water.  It is important to
note that crystals may form in the wash solution at cold temperature and will
re-dissolve upon warming to room temperature.
(2) The microplate wells are marked for each samples, standards and controls.
Samples, standards, and controls are assayed in duplicate.
(3) Using a semi-automatic pipette, 50 µl of the Incubation Buffer is added to
each well.
(4) 50 µl of each test samples, NSE standards or NSE control is added to the
appropriate well.  In order to ensure standard curve consistency, the following
order of addition is carried out: (i) test samples, (ii) NSE standards, and (c)
NSE controls.
(5) Cover the microwells with an adhesive plate cover and incubate for 15
minutes on an orbital microplate shaker at room temperature.
(6) Wash each microwell three times with 340 µl of the Wash Solution using a
microplate washer.  Blot dry by inverting plate on absorbent paper after each
wash.
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(7) 100 µl of the Peroxidase-antibody Conjugate solution is added to each well.
(8) Incubate the wells for 15 minutes at room temperature on an orbital
microplate shaker.
(9) Wash each of the microwells three times with 340 µl of the Wash Solution.
Blot dry by inverting the plate on absorbent paper.
(10) 100 µl of the TMB solution is added to each of the wells and incubate in the
dark at room temperature for 15 minutes.
(11) 100 µl of the Stopping Solution is added to each well and the absorbance of
the solution in the microwells is read using a microplate reader at 450 nm.
Calculation of Results
(1) The mean absorbance for each standard, control or test subject serum is
calculated.
(2) The mean absorbance reading for each of the standards is plotted against the
NSE concentration (ng/ml).
(3) The best fitting standard curve is then drawn through the mean of the
duplicate points.
(4) The NSE concentrations of the test subject sera and controls are determined
by interpolation from the standard curve.
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Nexus Dx™ S-100 Test Kit (Synx Pharma Inc.)
Reagents Supplied
(1) 96 microtitration wells coated with monoclonal anti-S100 protein antibody.
(2) Five vials of S-100 protein standards containing 0, 0.02, 0.1, 0.4, and 1.6
ng/ml of S-100 protein.
(3) One vial of Incubation Buffer.
(4) Three vials of S-100 protein control serum of low, medium and high levels of
S-100 protein.
(5) One vial of Detection Antibodies (anti-S-100 polyclonal antibodies).
(6) One vial of goat anti-rabbit immunoglobulins labelled with horseradish
peroxidase (Peroxidase Conjugate).
(7) One vial of concentrated Wash Solution which contains phosphate buffered
saline with non-ionic detergent.
(8) One vial of Chromogen Solution which contains tetramethylbenzidine (TMB)
in citrate/phosphate buffer with hydrogen peroxide
(9) One bottle of Stopping Solution containing 1N sulphuric acid.
Assay Procedures
(1) All specimens and reagents are bought to room temperature, which usually
takes 35 minutes, and mixed well by vortexing.  The concentrated Wash
Solution is diluted by addint 1500 ml of distilled de-ionised water.
(2) The microwells are marked for each sample, standards or controls.  Samples,
standards and controls are assayed in duplicate.
(3) 75 µl of the Incubation Buffer is added to each well using a semi-automatic
dispenser.
(4) Using a precision micropipette, 25 µl of each test serum sample, S-100
standard and control is added to the appropriate microwell.  In order to ensure
standard curve consistency, the following order of addition is carried out: (i)
test samples, (ii) S-100 standards, and (iii) S-100 controls.
(5) The microwells are covered using an adhesive plate cover and incubated at
room temperature for 15 minutes on an orbital microplate shaker.
(6) Each microwell is washed three times with 340 µl of the diluted Wash
Solution.  Blot dry by inverting the plate on absorbent paper after each wash.
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(7) 100 µl of the Detection Antibody Solution is added.  The wells are covered by
an adhesive plate cover and incubated for 15 minutes at room temperature on
an orbital microplate shaker.
(8) Each microwell is washed three times with 340 µl of the diluted Wash
Solution and blotted dry by inverting the plate on absorbent paper after each
wash.
(9) 100 µl of the Peroxidase Conjugate is added to each microwell and incubated
for 10 minutes at room temperature on an orbital microplate shaker after
being covered by an adhesive plate cover.
(10) Each microwell is washed three times with 340 µl of the diluted Wash
Solution and blotted dry after each wash on absorbent paper.
(11) 100 µl of the Chromogen Solution is added to each well before being
incubated in the dark for 5 minutes at room temperature on an orbital
microplate shaker.
(12) 100 µl of the Stopping Solution is added to each well and the absorbance of
the solution in the microwells is read at 450 nm using a microplate reader.
Calculation of Results
(1) The mean absorbance for each standard, control or test subject serum is
calculated.
(2) The mean absorbance reading for each of the standards is plotted against the
S-100 concentration in ng/ml.
(3) The best fitting standard curve is drawn through the mean of the duplicate
points.
(4) The S-100 concentrations of the test subject sera and controls is determined
by interpolation from the standard curve.
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Human sL-Selectin Immunoassay (R&D Systems)
Reagent Supplied
(1) 96 well microplate coated with a mouse monoclonal antibody to human sL-
Selectin.
(2) Six vials of recombinant human sL-Selectin standards with blue dye and
preservative.  The concentrations of sL-Selectin are shown on the vial labels
and vary between kits.
(3) Three bottles of Sample Diluent which is a buffered protein base with blue
dye and preservative.
(4) One vial of sL-Selectin Conjugate which contains sheep polyclonal antibody
to recombinant human sL-Selectin conjugated to horseradish peroxidase in
buffer, with red dye and preservative.
(5) One vial of sL-Selectin Control containing lyophilized human serum with sL-
Selectin.  The concentration of the control should fall within the range
specified on the vial label.
(6) One bottle of concentrated Wash Buffer which is a 25-fold concentrated
buffered surfactant with preservative.
(7) One bottle of Substrate (stabilized tetramethylbenzidine solution).
(8) One bottle of Stop Solution (acid solution)
(9) Plate sealers are included.
Sample Preparation
Both serum and plasma samples can be used with this assay but required to be
diluted 100 folds with the Sample Diluent.  For this particular children TBI study, the
plasma samples are used to determine the sL-Selectin concentrations.  Plasma
samples are thawed to room temperature which usually takes 35 minutes.  5 µl of the
plasma samples are added to 495 µl of the Sample Diluent and mixed by vortexing.
Reagent Preparation
(1) All reagents are bought to room temperature before use.
(2) 20 ml of the concentrated Wash Buffer is diluted with 480 ml of distilled de-
ionised water.  Crystals may be found in the cold Wash Buffer and will re-
dissolve upon warming to room temperature and gentle mixing.
(3) The sL-Selectin Control is reconstituted with 500 µl of distilled de-ionised
water immediately before use and allowed to sit at room temperature for at
least 10 minutes.  The Control is further diluted 100 folds with Sample




(1) The microwells are marked for each standards, control or test samples.  All
samples, standards, and control are assayed in duplicate.
(2) 100 µl of Standards, diluted sL-Selectin, and diluted sampled is added to the
appropriate microwells.  Samples addition is uninterrupted and completed
within 15 minutes.
(3) The plate is covered with the provided plate sealer and incubated at room
temperature for 1 hour on an orbital microplate shaker.
(4) 100 ml of the sL-Selecitn Conjugate is added to each well with sufficient
force to ensure mixing.
(5) The plate is covered with a new plate sealer and incubated at room
temperature for 30 minutes on an orbital microplate shaker.
(6) Each well is decanted and washed six times with 400 µl of the Wash buffer
dispensed by a multi-channel pipette.  Complete removal of liquid after each
wash is ensured and after the last wahs, the plate is blotted dry on clean
absorbent paper.
(7) 100 µl of the Substrate is added to each well.  The plate is covered before
being incubated in room temperture for 30 minutes on an orbital microplate
shaker.
(8) 100 µl of the Stop Solution is added to each well and the optical density of
each well is determined immediately using a microplate reader set at 450 nm,
with wavelength correction set at 620 nm.
Calculation of Result
(1) The mean absorbance values for each set of duplicate Standards are
calculated.
(2) A standard curve is created by reducing the data using Gensis which is a
computer software capable of generating a four parameter logistic (4-PL)
curve-fit.
(3) The concentration of each unknown diluted sample is determined by
calculating the concentration of sL-Selectin corresponding to the mean
absorbance from the standard curve.  The concentration determined from the
standard curve is then multiplied by the dilution factor to give the actual
concentration.
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Endothelin (1-21) Test Kit (Biomedica)
Reagent Supplied
(1) 96 microtitration wells (12 x 8 well microtiter strip in one stripholder) coated
with a polyclonal rabbit anti-Endothelin antibody.
(2) One vial of 10x concentrated Washing Buffer (100 ml).
(3) One bottle of ready to use Assay Buffer (100 ml).
(4) One vial of Detection Antibody (Green cap) containing monoclonal mouse
anti-Endothelin antibody lyophilized with green dye.
(5) Six vials of Standards (White caps) synthetic human Endothelin-1 (1-21) in
lyophilized human plasma ranging from 0 to 10 fmol/ml.  The concentrations
after reconstitution are stated on the label.
(6) Two vials of Controls (Yellow caps) containing synthetic human Endothelin-
1 (1-21) in lyophilized human plasma.  Concentration after reconstitution are
stated on the label.
(7) One bottle of ready to use Conjugate containing anti-mouse Ig G antibody
conjugated to horseradish peroxidase.
(8) One vial of Substrate which contains ready to use TMB solution.
(9) One vial of Stop Solution which is ready to use.
(10) One bottle of PAA (Precipitating Agent Additive) which requires 80 ml of
acetone p.a. before use.
(11) One bottle of PB-Buffer (Protocol B-Buffer).
(12) One vial of extra high plasma standard (Amber vial).
(13) Two self-adhesive plastic films
Reagent and Sample Preparation
Since the plasma samples used in this study are EDTA-plasma samples, the protocol
for direct measurement of Endothelin in human EDTA-plasma samples is used.
(1) Test samples are thawed at room temperature for 35 minutes and mixed well
by vortexing prior to assay.
(2) 1.5 ml of the Assay Buffer is added to each of the Standards (0 – 5) and left in
room temperature for 30 minutes.
(3) 1.5 ml of the Assay Buffer is added to each of the Controls and allowed to
stand in room temperature for 30 minutes before use.
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(4) 5.5 ml of the Assay Buffer is added to the Detection Antibody which is left to
stand in room temperature for 30 minutes.
(5) Positions for blanks, standards, controls and samples are marked on the
protocol sheet supplied.
(6) The concentrated Washing Buffer is diluted by adding 900 ml of distilled de-
ionised water.  The solution is mixed well without the formation of foam.
Crystals in the concentrated buffer is dissolved upon re-warming in room
temperature.
(7) 200 µl of standards, controls, and samples are introduced into the appropriate
wells.
(8) 50 µl of the Detection Abtibody is added to all wells except the blanks.
(9) The plate is covered and incubated overnight (16-24 hours) at room
temperature on an orbital microplate shaker.  It is vital that the wells are
sealed with the film to prevent evaporation.
(10) The contents of the wells are discarded and each well is washed five times
with at least 300 µl diluted Washing Buffer.  The plate is blotted dry on
absorbent paper after each wash.
(11) 200 µl of the Conjugate is added to all wells.  The plate is sealed with a new
plastic film and incubated for three hours at 370C without shaking.  If an
incubator/shaker is available, the incubation time can be reduced to one hour.
(12) The contents of the wells are discarded and each well is washed five times
with at least 300 µl of the diluted Washing Buffer.  The plate is blotted dry
after each wash on absorbent paper.
(13) 200 µl of the Substrate is added to each wells and the plated is incubated at
room temperature in the dark for 30 minutes on an orbital microplate shaker.
(14) 50 µl of the Stop Solution is added to the wells.  Absorption is determined
immediately using a microplate ready at 450 nm against a correction
wavelength of 690 nm as reference.
Calculation of Results
(1) The mean absorbance values for each set of the duplicate Standards are
calculated.
(2) A standard curve, which is expected to be non-linear, is created by using
Genesis to reduce the data and generate a four parameter logistic (4-PL)
curve-fit.
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(3) The concentration of each unknown diluted sample is determined by
calculating the concentration of Endothelin corresponding to the mean
absorbance from the standard curve.
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SICAM-1 ELISA Kit (Diaclone Research)
Reagents Supplied
(1) 96 wells microtiter plate coated with a monoclonal antibody specific for
ICAM-1.
(2) Two plastic covers
(3) Two vials of Standards (8ng/ml) which required to be reconstituted.
(4) Two vials of Controls which require reconstitiution.
(5) One vial of 10x concentrated Standard Diluent Buffer which requires dilution
with distilled water.
(6) One vial of Biotinylated anti-sICAM-1 which needs to be diluted with
biotinylated antibody diluent.
(7) One vial of ready to use Biotinylated Antibody Diluent.
(8) Two vials of Streptaviin-HRP which requires to be re-constitute with HRP-
Diluent.  Further dilutions are required prior to assay.
(9) One vial of ready to use HRP-Diluent
(10) One vial of 200x concentrated Washing Buffer.  Dilution in distilled water is
required prior to use.
(11) One vial of Chromogen TMB which is ready to use.
(12) One vial of ready to use H2SO4: Stop Reagent.
Preparation of Reagents & Samples
Both serum and plasma samples are suitable for use with this ELISA kit.  For the
purpose of this study, frozen plasma samples are used.
(1) 10 ml of the 10x concentrated Standard Buffer Diluent is diluted with 990 ml
of distilled de-ionised water and allowed to stand in room temperature for 30
minutes prior to use.
(2) Tests samples are thawed in room temperature for 35 minutes.  5 µl of each
sample is diluted with 495 µl of the diluted Standard Diluent i.e 100x dilution.
(3) Reconstitution of the Standard is done according to the instruction on the vial
to give a stock solution of 8 ng/ml of sICAM-1.  The solution is allowed to
stand for 5 minutes with gentle swirling prior to further dilutions.
(4) Control is reconstituted as per instruction on the vial and left to stand for 5
minutes with gentle swirling before distribution into the control wells.
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(5) 10 ml of the Washing buffer is added to 1990 ml of distilled de-ionised water
at room temperature.
Assay Procedure
(1) The position of standards, controls and samples are marked.  Each sample,
standard, blank, and control samples are assayed in duplicate.
(2) 100 µl of the diluted Standard Diluent is added to standard wells labelled B1,
B2, C1, C2, D1, D2, E1, E2, F1, and F2.  200 µl of the reconstituted Standard
is added to the wells labelled A1 and A2.  100 µl of the Standard in wells A1
and A2 is transferred into wells B1 and B2.  The contents are mixed by
repeated aspiration and ejections.  The procedure is repeated from the wells
B1, B2 to wells C1, C2, and from wells C1, C2 to D1, D2 and so on creating
two parallel rows of sICAM-1 standard dilutions ranging from 8 ng/ml to 0.25
ng/ml.  100 µl of the content of the last microwells F1 and F2 is discarded.
Care is taken to ensure the inner surface of the microwells are not scratched.
(3) 100 µl of the Standard Diluent is added to each of the blank wells (G1 and
G2).
(4) 100 µl of the reconstituted Control is added into the Control wells (H1 and
H2) and 100 µl of each test sample is added to the appropriate well.
(5) 240 µl of the Biotinylated anti-sICAm-1 is diluted with 6360 µ l of the
Biotinylated Antibody Diluent immediately before use.  50 µl of the diluted
Biotinylated Antibody is added to all wells.
(6) The plate is covered with the plastic film and incubated at room temperature
for 1 hour on an orbital microplate shaker.
(7) The fluid in each well is discarded.  Each well is then washed three times with
300 µl of the diluted Washing Buffer.  The plate is blotted dry after each wash
on absorbent paper.
(8) 500 µl of the HRP Diluent is added to the Streptavidin-HRP to make up a
stock solution.  150 µl of this stock solution is further diluted with 10 ml of
HRP Diluent immediate prior to assay.  100 µl of the diluted Streptavidin-
HRP is added to each wells including the blank wells before being covered
and incubated at room temperature for 30 minutes on an orbital microplate
shaker.
(9) The fluid in each well is discarded.  Each well is then washed three times with
300 µl of the diluted Washing Buffer.  The plate is blotted dry after each wash
on absorbent paper.
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(10) 100 µl of the TMB substrate solution is added to each well including the
blank wells.  Incubation in the dark for 15 minutes is done at room
temperature on an orbital microplate shaker.
(11) 100 µl of the H2SO4: Stop Reagent is added quickly to each well.  Absorbance
of each well is read immediately using a microplate reader at 450 nm against
a reference wavelength of 620 nm.
Calculation of Result
(1) The mean absorbance for each set of the standard duplicate is calculated.
(2) A linear standard curve is generated by plotting the average absorbance
against the corresponding sICAM-1 standard concentration.
(3) The sICAM-1 concentration in each sample is determined by extrapolating
OD values to sICAM-1 concentration using the standard curve.  The actual
concentration of sICAM-1 in each sample is obtained by multiplying the
dilution factor (100x).
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IL-10 ELISA Kit (Diaclone Research)
Reagents Supplied
(1) 96 wells microtiter plate coated with a monoclonal antibody specific for Il-10.
(2) Two plastic covers
(3) Two vials of Standards (400pg/ml) which require reconstitution.
(4) Two vials of Controls which require reconstitution.
(5) One vial of 10x concentrated Standard Diluent Buffer which requires dilution
with distilled water.
(6) One vial of ready to use Standard Diluent: Human Serum.
(7) One vial of Biotinylated anti-IL-10 which needs to be diluted with
biotinylated antibody diluent.
(8) One vial of ready to use Biotinylated Antibody Diluent.
(9) Two vials of Streptaviin-HRP which requires to be re-constituted with HRP-
Diluent.  Further dilutions are required prior to assay.
(10) One vial of ready to use HRP-Diluent
(11) One vial of 200x concentrated Washing Buffer.  Dilution in distilled water is
required prior to use.
(12) One vial of Chromogen TMB which is ready to use.
(13) One vial of ready to use H2SO4: Stop Reagent.
Preparation of Reagents and Samples
Both plasma and serum samples are suitable for use with this assay kit.  For the
purpose of this study, EDTA-tracalon plasma samples are used.
(1) Test specimens are thawed at room temperature for 35 minutes.
(2) Standard is reconstituted with Standard Diluent: Human Serum as per
instruction on the vial to provide a stock solution of 400 pg/ml.  This is
allowed to stand in room temperature for 5 minutes prior to assay.
(3) Control is reconstituted with Standard Diluent: Human Serum in accordance
with the instruction on the vial.  This is left in room temperature for 5 minutes
before use.
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(4) 10 ml of the concentrated Washing Buffer is diluted with 1990 ml of distilled
de-ionised water and left in room temperature at least 30 minutes before
assay.
Assay Procedure
(1) The position of standards, controls and samples are marked.  Each sample,
standard, blank, and control samples are assayed in duplicate.
(2) 100 µl of the diluted Standard Diluent:Human Serum is added to standard
wells labelled B1, B2, C1, C2, D1, D2, E1, E2, F1, and F2.
(3) 200 µl of the reconstituted Standard is added to the wells labelled A1 and A2.
(4) 100 µl of the Standard in wells A1 and A2 is transferred into wells B1 and
B2.  The contents are mixed by repeated aspiration and ejections.
(5) The procedure is repeated from the wells B1, B2 to wells C1, C2, and from
wells C1, C2 to D1, D2 and so on creating two parallel rows of IL-10
standard dilutions ranging from 400 pg/ml to 12.5 pg/ml.  100 µl of the
content of the last microwells F1 and F2 is discarded.  Care is taken to ensure
the inner surface of the microwells are not scratched.
(6) 100 µl of the Standard Diluent: Human Serum is added to each of the blank
wells (G1 and G2).
(7) 100 µl of the reconstituted Control is added into the Control wells (H1 and
H2) and 100 µl of each test sample is added to the appropriate well.
(8) 240 µ l of the Biotinylated anti-Il-10 is diluted with 6360 µ l of the
Biotinylated Antibody Diluent immediately before use.  50 µl of the diluted
Biotinylated Antibody is added to all wells.
(9) The plate is covered with the plastic film and incubated at room temperature
for 2 hours on an orbital microplate shaker.
(10) The fluid in each well is discarded.  Each well is then washed three times with
300 µl of the diluted Washing Buffer.  The plate is blotted dry after each wash
on absorbent paper.
(11) 500 µl of the HRP Diluent is added to the Streptavidin-HRP to make up a
stock solution.  150 µl of this stock solution is further diluted with 10 ml of
HRP Diluent immediate prior to assay.  100 µl of the diluted Streptavidin-
HRP is added to each well including the blank wells before being covered and
incubated at room temperature for 30 minutes on an orbital microplate shaker.
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(12) The fluid in each well is discarded.  Each well is then washed three times with
300 µl of the diluted Washing Buffer.  The plate is blotted dry after each wash
on absorbent paper.
(13) 100 µl of the TMB substrate solution is added to each well including the
blank wells.  Incubation in the dark for 12 minutes is done at room
temperature on an orbital microplate shaker.
(14) 100 µl of the H2SO4: Stop Reagent is added quickly to each well.  Absorbance
of each well is read immediately using a microplate reader at 450 nm against
a reference wavelength of 620 nm.
Calculation of Result
(1) The mean absorbance for each set of the standard duplicate is calculated.
(2) The average absorbance is plotted against the corresponding IL-10 standard
concentration and the best fitting curve is drawn through the mean of the
duplicate points using 4-PL protocol.
(3) The IL-10 concentration in each sample is determined by extrapolating OD
values to IL-10 concentration using the standard curve.
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IL-6 ELISA Kit (Diaclone Research)
Reagents Supplied
(1) 96 wells microtiter plate coated with a monoclonal antibody specific for IL-6.
(2) Two plastic covers
(3) Two vials of Standards (200 pg/ml) which require reconstitution.
(4) Two vials of Controls which require reconstitution.
(5) One vial of 10x concentrated Standard Diluent Buffer which requires dilution
with distilled water.
(6) One vial of ready to use Standard Diluent: Human Serum.
(7) One vial of Biotinylated anti-IL-6 which needs to be diluted with biotinylated
antibody diluent.
(8) One vial of ready to use Biotinylated Antibody Diluent.
(9) Two vials of Streptaviin-HRP which requires to be re-constituted with HRP-
Diluent.  Further dilutions are required prior to assay.
(10) One vial of ready to use HRP-Diluent
(11) One vial of 200x concentrated Washing Buffer.  Dilution in distilled water is
required prior to use.
(12) One vial of Chromogen TMB which is ready to use.
(13) One vial of ready to use H2SO4: Stop Reagent.
Preparation of Reagents and Samples
Both plasma and serum samples are suitable for use with this assay kit.  For the
purpose of this study, EDTA-tracalon plasma samples are used.
(1) Test specimens are thawed at room temperature for 35 minutes.
(2) Standard is reconstituted with Standard Diluent: Human Serum as per
instruction on the vial to provide a stock solution of 200 pg/ml.  This is
allowed to stand in room temperature for 5 minutes prior to assay.
(3) Control is reconstituted with Standard Diluent: Human Serum in accordance
with the instruction on the vial.  This is left in room temperature for 5 minutes
before use.
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(4) 10 ml of the concentrated Washing Buffer is diluted with 1990 ml of distilled
de-ionised water and left in room temperature at least 30 minutes before
assay.
Assay Procedure
(1) The position of standards, controls and samples are marked.  Each sample,
standard, blank, and control samples are assayed in duplicate.
(2) 100 µl of the diluted Standard Diluent:Human Serum is added to standard
wells labelled B1, B2, C1, C2, D1, D2, E1, E2, F1, and F2.
(3) 200 µl of the reconstituted Standard is added to the wells labelled A1 and A2.
(4) 100 µl of the Standard in wells A1 and A2 is transferred into wells B1 and
B2.  The contents are mixed by repeated aspiration and ejections.
(5) The procedure is repeated from the wells B1, B2 to wells C1, C2, and from
wells C1, C2 to D1, D2 and so on creating two parallel rows of IL-10
standard dilutions ranging from 200 pg/ml to 6.25 pg/ml.  100 µl of the
content of the last microwells F1 and F2 is discarded.  Care is taken to ensure
the inner surface of the microwells are not scratched.
(6) 100 µl of the Standard Diluent: Human Serum is added to each of the blank
wells (G1 and G2).
(7) 240 µl of the Biotinylated anti-IL-6 is diluted with 6360 µl of the Biotinylated
Antibody Diluent immediately before use.  50 µl of the diluted Biotinylated
Antibody is added to all wells.
(8) The plate is covered with the plastic film and incubated at room temperature
for 1 hour on an orbital microplate shaker.
(9) The fluid in each well is discarded.  Each well is then washed three times with
300 µl of the diluted Washing Buffer.  The plate is blotted dry after each wash
on absorbent paper.
(10) 500 µl of the HRP Diluent is added to the Streptavidin-HRP to make up a
stock solution.  150 µl of this stock solution is further diluted with 10 ml of
HRP Diluent immediate prior to assay.  100 µl of the diluted Streptavidin-
HRP is added to each well including the blank wells before being covered and
incubated at room temperature for 30 minutes on an orbital microplate shaker.
(11) The fluid in each well is discarded.  Each well is then washed three times with
300 µl of the diluted Washing Buffer.  The plate is blotted dry after each wash
on absorbent paper.
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(12) 100 µl of the TMB substrate solution is added to each well including the
blank wells.  Incubation in the dark for 12 minutes is done at room
temperature on an orbital microplate shaker.
(13) 100 µl of the H2SO4: Stop Reagent is added quickly to each well.  Absorbance
of each well is read immediately using a microplate reader at 450 nm against
a reference wavelength of 620 nm.
Calculation of Result
(1) The mean absorbance for each set of the standard duplicate is calculated.
(2) The average absorbance is plotted against the corresponding IL-6 standard
concentration and the best fitting curve is drawn through the mean of the
duplicate points using 4-PL protocol.
(3) The IL-6 concentration in each sample is determined by extrapolating OD
values to IL-6 concentration using the standard curve.
In samples with concentration below detection level (<6.25 pg/ml), the High
Sensitivity Human IL-6 ELISA Kit (Diaclone Research) is used to repeat the assay.
This provides a detection range from 1.56 pg/ml to 50 pg/ml.  The assay protocol for
the High Sensitivity Human IL-6 ELISA Kit is identical to that of IL-6 ELISA Kit
with the only difference being the concentration of the Standard provided in the High
Sensitivity Kit is 50 pg/ml.
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IL-8 ELISA Kit (Diaclone Research)
Reagents Supplied
(1) 96 wells microtiter plate coated with a monoclonal antibody specific for IL-8.
(2) Two plastic covers
(3) Two vials of Standards (2000 pg/ml) which require reconstitution.
(4) Two vials of Controls which require reconstitution.
(5) One vial of 10x concentrated Standard Diluent Buffer which requires dilution
with distilled water.
(6) One vial of ready to use Standard Diluent: Human Serum.
(7) One vial of Biotinylated anti-IL-8 which needs to be diluted with biotinylated
antibody diluent.
(8) One vial of ready to use Biotinylated Antibody Diluent.
(9) Two vials of Streptaviin-HRP which requires to be re-constituted with HRP-
Diluent.  Further dilutions are required prior to assay.
(10) One vial of ready to use HRP-Diluent
(11) One vial of 200x concentrated Washing Buffer.  Dilution in distilled water is
required prior to use.
(12) One vial of Chromogen TMB which is ready to use.
(13) One vial of ready to use H2SO4: Stop Reagent.
Preparation of Reagents and Samples
Both plasma and serum samples are suitable for use with this assay kit.  For the
purpose of this study, EDTA-tracalon plasma samples are used.
(1) Test specimens are thawed at room temperature for 35 minutes.
(2) Standard is reconstituted with Standard Diluent: Human Serum as per
instruction on the vial to provide a stock solution of Il-8 with concentration of
2000 pg/ml.  This is allowed to stand in room temperature for 5 minutes prior
to assay.
(3) Control is reconstituted with Standard Diluent: Human Serum in accordance
with the instruction on the vial.  This is left in room temperature for 5 minutes
before use.
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(4) 10 ml of the concentrated Washing Buffer is diluted with 1990 ml of distilled
de-ionised water and left in room temperature at least 30 minutes before
assay.
Assay Procedure
(1) The position of standards, controls and samples are marked.  Each sample,
standard, blank, and control samples are assayed in duplicate.
(2) 100 µl of the diluted Standard Diluent:Human Serum is added to standard
wells labelled B1, B2, C1, C2, D1, D2, E1, E2, F1, and F2.
(3) 200 µl of the reconstituted Standard is added to the wells labelled A1 and A2.
(4) 100 µl of the Standard in wells A1 and A2 is transferred into wells B1 and
B2.  The contents are mixed by repeated aspiration and ejections.
(5) The procedure is repeated from the wells B1, B2 to wells C1, C2, and from
wells C1, C2 to D1, D2 and so on creating two parallel rows of IL-8 standard
dilutions ranging from 2000 pg/ml to 62.5 pg/ml.  100 µl of the content of the
last microwells F1 and F2 is discarded.  Care is taken to ensure the inner
surface of the microwells are not scratched.
(6) 100 µl of the Standard Diluent: Human Serum is added to each of the blank
wells (G1 and G2).
(7) 240 µl of the Biotinylated anti-IL-8 is diluted with 6360 µl of the Biotinylated
Antibody Diluent immediately before use.  50 µl of the diluted Biotinylated
Antibody is added to all wells.
(8) The plate is covered with the plastic film and incubated at room temperature
for 1 hour on an orbital microplate shaker.
(9) The fluid in each well is discarded.  Each well is then washed three times with
300 µl of the diluted Washing Buffer.  The plate is blotted dry after each wash
on absorbent paper.
(10) 500 µl of the HRP Diluent is added to the Streptavidin-HRP to make up a
stock solution.  150 µl of this stock solution is further diluted with 10 ml of
HRP Diluent immediate prior to assay.  100 µl of the diluted Streptavidin-
HRP is added to each well including the blank wells before being covered and
incubated at room temperature for 30 minutes on an orbital microplate shaker.
(11) The fluid in each well is discarded.  Each well is then washed three times with
300 µl of the diluted Washing Buffer.  The plate is blotted dry after each wash
on absorbent paper.
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(12) 100 µl of the TMB substrate solution is added to each well including the
blank wells.  Incubation in the dark for 12 minutes is done at room
temperature on an orbital microplate shaker.
(13) 100 µl of the H2SO4: Stop Reagent is added quickly to each well.  Absorbance
of each well is read immediately using a microplate reader at 450 nm against
a reference wavelength of 620 nm.
Calculation of Result
(1) The mean absorbance for each set of the standard duplicate is calculated.
(2) The average absorbance is plotted against the corresponding IL-8 standard
concentration and the best fitting curve is drawn through the mean of the
duplicate points using 4-PL protocol.
The IL-8 concentration in each sample is determined by extrapolating OD values to
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Paediatric Traumatic Brain Injury
T.Y.M. Lo1&2, P.A. Jones1, I.R. Chambers3,
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In children, duration of age-specific abnormal CPP predict outcome
• Dead vs alive (p = 0.003)
• ‘Poor’ vs ‘independent’ (p = 0.004)
(Jones et al. British Journal of Neurosurgery 2003; 17(1):29-39.)
Aims
In children with TBI
1. Quantify the physiological derangement
! Using a cumulative pressure-time index (CP-T)
2. Correlate physiological derangement (mean
values & CP-T) with outcome






– 52 boys, 27 girls
– Severe 58, moderate 19,
minor 2
• Two regional centres
2
Patients & Methods
• Outcome assessment (GOS at 6 months)
– ‘independent’ vs ‘poor’
• Severity of derangement
– ROC curve
• Predictors of outcome
– Univariate & multivariate logistic regression
modelling
Patients & Methods
Critical CPP Thresholds & CP-T
Age Mean CPP
threshold
2-6 years ! 48 mmHg
7-10 years ! 54 mmHg
11-16 years ! 58 mmHg
( )! "#= interval samplethreshold tCPPCPPCPT
Patients & Methods
Cumulative pressure-time index (CP-T)
Cumulative area between the threshold and the curve
( )! "#= interval samplethreshold tCPPCPPCPT
Results -
Physiological Derangement
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(95% CI 1557, 4898)
Independent
Mean CP-T ValueOutcome
Significant difference between the CP-T area








ROC Curve for CPP Threshold
Conclusion - 1
In children with traumatic brain injury:
• CPP was the best predictor of outcome





58 mmHg11 - 16 years
54 mmHg7 - 10 years
48 mmHg2 - 6 years
Mean CPP thresholdAge
1
Variation in cerebral perfusion pressure insults
among apolipoprotein E genetic polymorphisms
and associations with outcome following
childhood trauamtic brain injury
Dr. T.Y.M Lo1&2, Mrs. P.A. Jones1&2, Dr. I.R. Chambers3,
Dr. T.F. Beattie2, Ms. J. Croft3, Ms. G. Wilson3,
Dr. R. Forsyth3, Prof. A.D. Mendelow3,
Prof. R.A. Minns1&2
1Child Life & Health, University of Edinburgh, Edinburgh
2Royal Hospital for Sick Children, Edinburgh
3Newcastle General Hospital, Newcastle upon Tyne Despite vigilant trauma management & neuro-intensive care,
outcome remains diverse after childhood traumatic brain injury
Background
APO E Genotypes & Brain Injury
Apolipoprotein E Gene
• Polymorphism in human
–  !2, !3, !4
• Gene product (apo E) & CNS lipid transport system
• In adults, APO E !4
–  Poor recovery from head injury
(Teasdale et al, The Lancet 1997)
(Friedman et al, Neurology 1999)
(Teasdale et al, Brain 2005)
–  Increased risk for Alzheimer’s Disease
(Horsburgh et al, Neurobiol Aging 2000)
Aim
To determine:
(1) The distribution of APO E alleles:
– Critically ill head injured children
– Healthy active controls
(2) The influence of APO E alleles on:
– Amount of age-specific CPP insult




• 65 critically ill head
injured children
• 160 active healthy
children (Controls)
Patients & Methods
• Buccal smear for DNA
extractions












T.Y.M. Lo Aug 2003
2
Patients & Methods
Cumulative pressure-time index (CPT)
Cumulative area between the critical threshold and the curve
(Chambers et al, JNNP 2005 In Press)
( )! "#= interval samplethreshold tCPPCPPCPT
Patients & Methods
• Outcome assessment @ 6 months post injury
– GOS (‘Good recovery’ vs ‘Poor outcome’)
• Genotype distribution comparisons
– Chi square test















HI vs Population APO E !2 p < 0.0001, 
Controls vs Population APO E !2 p < 0.0001, 
HI vs Controls p = NS
(Chi Square Test)
Results -










e2/e2 e2/e3 e2/e4 e3/e3 e3/e4 e4/e4
APO E Genotype
Good Recovery Poor Outcome
Good recovery - 57
Poor outcome - 8
13/16 !2 - good recovery
3/14 !4 - poor outcome
(p = NS, Fisher’s Exact Test) 
Secondary Brain Insult (CPT of CPP) for
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• No difference in distribution of APO E
genotypes in active children with / without
head injury
• Distribution of APO E genotype (APO E !2) in
active children with / without head injury
differs significantly from those previously
reported in adults.
Summary - 2
• The possession of different APO E alleles are associated with
different amounts of CPP insults (as measured by CPT).
• Carriers of the APO E !4 allele experienced the least amount
of CPP insult.
• The degree of CPP insult for APO E !4 possessors with a poor
outcome was less than half that expected for the whole group,
and at a level where a good recovery should have been
expected, suggesting other mechanisms influenced by the
genotype, were responsible for the poor outcome.
Conclusion
• Better understanding of how APO E genetic
polymorphisms affect outcome after brain
trauma.
• Development of novel supplemental Rx to
current Rx strategy (secondary insult
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Abstract
A prospective observational study was undertaken to examine time series ICU
data of pressure variables (mean arterial pressure (MAP), intracranial pressure
(ICP) and cerebral perfusion pressure (CPP)) and relate their variability (SD)
to outcome, together with simple graphical displays which could be useful at
the ICU bedspace.
Forty-three children (aged <1–15 years) were admitted to the intensive care
unit for Regional Neurosurgical Service, Edinburgh, following traumatic brain
injury (TBI). The standard deviations from 221 291 validated pressure data
measurements (representing three variables) were calculated for the duration
of ICP monitoring (and in 48 h epochs from the time of injury). Data were
displayed on polygraphs, and several well-defined ‘patterns’ were described.
The standard deviations of MAP, ICP and CPP for the total duration of
monitoring were found to be significantly related to survival (p = 0.003,
<0.001 and 0.005, respectively), while the SD of ICP alone was strongly
related to global recovery (p = 0.008) in the first 48 h post-injury. Patterns in
104 epochs (each of 48 h) were identified. Ninety-two were of the type I
(MAP > CPP > ICP) pattern and 12 were of the non-type I pattern.
Glasgow Outcome Scale scores at 12 months were significantly related to the
dichotomized pattern type (Fisher’s exact test p < 0.001 for both alive versus
7 Author to whom correspondence should be addressed. Department of Child Life and Health, 20 Sylvan Place,
Edinburgh, Edinburgh, EH9 1UW, UK.
8 Formerly at Royal Hospital for Sick Children, 9 Sciennes Road, Edinburgh, UK.
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dead and independent versus dependent outcomes). Only one patient with
type I pattern died in this series.
While variability of ICP during the first 48 h post-injury is predictive
of the outcome, the pattern behaviour of three pressure signals gives useful
outcome prediction information throughout monitoring. These displays may
help interpret some of the plethora of data produced at the bedside.
Keywords: children, head injury, intracranial pressure, cerebral perfusion
pressure, variability, pattern recognition
1. Introduction and background
Modern intensive care monitoring systems allow displays of many simultaneous biosignals,
which generate large quantities of raw data for later off-line analysis. Various summary
measures are required to condense the data for analysis, the results of which drive changes
towards improving treatments.
The pressure signals of intracranial and cerebral perfusion pressure have generated a
great deal of interest, but despite the vast quantity of literature available, there have been
relatively few describing their variability after traumatic brain injury. Early methods using
data from paper recordings (Griffith and Becker 1979, Sklar et al 1980, Gaab et al 1986) were
made, but were hindered by the many technical difficulties, including lengthy traces, chart
speed variations, and a lack of objectivity in the quantification and analysis of the data.
Computerized monitoring is now the established norm, but there have been few attempts to
re-examine these early findings.
Clinical observations of the variability of intracranial pressure, mean arterial pressure and
cerebral perfusion pressure (as measured by the standard deviation) led to the hypothesis that
the variability of the pressure signals recorded over time after head injury in children may be
important in relation to outcome.
This study seeks to view time series data (artefact-excluded) over extended time periods,
to investigate the significance of the observed variability and to identify other practical but
simple visual displays available at the bedside.
2. Materials and methods
A group of 43 children aged 15 years or younger were identified, with recorded time series
data from intensive care monitors, after admission with traumatic head injury. They were
included in this study if they fulfilled the following criteria: (a) there was a post-resuscitation
pre-intubation Glasgow Coma Score (Teasdale and Jennett 1974) sumscore (GCSs) of 12 or
less (the Pediatric Glasgow Coma Score (Reilly et al 1988) was used for children 5 years and
under) or the GCSs was >12 in association with an Injury Severity Score (Baker and O’Neill
1976) (ISS) of 16 or more, (b) there were clinical indications for monitoring the patients in the
intensive care unit and (c) there was a computerized data collection (CDC) system available
for use within 24 h of injury.
Clinical notes and nurses’ ICU charts were reviewed. Admission details were retrieved,
and data including cause and nature of injury, age, post-resuscitation Glasgow Coma Score,
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pupil responses, x-ray and computerized tomography (CT), operative and treatment details
were extracted.
Children were excluded from the study if they had sustained a previous head injury.
Ethical approval for this study was granted through the local ethics committee as part of a
larger study of secondary insults, and assent obtained from parent or guardian.
2.1. General management
The management of these children was carried out by experienced neurosurgical, anaesthetic
and nursing staff in a specialist unit. The indications for mechanical ventilation and ICP
monitoring were: (i) following evacuation of an intracranial haematoma where the patients’
GCSs was !8; (ii) where there was a diffuse cerebral injury or GCS !6; (iii) where there was
CT or operative evidence of brain swelling; and (iv) where other injuries dictated the need for
ventilation. Other monitoring (including arterial pressure, temperature, oxygen saturation and
heart rate) was employed as clinically indicated. The ICP was recorded by a Camino catheter
or fluid-filled pressure transducer system which was optimally damped using an accudynamic
adjustable damping device (Abbott Critical Care System). All monitors were calibrated at least
once per day. The management protocol for initiating treatment was a CPP of !50 mmHg and
intracranial pressure (ICP) of "15 mmHg for children aged <1–13 years, and for those aged
14–15 years, !60 and "20 mmHg respectively. The management protocol was designed to
maintain the CPP. If the MAP was low this may have required plasma protein solution (PPS)
or noradrenaline. If the MAP was satisfactory but ICP elevated above 20 mmHg, then (1) CO2
was lowered to 4 kPa; (2) mannitol treatment was instigated (mannitol plus frusemide plus
plasma expander) and (3) if ICP remained above 20 mmHg, thiopentone infusion was started.
These represent the essentials of an extensive protocol (Miller et al 1992) which was set prior
to, and maintained for the duration of this study.
2.2. Data acquisition
Data for each patient were collected every minute until clinical monitoring ceased, then
manually validated, and any artefact or unreliable data excluded. However, potential iatrogenic
derangements, occurring during procedures such as physiotherapy, suction or handbagging,
were retained. For this study of pressure signals (ICP, MAP and CPP) data used were restricted
to the duration of the ICP monitoring which was continued as long as required for clinical
management of raised intracranial pressure. From quantitative statistics the mean, range and
standard deviation were calculated for each of these parameters, for each patient. In addition,
the data were divided into 48 h epochs, taken from the time of injury, and the same descriptors
recorded for each epoch. The first epoch, taken from the time of injury, always had less than
48 h of data, as this epoch necessarily included the transfer time, admission time and ‘set-up’
time. Similarly, the last epoch for each child could be less than 48 h, as this depended on a
clinical decision as to when the ICP monitor was removed.
For each patient time series plots were prepared for each epoch, where the three pressure
signals were displayed using the same vertical axis of mmHg. Each 48 h epoch was then
assigned a ‘pattern type’ by consensus among three researchers.
2.3. Outcome
An experienced researcher without access to the physiological data assigned a modified
Glasgow Outcome Scale score suitable for children (Adelson et al 1997) at 12 months post-
injury, after a questionnaire was sent to the parents, and the child’s follow-up records were
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Grade Severe (GCS ! 8) 32
Moderate (GCS 9–12) 9
Minor (GCS 13–15 with ISS " 16) 2






Outcome at 12 months by grade on admission
Severe Moderate Mild Total
Dead (GOS 1) 8 1 – 9
Vegetative (GOS 2) – – – –
Severe disability (GOS 3) 2 – – 2
Moderate disability (GOS 4) 6 3 – 9
Good recovery (GOS 5) 16 5 2 23
Total 32 9 2 43
scrutinized. Outcome was dichotomized into independent versus non-recovery (i.e., good
recovery and moderate disability (GOS 4–5) versus severe disability, vegetative state or death
(GOS 1–3)), and also survival versus death.
3. Analysis
Microsoft© Excel 97 and SPSS© for Windows (Release 9.0.0) packages were used to analyse
the data. Mann–Whitney U-tests were used, with the significance level of p < 0.01 to ensure
non-chance relationships, to test for differences between the outcome categories.
4. Results
The demographic features of the group of 43 children, including age, sex and outcome at
12 months post-injury, are given in table 1.
The duration of ICP monitoring time ranged from 97 to 17 778 min (mean = 6319;
median = 3446), with equivalent times for both MAP and CPP, and from the three variables
a total of 221 291 usable data points were available for analysis. A total of 104 48 h epochs
were identified, the maximum for any individual patient being six epochs (or 12 days). Epochs
1 through 6 had data from 42, 28, 19, 10, 4 and 1 patients, respectively. The mean number
of epochs per patient was 2.4. In one case, for technical reasons, computer data were only
available from epoch 2 onwards.
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Table 2. Significance values of tests for standard deviations and means for both outcome
comparisons: alive versus dead and recovered versus not recovered at 12 months post-injury,
for epochs 1 to 3, and for total duration of ICP monitoring time.
Alive versus dead Independent versus
( p-value) not recovered ( p-value)
1st epoch (injury to 48 h)
Mann–Whitney U-test (42)
ICP Mean <0.001! 0.001!
SD 0.011 0.008!
MAP Mean 0.053 0.021
SD 0.193 0.191
CPP Mean 0.049 0.380
SD 0.716 0.275
2nd epoch (48–96 h post-injury)
Mann–Whitney U-test (28)
ICP Mean <0.001! 0.006!
SD 0.365 1.000
MAP Mean 0.806 0.709
SD 0.682 0.784
CPP Mean <0.001! 0.006!
SD 0.978 0.901
3rd epoch (96–144 h post-injury)
Mann–Whitney U-test (17)
ICP Mean 0.006! 0.279
SD 0.953 0.879
MAP Mean 0.300 0.442
SD 0.953 0.721
CPP Mean 0.244 0.646
SD 0.859 0.959
Total duration of ICP monitoring
Mann–Whitney U-test (43)
ICP Mean <0.001! <0.001!
SD <0.001! <0.001!
MAP Mean 0.067 0.036
SD 0.003! 0.017
CPP Mean <0.001! 0.003
SD 0.005 0.021
! Significant at p < 0.01.
4.1. Variability
Table 2 reports results for the first three consecutive epochs (admission to 48 h post-injury
(epoch 1); 48–96 h (epoch 2) and 96–144 h post-injury (epoch 3)) and for the total duration
of acute monitoring, i.e., ICP monitoring time. There were insufficient cases for the analysis
of variability in epochs 4 to 6.
The variability of ICP, MAP and CPP (as measured by the standard deviation) over the
whole time that the patients had an ICP monitor in place, was significantly greater in those
who died compared to survivors. Variability of ICP was also significantly greater in those who
did not recover compared to those who recovered. Of the three time epochs considered, only
the first (i.e., injury to 48 h) showed any relationship between variability and outcome, and
then only for ICP. The variability was unrelated to whether on imaging the injury was diffuse
or focal.
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However, mean ICP was significantly related to survival in each of the three time epochs
and over the total monitored duration (ICP time), and also to independent recovery (compared
to non-recovery) in epochs 1 and 2, and for the total duration. Mean CPP appeared to be
important during the second epoch, i.e. between 48 and 96 h post-injury, and also for the total
duration of monitoring.
4.2. Patterns
When three variables are displayed on the same graph using a common vertical axis, there
are necessarily six permutations, in terms of the order of magnitude in which the variables
could theoretically be presented. However, because of the mathematical relationship, CPP =
MAP " ICP, only three physiologically ordered combinations are possible.
4.3. Descriptions of patterns (see figure 1)
• Type I—where MAP was greater than CPP, which was greater than ICP. This would be
considered the ‘normal’ and desirable relationship between the variables.
• Type II—where MAP was greater than ICP, which was greater than CPP. The ICP is so
high that there is insufficient compensation in systemic pressure to maintain adequate
CPP.
• Type III—where ICP was greater than MAP, which was greater than CPP. With grossly
elevated ICP, there is total failure of compensation by systemic pressure and CPP is absent.
• Type II/I cross-over—where MAP remains greatest, but CPP changes from being lower
than ICP to greater than ICP (i.e., an improving pattern, and is actually a changing pattern
from type II to type I).
• Type I/II cross-over—where MAP was greatest, but CPP changes from being greater than
ICP to less than ICP (i.e. a deteriorating pattern, or changing from type I to type II).
• Type I/II/III cross-over—where the three variables MAP, ICP and CPP repeatedly change
their relative positions within the epoch, i.e. fluctuating between types I, II and III, although
the sequence generally began as a type I.
4.3.1. Patterns in relation to outcome scores. One hundred and four epochs (each of 48 h)
were identified from the data of 43 patients and each epoch was classified according to type
(figure 2). Type I was the dominant pattern seen in 92 (88.5%) of the 104 epochs and was
seen during all 48 h intervals following injury. Of the 34 patients who only displayed type
I throughout, only one died, compared to eight deaths in the group of nine patients with
non-type I patterns (Fisher’s exact test, p < 0.001). A small number of patients (3) had no
type I patterns at any time. There were three epochs of type II (MAP > ICP > CPP), and
one epoch of type III (ICP > MAP > CPP). Eight were ‘cross-over’ changing patterns, one
of which (in one patient) was an improving cross-over pattern (i.e. type II/I, where the patient
recovered well). All patients with other cross-over patterns, or patterns of type II or III died.
We found no instances of type III reverting to type I.
4.3.2. Patterns in relation to fatal cases. Nine children died, contributing a total of 20 epochs
and nine of these epochs were described as type I. Four patients who died only displayed non-
type 1 patterns and at no time had a type I pattern. Of the remaining five patients who
died, four had episodes of type I (nine epochs) that subsequently changed to cross-over
type I/II or I/II/III. No patient survived if they displayed at any time epoch any of the
following patterns: type II, type III, cross-over type I/II or type I/II/III.
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Minutes: start of ICP monitoring to end (Epoch 1)
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Figure 1. Illustrations of all pattern types identified. MAP displayed in red, mean ICP shown
in green and mean CPP shown in blue. Vertical axis in mmHg; horizontal axis in minutes, with
tickmarks every 120 min.
The final non-surviving patient had just one epoch of data available which was of the
type I pattern. Unfortunately, data were lost for the subsequent epochs, but he eventually died
after all monitoring was withdrawn, some 2 days later.
5. Discussion
Clinicians are required to interpret and respond to a great number of increasingly complex
clinical parameters displayed on new electronic medical devices, the function of which is to
















































Figure 2. Distribution of 104 pattern types from 43 patients (not mutually exclusive) occurring in
epochs 1–6. Each epoch is of 48 h duration, commencing at time of injury. All those displaying
types II, III, I-II or I-II-III died.
alert clinicians to significant changes or trends in the patient’s condition. With potential data
overload, there is a need to summarize data for meaningful interpretation.
One way is for nurses to spend valuable time transcribing data displayed on the ITU
monitors, onto specially designed charts, at specific time points, e.g. hourly, creating a snapshot
in time. This provides a permanent copy of patient information and condenses much of the
information into understandable and manageable formats. This has the advantage of being able
to view trends over longer time periods than as seen on the monitor screen. The disadvantage
is that almost all of the data which have become available with this new technology have been
excluded. Most ICP research still uses these hourly transcribed data.
Because on-line data produce lengthy files we conducted our analysis in arbitrary 48 h
epochs as well as for the total time. Other researchers have discussed trends over different time
points such as (i) overall time taken from commencement of monitoring (Chambers et al 2000,
Jones et al 1994) which gives no indication of time between injury and arrival in ICU, (ii) data
truncated to particular time duration of 24, 48 and 72 h from point of impact (Signorini et al
1999), or (iii) averaged data over 24 h (Marmarou et al 1991b) or 12 h periods (Stocchetti et al
1999).
All of the above have disadvantages because the duration of ICP monitoring continues
to be dictated by the patient’s clinical state. Monitoring may be removed early in those who
recover quickly or after physiological stability is achieved. Cortbus (Cortbus et al 1994),
describing the ‘stages’ in the pathophysiology of TBI, found that the majority of hypotensive
insults occurred within the first 24 h, and ICP derangements clustered around days 5 and 6,
although insults were detected up to 12 days. Therefore, by choosing 48 h as our standard
epoch, we compromised between a duration long enough to show variations (the cross-over
patterns generally take more than 12 h to develop),but not so long that there were overwhelming
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Table 3. Methods of analysis of pressure signals.
1. ICP stratified (in 10 mmHg bands) from ICP paper traces (Miller et al 1977); or raised ICP over
20 mmHg ICP (Miller et al 1981)
2. Digitally averaged ICP, recorded by nurse at the end of each hour (i.e. end hour readings used as estimate
of mean ICP), also variance using end hour data (Marmarou et al 1991a)
3. Digital data collected every minute from bedside monitors to use cumulated durations of ‘Insults’ at three
levels of pre-set thresholds (Jones et al 1994)
4. Digital recording (sampled at a rate of 20 Hz), averaged every 12 h, where the highest (ICP) and lowest
(CPP) of these values were summarized as ‘mean worst’ ICP and CPP: the mean for all these 12 h intervals
was further summarized as ‘mean average’ for ICP and CPP (Stocchetti et al 1999)
5. Decision-tree induction from time series (minutely) and demographic data (McQuatt et al 1999)
6. Percentage of total monitored time above ICP (or below (MAP, CPP)) specific thresholds (electronically
sampled every 2 min) (Chambers et al 2000)
7. Percent of time CPP in ranges 60–70, 50–60 and <50 mmHg (Jackson et al 2000)
8. Mean CPP, MAP and ICP (using at least hourly data points, from ICU flow sheet for first 48 h), and reduced
to single measure of mean and SD for the first 48 h) (Downard et al 2000)
9. Maximum value of 2 min rolling averages of ICP readings calculated over each 1 h period (or minimum
value for CPP). ROC curves to attempt to identify thresholds to predict outcome (Chambers et al 2001)
10. Pattern recognition using Bayesian neural networks (Howells 2002)
11. Standard deviations of ICP, MAP and CPP from digital minutely ICU data in 48 h time frame, and
graphical displays (Jones et al, this paper)
amounts of data to handle. Epochs were well represented with patient deaths occurring in
each epoch.
We have not recorded the presence of abnormal ICP wave forms (e.g. plateau, B waves
etc) which may influence the standard deviation, but their effect would be relatively minimal
when compared to all ICP data points over a 48 h epoch. Additionally, data prior to the last 4 h
before death were excluded. We have only considered ICP and BP for analyses here as other
monitored physiology (temperature, oxygen saturation and pulse) is not significantly related
to the outcome in this dataset (Jones et al 2002).
Many methods of analysing physiological data have been described, and these are
summarized in table 3. Each of these methods found a relationship with outcome, suggesting
that there is no universally accepted standard analysis. We describe a further simple method
to aid interpretation of the plethora of data at the bedside.
5.1. Variability
While the mean values of ICP and CPP were highly significant in most of the epochs in relation
to outcome as in other studies, the standard deviation of ICP was the only significant predictor
(at ! = 0.01) of non-recovery, and only then in the first 48 h from injury.
Signorini and colleagues examined the ‘insults added to injury’ at 24, 48 and 72 h post-
injury in a population of head-injured adults (Signorini et al 1999) and concluded that raised
ICP, however summarized, was independently predictive of mortality at each of these times.
Our findings add a further simple summary measure at a stringent 1% significance level, at a
clinically useful time (48 h after injury) which is predictive of morbidity.
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A different picture was seen, however, when considering the three pressure signals over
the total duration of ‘acute’ monitoring time (i.e. time that ICP monitoring was in situ). The
variability of all three traces was highly significant in those who died, and the variability of ICP
was significantly related to outcome, reflecting the cumulated changes over time. Practically,
however, the standard deviation (i.e. the variability) over the whole trace (if more than
48 h) is not prognostically useful during the acute care of these children, as the variability
only becomes significant in retrospect (when it is already evident that the child has survived,
or has died).
Marmarou (Traumatic Coma Data Bank group) (Marmarou et al 1991a) used ICP
‘variance’ (standard deviation squared), which was considered to be an indirect measure
of the pressure stability, but found that it was only poorly related to outcome. This may be
because only ‘end hour’ readings were used which were considered to be an average estimate
of the whole hour, giving only 24 data points per day, compared to our 1440 data points per
day for each variable. Clearly, the fewer the data points used, the less variability there is
to measure. Gaab (Gaab et al 1986) studied a group of 16 head injury patients (including
both adults and children) and found that the mean ICP ranged from 20 to 50 mmHg, and the
standard deviation ranged from 4 to 21 mmHg: both parameters showed less variability than
found in our study of 43 children (mean range 3–99 mmHg; SD range 2–32 mmHg) after
artefactual data were removed.
5.2. Pattern types
By categorizing the patterns in this way using the ‘order of magnitude’, there was ready
agreement between the researchers as to the pattern type.
All patients who exhibited patterns of type II or III died, as did all with multiple cross-
over (type I/II/III) or simple cross-over (type I/II) patterns. However, the patient with
type II/I (changing from a ‘poor’ to ‘better’ type of pattern) survived, indicating a response
to treatment.
By plotting these three variables on the same vertical scale, patterns emerge that are
predictive of survival or death. This would be a simple and useful addition to the ICU nursing
charts, where generally numerical values for ICP and CPP are recorded on a separate section
of the chart, thus obscuring the information.
However, it was noted that it would be possible to further subdivide type I patterns
depending on the amount of variability seen in the ICP trace, for example, by identifying
those with only 10 mmHg within-trace variation, or 20, 30, 40 or >40 mmHg within-trace
variability, or combinations of these values. We were unable to relate these sub-group patterns
to the outcome in this sample group of patients as examples were found in all outcome groups.
By viewing these patterns over 48 h time periods, it appeared in some cases as if there
was a 4-hourly rhythmicity evident, but on close inspection these were 4 h treatment-related
events and not an inherent hydro- or haemo-dynamic pulse.
6. Conclusion
The standard deviation (or variability) of ICP signals frequently recorded during ICU care
of paediatric TBI patients gives useful predictive information about outcome during the first
48 h after injury.
The ‘time series patterns’ generated from traces of three variables (ICP, MAP and CPP)
when plotted on the same vertical axis, show clearly which patients are likely to survive or
die, and these are useful throughout the whole acute monitoring time. If these values were
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plotted on standard ICU nursing charts, they could form a visually useful, simple adjunct to
the other methods already available in the management of TBI in the intensive care unit.
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Summary
Purpose of the study: To determine the frequency of cerebral
atrophy and microcephaly in a group of children with sequen-
tial MRI brain scans after surviving a non-accidental head
injury (n ! 16).
Methods: Serial head circumference measurements (OFC)
were extracted and plotted on standard growth charts for
each child retrospectively to determine the frequency of sec-
ondary microcephaly. Cerebral atrophy was diagnosed and
quantified by measurement of the ventricular/cortical ratio
on coronal images of the sequential scans.
Results: Acquired microcephaly was found in 15 children
(93.8%) over a median follow-up period of 67.93 weeks.
There was a significant reduction in the median Z-score for
the OFC at the most recent follow-up when compared with
that at presentation (p < 0:001, Wilcoxon Signed Rank Test).
Cerebral atrophy was found to be the cause of the microce-
phaly in eight of the 15 children and was evident as early as 9
days after presentation.
Conclusion: A large proportion of the cohort (93.8%) devel-
ops acquired microcephaly after an inflicted head injury and
cerebral atrophy is responsible in half of these cases.
Introduction
‘Shaken Baby Syndrome’ and other non-accidental
head injuries (NAHI) are serious conditions of infancy
with an annual incidence of 24.6 per 100 000 children
younger than 1 year of age [1]. The prognosis following
NAHI is extremely poor with a high mortality rate of
26–36% [2, 3] and up to 78% of the survivors su!ering
from long-term disability [4]. The morbidity includes
epilepsy, visual loss and blindness, language and cogni-
tive impairment, motor disability and other neurode-
velopmental delay [5–10] resulting in a significant
burden for the carers. This unfavourable outcome is
thought to be the result of extensive brain damage
arising from both the primary brain injury and
additional secondary pathophysiological insults [11] fol-
lowing the trauma. Interference with brain growth fol-
lowing shaking injury, as measured by head
circumference, has been reported to occur in three
cases reported by Oliver [12] and four of the 12 patients
studied by Bonnier et al. [9]. This may theoretically be
due to either a generalized slowing of brain growth from
a global brain insult or it may result from acquired
brain atrophy consequent on the injury. The aim was
to investigate the frequency of microcephaly and brain
atrophy in a cohort of infants who have had sequential
MRI scanning following a shaking/impact injury.
Methods
A retrospective review of the clinical and imaging
findings from a cohort of children who had been
admitted to the Royal Hospital for Sick Children,
Edinburgh, with a suspected inflicted head injury was
undertaken. The inclusion criteria included all patients
(i) who presented with an acute encephalopathy and
had at least two of the following features: retinal hae-
morrhages, skeletal fractures such as rib fractures or
metaphyseal avulsions, a history that is changing or
inconsistent with the examination findings, subdural
haemorrhage or evidence of other malicious injury
such as burns; and (ii) had sequential MRI scanning
of the brain following the primary injury (table 1).
Serial measurements of the head circumference
(OFC) were extracted from the case notes and plotted
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on normal growth centile charts for each patient. The
frequency of microcephaly, defined as 2 SD below the
mean, was determined. The Z-score (the number of
standard deviations from the mean) was calculated for
the OFC measurement at presentation and at the most
recent follow-up.
All the MRI brain images were obtained using a
Siemens Magetom 1.5T Scanner or a Picker Outlook
0.23T Scanner. The timing of the scans after the acute
presentation was recorded. Two neuroradiologists
reviewed the sequential scans independently and deter-
mined the bifrontal ventricular diameter (Vm) and the
maximum cortical diameter (C) on the coronal image at
the level of Foramen of Monro (figure 1). The ven-
tricular/cortical (V/C) ratio was then calculated.
Cerebral atrophy was recognized both by the promi-
nence of the gyri and sulci pattern with increased CSF
spaces and was deemed the cause of the microcephaly
when the Vm and V/C ratio was increasing.
Statistical analysis using Wilcoxon Signed Rank Test
was carried out on the Z-scores of the OFC, the Vm and
the V/C ratio on the scans at presentation and the most
recent follow-up examination.
Results
Sixteen infants (10 boys and six girls) who fulfilled the
study criteria were identified. The median age at pre-
sentation was 7 weeks (2.43–28.86 weeks). A total of
143 OFC measurements (a median of eight measure-
ments per patient, range 2–16) were extracted over a
median follow-up period of 67.93 weeks (range 24–92)
post-injury. There were 52 MRI scans (a median of
three MRI scans per patient, range 2–4 scans) obtained
over a median follow-up period of 19.86 weeks (range
1.14–134.70 weeks) after presentation.
Fifteen of the 16 infants (93.75%) had evidence of
microcephaly at the most recent follow-up. The serial
OFC measurements obtained from each of these 15
infants crossed the centiles to more than 2 SD below
50
T. Y. M. Lo et al.
Figure 1 A coronal MRI brain image at the level of Foramen of
Monro is used to measure the bifrontal ventricular diameter (Vm)
and the maximum cortical diameter (C). The ventricular/cortical (V/
C) ratio is then calculated by Vm/C.
Figure 2 Box plot showing the median Z-score (number of standard
deviations from the mean) of the head circumference (OFC) at pre-
sentation and at the most recent follow-up. (p < 0:001, Wilcoxon
Signed Rank Test.)
Figure 3 Box plot showing the bifrontal ventricular diameter (Vm)
obtained from the MRI scans done at presentation and at most recent
follow-up.
the mean when plotted on the growth charts for head
circumference, indicating a failure to maintain a normal
head growth pattern. The median Z-score for the OFC
at presentation was " 1:23 (#1:25 to " 3:92) and at
most recent follow-up was # 2:51 (# 6:11 to " 0:58),
which was statistically significant (p < 0:001) (figure
2). The median time for the OFC to first crossing the
third centile was 59.0 weeks from presentation (range
8.0–90.5 weeks).
The median Vm and V/C ratios on the first scan after
admission were 28.5mm (18–52mm) and 0.30 (0.19–
0.41) respectively, while those on the most recent fol-
low-up scan were 33.00mm (21–53mm) and 0.32 (0.21–
0.47) respectively. The changes in Vm and V/C ratio did
not reach statistical significance (figure 3 and 4). The
sequential MRI brain scans from eight of the 15 infants
(53.3%) with microcephaly showed evidence of progres-
sive increase in Vm and V/C ratio, indicating cerebral
atrophy was the cause of the microcephaly in these
patients. The earliest recognition of cerebral atrophy
on MRI scan in this study was 9 days after presentation.
case 1
A 6 week-old girl presented with an acute encephalo-
pathy, bilateral retinal haemorrhages and bilateral sub-
dural haematomata, but without any signs of physical
neglect or fractures. MRI brain scans were performed
on the day of presentation, and 6, 14 and 60 days after
admission (figure 5). The V/C ratio increased with time
and the serial OFC measurements declined below the
normal growth centiles indicating an acquired microce-
phaly. The most recent OFC measurement was 4.66 SD
below the mean (figure 6).
case 2
This 10 week-old boy presented with an acute ence-
phalopathy, bruising below the left eye, bilateral retinal
haemorrhages and bilateral subdural haematomata
with hypovolaemic shock requiring mechanical ventila-
tion and inotropic support. The first MRI brain scan
was performed 3 days after admission. Evidence of
cerebral atrophy was first observed from the scans 12
days after presentation. The most recent follow-up scan,
1.07 years after presentation, showed marked cerebral
atrophy (figure 7). Serial OFC measurement demon-
strated the evolution of severe microcephaly with an
OFC at the most recent follow-up being 6.11 SD
below the mean (figure 8).
case 3
A 5 week-old boy presented with acute encephalopa-
thy, multiple rib fractures, bilateral retinal haemor-
rhages and bilateral subdural haematomata with
raised intracranial pressure and requiring neurointen-
sive care. MRI brain scans were obtained on the first
and ninth days after admission, 9 months and 2 years
post-presentation and showed the rapid development of
asymmetrical cerebral atrophy (figure 9). Acquired
microcephaly was evident from the serial OFC meas-
51
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Figure 4 Box plot showing the ventricular/cortical (V/C) ratio
















Figure 5 Sequential MRI brain scans showing the development of
acquired cerebral atrophy from (i) the day of presentation, (ii) 6
days, (iii) 14 days to (iv) 2 months post-presentation in a 6 week-old
girl who presented with acute encephalopathy, bilateral retinal hae-
morrhages and bilateral subdural haematoma.
urement with the most recent follow-up OFC being 5.88
SD below the mean (figure 10).
Discussion
This retrospective study of infants surviving a NAHI
who additionally had sequential brain MRI scans has
demonstrated that over half (53.3%) of the cohort
developed cerebral atrophy, with the earliest imaging
evidence of atrophy being observed as soon as 9 days
after presentation. Cerebral atrophy is well recognized
after various brain insults. Jaworski et al. [13] reported
the presence of cerebral atrophy in 91% of microcepha-
lic children following perinatal or post-natal insults
including hypoxic ischaemic encephalopathy, intra-
cranial haemorrhage or meningitis. Adults who under-
went sequential CT scanning after sustaining severe
brain trauma developed cerebral atrophy in 28% of
cases, but this incidence rose to 83% in those patients
who had su!ered an acute subdural haematoma [14].
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Figure 6 (a) Head circumference (OFC) falling o! the normal growth
centiles with the latest OFC being 4.66 SD below the mean. (b) Plot














Figure 7 Serial MRI brain scans performed on a 10 week-old boy
with bruising below the left eye, acute encephalopathy, bilateral ret-
inal haemorrhages, bilateral haematoma and hypovolaemic shock
requiring intensive care treatment at (i) 3 days, (ii) 12 days, (iii) 3.71






























Figure 8 (a) A head circumference growth chart demonstrating fail-
ure to maintain a normal head growth pattern with the latest OFC
measurement being 6.11 SD below the mean. (b) Increased V/C ratio
was shown over time.
The incidence of cerebral atrophy is less well docu-
mented in children following accidental head injury,
but Onuma et al. [15] reported on five children with
severe cerebral atrophy demonstrated on CT scans
and all were associated with poor outcome. There is
no previous report on the frequency of acquired cere-
bral atrophy following NAHI.
The mechanisms responsible for inflicted brain injury
are largely rotational deceleration forces experienced in
the infant’s cranium [8, 16] although other additional
impact and compression injuries may also be respons-
ible in some cases. Only in high velocity road tra"c
accidents do children experience similar impact and
rotational injuries. Virtually all infants su!ering from
NAHI have extensive subdural haematoma [17] and the
subdural haemorrhage may be very extensive and
involve the convexity, interhemispheric, sub-temporal
and sub-occiptal regions [17]. Beneath the subdural
haematoma, in the underlying cerebral parenchyma, in
particular the white matter, there is hypoperfusion
with ischaemia and infarction, an uncoupling of flow
and metabolism, and oedema (cytotoxic compressive
and vasogenic) with resultant atrophy in the long term
[18]. Cytokine induced gliosis may also contribute to the
resultant atrophy. The other imaging evidence of brain
injury following shaking with or without impact
includes tearing of the bridging veins [8, 16, 17], di!use
axonal injury (petechiae at the grey–white matter junc-
tion, corpus callosum and sub-cortical white matter
tears) [19–21], cerebral oedema and hypoxic ischaemic
changes. It is believed that this is the first documented
report of cerebral atrophy following NAHI in children.
Although radiological description of cerebral atrophy
is often subjective and dependent on pattern recogni-
tion, one has attempted a more objective assessment
by measurements of ventricular dimension and ven-
tricular/cortical ratio allowing for more accuracy and
better comparison between sequential scans obtained
in the same patient as well as between di!erent patients
and allows for the non-linear segmental increase in ven-
tricular volume which occurs with normal growth
throughout childhood [22].
Global slowing of brain growth will result in micro-
encephaly with a proportional loss of cortex, sub-
cortical grey and white matter, and the Vm and V/C
ratio will, therefore, remain constant on sequential
scanning. Specific white matter atrophy will result in a
disproportional loss of white matter in relation to the
sub-cortical grey matter and global atrophy (of both
















Figure 9 A 5 week-old boy who presented with acute encephalopa-
thy, multiple rib fractures, bilateral retinal haemorrhages and bilateral
subdural haematoma with resultant raised intra-cranial pressure
requiring neurointensive care had sequential MRI scans done at (i) 1
day, (ii) 11 days, (iii) 9 months and (iv) 2.3 years after presentation.
































Figure 10 (a) The serial OFC measurements showed a slowing of
head growth below the normal with the latest OFC being 5.88 SD
below the mean. (b) The V/C ratio increased steadily over time until a
plateau was reached.
the increasing V/C ratio on sequential scans in the pres-
ence of slowing of head growth.
In this study, the first imaging evidence of cerebral
atrophy was seen at 9 days after presentation, earlier
than the 2 weeks reported for its appearance after acci-
dental head injury [14, 15]. Barlow et al. [17] reported
the additional information obtained from acute MRI
scans about the nature and extent of the inflicted inju-
ries compared to those provided by CT scans, and it is
postulated that follow-up MRI scans will likewise con-
tribute additionally to the knowledge of the evolving
intraparenchymal pathology as well as the changing
appearance of the sub-temporal and posterior fossa
regions during the rehabilitation process.
All of the patients in this study with cerebral atrophy
also had microcephaly. Significant global insults to the
immature brain will frequently result in secondary
microcephaly, which is seen in 17.6–48% of infants at
12 months after perinatal hypoxic ischaemic encephalo-
pathy [23, 24]. Microcephaly is also well recognized to
occur after central nervous system infections from cyto-
megalovirus [25], varicella zoster [26], HIV [27] and
other pyogenic meningitis [28]. Oliver [12] described
the development of acquired microcephaly in three chil-
dren following shaking, swinging, hitting or throwing
injury in 1979 and Bonnier et al. [9] reported four of
their 12 abused children surviving an inflicted head
injury who developed atrophy with interference of
head growth occurring 4 months after the presumed
time of injury. Thus, this study has suggested a much
higher frequency of NAHI induced microcephaly than
previously reported. Furthermore, although the first
evidence of cerebral atrophy can be observed soon
after presentation in the cohort, the first evidence of
microcephaly took much longer to become clinically
apparent.
The social circumstances for many of these infants
are often complex, making the pre-injury details includ-
ing head size di"cult to obtain. Only five of the 16
infants had records of earlier OFC measurements, all
of which were within normal centiles. Four of these
children had OFC measurements at follow-up signifi-
cantly lower than their pre-morbid centiles. The head
circumference may be transiently and artificially
increased in the acute encephalopathy as a result of
scalp oedema, subgaleal haemorrhage and acute sub-
dural haematomata. All but one of the cohort had
microcephaly at the most recent follow-up and, more
importantly, their serial OFC measurements obtained
during the rehabilitation period showed failure to main-
tain a normal rate of head growth confirming the patho-
logical nature of the pattern.
Nineteen per cent of the cohort had age-appropriate
development without any neurological deficits, which
was similar to the proportion of symptom-free NAHI
survivors reported in the literature [29–34]. Although it
is clearly important to study the neuropsychological
and neuropsychometric deficits consequent on an
inflicted brain injury during infancy, the very young
age of the population (median age of 7 weeks at pre-
sentation), which also included some ex-preterm babies,
and the relatively short period of clinical follow-up
(median 67.93 weeks) meant that only significant seque-
lae could be deduced at the time of out-patient clinic
visits from routine developmental examination and
recognition of specific neurological deficits such as
blindness and epilepsy.
The neurological deficits are very much in evolution
and deciding the definitive outcome based on any dura-
tion less than the whole of childhood may be mislead-
ing, as Bonnier et al. [9] have demonstrated in their
cohort of 13 infants (mean age of 5.5 months at pre-
sentation, who were followed up for a mean of 7 years)
that, although an interruption of brain growth was
demonstrable at 4 months post-injury, the evolution
of long tract signs took 6–12 months, epilepsy took 2
years and behavioural and psychological consequences
took between 3–6 years to develop following the initial
insult. A detail neuropsychological study on a larger
cohort has been completed and will be reported in the
near future (Barlow et al., personal communication).
The true incidence of microcephaly and acquired cer-
ebral atrophy following NAHI in childhood remain
unknown, but in this study where patients were chosen
because of the nature of their injuries together with
the availability of their sequential MRI brain scans, it
is suggested that microcephaly and cerebral atrophy
occur in a very high proportion of infants (93.75%
and 53.3%, respectively). This has highlighted the
need to anticipate deficits that are likely to evolve as
the infants mature particularly in the areas of speech,
language and psychomotor development. Development
of future management strategies in these areas should
be anticipatory and concentrate on preventative meas-
ures and early intervention before the appearance of the
psychomotor deficits.
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Summary
This paper describes and validates a new Cumulative Pressure-
Time Index (CPT) which takes into account both duration and de-
gree of cerebral perfusion pressure (CPP) derangement and deter-
mines critical thresholds for CPP, in a paediatric head injury dataset.
Sixty-six head-injured children, with invasive minute-to-minute
intracranial pressure (ICP) and blood pressure monitoring, had their
pre-set CPP derangement episodes (outside the normal range) identi-
fied in three childhood age-bands (2–6, 7–10, and 11–16 years) and
global outcome assessed at six months post injury.
The new cumulative pressure-time index more accurately pre-
dicted outcome than previously used summary measures and by
varying the threshold CPP values, it was found that these physiolog-
ical threshold values (a48,a52 anda56 mmHg for 2–6, 7–10, and
11–16 years respectively) best predicted brain insult in terms of
subsequent mortality and morbidity.
Keywords: Paediatric head injury; cumulative pressure-time index;
critical CPP thresholds; outcome.
Introduction
Cerebral perfusion pressure (CPP) has been shown
to be the best predictor of outcome in both adult and
paediatric head injuries [1, 2, 4–6]. Previously a num-
ber of di¤erent summary measures of CPP, (e.g. means
over hourly recordings or other time-frames, maxi-
mum or minimum values, percentage duration of de-
rangement etc.), have been used as predictors of out-
come. These are pragmatic and loose much of the
detail by virtue of averaging the peaks and troughs of
the perfusion pressure recording.
A measure is required that incorporates more than
one dimension (duration and degree), to give a more
accurate quantification of the total burden of second-
ary insult. It should be equally applicable to children
and adult monitoring.
This paper describes a novel Cumulative Pressure-
Time index (CPT) that has been applied to a paediatric
head injury dataset, and has been used to help deter-
mine critical thresholds for CPP in children.
Materials and methods
Sixty-six head-injured children (aged 2–16 years) from two re-
gional UK centres had minute-to-minute recordings of physiological
parameters including intracranial pressure (ICP), systolic, diastolic
and mean arterial blood pressure (MAP), with automatically calcu-
lated CPP. Data were downloaded from bedside monitors and ana-
lysed o¤-line. Entry to this study included i) a post-resuscitation, pre-
intubation Glasgow Coma Score (GCS) of 12 or less, or an Injury
Severity Score of b16 in association with a GCS of 13–15 after
head injury; ii) monitoring within 24 hours from the time of injury
until removal of the ICP monitor.
Demographic data including age, gender, cause of injury, data and
time of injury were collected, and a modified Glasgow Outcome
Scale score was assigned at 6 months post-injury from a postal ques-
tionnaire completed by parents/carers or General Practitioners. Out-
come was dichotomised into independent (GOS 4 & 5) and poor
(GOS 1, 2 & 3) outcome, and alive vs. dead.
Pre-set levels of CPP derangement (i.e. values that were outside
the normal range) were used for each year of age [4]. The 66 children
were then grouped into 3 practical age-bands (2–6, 7–10, 11–16)
such that the mean CPP for each band was within a 5 mmHg span,
giving mean CPP threshold values ofa48 mmHg for the 2–6 year
olds, a54 mmHg for the 7–10 year olds, and a58 mmHg for the
oldest group (11–16 years of age).
Method for calculating the CPT
Figure 1 outlines the steps in calculating the Cumulative Pressure-
Time Index. Using the Edinburgh Browser6 program [3] the minute-
by-minute time series data were first validated to remove artefact and
identify derangements lasting>5 minutes (Fig. 1a). Figure 1b shows
a continuous trace of the resulting CPP data, with the selected
threshold level. Each episode was identified and the summated areas
between the CPP tracing and the threshold calculated.
This produced a single value representing both severity and dura-
tion of derangements. This can be shown mathematically by the
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The relationship between this new summary measure, and some
alternative summary measures for CPP calculated from this dataset
[i.e. the overall mean value for CPP (in mmHg); the accumulated
total duration of all episodes of CPP derangement as specified by
Browser as absolute time and as a percentage of the total CPP mon-
itoring time] and outcome was explored.
Using the above, Receiver Operator Characteristic (ROC) curves
were constructed. To test if there were significant di¤erences between
the ROC curves, 6 pairwise comparisons were made for each dichot-
omous outcome to establish which of the above summary measures
were the best predictors of outcome.
The pre-set threshold levels for CPP for each age-band were then
reduced by 10% and 20%, and the CPT recalculated for each, and
related to outcome to identify which of the chosen thresholds were
best discriminators of outcome.
Results
Of the 66 children, 47 su¤ered a severe head injury,
17 a moderate and 2 a mild head injury according to
the entry criteria. There were 41 boys and 25 girls. Fif-
teen children were aged 2–6 years, 24 aged 7–10 years
and 27 were in the oldest group (11–16 years). At 6
months outcome, 11 had died, none were vegetative,
6 were severely disabled (17 poor outcome), 19 were
moderately disabled and 30 had made a good recovery
(49 independent outcome).
CPT vs. outcome
The mean CPT values for those with poor and inde-
pendent outcome were 31785 (mmHg%min) and 3391
respectively, and for the dead and alive were 48126 and
3220 respectively. Both were significantly predictive of
outcome (p < 0:001). When the ROC curves were ex-
amined the areas under the curve for poor vs. indepen-
dence and dead vs. alive were 0.839 (95% C.I. 0.731,
0.9470) and 0.957 (95% C.I. 0.901, 1.013) respectively.
CPT values by age vs. outcome
The CPT values for the 3 childhood age bands
were also separately highly predictive for mortality
(p < 0:001), and morbidity (p ! 0:027, p ! 0:014,
and p ! 0:001 for the 2–6, 7–10 and 11–16 year old
groups respectively). The CPT derangement value was
not significantly di¤erent (ANOVA) across the 3 child-
hood age bands for mortality and morbidity.
All summary measures related to outcome
A comparison of the other summary measures de-
scribed above with the CPT index has been assessed
utilising multiple ROC constructions (Fig. 2). The
areas under the ROC curves for poor vs. independent
outcome for the 4 measures were: – overall mean CPP
Fig. 1. Schematic representation of CPP and CPT: (a) The Edinburgh Browser6 screen shows the recorded physiological values minute-by-
minute below, and deranged physiology (i.e.>5 minutes) as horizontal black bars above. (b) A sample of the CPP trace from Fig. 1a is enlarged
to illustrate the Cumulative Pressure-Time Index, shown as the area below the pre-selected threshold for CPP for age (horizontal line)
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0.717; CPP insult duration 0.764; percentage CPP in-
sult 0.776, and CPT at threshold 0.839.
Pairwise comparison of ROC curves for poor vs.
independent outcome
The 6 possible pairwise comparisons were made
of these ROC curves (MedCalc). This showed the
CPT index was a significantly better measure than
overall mean CPP (p ! 0:008), CPP insult duration
(p ! 0:02), and percent duration of CPP (p ! 0:055).
None of the other possible paired comparisons were
significant.
Pairwise comparison of ROC curves for dead vs. alive
Although all summary measures were highly predic-
tive of mortality at 6 months, the area under the ROC
curve for CPT index was 0.957, slightly greater than
for the percentage insult duration (0.909), mean CPP
(0.907) and CPP insult duration (0.886), but not statis-
tically significant.
Threshold alteration and outcome
Although our chosen threshold levels above provide
impressive ROC values, we considered whether a dif-
ferent CPP threshold might even better relate to out-
come. Accordingly we carried out similar analyses of
CPT and ROC curves when the CPP threshold value
was reduced by 10% and 20% (Table 1). For indepen-
dent and poor outcome the area under the ROC curve
for our threshold value was 0.839, greater than the
value 0.818 for threshold minus 10%, and the value
0.809 for threshold minus 20%, but not significantly
di¤erent.
For non-survival the area under the ROC curve
did not improve prediction by reducing the threshold
values.
Discussion
The CPT index that we have described takes into ac-
count both the severity and the duration of the physio-
logical derangement of CPP and this index is highly
Fig. 2. ROCs for two dichotomised outcomes (death vs. survival on the left hand graph, and poor vs. independent outcome on the right hand
graph) for CPP derangement when measured by i) overall Mean CPP in mmHg, ii) duration of CPP derangement; iii) derangement as a per-
centage of the acute monitoring time (% CPP derangement), and iv) using the Cumulative Pressure Time Index (CPT) for CPP
Table 1. Values of the ‘area under the ROC curves’ for the cumulative
pressure-time (CPT) at ‘threshold CPP for age-band’, ‘threshold
minus 10%’, and ‘threshold minus 20%’ levels of CPP for mortality
and morbidity
Area under the





CPP at ‘threshold level’ 0.839 0.957
Threshold minus 10% 0.818 0.974
Threshold minus 20% 0.809 0.975
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significantly related to outcome (classified as either in-
dependent vs. poor or alive vs. dead). This relationship
to outcome also applies to children of di¤erent ages
(2–6, 7–10 and 11–16 years of age). Our results show
that there is a similar insult burden, measured by CPT,
in young as in older children with head injury.
Previous studies on the relationship between CPP
and outcome in head injury have normally used a uni-
dimensional measure of the CPP insult, such as calcu-
lating the mean CPP value from the whole record, or
the duration of reduced CPP, or the percentage time
of the CPP reduction to the whole record, all of which
we have similarly used. We have created a new index
and demonstrated that the use of the CPT index at
our threshold levels for children was a significantly
better predictor of outcome.
Although CPT and the other indices were all signifi-
cantly predictive of mortality, because of the absolute
prediction of mortality with progressively lowered
CPP values, there was no additional benefit from any
one measure.
The threshold values chosen were inferred from
physiological normative data [4] and it was not known
at the outset whether those chosen values would prove
to be definitive thresholds for sustaining brain ‘‘insult’’
(and be crucial to the determination of outcome). We
therefore investigated alternative threshold levels of
CPP, (of minus 10% and minus 20% below the physio-
logical threshold), however these were not more pre-
dictive of outcome, indicating that the physiological
threshold (after appropriate homeostatic compensa-
tion) best approximates the secondary brain insult
threshold.
The brain insult may be acquired by either an exag-
gerated ICP or low MAP, and the CPT as a total CPP
insult measure, will not recognise which is the major
contributing cause. This is a common di‰culty with
any CPP measure.
Clearly the CPT index is a retrospective tool for use
in future clinical trials and retrospective studies, al-
though it could theoretically be applied after 24 hours
or other epochs of patient monitoring. It is likely that
the age-specific critical threshold CPP value will be
the practical value which will guide the clinician in the
bedside care of the head injured child.
The CPP threshold values described are particularly
useful for discriminating brain insult, but ‘‘treatment’’
or ‘‘intervention’’ thresholds, which would be arbi-
trary, would probably require higher target levels of
CPP for treatment intervention in any formal clinical
trial.
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Background: The principal strategy for managing head injury is to reduce the frequency and severity of
secondary brain insults from intracranial pressure (ICP) and cerebral perfusion pressure (CPP), and hence
improve outcome. Precise critical threshold levels have not been determined in head injured children.
Objective: To create a novel pressure–time index (PTI) measuring both duration and amplitude of insult,
and then employ it to determine critical insult thresholds of ICP and CPP in children.
Methods: Prospective, observational, physiologically based study from Edinburgh and Newcastle, using
patient monitored blood pressure, ICP, and CPP time series data. The PTI for ICP and CPP for 81 children,
using theoretical values derived from physiological norms, was varied systematically to derive critical insult
thresholds which delineate Glasgow outcome scale categories.
Results: The PTI for CPP had a very high predictive value for outcome (receiver operating characteristic
analyses: area under curve = 0.957 and 0.890 for mortality and favourable outcome, respectively) and
was more predictive than for ICP. Initial physiological values most accurately predicted favourable
outcome. The CPP critical threshold values determined for children aged 2–6, 7–10, and 11–15 years
were 48, 54, and 58 mm Hg. respectively.
Conclusions: The PTI is the first substantive paediatric index of total ICP and CPP following head injury. The
insult thresholds generated are identical to age related physiological values. Management guidelines for
paediatric head injuries should take account of these CPP thresholds to titrate appropriate pressor therapy.
D
espite advances in resuscitation and trauma care the
mortality and morbidity associated with head injury
remains high.1 If improvements are to be made in
outcome from childhood head injury then a key challenge to
neurointensive care is to minimise secondary ischaemic brain
insults. Thresholds for intracranial pressure (ICP) and
cerebral perfusion pressure (CPP) have become generally
accepted in adult practice, although they have not been
formally validated.2–9 There remains a pressing need to define
critical thresholds in children that can be used to define levels
for treatment intervention and insult detection in the
intensive care environment. That these clinically important
thresholds have not yet been established in children reflects
the ever changing cardiovascular physiology during growth
and development, which will alter thresholds with age until
they approach adult values. There has also been a reluctance
to define normal CPP values for different childhood age
groups because of the lack of normative ICP data in growing
children resulting from the changing intracranial dynamics.
The rationale for attempting to define critical thresholds of
CPP was based on the findings of Jones et al10 who, using age
specific norms, showed that the duration of age specific
abnormal CPP predicted outcome (unfavourable/favourable)
(p=0.004) and mortality (p=0.003) in a series of 71
children aged under 15 years. Similarly, Chambers et al11
found important age related differences in CPP over the first
six hours of monitoring, which were related to outcome.
Chambers et al4 have suggested a minimum target CPP
value of 45 mm Hg in children, based on a single point from a
receiver operating characteristic (ROC) curve that had been
created using a minimum of a rolling mean CPP value in 84
children aged three months to 16 years. In a pilot study
addressing the same issue, Jackson et al12 calculated the CPP
insults determined for different arbitrary CPP thresholds (70,
60, and 50 mm Hg). For nine children aged less than 16
years, these median CPP thresholds were associated with
median ICP values of 12, 14, and 24 mm Hg, and median
blood pressure values were 77, 71, and 71 mm Hg,
respectively.
All preceding studies that relate ICP/CPP to outcome in
traumatic and non-traumatic encephalopathies in children
have measured individual excursions of pressure, or the
duration of derangement. Such approaches, which use a
single summary measurement and do not combine severity
and duration of derangement, may not capture the total
insult burden. A measure that incorporates both degree and
duration would theoretically be a better reflection of the total
potential insult.
The sequential objectives of this study were, first, to create
a novel index quantifying the secondary ischaemic brain
insult, which combines both duration and intensity of
derangement (for ICP and CPP), using detailed (one minute
time resolution) physiological data; second, to derive age
related physiological thresholds for ICP and CPP; and third,
after establishing the sensitivity and specificity of the index
in relation to outcome, to use it to define age related critical
thresholds.
METHODS
This was a prospective observational study of 99 head injured
children aged less than 16 years, admitted to two regional
Abbreviations: CPP, cerebral perfusion pressure; GOS, Glasgow
outcome scale; ICP, intracranial pressure; ISS, injury severity score; PTI,
pressure–time index; PTIc, pressure–time index for CPP; PTIi, pressure–
time index for ICP; ROC, receiver operating characteristic
234
www.jnnp.com
 on 23 January 2006 jnnp.bmjjournals.comDownloaded from 
centres in Edinburgh (n=69) and Newcastle upon Tyne
(n=30) in 62 non-consecutive months up to July 2003. The
study had local ethics committee and management approval
in both centres and informed consent was obtained before
enrolment in the study. The criteria for enrolment for entry to
the study are given in table 1.
In all, 81 children (22 girls, 59 boys) aged two years or over
(median 10.3 years, range 2 to ,16) who fulfilled the criteria
for entry into the study had ICP and arterial blood pressure
monitoring. ICP and CPP treatment goals and general
management guidelines were previously reported.10 These
were as follows: age 0–13 years: CPP .50 mm Hg; ICP ,15
mm Hg; age 14–15 years: CPP.60 mm Hg, ICP,20 mm Hg.
The causes of injury are listed in table 2. There were 37 cases
that had a surgical evacuation and 44 cases managed
conservatively. The numbers of diffuse and focal injuries
were 65 and 35, respectively, based on a Marshall computed
tomography classification.
Outcome for all 81 children was recorded at six months
post-injury using a questionnaire completed by parents,
carers, or general practitioner. This was based upon the
model of Adelson et al15 and allowed a modified Glasgow
outcome scale (GOS) score to be assigned. In our analysis we
used three different outcome dichotomies (table 3).
Monitoring of physiological variables
Intracranial pressure was monitored using an intraparench-
ymal transducer tipped catheter (Camino Laboratories, San
Diego, California, USA) and continued for as long as was
clinically indicated. Arterial blood pressure (systolic, diasto-
lic, and mean) was monitored continuously using an intra-
arterial line referenced to the right atrium. The bedside
physiological monitors derived cerebral perfusion pressure.
Oxygen saturation, heart rate, and body temperature (core
and peripheral) were also recorded continuously.
Data acquisit ion and validation
Continuous recordings of variables at one minute time
resolution were made from a networked paediatric intensive
care unit in Newcastle and a mobile data collection system in
Edinburgh. Both types of data recording were then trans-
ferred into the Edinburgh BrowserE computer software
system16 for later off-line validation, review, and analysis.
Invalid data were identified and discarded for various
artefactual reasons such as detached probes, line flushing etc.
Abnormal but valid data (e.g. during chest physiotherapy)
were retained. Agonal data were retrospectively excluded for
the final four hours and terminal readings were noted from
the last available simultaneous measurement of ICP and CPP.
Because of the limited number of patients at each year age
and the obvious physiological differences between the ages of 2
and 15 it was necessary to group children into clearly defined
age bands. The age bands chosen were based upon physiological
tables of blood pressure17 and by determining at what age the
greatest incremental changes in blood pressure normally
occurred. The age bands chosen were 2–6, 7–10, 11–15 years,
and the lower limit means of mean arterial pressure (MAP)
calculated for these age bands. These were considered to be the
lowest acceptable value of MAP10 and are shown in Table 4.
Given the relatively small contribution of ICP to the normal
CPP value in young children, we chose the lowest acceptable
CPP value to be the same as the lowest normal mean MAP
value. This is likely to be numerically as accurate as formally
estimating the true mean ICP level, even if data existed to
allow such a calculation, and is described in detail in a
previous study by Jones et al.10
Employing these values for each age band, the Edinburgh
Browser system was then used to identify when the validated
CPP value fell below or the ICP above these age related
thresholds. Derangements were defined as abnormal values
persisting for >5 minutes.18 The commencement, number,
and duration of all derangements were identified.
Derivation of index
For each patient recording the duration of each CPP or ICP
insult was detected by the Edinburgh Browser program, the
difference between the specific age threshold and the
recorded pressure value was calculated for each minute
value. These were then summed to produce what we have
termed the pressure–time index for CPP (PTIc) and for ICP
(PTIi), which can be mathematically described by
A PTIc value of 40 mm Hg hours could represent a single
insult of two hours’ duration at a constant level of 20 mm Hg
Table 1 Criteria for enrolment
l Traumatic brain injury
l Post-resuscitation Glasgow coma score13 14 (12 or(15, with injury
severity score >16 or more
l Minute to minute computer data recording equipment available
l Physiological monitoring began within 24 hours of injury
l No previous head injury












Table 3 Outcome dichotomies
1. Favourable outcome (good recovery or moderate disability) v
unfavourable outcome (severe disability or death)
2. Mortality (death) v survival (good recovery, moderately disabled, or
severely disabled)
3. Morbidity (good recovery) v others (moderately disabled, severely
disabled, or dead)
Table 4 Predefined threshold values of
intracranial pressure (ICP) and cerebral
perfusion pressure (CPP)
Age Mean MAP or CPP threshold
2–6 years (48 mm Hg
7–10 years (54 mm Hg
11–15 years (58 mm Hg
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below the threshold level. It could equally represent an insult
lasting four hours where the CPP was 10 mm Hg below the
threshold. In practice, insults are likely to vary considerably
in both duration and depth, and the index will be a
cumulative total of all such insults. Clearly the PTI will
provide a valid comparison of total secondary insult between
different patients only when either the data acquisition is
limited to the point where the ICP values have been
consistently stable or within the normal range, or when data
acquisition is continued up to the point of death. Varying a
cut off point between 0 and the maximum PTI value, we
calculated the sensitivity and specificity of the index for PTIi
and PTIc for each of the three outcome divisions.
The sensitivity of PTIc will fall as the cut off point rises
(fewer favourable outcomes with greater insult severity),
while the specificity will rise with an increasing level of PTIc
(greater number of unfavourable outcomes with increasing
insult severity). Using the values of specificity and sensitivity
calculated at each cut off point, ROC curves were plotted for
each of the three outcome measures.
In order to investigate the effect of different threshold
levels for insult detection and whether these might better
differentiate outcome, each age band threshold was reduced
first by 10% and then by 20%, and the PTIc recalculated. The
age thresholds were then increased by 10% and the PTIc
calculated again. Using the favourable versus unfavourable
outcome dichotomy, ROC curves were plotted for each of the
new threshold test levels and the area under each curve
determined. For ICP the effect of altering the thresholds was
also investigated by reducing the thresholds by 10% and then
increasing them by 10% and then 20% (table 5).
The ICP monitoring was discontinued by the attending
clinician when considered normal and no longer clinically
appropriate. In order to ensure that the duration of
monitoring did not significantly affect the PTI we have
considered whether different durations or the severity of the
primary injury would have influenced the PTI.
RESULTS
Based upon a post-resuscitation Glasgow coma score (GCS),
63 of the 81 children were considered to have suffered a
severe head injury (GCS 3–8, E1, V=,2, and M=,5) and
16 children suffered a moderate head injury (GCS 9–12).
There were two with a mild head injury (GCS13–15, with
injury severity score (ISS) >16). The mean ISS was 20 (range
9–38).
Of the 81 children, 35 made a good recovery, 30 were
moderately disabled (65 favourable outcome), five were
severely disabled at six months post-injury, and 11 died (16
unfavourable outcome). None remained in a vegetative state.
Cerebral perfusion pressure
Using the initial age specific physiologically based threshold
values, the PTIc ranged from 0 to 1959 mm Hg hours. The
median PTIc values varied significantly with GOS (good
recovery 4.2; moderate disability 16.5; severe disability 73.6;
dead 769.1 mm Hg hours, Kruskall–Wallis p,0.001). There
was no significant difference in the mean values of PTIc
between the three age groups taken as a whole (not
subdivided by outcome)—that is, comparable amounts of
insult were found in all childhood age groups.
Separately, within both favourable and unfavourable
outcome, there were no significant differences in the
magnitude of PTIc across the three age bands (fig 1A,
p=0.3). However, there was a very significant difference
between the PTIc values in the unfavourable v favourable
outcome categories (p,0.001).
The PTIc value associated with an 80% sensitivity for a
favourable outcome was 73.1 mm Hg hours. The correspond-
ing values for mortality and morbidity were 331 and 1.4
mm Hg hours, respectively (fig 2A).
Table 5 Calculated ICP and CPP insult threshold values
Age (years)
CPP ICP
220% 210% Threshold +10% 210% Threshold +10% +20%
2–6 38 43 48 53 5.8 6.4 7.0 7.7
7–10 43 49 54 59 7.9 8.7 9.6 10.5
11–15 46 52 58 64 11.7 13 14.3 15.6



























































Figure 1 Box and Whisker plots of pressure–time index for (A) cerebral
perfusion pressure (PTIc) and (B) intracranial pressure (PTIi) for the three
age bands against outcome (favourable and unfavourable).
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When the threshold levels were changed (increased by 10%
and lowered by 10% and 20%), the sensitivity fell more
rapidly with lower threshold values, but there remained a
clear delineation between each of the curves of sensitivity
(fig 3A and B). For a specificity of 80% the PTIc values for
each of the outcome groups were poorly separated, at 99.5,
96.9, and 101.4 mm Hg hours for mortality, independence,
and morbidity, respectively, and with reduction in threshold
values, the patterns were almost identical.
The ROC curves for PTIc created using the initial CPP
threshold values for the three different outcome dichotomies
are shown in fig 4A and the areas under the curves (AUCs)
for all the ROC curves, along with their standard errors, are
shown in table 6. The PTIc index had a very high predictive
value for mortality (AUC=0.957), and for a favourable
outcome it was only slightly lower (AUC=0.890). The
predictive power was the lowest for separating the good
outcome group from all the remaining outcome categories
(AUC=0.681).
When the threshold levels were altered by the previously
described amounts, the resultant ROC curves for each of the
three different outcome comparisons had smaller AUC values
than that of our original threshold, indicating that our
original thresholds were better predictive values.
For both favourable outcome and morbidity the original
CPP threshold remained the best predictor of outcome, but
for mortality the predictive value increased very slightly as
the threshold level was decreased (table 6).
Intracranial pressure
The results for PTIi were similar but not identical to those for
PTIc. The range of PTIi values was 0 to 5887 mm Hg hours,
with a significant difference in median values of 232.8, 134.1,
776.3, and 1763.6 mm Hg hours in those who had good
recovery, were moderately disabled, severely disabled, or
died, respectively (Kruskall–Wallis, p,0.001). There was a
greater variation in the index across the two older age groups
for both favourable and unfavourable outcome than for PTIc
(p=0.026 and p,0.001) (fig 1B). There was a significant
difference in the mean PTIi for favourable v unfavourable
outcome (p,0.001).
The rate of change in specificity was very similar to that of
the CPP index for the three outcome comparisons. Although
the shapes of the sensitivity curves were similar to those of
PTIc, they were spread over a much wider range of values


































Figure 2 The sensitivities from the receiver operating characteristic
(ROC) curve plotted against the pressure–time index for (A) cerebral
perfusion pressure (PTIc) and (B) intracranial pressure (PTIi) in relation to



































Figure 3 Sensitivity and specificity curves for the pressure–time index
for cerebral perfusion pressure (PTIc) in relation to the tested threshold
levels.
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different threshold levels produced very similar sensitivity
and specificity curves, with little difference between mortal-
ity, independence, and morbidity values—unlike those for
CPP.
The areas under the ROC curves for the PTIi for mortality,
favourable outcome, and morbidity were smaller than the
respective PTIc values (fig 4 and table 6). The PTIi index had
a very high predictive value for mortality (AUC=0.871) and
a slightly lower value for favourable outcome (AUC=0.819).
For morbidity, the ROC curve stayed near to the diagonal,
indicating that the predictive value was always close to 50%.
The terminal ICP values for children aged 2–6 years were
12 mm Hg, for 7–10, 18 mm Hg, and for 11–15, 16 mm Hg,
corresponding to terminal CPP values of 78, 74, and 79
mm Hg, respectively. Although 42 children had terminal ICP
values that were a mean of 11 mm Hg above their age specific
thresholds, this was obviously compensated because there
was a negligible amount of corresponding terminal CPP
insult, with only five children having had terminal CPP
values of a mean of 3 mm Hg below threshold levels. Even if
this level of insult in these five patients continued for the
next hour, the PTI would still have estimated 98.6% of all CPP
insult. It can be seen, therefore, that the pressure recordings
had been discontinued only when there was virtually no
ongoing CPP derangement.
The duration of ICP monitoring bore no relation to the
severity of the primary injury, as assessed by the initial GCS
motor score level (p=0.572), nor to the ISS (p=0.237). In
addition, there was no significant difference between the two
participating children’s head injury units in the duration of
ICP monitoring (p=0.749).
DISCUSSION
For the clinician managing head injured patients, cerebral
perfusion pressure is a crucially important variable for
determining management decisions. We have developed a
novel pressure–time index that, for cerebral perfusion
pressure, is independent of age and has similar values across
our three different age bands for a favourable outcome
(p,0.02) and survival (p,0.001)—that is, insult occurs in all
age groups and is always predictive of outcome, thus allowing
comparability of CPP insults at any age. The PTI was
therefore a measure solely of secondary brain insult and
was independent of the duration of ICP monitoring and
highly comparable between the two centres in this study.
This cohort of head injured children is similar with respect
to the type, cause, and severity of injury and their outcome to
other reported British and European case series of head
injured children.19–23 Previous studies have focused on the
relation between CPP and outcome in children’s head injury,
using a single measurement of derangement of CPP values
(either mean, minimum, absolute, or percentage duration),
but all failed to incorporate both duration and severity in the
total burden of CPP insults.
Within the childhood population there are major differ-
ences between the blood pressure (and other physiological
variables) of a 2 year old and a 10 year old, for example,
unlike the adult population which recognises a single
standard CPP value. However, the numbers of children in
our study at each year from 2 to 15 are necessarily small and
require banding for predictive statistics. The three age bands
that we have used in determining insult thresholds have been
described previously.11 Although these bands could be
refined, in practice the rate of development of the physiology
of children can vary quite markedly and therefore the
banding provides a measure of spread. We are conscious
that we have not addressed ages between 0 and 2 years,
because the rapidly changing physiology at this stage of
development would require a larger cohort of patients and
may only be possibly with a large multicentre study.
Cerebral perfusion pressure
The values of PTIc are significantly related to each of the GOS
outcome categories or the combinations we have used
(favourable v unfavourable, mortality, morbidity). Other
studies cited above have shown a similar relation of ‘‘single
dimension’’ CPP derangement to outcome. However, and
uniquely, the PTIc is independent of age and was a very
sensitive predictor of outcome, demonstrating a higher insult
burden with worsened outcome on all three outcome
measurers, although the specificity proved to be less
discriminating (that is, some children made a relatively good
recovery with a high PTIc value).
The threshold levels that were chosen were based on
physiological norms (2–6 years, 48 mm Hg; 7–10 years,
54 mm Hg; 11–16 years, 58 mm Hg) and were not known
at the outset to be insult thresholds or treatment thresholds.
We reduced the CPP thresholds arbitrarily by a factor of 10%


































Figure 4 Receiver operating characteristic (ROC) curves for pressure–
time index for (A) cerebral perfusion pressure (PTIc) and (B) intracranial
pressure (PTIi) in relation to mortality, favourable outcome, and
morbidity.
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values), and our analysis showed that the performance of
PTIc was robust.
ROC curves are a very suitable method for analysing a
process that has a binary outcome. The area under the curve
gives a measure of the predictive value of a test and can be
used to compare different variables.24 Our ROC analysis has
clearly shown that the PTI value for CPP, using our original
CPP threshold values (at different ages), most accurately
separated the outcome categories. Theoretical threshold
levels above or below were less predictive than the original
physiologically based thresholds.
Intracranial pressure
It is generally accepted that raised intracranial pressure is a
secondary insult that adversely effects outcome.4 25 26 For ICP
our new index has an ROC area under the curve of 0.871 (for
mortality), and 0.819 (favourable v unfavourable), and
although this is lower than the CPP value it clearly has a
considerable relation to outcome.
The children who were severely disabled or died had
progressively larger amounts of ICP insult, as would be
expected, but there was an apparently anomalous finding of
median PTIi values in those children who made a good
recovery (232.8 mm Hg hours) compared with those who
were moderately disabled, who had less insult (134.1
mm Hg hours). However, this represents only a 6% differ-
ence in the total PTIi, and may be a reflection of several
outliers. Investigating this, we found there was no significant
difference in the duration of monitoring between those with
a good recovery and those with moderate disability, but the
significant differences in the mean values of PTIi between the
three age groups (p=0.017) might suggest that the a priori
ICP threshold levels do not equate to the insult thresholds as
they are too low.
Increasing or decreasing the ICP thresholds by 10% or 20%
(of a relatively small numerical ICP value) did not signifi-
cantly change the sensitivity or specificity and hence did not
improve the predictive value in relation to outcome—that is,
it is the CPP at our age specific thresholds that is the more
influential factor in the outcome of paediatric head injury.
Critical thresholds
Using this new index (PTI), which combines the degree and
duration of derangement, to quantitate the totality of brain
insult from pressure derangement, and when applied to
predefined insult threshold values for ICP and CPP, we have
shown that the index is robust and relates extremely well to
both morbidity and favourable outcome. We have tested
limits of these physiological thresholds by both increasing
and decreasing them, and have shown clearly by calculating
sensitivity and specificity of PTI that our initial physiological
thresholds best separated children with head injuries for both
mortality and favourable outcome using CPP. These critical
threshold values for children aged 2–6, 7–10, and 11–,16
years were 48, 54, and 58 mm Hg, respectively. In relation to
ICP, the predictive value of the PTI index improved slightly as
the threshold level was increased. This may have been
because the initial values, although developed from normal
age related values, were at a relatively low level, but even a
20% change did not bring about a large absolute difference.
This is the first study that includes more than one
dimension in the analysis of ICP and CPP data collected
from head injured children. We consider that the PTI will
therefore be needed for future studies that determine the
totality of cerebral perfusion pressure insults. Further work is
required to establish whether the shorter more severe
insults have comparable effects to longer but less severe
derangements.
There may, in theory, be three different types of threshold:
physiological thresholds, treatment thresholds, and brain
insult thresholds. Each of these would need to be precisely
defined and understood, but we believe that for children the
physiological thresholds (of CPP) are identical to the insult
thresholds. Treatment thresholds are likely to be more
arbitrary and individual, and what is defined here are
absolute CPP values below which secondary brain injury
Table 6 Areas under the receiver operating characteristic (ROC) curves for the pressure–
time index of intracranial pressure and cerebral perfusion pressure at each of the
threshold levels
Outcome dichotomy Threshold level ROC area SE
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has a significant impact of the injured child’s outcome.
Critical care guidelines emphasise the value of ICP monitor-
ing, and a more exact knowledge of the level of damaging
thresholds of ICP and CPP should enhance the ability of the
clinician to recognise abnormal pressures and to take
therapeutic steps to avoid the insult extending beyond these
thresholds.
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Abstract
Objective The aim of this study was to determine the
relationship between apolipoprotein E (APO E) alleles, the
amount of cerebral perfusion pressure (CPP) insult and
outcome in children after brain trauma.
Materials and methods In a prospective two-centre case–
control study, the APO E genotypes of 65 critically ill
children admitted after brain trauma were correlated with
age-related CPP insult quantification, conscious state at the
time of discharge from intensive care and global outcome at
6 months post-injury. One hundred sixty healthy age- and
sex-matched children were genotyped as controls.
Results The CPP insult level among the e4 carriers with
poor outcome was significantly less than the non-e4 carriers
(p=0.03). Homozygotic e3 patients with good recovery did
so despite having suffered nearly 26 times more CPP insult
than those who were not e3 homzygous (p=0.02).
Conclusion Different APO E alleles may potentially affect
cerebral ischaemic tolerance differently in children after
brain trauma.
Keywords Traumatic brain injury . Apolipoprotein E genetic
polymorphisms . Cerebral perfusion pressure . Outcome .
GCS . Paediatrics
Introduction
Cerebral perfusion pressure (CPP) insult is a proven determi-
nant of outcome after brain trauma in children [1, 2] and
adults [3, 4]. Despite vigilant brain trauma management to
minimise CPP insult, outcome of childhood traumatic brain
injury (TBI) remains diverse and sometimes appears to be
out of proportion to the severity of the primary brain injury
and the amount of secondary brain insult experienced. This
suggests that there may be other influences, for example
genetic makeup, which might be an additional determinant
of outcome following brain trauma.
The polymorphic Apolipoprotein E (APO E) gene, located
on chromosome 19, has been reported to affect outcome after
brain trauma in adults [5–7]. Teasdale et al. [8] have recently
suggested that its influence on the recovery of childhood
head injury may be even more important. However, the
mechanisms through which the APO E genetic polymor-
phisms affect outcome remain unknown. Postulated mecha-
nisms have originated mostly from animal or in vitro
investigations and include potential allelic-related differential
influence on oxidative stress [9] or excitotoxicity [10, 11]
and the rate of conversion of the neuroprotective ! amyloid
precursor protein (!APP) to the neurotoxic ! amyloid (!A4)
[12], but the clinical relevance of these mechanisms remains
unclear. Despite the vast literature supporting the predictive
value of CPP insult on brain trauma outcome in adults and
children, the relationships between APO E genotypes and
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CPP insult following brain trauma has not been assessed
previously.
This study aimed to determine the APO E allelic
distributions in critically ill children following brain trauma
and normal control children and to assess whether possessions
of the various APOE alleles differentially affect the amount of
CPP insult and outcome in childhood brain trauma.
Materials and methods
Participants
Sixty-five children requiring neuro-intensive care post-brain
trauma were enrolled into a prospective two-centre case-
controlled study over a two and a half-year study period.
Forty-five children had continuous intracranial pressure (ICP)
monitoring, but seven were excluded from this subgroup
analyses because significant amounts of ICP data were lost
during the first 24 h post-injury from computer downtime.
Control subjects comprised 160 attendees at the emergency
department follow-up clinic following minor injuries (exclud-
ing head injuries) and were age- and sex-matched to the brain-
injured children. The study was approved by the local ethics
and hospital research management committees. Parental
consent was obtained for inclusion in the study.
APO E genotyping
Buccal smears were collected from all participants for DNA
extraction using the commercially available PUREGENE
DNA Buccal Smear Isolation Kit™ (produced by Gentra
Systems). The extracted DNAwas used for subsequent APO E
genotyping employing polymerase chain reaction methodol-
ogy, restriction enzyme (Hhla) digestion andmetaphor agarose
gel electrophoresis adapted from Hixson and Vernier [13].
Quantification of CPP insult and outcome
In brain-injured children, routinely monitored physiological
parameters in minute resolutions were prospectively down-
loaded from the PICU bedside monitors for detection of
age-specific physiological derangements as described pre-
viously using the Edinburgh Browser programme [2]. The
total burden of CPP insult was quantified using the
cumulative pressure time index for CPP (PTIc) [14] in
patients with ICP monitoring.
Conscious level was determined at PICU discharge
which equated to the end of neuro-intensive care when
the brain-injured children no longer required airway
protection, ventilatory and circulatory support. The modi-
fied Glasgow Coma Scale (GCS) was used for this
assessment, and the children were dichotomised to those
who had ‘regained consciousness’ (GCS>8) and those with
‘delayed return of consciousness’ (GCS 8 or less). Global
outcome was assessed at 6 months post-injury using the
modified Glasgow Outcome Score (GOS) and dichotom-
ised into ‘good recovery’ when GOS 4 and 5 was achieved
and ‘poor outcome’ when GOS was between 1 and 3.
Analyses
Comparisons of the APO E allelic distribution ratios were
made among brain-injured children, their controls and a
previously reported cohort of healthy Scottish adults (n=
400) [15]. Chi-square tests were employed to assess any
statistical difference. To determine whether children with
different allelic groups experienced different amounts of
CPP insult, the patients were divided into the following
dichotomies for analyses: children with the e2 allele vs
those without; children carrying the e4 allele vs the non-e4
carriers and the e3 homozygous vs the non-e3 homozygous.
Mann–Whitney U tests were used to detect any statistical
significance. Relationships between the various outcome
dichotomies and different APO E allelic groups detailed
above were assessed using Fisher’s exact tests.
Results
Demographics
The subgroup of children with CPP insult measurement had
more severe brain injury and longer ICU duration of stay
than those of the whole cohort, but other demographic
details such as age, sex distribution and initial brain
computed tomography findings did not otherwise differ
significantly. The demographic details were similar be-
tween the different allelic groups.
APO E allelic distribution
APO E genotyping was successful in all participants. The
APO E allelic distributions for brain-injured children and
their controls are summarised in Table 1. The distribution
ratios of the three APO E alleles were similar between the
brain-injured children and their controls, but when com-
pared with healthy adults from a previously reported
Scottish population [15], the e2 allele was significantly
overrepresented (p=0.04) among our participants (Table 1).
APO E alleles and outcome
Of the whole brain trauma cohort, 46 children ‘regained
consciousness’, whilst 19 remained in a coma at the time of
PICU discharge. At 6 months post-injury, eight children had
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‘poor outcome’, of whom only one had ‘regained conscious-
ness’ at PICU discharge (p<0.001, Fisher’s exact test).
Table 2 summarises the relationships between the
different allelic dichotomies and outcome at PICU dis-
charge and 6 months post-injury. Only three of the 38 e3
homozygous (8%) had ‘poor outcome’ at 6 months post-
injury, whilst three of the 16 e2 carriers (19%) and three of
the 14 e4 possessors (21%) had ‘poor outcome’. There was
a trend for the e2 allele possessors to remain in a coma at
PICU discharge (p=0.05, Fisher’s exact test; Table 2).
APO E alleles and CPP insult
Children with various APO E alleles experienced differential
amounts of CPP insult, with e3 homozygous experiencing the
most whilst e4 carriers had the least CPP insult. Children
carrying the e4 alleles had significantly less (13.3 times) CPP
insult than those without the e4 allele (p=0.04, Mann–
Whitney U test; Fig. 1). E3 homozygous suffered 9.2 times
more CPP insult than the non-e3 homozygous (p=0.03,
Mann–Whitney U test; Fig. 1). In general, children in
possession of the e2 allele experienced 2.2 times less CPP
insult than non-e2 carriers, but this did not reach statistical
significance (p=0.58, Mann–Whitney U test; Fig. 1).
APO E alleles, CPP insult and outcome
At PICU discharge
Children with delayed recovery of consciousness at PICU
discharge tended to have experienced more CPP insult than
those who regained consciousness early with the exception
of those who were e3 homozygous where little variation of
CPP insult was found (Table 3).
When considering children who regained consciousness
(GCS>8) at PICU discharge, e3 homozygous had suffered
significantly more CPP insult than non-e3 homozygous (p<
0.01, Mann–Whitney U test), whilst children with the e4
allele experienced significantly less CPP insult than those
without the e4 allele (p=0.03, Mann–Whitney U test;
Table 4). There was a trend suggesting that e2 carriers
who had ‘regained consciousness’ had suffered less CPP
insult than those without the e2 allele (p=0.05, Mann–
Whitney U test; Table 4).


















e2 allele present 8 8 p=0.05 13 3 p=0.40
No e2 allele present 38 11 44 5
e3 homozygous 30 8 p=0.10 35 3 p=0.26
Non-e3 homozygous 16 11 22 5
e4 allele present 8 6 p=0.32 11 3 p=0.35
No e4 allele present 38 13 46 5
There is a trend for the e2 allele possessors to remain in a coma at PICU discharge (p=0.05, Fisher’s exact test)
Table 1 APO E Allelic distributions
APO E alleles APO E genotypes
e2 e3 e4 Total e2/e2 e2/e3 e2/e4 e3/e3 e3/e4 e4/e4
TBI Children (whole cohort, n=65) 18 (0.14) 96 (0.74) 16 (0.12) 130 2 11 3 38 9 2
Control children (n=160) 36 (0.11) 238 (0.74) 46 (0.15) 320 3 26 4 90 32 4
!2 for trend: e2 p=0.44; e3 p=0.91; e4 p=0.86
TBI children (whole cohort n=65) 18 (0.14) 96 (0.74) 16 (0.12) 130
TBI children (CPP insult measured, n=38) 13 (0.15) 53 (0.73) 10 (0.12) 76 1 8 3 20 5 1
!2 for trend: e2 p=0.53; e3 p=0.53; e4 p=0.86
TBI children (whole cohort n=65) 18 (0.14) 96 (0.74) 16 (0.12) 130
Healthy adults [15] (n=400) 66 (0.08) 616 (0.77) 118 (0.15) 800 2 51 11 233 99 4
!2 for trend: e2 p=0.04; e3 p=0.43; e4 p=0.46
Brain trauma children and their controls have similar distribution ratios for the three APO E alleles, but a significant overrepresentation of the e2
allele (p=0.04) is noted among our participants when they are compared with healthy adults from a previously reported Scottish population [15]
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6 months post-injury
At 6 months post-injury, regardless of the APO E
genotypes, brain-injured children with a good recovery
had suffered less CPP insult than those who had poor
outcome (Table 3). When considering children with a
good recovery, e3 homozygotic patients recovered well
despite having suffered significantly (nearly 26 times)
more CPP insult during their ICU management than those
who were not e3 homozygous (p=0.02, Mann–Whitney U
test; Table 4). Children possessing the e4 allele with a poor
outcome experienced significantly less CPP insult than
those without the e4 allele (p=0.03, Mann–Whitney U
test; Table 4). Furthermore, the median PTIc for the e4
carriers with poor outcome was 22.8 mmHg h, which
should have conferred good recovery given that the
median PTIc for the whole cohort with good recovery
was 32.3 mmHg h (Table 3).
Discussion
This study evaluated the association between APO E
genotypes, the measured CPP insult after paediatric brain
trauma, conscious state at PICU discharge and outcome at
6 months post-injury and demonstrated that children
carrying various APO E alleles experienced different
amounts of CPP insult following brain trauma. Additional-
ly, we established an e2 allelic overrepresentation among
our exclusive child cohort.
Table 3 APO E allelic groups, cerebral perfusion pressure insult, and outcome dichotomies







Good recovery Poor outcome Significance
(Mann–Whitney U)
Whole group 33.03 60.83 p=0.30 32.33 150.20 p=0.04
(0.00–273.22) (0.00–1169.27) (0.00–388.58) (5.10–1169.27)
(n=22) (n=16) (n=31) (n=7)
e2 allele present 2.22 82.47 p=0.06 4.43 150.20 p=0.03
(0–13.77) (0–1169.27) (0.00–121.28) (48.98–1169.27)
(n=4) (n=8) (n=9) (n=3)
e3 homozygous 75.26 79.95 p=0.93 70.13 495.86 p=0.04
(2.27–273.22) (0.00–830.40) (0.00–388.58) (161.32–830.40)
(n=14) (n=6) (n=18) (n=2)
e4 allele present 1.33 22.83 p=0.14 1.33 22.83 p=0.20
(0.00–11.93) (0.00–115.95) (0.00–115.95) (5.10–48.98)
(n=4) (n=5) (n=6) (n=3)
Children with poor outcome have significantly more CPP insult than those with good recovery (p=0.04). This is also true for children carrying the
e2 allele (p=0.03) and the e3 homozygotic children (p=0.04)
Fig. 1 The e3 homozygous had
more CPP insult than the non-e3
homozygous (p=0.03, Mann–
Whitney U test), whilst the e4
carriers had less insult than the
non-e4 carriers (p=0.04, Mann–
Whitney U test)
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Differential CPP insult between the carriers of the different
APO E alleles
Over the last decade, growing numbers of reports have
described the association between the APO E e4 allele and
poorer outcome after brain trauma in adults [5–7, 16], but
its relationships with secondary CPP insult and influence on
outcome after childhood brain trauma has not been
previously investigated. Our study confirms the importance
of CPP insult on outcome after childhood brain trauma
regardless of the patient’s APO E status. Additionally, this
study was the first to report children carrying the e4 allele
to have experienced the least amount of CPP insult, whilst
the e3 homozygotic patients suffered the most after brain
trauma despite having sustained primary brain injury of
similar severity and being treated with standardised
intensive care management. This suggests that APO E
genetic polymorphisms may have a potential differential
influence on the body’s response to primary brain injury or
its management.
Raised ICP, arterial hypotension or a combination of
both may cause low CPP. Post traumatic cerebral swelling
is an important cause of intracranial hypertension, and its
severity in experimental brain trauma may be modulated by
the APO E gene product [17]. However, recent evidence
demonstrated that e4 allelic possession did not increase the
degree of post traumatic cerebral swelling in adult TBI [18]
and fatal paediatric brain trauma [19].
Arterial hypertension in adults was reported with the
presence of either an e4 or e2 allele [20–23], but other
studies including an adult brain trauma cohort failed to
demonstrate any genetic effects on arterial blood pressure
measurements [24–26]. Our observed difference in CPP
insult is therefore unlikely to be caused by genetic
modulation of blood pressure.
Our patients possessing the e4 allele with poor outcome
had experienced a lesser burden of CPP insult than the non-
e4 carriers, and the amount of CPP insult was at a level that
should have conferred good recovery. Carriers of the e4
allele may be less tolerant of CPP insult and develop more
cerebral ischaemic damage than children without this allele
so that even with the small amount of CPP insult they
suffered, which should have conferred good recovery, the
e4 carriers had poor outcome. This interpretation would
support the observed trend of an increased incidence of
severe ischaemic brain damage among the e4 carriers from
a recent report of a postmortem study evaluating brain
specimens from 239 fatal cases of TBI aged between
2 months and 84 years [27], although the burden of
secondary CPP insult suffered by these patients were
unknown.
Cerebral ischaemia may be caused by an imbalance of
cerebral metabolic demand and substrate delivery. Healthy
young adults and patients with Alzheimer’s disease carry-
ing the e4 allele were reported to have a reduced cerebral
blood flow to selected regions of the brain [28, 29], but it
remains unknown whether a similar effect occurs in
children. If the potential increased ischaemic vulnerability
observed in the e4 carriers is caused by allelic-related
reduced cerebral blood flow, it will be particularly
Table 4 APO E allelic dichotomies, cerebral perfusion pressure insult and outcome. Median PTIc values (ranges, mmHg h) are given
Regained consciousness
(PICU discharge)
Good recovery (6 months post-injury) Poor outcome (6 months post-injury)
e2 Present 2.22 (0.00–13.97) 4.43 (0.00–121.28) 150.20 (48.98–1,169.27)
(n=4) (n=9) (n=3)
No e2 present 51.17 (0.00–273.22) 51.17 (0.00–388.58) 92.08 (5.10–830.40)
(n=18) (n=22) (n=4)
p value 0.05 0.23 0.48
e3 Homozygous 75.26 (2.23–273.22) 70.13 (0.00–388.58) 495.86 (161.32–830.40)
(n=14) (n=18) (n=2)
Non-e3 homozygous 1.33 (0.00–13.77) 2.67 (0.00–121.28) 48.98 (5.10–1,169.27)
(n=10) (n=13) (n=5)
p value <0.01 0.02 0.25
e4 Present 1.33 (0.00–11.93) 1.33 (0.00–115.95) 22.83 (5.10–48.98)
(n=4) (n=6) (n=3)
No e4 allele 51.17 (0.00–273.22) 49.95 (0.00–488.58) 495.86 (150.20–1,169.27)
(n=18) (n=25) (n=4)
p value 0.03 0.09 0.03
For patients who have regained consciousness at PICU discharge, the e4 allelic carriers have experienced significantly less CPP insult than the
non-e4 carriers (p=0.03), whilst e3 homozygotic children have experienced significantly more CPP insult than those who are not e3 homozygous
(p<0.01). For patients with poor outcome at 6 months, significantly less CPP insult is found among those carrying the e4 allele when compared to
those without the e4 allele (p=0.03). E3 homozygotic children with good recovery at 6 months post-injury have suffered significantly more CPP
insult than those who are not e3 homozygous (p=0.02)
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important to avoid low CPP in these patients after brain
trauma.
Cerebral metabolic rate in severely brain-injured children
was shown to be normal in 81%, and this subsequently fell
between the first and third day following brain trauma [30].
One may therefore postulate that the e4 allele increases its
carriers’ cerebral metabolic demand after brain trauma,
thereby increasing their susceptibility to cerebral ischaemia.
To assess this postulate, continuous measurements of
cerebral metabolism and cerebral substrate supply would
be required.
Recent animal studies have suggested that brain trauma
causes an increased neuro-inflammation in transgenic ani-
mals carrying the human e4 allele when compared with those
with the e3 allele [31, 32]. Circulating IL-10 levels among
the e4 carriers with coronary artery disease were found to
be significantly lower than the non-e4 carriers [33], but it is
unknown whether APO E genotypes affect the degree of
neuro-inflammation in TBI patients. Further studies are
required to ascertain whether this may explain our
observation on outcome which appeared out of proportion
to the allelic-related variations in CPP insult post brain
trauma. Another possible explanation for this observation is
that the APO E e4 allele adversely affects outcome through
mechanisms independent of the amount of CPP insult.
Almost all previous reports in the literature have
suggested that the adverse effect of the APO E gene on
outcome was related to the possession of the e4 allele.
However, despite transgenic animal data suggesting a
potentially more superior neurological repair offered by
the e3 allele [34], no study has investigated whether APO E
allelic influence on neurological recovery may be related to
the absence of the e4 allele. The e3 homozygotic children
in our cohort experienced more CPP insult than those in the
other allelic groups which, by conventional evidence on the
positive correlation between CPP insult and poor outcome
[3, 4, 14], more of the e3 homozygous would have been
expected to have an unfavourable outcome. However, we
found fewer e3 homozygotic patients among the brain-
injured children with a poor outcome. Additionally,
children possessing only the e3 allele with ‘good recovery’
in our cohort had achieved that despite having suffered
nearly 26 times more CPP insult than non-e3 homozygous.
This would suggest that the e3 homozygous potentially
enjoys a protective effect from ischaemic insult. This
benefit may be due to the lack of the e4 or e2 alleles and
warrants further investigations in a larger cohort.
APO E genetic polymorphisms and brain trauma outcome
The proportion of patients with poor outcome was
unexpectedly low in our cohort and was a third less than
the projected figure from previous report [5]. Fewer
unfavourable outcomes following childhood brain trauma,
although a welcome finding, makes our study insufficiently
powered to assess whether there is any allelic influence on
neurological recovery after childhood brain trauma. Despite
these limitations, we demonstrated that unfavourable
outcome was 2.6 times more common among the e4
carriers than the e3 homozygotic patients, although 58%
of the cohort were e3 homozygous and 22% were e4
carriers, who suffered the least amount of CPP insult. This
highlighted the need to further investigate APO E allelic
influence on childhood brain trauma.
Overrepresentation of the e2 allele in active children
with or without brain injury
The patients in the previously reported APO E brain trauma
studies [5–7, 16] were either exclusively or predominantly
adults with very few children included. Although the APO
E allelic distribution ratios from all these cohorts [5, 6, 16]
were reported to be similar to previously published
population data, none have actually included appropriate
population controls for their injured cohorts. To our
knowledge, this is the first study to investigate the
relationship between APO E genotypes and outcome after
brain trauma in an exclusive child cohort which includes an
appropriate same population control group.
Our control subjects comprised healthy active children
who had sustained minor injuries from their normal life
styles and were age- and sex-matched to the brain-injured
group. They were chosen to ensure as similar a risk for
sustaining brain injury as possible to allow accurate
comparison of the APO E allelic distribution frequency
which we found to be similar between the groups. Our
decision to include a separate paediatric population control
group was further justified by the finding of a significant e2
allelic overrepresentation among our participants when
compared to that of a previously reported group of healthy
adults who were born in Northeast Scotland [15]. This adult
cohort was chosen for comparison because it represented
the largest reported healthy Scottish adult cohort to have
their APO E genotyped, and its allelic distribution ratio
(0.08 for e2, 0.77 for e3, and 0.15 for e4) was similar to
those described in other adult brain trauma cohorts [5, 6,
16] and general populations worldwide [15, 35, 36],
including different regions of Scotland, Germany, Taiwan
and the USA. Geographic variation of the APO E allelic
distribution is therefore unlikely to explain our observed
overrepresentation of the e2 allele.
The frequency of the e2 allele among a previously
reported healthy Scottish newborn population [37] recruited
from the same geographic area as our cohort was similar to
the e2 allele frequency of the above adult reports rather than
to our study. Thus, our participants, children with minor
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injuries and critically ill children post-brain trauma, may
represent a different population to brain-injured adults and
the general (adult and neonatal) populations. Paediatric
injuries tend to occur more frequently because of the level
of activity among normal young children, whilst adult
injuries (include the elderly population) may occur regard-
less of their activity levels. Further investigation is required
to determine whether APO E e2 allele relates to a
heightened physical activity level.
Conclusion
Our result suggests that after childhood brain trauma,
carriers of the APO E e4 allele may tolerate CPP insult
less well than those with other allelic possession. APO E e3
homozygotic patients may enjoy a relative protective effect,
mitigating CPP insult.
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SUMMARY
Paediatric Head Injury management guidelines have been published in recent years, by
SIGN (2000), RCPCH (2001), NICE (June 2003), and jointly by Critical/Intensive Care
Societies (C/ICS July 2003).
We investigated whether outcome of children’s Head Injury (HI) and total burden of
secondary CPP insult has changed i) annually; ii) before and after the introduction of any HI
guidelines, and iii) following other service changes.
76 children (aged 1 -<15 years with severe HI) were admitted to the Edinburgh Regional
Head Injury Service between 1989 and 2006, and dichotomised at various time points and
compared in terms of: demographic factors, age-banded Pressure-Time Index (PTI)), and
Glasgow Outcome Scale (GOS) score.
When dichotomised around the SIGN guidelines, the outcome profiles were different
(p=0.03), with 6, 2, 5 & 23 having GOS1 (died), GOS3 (severely disabled), GOS 4
(moderately disabled) and GOS5 (good recovery) before, compared to 4, 4, 17 & 15
respectively post-2000, with especially more cases of GOS4 than GOS5 (p=0.007).  After
the introduction of the C/ICS guidelines there was significantly less mean CPP insult
(p=0.030). This lower amount of CPP insult has yet to be reflected in significantly better
outcomes although the trend was for fewer deaths and severe disabilities.
Key Words:  Paediatric Head Injury, Secondary Brain Insult, Outcome, Guidelines
Introduction:
Secondary pathophysiological CPP insult has been consistently shown to be related to
outcome after head injury in both adults (4,5,6,9,11,13,16) and children (8,3,2,7), and
improved management would be expected to reduce 2ndry brain insult in both duration and
intensity. Paediatric Head Injury management guidelines have been published in recent
years, by the Scottish Intercollegiate Guidelines Network (SIGN; 2000) (15), the Royal
College of Paediatrics and Child Health (RCPCH; 2001) (14), the NHS National Institute for
Clinical Excellence (NICE; June 2003) (12), and jointly by the Society of Critical Care
Medicine, the World Federation of Pediatric Intensive and Critical Care Societies, and the
Paediatric intensive Care Society UK (C/ICS; July 2003) (1). We investigated whether
outcome after children’s Head Injury and total burden of secondary brain insult, (particularly
CPP insult) has changed i) annually; ii) before and after the introduction of any HI
guidelines, and iii) following other service changes.
Materials and Methods:
Seventy-six children (aged 1 -<15 years with severe HI) were admitted to the Edinburgh
Regional Head Injury Service for adults and children between 1989-1996 (Western General
Hospital), and between 2000-2006 to a new Paediatric ICU (Royal Hospital for Sick
Children).  Demographic (age, gender, cause of injury, GCS, ISS, Marshall CT score, pupil
response etc.) and physiological data were stored from the ICU bedside monitors, collected
prospectively and analysed.
Outcome at 6-months post injury was assigned from responses to a questionnaire sent to all
parent/carers. The groups were dichotomised at various time points, and compared in terms
of: (i) demographic factors, (ii) secondary brain insults including Intracranial Pressure (ICP)
and Cerebral Perfusion Pressure (CPP) insults, and (iii) Glasgow Outcome Scale (GOS –
paediatric modification) score. We used a previously developed age-banded Pressure-Time
Index (PTI) (10) to give a measure of the amount of ‘brain insult’ which occurred during the
ICU management period.
The Pressure-Time Index is a two-dimensional cumulative measure combining intensity and
duration of secondary insult found in both ICP and CPP, calculated from data recorded every
minute from the bed-side monitors in the Intensive Care Unit, using the example formula
below for the cPTI for CPP:
! 
cPTI = (CPPthreshold "CPP) # tsample$ mmHg.min, where cPTI is the Cumulative Pressure
Time Index, and t is the time at which the data was sampled.
The data set was divided so that cases admitted before any of the mentioned guidelines were
published, were compared with those of later years (i.e. division point immediately pre SIGN
guidelines - 2000). Data was also analysed on an annual basis to look for trends over time,
and finally, the data set was split by admission date before and after July 2003, when the
treatment specific guidelines of the C/ICS became widely available.
The statistical package of SPSS! for Windows 14.0 (SPSS Inc. U.S.A), was used for the
analysis.
Results:
Pre- and post – SIGN Guidelines
When dichotomised around the SIGN guidelines, the groups were comparable with no
statistically significant differences between the demographic features (age, sex, cause of
injury, GCS, ISS, ICP monitoring characteristics etc) or in primary brain injury. The
outcomes however, were different (Chi Square 9.11, p=0.028), with 6, 2, 5 & 23 having
GOS 1 (died), GOS 3 (severely disabled), GOS 4 (moderately disabled) and GOS 5 (good
recovery) before, compared to 4, 4, 17 & 15 respectively post-2000.  In particular, the
change in relative positions of the GOS 4 and 5 outcomes was highly significant  (Chi Sq=
7.99, p<0.007) (Figure 1)
Insert Figure 1 about here
There was a (non-significant) trend for the later years to have longer mean insult durations of
ICP, hypertension, CPP, hypoxia, pyrexia, tachycardia and bradycardia, greater mean cPTI
for ICP, and a significantly greater mean number of episodes of CPP insults (p=0.005). i.e. a
less optimal trend.
Fluctuations Annually
When these head injury cases were analysed year-by-year, there were no overall significant
differences found but a closer look at the referral pattern (Figure 2) indicated that a change
had taken place, with more children being referred from tertiary centres from 2001 onwards.
There were 17, 1, and 18 admitted from the hospital Accident and Emergency department, a
GP, and from tertiary referral centre before 2000, compared to 6,1, and 33 respectively after
2000 (Chi Square = 9.49, p=0.009).
Insert Figure 2 about here
The PTIicp and PTIcpp by year  (see figure 3) for all 76 patients from 1989 to 2006, and the
median amount of measured secondary insult (cPTI) per patient, independent of outcome,
was similar.
Insert Figure 3 about here
Pre- and post C/ICS Guidelines
When dichotomised around the time point of July 2003, when the paediatric C/ICS Head
Injury guidelines were published, the outcomes were 9,5,14 & 29, compared to 1,1, 8 & 9,
for GOS1,3,4, and 5 respectively, for the pre- and post- July2003 groups. While overall this
was not a significant difference, there was a trend for fewer deaths and poor (GOS 3)
outcomes
The mean cPTI for CPP was 10,000.53 mmHg.min (the product of duration and intensity)
compared to 4,218.37 mmHg.min respectively when the cohort was split pre-and post- July
2003. Although this gave an unequal distribution of cases (57 vs. 19), there was still
significantly less CPP insult overall (p=0.030) after the introduction of the more
management-oriented C/ICS guidelines, with a decrease of almost 60%. The mean cPTI for
ICP was 35,186.95 mmHg.min after July2003, having fallen from 58,355.07mmHg.min., a
decrease of about 40%. While this shows a trend in the desired direction, it was not
significant.
Discussion:
Pre- and Post- SIGN Guidelines
One of the notable guidelines advocated in the SIGN guidelines publication was for the
transfer of head injured patients to a Neurosurgical Centre. We showed there was a
significant change in referral pattern, with almost twice as many cases coming from other
hospitals, largely in the eastern half of Scotland. However, an unexpected finding was an
increase in the burden of ICP insult, as measured by the cPTI. We speculate that this could
have been due to more insult occurring before admission to our unit, or different treatment
routines employed before patient transfer. The difference however, was not due to the time
interval from injury to the instigation of Intracranial Pressure Monitoring in these two groups
and the later group were actually monitored on average, slightly more speedily (17.9 hours,
compared to 13.8hours). The mean duration of monitoring once at the PICU was 86.6 hours
compared to 92.0 hours, but again this was not statistically significant.
As there were no demographic factors or GCS differences, it is difficult to explain the
subsequent increase in numbers achieving only a moderate (GOS 4) recovery, compared to
GOS5 (good recovery). The same questionnaire was used throughout the whole study period,
and the same personnel were responsible for assigning the GOS score at 6 months, so
internal bias is unlikely. We explored the change in the outcome pattern of those with GOS4
and GOS 5 more closely, and found that after 2000, the mean cPTI for CPP increased 3 fold,
with a 4 fold increase in mean cPTI ICP in the same period, while those with GOS5 outcome
had a 10% and 17% reduction in cPTI CPP and ICP respectively.
Annual Evaluation
The amount of cPTI for both ICP and CPP on a year-to-year basis, independent of outcome,
was found to be not significantly different for the year groups as a whole. There were
however relatively small number of cases per year.
Unsurprisingly, those with the poorest outcome had the greatest burden of secondary brain
insult, whether considered annually, before and after 2000, or before and after the July 2003
dividing point.
Pre-and Post- C/ICS Guidelines
After the publication of the more management directed head injury C/ICS guidelines in July
2003, and despite the declining prevalence of paediatric head injury cases there was
significantly less secondary ‘pressure’ insult: cPTI, for CPP (p = 0.030) and a trend to less
ICP. This was accompanied by a trend to fewer deaths and GOS3 outcomes.
Clearly guidelines may be implemented completely or partially and will require some time to
show an effect. Additional time will also ensure larger study numbers, however the trend is
for a definite improvement in outcome and less secondary brain insult which may reach
significance in the future.
Reference List
1. Adelson PD, Bratton SL, Carney NA, Chesnut RM, Du Coudray HEM, Goldstein B,
Kochanek PM, Miller HC, Partington MD, Selden NR, Warden CR, Wright
DW  (2003) Guidelines for the acute medical management of severe traumatic
brain injury in infants children and adolescents. Journal of Trauma-Injury
Infection & Critical Care 54(SUPPL. 6): S237-S239
2. Chambers IR, Kirkham FJ  (15-12-2003) What is the optimal cerebral perfusion
pressure in children suffering from traumatic coma?. Neurosurgical Focus
15(6): E3-
3. Chambers IR, Treadwell L, Mendelow AD  (2000) The cause and incidence of
secondary insults in severely head-injured adults and children. British Journal
of Neurosurgery 14(5): 424-431
4. Chambers IR, Treadwell L, Mendelow AD  (2001) Determination of threshold levels
of cerebral perfusion pressure and intracranial pressure in severe head injury
by using receiver-operating characteristic curves: an observational study in
291 patients. Journal of Neurosurgery 94(3): 412-416
5. Huang SJ, Hong WC, Han YY, Chen YS, Wen CS, Tsai YS, Tu YK  (2006) Clinical
outcome of severe head injury using three different ICP and CPP protocol-
driven therapies. Journal of Clinical Neuroscience 13(8): 818-822
6. Huang SJ, Hong WC, Han YY, Chen YS, Wen CS, Tsan YS, Tu YK  (2007) Clinical
outcome of severe head injury in different protocol-driven therapies. Journal
of Clinical Neuroscience 14(5): 449-454
7. Jackson S, Piper IR, Wagstaff A, Souter M  (2000) A study of the effects of using
different cerebral perfusion pressure (CPP) thresholds to quantify CPP
"secondary insults" in children. Acta Neurochirurgica - Supplement 76453-
456
8. Jones PA, Andrews PJ, Easton VJ, Minns RA  (2003) Traumatic brain injury in
childhood: intensive care time series data and outcome. British Journal of
Neurosurgery 1729-39
9. Jones PA, Andrews PJ, Midgley S, Anderson SI, Piper IR, Tocher JL, Housley AM,
Corrie JA, Slattery J, Dearden NM  (1994) Measuring the burden of secondary
insults in head-injured patients during intensive care. Journal of Neurosurgical
Anesthesiology 6(1): 4-14
10. Jones PA, Chambers IR, Lo TY, Andrews PJ, Chaudhry W, Clark A, Croft J, Forsyth
R, Fulton B, Mendelow AD, Wilson G, Minns RA  (2005) Quantification of
secondary CPP insult severity in paediatric head injured patients using a
pressure-time index. Acta Neurochirurgica - Supplement 9529-32
11. Marmarou A, Saad A, Aygok G, Rigsbee M  (2005) Contribution of raised ICP and
hypotension to CPP reduction in severe brain injury: correlation to outcome.
Acta Neurochirurgica Suppl 95277-280
12. NHS National Institute for Clinical Excellence (NICE)  (2003) Head Injury. Triage,
assessment, investigation and early management of head injury in infants,
children and adults. Clinical Guideline 4
13. Rosner MJ, Rosner SD, Johnson AH  (1995) Cerebral perfusion pressure:
Management protocol and clinical results. Journal of Neurosurgery 83(6): 949-
962
14. Royal College of Paediatrics and Child Health  (2001) Good Practice Guidelines.
Early Management of Patients with a Head Injury.
15. Scottish Intercollegiate Guideline Network (SIGN)  (2000) Early Management of
Patients with a Head Injury. No 46
16. Young JS, Blow O, Turrentine F, Claridge JA, Schulman A  (15-12-2003) Is there an
upper limit of intracranial pressure in patients with severe head injury if
cerebral perfusion pressure is maintained? Neurosurgical Focus 15(6): E2-
Figure Legends
Figure 1.
Outcome at 6 months post-injury, illustrating that there were more GOS4 outcomes
in later years compared to earlier years of the study.
GOS= Glasgow Outcome Score, where GOS1 = dead, GOS3 = Severe Disability,
GOS4 = Moderate Disability, and GOS5= Good Recovery. (Note there were no
cases of GOS2 =vegetative state).
Figure 2
Referral Pattern year by year. Since 2001 the referral pattern has changed, with more
children being admitted from peripheral hospitals.
Figure 3
Box Plots of the yearly distribution of secondary brain insult assessed by the
cumulative Pressure Time Index (for both CPP and ICP), with all outcomes included
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Abstract:
Many potential brain trauma biomarkers have been reported but no previous study
has described outcome prediction using combinations of biomarker levels.  We
aimed to investigate the outcome predictive values of multiple biomarkers from
different mediator families and to determine whether combinations of 2 serum
biomarkers may achieve higher outcome predictive values than individual biomarker
levels.  A prospective observational study was conducted involving 28 children
requiring intensive care management following brain trauma.  Day 1 post injury
serum concentrations of 8 different biomarkers (S100b, NSE, IL-6, IL-8, IL-10,
SICAM, L-selectin, and endothelin) were quantified using ELISA.  Global outcome
was assessed at 6 months post injury using the Glasgow Outcome Score (GOS).
Receiver operator characteristic curve (ROC) analysis and its multivariate extension,
Multivariate ROC (MultiROC), were used to assess the outcome predictive values of
the individual and the paired biomarkers.  None of the 8 biomarkers assessed
individually achieved an area under the ROC curve (AUC) of more than 0.95 for
predicting unfavourable outcome, but 5 of the 20 biomarker pairs assessed had this
high degree of outcome predictability.  Two combinations using S100b as the
‘screening marker’ and either L-selectin or IL-6 as the ‘varying marker’ achieved an
AUC of 0.98, and their specificity and sensitivity for unfavourable outcome
prediction were 96% and 100% respectively.  Prognostic pairs combining serum
levels of 2 biomarkers (inflammatory mediators and brain specific proteins) offer
superior outcome predictive values for unfavourable outcome after childhood brain
trauma than may be achieved using individual marker levels.
(Abstract word count: 245)
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List of Biomarker Abbreviations:
IL-6 – Interleukin –6
IL-8 – Interleukin –8
IL-10 – Interleukin –10
S100b – S100b protein
SICAM – Soluble intracellular adhesion molecule
NSE – Neuron specific enolase
INTRODUCTION
Traumatic brain injury is the most common cause of death and disability in the
pediatric population (Suominen, et al. 1998, Walker and Cass 1987).  Accurate
outcome prediction during the acute management of brain trauma remains difficult.
Biochemical mediators are produced and released after brain trauma (Bell, et al.
1997, Ergun, et al. 1998, Fridriksson, et al. 2000, Kalabalikis, et al. 1999, Kossmann,
et al. 1995, McClain, et al. 1991, McKeating, et al. 1998, Persson, et al. 1987,
Pleines, et al. 1998, Raabe, et al. 1999, Raabe, et al. 1999, Skogseid, et al. 1992,
Takahashi, et al. 1989, Whalen, et al. 1998, Woertgen, et al. 1997, Yamazaki, et al.
1995) to regulate the complex cascade of secondary brain insult and repair processes,
or when there is neuronal or glial damage.  Many of these mediators are measurable
in blood or cerebrospinal fluid (CSF) making them potentially useful for outcome
prediction (Bell, et al. 1997, Ergun, et al. 1998, Fridriksson, et al. 2000, Kalabalikis,
et al. 1999, Kossmann, et al. 1995, McClain, et al. 1991, McKeating, et al. 1998,
Persson, et al. 1987, Pleines, et al. 1998, Raabe, et al. 1999, Raabe, et al. 1999,
Skogseid, et al. 1992, Takahashi, et al. 1989, Whalen, et al. 1998, Woertgen, et al.
1997, Yamazaki, et al. 1995).
The biochemical properties of potential brain trauma biomarkers previously
described in the literature are diverse and include brain specific proteins such as
S100b and NSE which represent the degree of astrocytic and neuronal damage
(Ergun, et al. 1998, Marangos and Schmechel 1987, Rothoerl, et al. 1998, Skogseid,
et al. 1992, Woertgen, et al. 1997, Yamazaki, et al. 1995); pro and anti-inflammatory
mediators such as IL-6 (Arand, et al. 2001, Chiaretti, et al. 2005, Minambres, et al.
2003) and IL-10 (Csuka, et al. 1999); chemotaxins such as IL-8 (Kossmann, et al.
1997, Kushi, et al. 2003, Whalen, et al. 2000); adhesion molecules such as L-selectin
(McKeating, et al. 1998); and vasoconstrictors such as endothelin (Yang, et al.
2002).  Most of these studies have only investigated the relationship between
individual biomarker concentration and outcome without comparing the outcome
predictive values of unrelated classes of biomarkers.  It is, therefore, unclear from the
existing literature whether inflammatory mediators or brain specific (neuronal or
glial) proteins have higher outcome predictive values.
Translation of brain trauma biomarker research into clinically useful prognostic tools
has not been successful.  This may be because potentially useful prognostic
thresholds have only been described in a few studies for a very limited number of
selected biomarkers to predict unfavourable outcome (Ross, et al. 1996).  In addition,
no previous report in the literature has described outcome prediction using
combinations of serum biomarker concentrations from different mediator families,
which may offer more accurate outcome prediction than may be achieved with
individual marker levels.
This study aims to determine the serum prognostic thresholds and predictive values
of 8 biomarkers from different mediator families for unfavourable outcome after
childhood isolated brain trauma.  We additionally aim to determine which paired
combinations of biomarkers are better at predicting unfavourable outcome after
isolated pediatric brain trauma than individual marker levels.
MATERIALS AND METHODS
Patient Enrollment
Twenty-eight children (21 boys and 7 girls) consecutively admitted to neuro-
intensive care after isolated accidental brain trauma were enrolled into a single-
centre prospective observational study.  The local ethics and hospital management
committees approved the study.  Parental consent was obtained for participation in
the study.
Clinical and demographic details including age, sex, injury severity and initial brain
CT findings were collected prospectively.  Primary brain injury severity was
assessed using the post-resuscitation/pre-intubation modified pediatric Glasgow
Coma Scale (GCS) (Reilly, et al. 1988), and was dichotomised into ‘severe injury’
where GCS was 8 or less and ‘non-severe injury’ where GCS was more than 8 to
assess their relationships with biomarker levels.  Initial brain CT findings were
dichotomised into ‘diffuse’ and ‘focal’ injuries.  Global outcome was assessed at 6
months post injury using the modified Glasgow Outcome Score (GOS) (Adelson, et
al. 1997) and dichotomised into ‘favourable recovery’ when GOS 4 and 5 were
achieved, and ‘unfavourable outcome’ when GOS were between 1 and 3.
Sample Collection and Measurement
All patients had an arterial blood sample collected at precisely 24 hours (day 1) post
injury.  The blood samples were collected in pyrogen-free plastic tubes and
centrifuged at 1200 g for 10 minutes.  The serum was removed immediately and
stored in pyrogen-free plastic tubes at –70 
0
C until analyses.
Commercially available enzyme linked immunoassays (ELISA) were used to
quantify the serum concentrations of 8 different biomarkers (Table 1).  Samples were
analysed in duplicate and averaged to provide the final marker concentrations.
Outcome Predictive Values and Prognostic Thresholds of Individual
Biomarkers
Mann Whitney U tests were employed to detect statistical difference (p < 0.05) in
mediator concentrations between the dichotomised injury severity and outcome
groups.  For each biomarker with significantly different levels between the outcome
dichotomy, sensitivity and specificity of incremental values for prediction of
unfavourable outcome at 6 months post brain injury were calculated.  Receiver
Operator Characteristic (ROC) curves were then plotted and the optimal cut-off
value (prognostic threshold) for each mediator, which was defined as the point
closest to the left upper corner of the ROC curve, was identified.  Areas under the
ROC curves (AUC) were measured to compare the outcome predictive values
between individual biomarkers.
Paired Biomarker Levels and Multivariate ROC Curves
The algorithm of paired biomarkers consisted of a Boolean expression of the
mediator concentrations related by an algebraic operator as the components of the
expression (i.e. biomarker A > a predefined ‘screening’ threshold AND biomarker B
> incremental thresholds predicting unfavourable outcome).  One of the paired
biomarkers was called the ‘screening marker’ and had a single cut-point (‘screening
threshold’) assigned.  The other biomarker (‘varying marker’) had incremental
thresholds, and corresponding sensitivities and specificities were calculated to plot
the multivariate ROC (MultiROC) curve.  Area under each MultiROC curve
(AUCm) was measured to compare the outcome prediction performance between the
different paired combinations.  AUCm of the pairs were then compared with the
AUC of the individual biomarkers to determine whether they or individual
biomarkers had higher outcome predictive values.
The ‘screening threshold’ of each biomarker was determined by plotting individual
mediator concentrations against the outcome dichotomy and was defined as the
highest biomarker level that identified most patients with favourable recovery
without including any patient with unfavourable outcome.  In order to investigate the
effect of different ‘screening threshold’ levels within each combination and whether
these might better differentiate outcome, the original ‘screening threshold’ within
each pair was reduced first by 10%, then 20%, and MultiROC curves were plotted
again with the new ‘screening threshold’ test levels, and the AUCm were
determined.  The analyses were repeated when the original ‘screening thresholds’
were increased by 10% and 20%.
The optimal threshold for the ‘varying marker’ of each combination was determined,
which was defined as the point closest to the left upper corner of the MultiROC




Table 2 summarises the demographic details.  The median GCS was 7 (range 3 to
13).  Median age of the patients was 8.59 years (range 0.33 to 14.17 years).  At 6
months post injury, 24 patients made a favourable recovery while 4 children had an
unfavourable outcome.
Biomarker Concentrations and Demographic Dichotomies
Of the 8 biomarkers assessed, only the SICAM and IL-6 levels were significantly
higher in patients with severe injury than those with non-severe injury (p = 0.01 for
SICAM, and p = 0.02 for IL-6).  The median NSE serum levels in patients with
diffuse brain injury (identified on the initial brain CT scan) were two times higher
than those with focal injury (p = 0.01).  None of the other biomarker levels
differentiated diffuse and focal injuries.
Individual Neurochemical Mediator Concentrations and Outcome
Patients with unfavourable outcome had significantly higher day 1 serum
concentrations of S-100b, NSE, L-selectin, IL-6, and IL-8 than those with favourable
recovery (Figure 1).  The outliners in the S100b and IL-8 figures did not have any
clinical, physiological or other apparent differences to explain their outlying
neurochemical levels.  The outliners in both of these figures (S100b and IL-8) were
different patients.  Day 1 L-selectin level had the highest predictive value for
unfavourable outcome at 6 months after brain trauma (AUC = 0.92).  Table 3
summarises the area under the ROC curves for individual biomarkers, their
prognostic thresholds (optimal cut-point), and the corresponding sensitivities and
specificities.
Paired Biomarker Levels and Outcome Prediction
Because IL-10, endothelin, and SICAM levels did not differentiate between the
outcome dichotomies, they were excluded from MultiROC analyses.  There were,
therefore, 5 possible screening markers.  ‘Screening threshold’ for each ‘screening
marker’ is shown in Figure 1.  Each ‘screening marker’ was paired in turn with the
remaining 4 biomarkers to form 20 different combinations.  Table 4 summarises the
top 10 combinations for unfavourable outcome prediction after childhood brain
trauma, their AUCm, and optimal threshold for the ‘varying marker’ within each of
these combinations.  Two pairs achieved 100% sensitivity and 96% specificity for
unfavourable outcome prediction (Table 4).
Comparison of the Predictability for Unfavourable Outcome after Brain
Trauma
When using individual biomarker level to predict unfavourable outcome, only the
day 1 L-selectin level had an AUC > 0.90 (Table 3).  15 of the 20 combinations
examined had AUC > 0.90 for prediction of unfavourable outcome after brain
trauma.  Combinations using S100b as the ‘screening marker’ had higher predictive
values for unfavourable outcome than those using other mediators as the ‘screening
marker’.  Outcome predictive values were higher in combinations that used L-
selectin as the ‘varying marker’ than those using it as the ‘screening marker’.
Increasing or decreasing the ‘screening threshold’ of each combination did not
improve prediction for unfavourable outcome (Table 5).
A day 1 L-Selectin level of 1200ng/ml was 75% sensitive and 88% specific for
predicting unfavourable outcome after brain trauma, but the specificity increased to
96% when this threshold was coupled with either S100b or NSE as the ‘screening
marker’ (Figure 2).
DISCUSSION
This paediatric brain trauma study demonstrated that the day 1 serum concentrations
of inflammatory mediators had higher prognostic values than brain specific proteins,
but the best outcome predictive value was achieved with combinations of 2
biomarker levels from different mediator families.
Serum or CSF levels of brain specific proteins and inflammatory mediators such as
S100b, NSE, IL-6, and IL-8 measured at various time points after brain trauma have
individually been described in the literature as potentially useful predictors of
unfavourable outcome (Arand, et al. 2001, Bandyopadhyay, et al. 2005, Chiaretti, et
al. 2005, Jackson, et al. 2000, Kushi, et al. 2003, Minambres, et al. 2003, Ross, et al.
1996, Rothoerl, et al. 1998, Spinella, et al. 2003).  It has not, however, been possible
to ascertain from the existing literature which class and specific biomarker offers the
most accurate outcome prediction after brain trauma.  This may be because the
majority of previous studies have concentrated on evaluating a single mediator or
limited numbers of mediators from the same biomarker family.  Additionally, reports
in the literature often use different specimen types (CSF, arterial or venous blood),
sample collection time-points, and data analyses, making comparison between
studies difficult.
Buttram and colleagues recently used multiplex bead array to quantify the CSF levels
of 21 different cytokines at 4 various time points after pediatric brain trauma but
failed to demonstrate any associations with outcome (Buttram, et al. 2007).  Their
cohort comprised of 36 infants and children who had diverse mechanisms of injury
which included isolated traumatic brain injury, inflicted brain trauma, and
polytrauma with widely variable time ranges for each sample collection point
(Buttram, et al. 2007).  Our study, in contrast, restricted evaluations to serum
biomarker levels measured at exactly 24 hours and only in isolated accidental brain
trauma.  This may explain the difference in outcome prediction of biomarkers
between both studies, and the high predictive values for unfavourable outcome
observed in our study.  A recent study has demonstrated that the time courses of
serum brain specific protein levels differ significantly between different types of
pediatric brain injury (Berger, et al. 2006).
Our study also evaluated biomarkers from different mediator families and
demonstrated for the first time that some inflammatory markers (L-selectin and IL-8)
had higher predictive values for unfavourable outcome than brain specific (glial or
neuronal) proteins.  One possible explanation for our findings is that although serum
levels of proteins released from glia or neurons after brain injury may not accurately
reflect the extent of cellular damage.  Serum inflammatory marker levels may, on the
other hand, have better associations with the actual burden of neuro-inflammation
which in turn has a higher outcome predictive value.  Alternatively, neuro-
inflammation may have a greater influence on outcome after brain trauma than
previously expected.
We demonstrated for the first time that the outcome predictive values vary between
inflammatory mediators with L-selectin offering a higher predictive value than IL-6
and IL-8, while IL-10 and SICAM serum levels had no association with outcome.
Neuro-inflammation is a heterogeneous process with different pathways operating
and subsiding at various time-points after brain trauma.  To investigate this complex
relationship between different biomarkers, their different time-courses and outcome
prediction will require a larger cohort with sufficient numbers of patients with poor
outcome.  This may be difficult to achieve in the light of the Western world-wide
declining incidence of childhood brain trauma (Engberg and Teasdale 1998, Ponsky,
et al. 2005, Thurman and Guerrero 1999), and improvement in brain trauma
management and outcome.
Increasing numbers of biomarkers have been described as potentially useful
prognosticators of brain trauma outcome, but none have actually been translated into
clinically useful entities.  This may be because the majority of papers in the literature
have only reported on the varying concentrations of the different biomarkers in
relation to outcome and only a few prior studies have proposed potentially useful
prognostic thresholds, such as NSE (Ross, et al. 1996).  Our study is the first to
describe serum prognostic thresholds for unfavourable outcome in 5 biomarkers
simultaneously and includes some of the previously less well investigated
biomarkers such as L-selectin.
Previous studies using individual biomarkers rarely yielded sensitivity and
specificity of more than 85% (as reported here) for unfavourable outcome prediction
(Ross, et al. 1996).  Brain trauma outcome is dependent upon many factors such as
the severity of the primary brain injury (Bruce, et al. 1978, Facco, et al. 1986, Pal, et
al. 1989, Prasad, et al. 2002) and the burden of secondary insults (Chambers, et al.
2006, Chambers, et al. 2000, Chesnut, et al. 1993, Jones, et al. 2003, Miller and
Becker 1982), and to expect successful and accurate prognostication with a single
serum biomarker is unrealistic.  Bergers and colleagues investigated the outcome
predictive values of the serum levels of 3 brain specific proteins (S100b, NSE and
myelin basic protein) in 152 children with brain trauma (Berger, et al. 2007).  Using
binary logistic regression to evaluate the simultaneous effects of these 3 biomarkers
on outcome, they described a 77% correct classification rate and a positive predictive
value of 75%.  However, no biomarker prognostic threshold was described in their
report (Berger, et al. 2007).  In 2 recent independent reports, Bergers and colleagues
described the usefulness of combined serum biomarker levels to respectively
diagnose pediatric brain trauma (Berger, et al. 2005), and inflicted brain injury
among well infants with GCS of 15 (Berger, et al. 2008).  Neither of these studies
investigated outcome predictive values using combinations of biomarkers (Berger, et
al. 2005, Berger, et al. 2008).  Our study is, therefore, the first to report brain trauma
outcome prediction using biomarkers from different mediator families, and to
describe prognostic thresholds for several paired biomarker combinations.
We used multivariate ROC (MultiROC) curves for our analyses because they retain
all the simplicity of interpretations of the traditional ROC curve analysis but
additionally allow comparisons between the performance of multivariate
combinations without being restricted to the display of a single variable’s
performance and comparisons of individual tests (Shultz 1995).  Our chosen
‘screening thresholds’ were based upon the highest concentration of each biomarker
that identified as many patients with favourable recovery without including any of
those with unfavourable outcome.  We did not know at the outset of the study
whether these thresholds would offer the highest predictive values but have
subsequently demonstrated that arbitrary increasing or decreasing the original
threshold levels by 10% and 20% did not improve the outcome predictive values of
these combinations.  Using the MultiROC curves, we further refined our prognostic
algorithm by defining the optimal threshold for the ‘varying biomarker’ within each
combination, and were able to propose for the first time pairs of biomarker levels
that were highly predictive of unfavourable outcome.
Combinations using a brain specific protein (S100b or NSE) as the ‘screening
marker’ had higher predictive values for unfavourable outcome than those that used
either of these proteins as the ‘varying marker’.  On the other hand, L-selectin
offered a higher outcome predictive value when it was used as the ‘varying marker’
rather than the ‘screening marker’ within the prognostic algorithm.  One possible
explanation for these observations was that the ‘screening marker’ thresholds we
chose for S100b or NSE were more sensitive in screening for patients with
unfavourable outcome than that chosen for L-selectin.  Alternatively, although
elevated brain specific proteins levels signalled glial and neuronal damage, their
relatively short serum half life meant that their serum levels at the time of sampling
in our cohort might have been better employed as a screening tool for unfavourable
outcome.
The main limitation of our study is relatively small cohort size and the few patients
with unfavourable outcome resulting in the need to assess outcome simply, rather
than using more elegant measures such as detailed cognitive tests (Beers, et al.
2007).  Another limitation is that our findings may not be used to predict outcome of
brain trauma patients with extra-cranial injuries who may have greatly altered serum
cytokine profiles independent of the brain injury because our cohort only includes
patients with isolated traumatic brain injuries.  Despite these limitations, we have
successfully defined prognostic thresholds for 5 individual biomarkers and
combinations of paired biomarker levels with very high outcome predictive values.
Our proposed prognostic thresholds and their outcome predictive values were not
validated because of the small sample size.  Our findings may, however, be used as
starting points for validation in future studies involving larger and independent
cohorts before translation into potentially useful clinical tools for brain trauma
outcome predictions.
CONCLUSION
Combining brain specific protein and inflammatory mediator levels offer higher
outcome predictive values than may be achieved with the individual biomarkers.
(Manuscript word count: 3088)
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Table 1: Commercially available ELISA used in the study
Brain Specific Proteins:
Glial Protein:
o S-100b (Nexus Dx™ S-100 Test Kit, Synx Pharma Inc)
Neuronal Protein:
o NSE (Nexus Dx™ NSE Test Kit, Synx Pharma Inc)
Inflammatory Mediators:
Pro-inflammatory mediator:
o IL-6 (IL-6 ELISA Kit, Diaclone Research)
Chemotaxin:
o IL-8 (IL-8 ELISA kit, Diaclone Research)
Anti-inflammatory mediator:
o IL-10 (IL-10 ELISA Kit, Diaclone Research)
Adhesion Molecules:
o L-selectin (human sL-Selectin Immunoassay, R&D Systems)
o SICAM (sICAM-1 ELISA Kit, Diaclone Research)
Vasoconstrictor:
o Endothelin (Endothelin 1-21 Test Kit, Biomedica)
Table 1 Legend:
Table 1 summarises the commercially available ELISA used in the study.
Table 2: Demographic details and outcome of the cohort
Favourable Outcome Unfavourable Outcome
Median age 7.92
(Range 0.33 – 14.17 yrs)
10.50 years











GCS 13 – 15 (Non-severe)
GCS 9 – 12 (Non-severe)















Table 2 summarises the demographic details and outcome of the cohort.
Table 3: The optimal cut-off value of individual biomarkers and their sensitivity
and specificity for unfavourable outcome prediction.






1200 ng/ml 0.92 88% 75%
IL-8 Day 1 Level 30 pg/ml 0.88 92% 75%
NSE Day 1 Level 25 ng/ml 0.83 83% 75%
S100B Day 1
Level
0.05 ng/ml 0.83 79% 75%
IL-6 Day 1 Level 60 pg/ml 0.83 71% 75%
Table 3 Legend:
Table 3 summarises the optimal cut-off value of individual biomarkers and their
sensitivity and specificity for unfavourable outcome prediction.
Table 4: Top 10 paired biomarker levels for unfavourable outcome prediction,
the optimal prognostic threshold for their ‘varying marker’, AUCm, specificity
and sensitivity.




















1000 ng/ml 0.98 96% 100%
S100b > 0.04
ng/ml AND IL-6
40 pg/ml 0.98 96% 100%
S100b > 0.04
ng/ml AND NSE
10 ng/ml 0.97 92% 100%
IL-6 > 30 pg/ml
AND L-selectin
1000 ng/ml 0.96 88% 100%
NSE > 12 ng/ml
AND L-selectin
1200 ng/ml 0.95 96% 75%
NSE > 12 ng/ml
AND S100b
0.05 ng/ml 0.94 92% 75%
IL-6 > 30 pg/ml
AND IL-8
30 pg/ml 0.93 96% 75%
S100b > 0.04
ng/ml AND IL-8
30 pg/ml 0.93 92% 75%
IL-8 > 20 pg/ml
AND L-selectin
1200 ng/ml 0.92 88% 75%
L-selectin > 700
ng/ml AND IL-8
30 pg/ml 0.92 96% 75%
Table 4 Legend:
Table 4 shows the top 10 paired biomarker levels for unfavourable outcome
prediction, the optimal prognostic threshold for their ‘varying marker’, AUCm,
specificity and sensitivity.
Table 5: Area under each Multivariate ROC curves (AUCm) using original



















S100b L-selectin 0.98 0.94 0.94
S100b IL-6 0.98 0.94 0.88
S100b NSE 0.97 0.96 0.89
IL-6 L-Selectin 0.96 0.95 0.95
NSE L-selectin 0.95 0.93 0.93
NSE S100b 0.94 0.93 0.84
IL-6 IL-8 0.93 0.91 0.89
S100b IL-8 0.93 0.90 0.89
IL-8 L-selectin 0.92 0.90 0.89
L-selectin IL-8 0.92 0.91 0.90
L-selectin S100b 0.92 0.88 0.87
IL-6 NSE 0.91 0.87 0.78
IL-8 IL-6 0.91 0.89 0.89
NSE IL-8 0.90 0.88 0.88
IL-6 S100b 0.90 0.89 0.89
IL-8 S100b 0.89 0.84 0.82
NSE IL-6 0.88 0.86 0.83
IL-8 NSE 0.88 0.84 0.80
L-selectin IL-6 0.88 0.86 0.86
L-selectin NSE 0.83 0.83 0.75
Table 5 Legend:
Table 5 demonstrates that the original ‘screening thresholds’ of each prognostic




Figure 1 shows the day 1 biomarker levels that were significantly different between
patients with favourable and unfavourable outcome.  Screening thresholds were 0.04
ng/ml for S100b, 12 ng/ml for NSE, 700 pg/ml for L-selectin, 30 pg/ml for IL-6, and
20 pg/ml for IL-8.
Figure 2:
Figure 2 Legend:
Figure 2 shows that the specificity and sensitivity for predicting unfavourable
outcome improved when L-selectin was paired with another biomarker.  The highest
outcome predictive value for unfavourable outcome was achieved when L-selectin
was paired with S100b.
